id	sid	tid	token	lemma	pos
work_6edatbslnjhz3kb2pkbphqv5py	1	1	Vol	Vol	NNP
work_6edatbslnjhz3kb2pkbphqv5py	1	2	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	2	1	4	4	CD
work_6edatbslnjhz3kb2pkbphqv5py	2	2	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	2	3	935	935	CD
work_6edatbslnjhz3kb2pkbphqv5py	2	4	-	-	SYM
work_6edatbslnjhz3kb2pkbphqv5py	2	5	939	939	CD
work_6edatbslnjhz3kb2pkbphqv5py	2	6	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	2	7	April	April	NNP
work_6edatbslnjhz3kb2pkbphqv5py	2	8	1998	1998	CD
work_6edatbslnjhz3kb2pkbphqv5py	2	9	Clinical	Clinical	NNP
work_6edatbslnjhz3kb2pkbphqv5py	2	10	Cancer	Cancer	NNP
work_6edatbslnjhz3kb2pkbphqv5py	2	11	Research	Research	NNP
work_6edatbslnjhz3kb2pkbphqv5py	2	12	935	935	CD
work_6edatbslnjhz3kb2pkbphqv5py	2	13	3	3	CD
work_6edatbslnjhz3kb2pkbphqv5py	2	14	The	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	2	15	abbreviations	abbreviation	NNS
work_6edatbslnjhz3kb2pkbphqv5py	2	16	used	use	VBN
work_6edatbslnjhz3kb2pkbphqv5py	2	17	are	be	VBP
work_6edatbslnjhz3kb2pkbphqv5py	2	18	:	:	:
work_6edatbslnjhz3kb2pkbphqv5py	2	19	5-FU	5-fu	CD
work_6edatbslnjhz3kb2pkbphqv5py	2	20	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	2	21	5-fluorouracil	5-fluorouracil	CD
work_6edatbslnjhz3kb2pkbphqv5py	2	22	;	;	:
work_6edatbslnjhz3kb2pkbphqv5py	2	23	NCCTG	NCCTG	NNP
work_6edatbslnjhz3kb2pkbphqv5py	2	24	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	2	25	North	North	NNP
work_6edatbslnjhz3kb2pkbphqv5py	2	26	Central	Central	NNP
work_6edatbslnjhz3kb2pkbphqv5py	2	27	Cancer	Cancer	NNP
work_6edatbslnjhz3kb2pkbphqv5py	2	28	Treatment	Treatment	NNP
work_6edatbslnjhz3kb2pkbphqv5py	2	29	Group	Group	NNP
work_6edatbslnjhz3kb2pkbphqv5py	2	30	:	:	:
work_6edatbslnjhz3kb2pkbphqv5py	2	31	KPS	KPS	NNP
work_6edatbslnjhz3kb2pkbphqv5py	2	32	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	3	1	Karnofsky	karnofsky	JJ
work_6edatbslnjhz3kb2pkbphqv5py	3	2	performance	performance	NN
work_6edatbslnjhz3kb2pkbphqv5py	3	3	status	status	NN
work_6edatbslnjhz3kb2pkbphqv5py	3	4	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	4	1	Prospective	prospective	JJ
work_6edatbslnjhz3kb2pkbphqv5py	4	2	Randomized	Randomized	NNP
work_6edatbslnjhz3kb2pkbphqv5py	4	3	Trial	trial	NN
work_6edatbslnjhz3kb2pkbphqv5py	4	4	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	4	5	5-Fluorouracil	5-fluorouracil	CD
work_6edatbslnjhz3kb2pkbphqv5py	4	6	versus	versus	IN
work_6edatbslnjhz3kb2pkbphqv5py	4	7	5-Fluorouracil	5-fluorouracil	CD
work_6edatbslnjhz3kb2pkbphqv5py	4	8	plus	plus	CC
work_6edatbslnjhz3kb2pkbphqv5py	4	9	Levamisole	Levamisole	NNP
work_6edatbslnjhz3kb2pkbphqv5py	4	10	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	4	11	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	4	12	Treatment	Treatment	NNP
work_6edatbslnjhz3kb2pkbphqv5py	4	13	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	4	14	Metastatic	Metastatic	NNP
work_6edatbslnjhz3kb2pkbphqv5py	4	15	Colorectal	Colorectal	NNP
work_6edatbslnjhz3kb2pkbphqv5py	4	16	Cancer	Cancer	NNP
work_6edatbslnjhz3kb2pkbphqv5py	4	17	:	:	:
work_6edatbslnjhz3kb2pkbphqv5py	4	18	A	a	DT
work_6edatbslnjhz3kb2pkbphqv5py	4	19	Hoosier	Hoosier	NNP
work_6edatbslnjhz3kb2pkbphqv5py	4	20	Oncology	Oncology	NNP
work_6edatbslnjhz3kb2pkbphqv5py	4	21	Group	Group	NNP
work_6edatbslnjhz3kb2pkbphqv5py	4	22	Trial	Trial	NNP
work_6edatbslnjhz3kb2pkbphqv5py	4	23	’	'	''
work_6edatbslnjhz3kb2pkbphqv5py	4	24	Malik	Malik	NNP
work_6edatbslnjhz3kb2pkbphqv5py	4	25	T.	T.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	4	26	Bandealy	Bandealy	NNP
work_6edatbslnjhz3kb2pkbphqv5py	4	27	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	4	28	Ren#{233}Gonin	ren#{233}gonin	NN
work_6edatbslnjhz3kb2pkbphqv5py	4	29	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	4	30	Patrick	Patrick	NNP
work_6edatbslnjhz3kb2pkbphqv5py	4	31	J.	J.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	4	32	Loehrer	Loehrer	NNP
work_6edatbslnjhz3kb2pkbphqv5py	4	33	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	4	34	Frank	Frank	NNP
work_6edatbslnjhz3kb2pkbphqv5py	4	35	Monaco	Monaco	NNP
work_6edatbslnjhz3kb2pkbphqv5py	4	36	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	4	37	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	4	38	Lawrence	Lawrence	NNP
work_6edatbslnjhz3kb2pkbphqv5py	4	39	H.	H.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	4	40	Einhorn2	Einhorn2	NNP
work_6edatbslnjhz3kb2pkbphqv5py	4	41	Divisions	Divisions	NNPS
work_6edatbslnjhz3kb2pkbphqv5py	4	42	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	4	43	Hematology	Hematology	NNP
work_6edatbslnjhz3kb2pkbphqv5py	4	44	/	/	SYM
work_6edatbslnjhz3kb2pkbphqv5py	4	45	Oncology	Oncology	NNP
work_6edatbslnjhz3kb2pkbphqv5py	4	46	[	[	-LRB-
work_6edatbslnjhz3kb2pkbphqv5py	4	47	M.	M.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	4	48	T.	T.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	4	49	B.	B.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	4	50	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	4	51	P.	P.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	4	52	J.	J.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	4	53	L.	L.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	4	54	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	4	55	L.	L.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	4	56	H.	H.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	4	57	E.	E.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	4	58	]	]	-RRB-
work_6edatbslnjhz3kb2pkbphqv5py	4	59	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	4	60	Biostatistics	Biostatistics	NNP
work_6edatbslnjhz3kb2pkbphqv5py	4	61	[	[	-LRB-
work_6edatbslnjhz3kb2pkbphqv5py	4	62	R.	R.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	4	63	G.	G.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	4	64	]	]	-RRB-
work_6edatbslnjhz3kb2pkbphqv5py	4	65	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	4	66	Indiana	Indiana	NNP
work_6edatbslnjhz3kb2pkbphqv5py	4	67	University	University	NNP
work_6edatbslnjhz3kb2pkbphqv5py	4	68	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	4	69	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	4	70	Hoosier	Hoosier	NNP
work_6edatbslnjhz3kb2pkbphqv5py	4	71	Oncology	Oncology	NNP
work_6edatbslnjhz3kb2pkbphqv5py	4	72	Group	Group	NNP
work_6edatbslnjhz3kb2pkbphqv5py	4	73	[	[	-LRB-
work_6edatbslnjhz3kb2pkbphqv5py	4	74	F.	F.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	4	75	M.	M.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	4	76	]	]	-RRB-
work_6edatbslnjhz3kb2pkbphqv5py	4	77	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	4	78	Indianapolis	Indianapolis	NNP
work_6edatbslnjhz3kb2pkbphqv5py	4	79	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	4	80	Indiana	Indiana	NNP
work_6edatbslnjhz3kb2pkbphqv5py	4	81	46208	46208	CD
work_6edatbslnjhz3kb2pkbphqv5py	4	82	-	-	SYM
work_6edatbslnjhz3kb2pkbphqv5py	4	83	4646	4646	CD
work_6edatbslnjhz3kb2pkbphqv5py	4	84	ABSTRACT	ABSTRACT	NNP
work_6edatbslnjhz3kb2pkbphqv5py	4	85	The	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	4	86	purpose	purpose	NN
work_6edatbslnjhz3kb2pkbphqv5py	4	87	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	4	88	this	this	DT
work_6edatbslnjhz3kb2pkbphqv5py	4	89	study	study	NN
work_6edatbslnjhz3kb2pkbphqv5py	4	90	was	be	VBD
work_6edatbslnjhz3kb2pkbphqv5py	4	91	to	to	TO
work_6edatbslnjhz3kb2pkbphqv5py	4	92	compare	compare	VB
work_6edatbslnjhz3kb2pkbphqv5py	4	93	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	4	94	objective	objective	JJ
work_6edatbslnjhz3kb2pkbphqv5py	4	95	response	response	NN
work_6edatbslnjhz3kb2pkbphqv5py	4	96	rate	rate	NN
work_6edatbslnjhz3kb2pkbphqv5py	4	97	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	4	98	duration	duration	NN
work_6edatbslnjhz3kb2pkbphqv5py	4	99	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	4	100	remission	remission	NN
work_6edatbslnjhz3kb2pkbphqv5py	4	101	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	4	102	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	4	103	survival	survival	NN
work_6edatbslnjhz3kb2pkbphqv5py	4	104	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	4	105	5-flu-	5-flu-	NNP
work_6edatbslnjhz3kb2pkbphqv5py	4	106	orouracil	orouracil	NN
work_6edatbslnjhz3kb2pkbphqv5py	4	107	(	(	-LRB-
work_6edatbslnjhz3kb2pkbphqv5py	4	108	5-FU	5-fu	CD
work_6edatbslnjhz3kb2pkbphqv5py	4	109	)	)	-RRB-
work_6edatbslnjhz3kb2pkbphqv5py	4	110	versus	versus	IN
work_6edatbslnjhz3kb2pkbphqv5py	4	111	those	those	DT
work_6edatbslnjhz3kb2pkbphqv5py	4	112	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	4	113	5-FU	5-fu	CD
work_6edatbslnjhz3kb2pkbphqv5py	4	114	plus	plus	CC
work_6edatbslnjhz3kb2pkbphqv5py	4	115	levamisole	levamisole	NN
work_6edatbslnjhz3kb2pkbphqv5py	4	116	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	4	117	metastatic	metastatic	JJ
work_6edatbslnjhz3kb2pkbphqv5py	4	118	colorectal	colorectal	JJ
work_6edatbslnjhz3kb2pkbphqv5py	4	119	cancer	cancer	NN
work_6edatbslnjhz3kb2pkbphqv5py	4	120	using	use	VBG
work_6edatbslnjhz3kb2pkbphqv5py	4	121	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	4	122	same	same	JJ
work_6edatbslnjhz3kb2pkbphqv5py	4	123	dose	dose	NN
work_6edatbslnjhz3kb2pkbphqv5py	4	124	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	4	125	sched-	sched-	JJ
work_6edatbslnjhz3kb2pkbphqv5py	4	126	ule	ule	NN
work_6edatbslnjhz3kb2pkbphqv5py	4	127	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	4	128	these	these	DT
work_6edatbslnjhz3kb2pkbphqv5py	4	129	agents	agent	NNS
work_6edatbslnjhz3kb2pkbphqv5py	4	130	as	as	IN
work_6edatbslnjhz3kb2pkbphqv5py	4	131	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	4	132	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	4	133	North	North	NNP
work_6edatbslnjhz3kb2pkbphqv5py	4	134	Central	Central	NNP
work_6edatbslnjhz3kb2pkbphqv5py	4	135	Cancer	Cancer	NNP
work_6edatbslnjhz3kb2pkbphqv5py	4	136	Treat-	Treat-	NNP
work_6edatbslnjhz3kb2pkbphqv5py	4	137	ment	ment	JJ
work_6edatbslnjhz3kb2pkbphqv5py	4	138	Group	Group	NNP
work_6edatbslnjhz3kb2pkbphqv5py	4	139	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	4	140	intergroup	intergroup	NNP
work_6edatbslnjhz3kb2pkbphqv5py	4	141	studies	study	NNS
work_6edatbslnjhz3kb2pkbphqv5py	4	142	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	4	143	adjuvant	adjuvant	JJ
work_6edatbslnjhz3kb2pkbphqv5py	4	144	therapy	therapy	NN
work_6edatbslnjhz3kb2pkbphqv5py	4	145	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	5	1	Patients	patient	NNS
work_6edatbslnjhz3kb2pkbphqv5py	5	2	with	with	IN
work_6edatbslnjhz3kb2pkbphqv5py	5	3	no	no	DT
work_6edatbslnjhz3kb2pkbphqv5py	5	4	prior	prior	JJ
work_6edatbslnjhz3kb2pkbphqv5py	5	5	history	history	NN
work_6edatbslnjhz3kb2pkbphqv5py	5	6	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	5	7	chemotherapy	chemotherapy	NN
work_6edatbslnjhz3kb2pkbphqv5py	5	8	for	for	IN
work_6edatbslnjhz3kb2pkbphqv5py	5	9	meta-	meta-	NNP
work_6edatbslnjhz3kb2pkbphqv5py	5	10	static	static	NNP
work_6edatbslnjhz3kb2pkbphqv5py	5	11	disease	disease	NN
work_6edatbslnjhz3kb2pkbphqv5py	5	12	were	be	VBD
work_6edatbslnjhz3kb2pkbphqv5py	5	13	entered	enter	VBN
work_6edatbslnjhz3kb2pkbphqv5py	5	14	on	on	IN
work_6edatbslnjhz3kb2pkbphqv5py	5	15	this	this	DT
work_6edatbslnjhz3kb2pkbphqv5py	5	16	Hoosier	Hoosier	NNP
work_6edatbslnjhz3kb2pkbphqv5py	5	17	Oncology	Oncology	NNP
work_6edatbslnjhz3kb2pkbphqv5py	5	18	Group	Group	NNP
work_6edatbslnjhz3kb2pkbphqv5py	5	19	randomized	randomize	VBD
work_6edatbslnjhz3kb2pkbphqv5py	5	20	Phase	Phase	NNP
work_6edatbslnjhz3kb2pkbphqv5py	5	21	III	III	NNP
work_6edatbslnjhz3kb2pkbphqv5py	5	22	trial	trial	NN
work_6edatbslnjhz3kb2pkbphqv5py	5	23	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	6	1	Patients	patient	NNS
work_6edatbslnjhz3kb2pkbphqv5py	6	2	were	be	VBD
work_6edatbslnjhz3kb2pkbphqv5py	6	3	stratified	stratify	VBN
work_6edatbslnjhz3kb2pkbphqv5py	6	4	by	by	IN
work_6edatbslnjhz3kb2pkbphqv5py	6	5	Karnofsky	Karnofsky	NNP
work_6edatbslnjhz3kb2pkbphqv5py	6	6	performance	performance	NN
work_6edatbslnjhz3kb2pkbphqv5py	6	7	status	status	NN
work_6edatbslnjhz3kb2pkbphqv5py	6	8	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	6	9	presence	presence	NN
work_6edatbslnjhz3kb2pkbphqv5py	6	10	or	or	CC
work_6edatbslnjhz3kb2pkbphqv5py	6	11	absence	absence	NN
work_6edatbslnjhz3kb2pkbphqv5py	6	12	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	6	13	liver	liver	NN
work_6edatbslnjhz3kb2pkbphqv5py	6	14	metastases	metastasis	NNS
work_6edatbslnjhz3kb2pkbphqv5py	6	15	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	7	1	They	-PRON-	PRP
work_6edatbslnjhz3kb2pkbphqv5py	7	2	were	be	VBD
work_6edatbslnjhz3kb2pkbphqv5py	7	3	randomized	randomize	VBN
work_6edatbslnjhz3kb2pkbphqv5py	7	4	to	to	TO
work_6edatbslnjhz3kb2pkbphqv5py	7	5	receive	receive	VB
work_6edatbslnjhz3kb2pkbphqv5py	7	6	450	450	CD
work_6edatbslnjhz3kb2pkbphqv5py	7	7	mg	mg	NNP
work_6edatbslnjhz3kb2pkbphqv5py	7	8	/	/	SYM
work_6edatbslnjhz3kb2pkbphqv5py	7	9	rn2	rn2	NNP
work_6edatbslnjhz3kb2pkbphqv5py	7	10	5-FU	5-FU	NNP
work_6edatbslnjhz3kb2pkbphqv5py	7	11	i.v	i.v	NNP
work_6edatbslnjhz3kb2pkbphqv5py	7	12	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	8	1	for	for	IN
work_6edatbslnjhz3kb2pkbphqv5py	8	2	5	5	CD
work_6edatbslnjhz3kb2pkbphqv5py	8	3	days	day	NNS
work_6edatbslnjhz3kb2pkbphqv5py	8	4	followed	follow	VBN
work_6edatbslnjhz3kb2pkbphqv5py	8	5	by	by	IN
work_6edatbslnjhz3kb2pkbphqv5py	8	6	15	15	CD
work_6edatbslnjhz3kb2pkbphqv5py	8	7	mg	mg	NNP
work_6edatbslnjhz3kb2pkbphqv5py	8	8	/	/	SYM
work_6edatbslnjhz3kb2pkbphqv5py	8	9	kg	kg	NNP
work_6edatbslnjhz3kb2pkbphqv5py	8	10	i.v	i.v	NNP
work_6edatbslnjhz3kb2pkbphqv5py	8	11	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	9	1	weekly	weekly	NNP
work_6edatbslnjhz3kb2pkbphqv5py	9	2	(	(	-LRB-
work_6edatbslnjhz3kb2pkbphqv5py	9	3	arm	arm	NNP
work_6edatbslnjhz3kb2pkbphqv5py	9	4	1	1	CD
work_6edatbslnjhz3kb2pkbphqv5py	9	5	)	)	-RRB-
work_6edatbslnjhz3kb2pkbphqv5py	9	6	or	or	CC
work_6edatbslnjhz3kb2pkbphqv5py	9	7	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	9	8	same	same	JJ
work_6edatbslnjhz3kb2pkbphqv5py	9	9	dose	dose	NN
work_6edatbslnjhz3kb2pkbphqv5py	9	10	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	9	11	5-FU	5-fu	CD
work_6edatbslnjhz3kb2pkbphqv5py	9	12	plus	plus	CC
work_6edatbslnjhz3kb2pkbphqv5py	9	13	levamisole	levamisole	NNP
work_6edatbslnjhz3kb2pkbphqv5py	9	14	50	50	CD
work_6edatbslnjhz3kb2pkbphqv5py	9	15	mg	mg	NNP
work_6edatbslnjhz3kb2pkbphqv5py	9	16	p.o	p.o	NNP
work_6edatbslnjhz3kb2pkbphqv5py	9	17	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	10	1	every	every	DT
work_6edatbslnjhz3kb2pkbphqv5py	10	2	8	8	CD
work_6edatbslnjhz3kb2pkbphqv5py	10	3	h	h	NN
work_6edatbslnjhz3kb2pkbphqv5py	10	4	for	for	IN
work_6edatbslnjhz3kb2pkbphqv5py	10	5	3	3	CD
work_6edatbslnjhz3kb2pkbphqv5py	10	6	days	day	NNS
work_6edatbslnjhz3kb2pkbphqv5py	10	7	every	every	DT
work_6edatbslnjhz3kb2pkbphqv5py	10	8	2	2	CD
work_6edatbslnjhz3kb2pkbphqv5py	10	9	weeks	week	NNS
work_6edatbslnjhz3kb2pkbphqv5py	10	10	(	(	-LRB-
work_6edatbslnjhz3kb2pkbphqv5py	10	11	arm	arm	NN
work_6edatbslnjhz3kb2pkbphqv5py	10	12	2	2	CD
work_6edatbslnjhz3kb2pkbphqv5py	10	13	)	)	-RRB-
work_6edatbslnjhz3kb2pkbphqv5py	10	14	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	11	1	The	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	11	2	duration	duration	NN
work_6edatbslnjhz3kb2pkbphqv5py	11	3	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	11	4	treatment	treatment	NN
work_6edatbslnjhz3kb2pkbphqv5py	11	5	for	for	IN
work_6edatbslnjhz3kb2pkbphqv5py	11	6	both	both	DT
work_6edatbslnjhz3kb2pkbphqv5py	11	7	arms	arm	NNS
work_6edatbslnjhz3kb2pkbphqv5py	11	8	was	be	VBD
work_6edatbslnjhz3kb2pkbphqv5py	11	9	26	26	CD
work_6edatbslnjhz3kb2pkbphqv5py	11	10	weeks	week	NNS
work_6edatbslnjhz3kb2pkbphqv5py	11	11	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	12	1	From	from	IN
work_6edatbslnjhz3kb2pkbphqv5py	12	2	April	April	NNP
work_6edatbslnjhz3kb2pkbphqv5py	12	3	1990	1990	CD
work_6edatbslnjhz3kb2pkbphqv5py	12	4	to	to	IN
work_6edatbslnjhz3kb2pkbphqv5py	12	5	March	March	NNP
work_6edatbslnjhz3kb2pkbphqv5py	12	6	1995	1995	CD
work_6edatbslnjhz3kb2pkbphqv5py	12	7	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	12	8	199	199	CD
work_6edatbslnjhz3kb2pkbphqv5py	12	9	patients	patient	NNS
work_6edatbslnjhz3kb2pkbphqv5py	12	10	were	be	VBD
work_6edatbslnjhz3kb2pkbphqv5py	12	11	entered	enter	VBN
work_6edatbslnjhz3kb2pkbphqv5py	12	12	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	13	1	One	one	CD
work_6edatbslnjhz3kb2pkbphqv5py	13	2	hundred	hundred	CD
work_6edatbslnjhz3kb2pkbphqv5py	13	3	eighty	eighty	CD
work_6edatbslnjhz3kb2pkbphqv5py	13	4	-	-	HYPH
work_6edatbslnjhz3kb2pkbphqv5py	13	5	two	two	CD
work_6edatbslnjhz3kb2pkbphqv5py	13	6	patients	patient	NNS
work_6edatbslnjhz3kb2pkbphqv5py	13	7	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	13	8	91	91	CD
work_6edatbslnjhz3kb2pkbphqv5py	13	9	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	13	10	each	each	DT
work_6edatbslnjhz3kb2pkbphqv5py	13	11	arm	arm	NN
work_6edatbslnjhz3kb2pkbphqv5py	13	12	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	13	13	were	be	VBD
work_6edatbslnjhz3kb2pkbphqv5py	13	14	fully	fully	RB
work_6edatbslnjhz3kb2pkbphqv5py	13	15	evaluable	evaluable	JJ
work_6edatbslnjhz3kb2pkbphqv5py	13	16	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	14	1	The	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	14	2	response	response	NN
work_6edatbslnjhz3kb2pkbphqv5py	14	3	rates	rate	NNS
work_6edatbslnjhz3kb2pkbphqv5py	14	4	were	be	VBD
work_6edatbslnjhz3kb2pkbphqv5py	14	5	12	12	CD
work_6edatbslnjhz3kb2pkbphqv5py	14	6	%	%	NN
work_6edatbslnjhz3kb2pkbphqv5py	14	7	on	on	IN
work_6edatbslnjhz3kb2pkbphqv5py	14	8	arm	arm	NN
work_6edatbslnjhz3kb2pkbphqv5py	14	9	1	1	CD
work_6edatbslnjhz3kb2pkbphqv5py	14	10	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	14	11	13	13	CD
work_6edatbslnjhz3kb2pkbphqv5py	14	12	%	%	NN
work_6edatbslnjhz3kb2pkbphqv5py	14	13	on	on	IN
work_6edatbslnjhz3kb2pkbphqv5py	14	14	arm	arm	NN
work_6edatbslnjhz3kb2pkbphqv5py	14	15	2	2	CD
work_6edatbslnjhz3kb2pkbphqv5py	14	16	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	15	1	The	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	15	2	median	median	JJ
work_6edatbslnjhz3kb2pkbphqv5py	15	3	duration	duration	NN
work_6edatbslnjhz3kb2pkbphqv5py	15	4	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	15	5	response	response	NN
work_6edatbslnjhz3kb2pkbphqv5py	15	6	was	be	VBD
work_6edatbslnjhz3kb2pkbphqv5py	15	7	18	18	CD
work_6edatbslnjhz3kb2pkbphqv5py	15	8	weeks	week	NNS
work_6edatbslnjhz3kb2pkbphqv5py	15	9	on	on	IN
work_6edatbslnjhz3kb2pkbphqv5py	15	10	both	both	DT
work_6edatbslnjhz3kb2pkbphqv5py	15	11	arms	arm	NNS
work_6edatbslnjhz3kb2pkbphqv5py	15	12	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	16	1	The	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	16	2	median	median	JJ
work_6edatbslnjhz3kb2pkbphqv5py	16	3	survival	survival	NN
work_6edatbslnjhz3kb2pkbphqv5py	16	4	was	be	VBD
work_6edatbslnjhz3kb2pkbphqv5py	16	5	48	48	CD
work_6edatbslnjhz3kb2pkbphqv5py	16	6	weeks	week	NNS
work_6edatbslnjhz3kb2pkbphqv5py	16	7	on	on	IN
work_6edatbslnjhz3kb2pkbphqv5py	16	8	arm	arm	NN
work_6edatbslnjhz3kb2pkbphqv5py	16	9	1	1	CD
work_6edatbslnjhz3kb2pkbphqv5py	16	10	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	16	11	41	41	CD
work_6edatbslnjhz3kb2pkbphqv5py	16	12	weeks	week	NNS
work_6edatbslnjhz3kb2pkbphqv5py	16	13	on	on	IN
work_6edatbslnjhz3kb2pkbphqv5py	16	14	arm	arm	NN
work_6edatbslnjhz3kb2pkbphqv5py	16	15	2	2	CD
work_6edatbslnjhz3kb2pkbphqv5py	16	16	(	(	-LRB-
work_6edatbslnjhz3kb2pkbphqv5py	16	17	P	p	NN
work_6edatbslnjhz3kb2pkbphqv5py	16	18	=	=	SYM
work_6edatbslnjhz3kb2pkbphqv5py	16	19	0.20	0.20	CD
work_6edatbslnjhz3kb2pkbphqv5py	16	20	)	)	-RRB-
work_6edatbslnjhz3kb2pkbphqv5py	16	21	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	17	1	This	this	DT
work_6edatbslnjhz3kb2pkbphqv5py	17	2	study	study	NN
work_6edatbslnjhz3kb2pkbphqv5py	17	3	failed	fail	VBD
work_6edatbslnjhz3kb2pkbphqv5py	17	4	to	to	TO
work_6edatbslnjhz3kb2pkbphqv5py	17	5	show	show	VB
work_6edatbslnjhz3kb2pkbphqv5py	17	6	any	any	DT
work_6edatbslnjhz3kb2pkbphqv5py	17	7	improvement	improvement	NN
work_6edatbslnjhz3kb2pkbphqv5py	17	8	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	17	9	survival	survival	NN
work_6edatbslnjhz3kb2pkbphqv5py	17	10	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	17	11	response	response	NN
work_6edatbslnjhz3kb2pkbphqv5py	17	12	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	17	13	or	or	CC
work_6edatbslnjhz3kb2pkbphqv5py	17	14	duration	duration	NN
work_6edatbslnjhz3kb2pkbphqv5py	17	15	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	17	16	remission	remission	NN
work_6edatbslnjhz3kb2pkbphqv5py	17	17	with	with	IN
work_6edatbslnjhz3kb2pkbphqv5py	17	18	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	17	19	addition	addition	NN
work_6edatbslnjhz3kb2pkbphqv5py	17	20	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	17	21	levamisole	levamisole	NN
work_6edatbslnjhz3kb2pkbphqv5py	17	22	to	to	IN
work_6edatbslnjhz3kb2pkbphqv5py	17	23	5-FU	5-fu	CD
work_6edatbslnjhz3kb2pkbphqv5py	17	24	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	17	25	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	17	26	treatment	treatment	NN
work_6edatbslnjhz3kb2pkbphqv5py	17	27	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	17	28	metastatic	metastatic	JJ
work_6edatbslnjhz3kb2pkbphqv5py	17	29	colorectal	colorectal	JJ
work_6edatbslnjhz3kb2pkbphqv5py	17	30	cancer	cancer	NN
work_6edatbslnjhz3kb2pkbphqv5py	17	31	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	18	1	Received	receive	VBD
work_6edatbslnjhz3kb2pkbphqv5py	18	2	10/2/97	10/2/97	NNS
work_6edatbslnjhz3kb2pkbphqv5py	18	3	;	;	:
work_6edatbslnjhz3kb2pkbphqv5py	18	4	revised	revised	JJ
work_6edatbslnjhz3kb2pkbphqv5py	18	5	1/22/98	1/22/98	CD
work_6edatbslnjhz3kb2pkbphqv5py	18	6	;	;	:
work_6edatbslnjhz3kb2pkbphqv5py	18	7	accepted	accept	VBD
work_6edatbslnjhz3kb2pkbphqv5py	18	8	1/26/98	1/26/98	CD
work_6edatbslnjhz3kb2pkbphqv5py	18	9	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	19	1	The	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	19	2	costs	cost	NNS
work_6edatbslnjhz3kb2pkbphqv5py	19	3	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	19	4	publication	publication	NN
work_6edatbslnjhz3kb2pkbphqv5py	19	5	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	19	6	this	this	DT
work_6edatbslnjhz3kb2pkbphqv5py	19	7	article	article	NN
work_6edatbslnjhz3kb2pkbphqv5py	19	8	were	be	VBD
work_6edatbslnjhz3kb2pkbphqv5py	19	9	defrayed	defray	VBN
work_6edatbslnjhz3kb2pkbphqv5py	19	10	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	19	11	part	part	NN
work_6edatbslnjhz3kb2pkbphqv5py	19	12	by	by	IN
work_6edatbslnjhz3kb2pkbphqv5py	19	13	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	19	14	payment	payment	NN
work_6edatbslnjhz3kb2pkbphqv5py	19	15	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	19	16	page	page	NN
work_6edatbslnjhz3kb2pkbphqv5py	19	17	charges	charge	NNS
work_6edatbslnjhz3kb2pkbphqv5py	19	18	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	20	1	This	this	DT
work_6edatbslnjhz3kb2pkbphqv5py	20	2	article	article	NN
work_6edatbslnjhz3kb2pkbphqv5py	20	3	must	must	MD
work_6edatbslnjhz3kb2pkbphqv5py	20	4	therefore	therefore	RB
work_6edatbslnjhz3kb2pkbphqv5py	20	5	be	be	VB
work_6edatbslnjhz3kb2pkbphqv5py	20	6	hereby	hereby	RB
work_6edatbslnjhz3kb2pkbphqv5py	20	7	marked	mark	VBN
work_6edatbslnjhz3kb2pkbphqv5py	20	8	advertisement	advertisement	NN
work_6edatbslnjhz3kb2pkbphqv5py	20	9	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	20	10	accordance	accordance	NN
work_6edatbslnjhz3kb2pkbphqv5py	20	11	with	with	IN
work_6edatbslnjhz3kb2pkbphqv5py	20	12	18	18	CD
work_6edatbslnjhz3kb2pkbphqv5py	20	13	U.S.C.	U.S.C.	NNS
work_6edatbslnjhz3kb2pkbphqv5py	21	1	Section	section	NN
work_6edatbslnjhz3kb2pkbphqv5py	21	2	1734	1734	CD
work_6edatbslnjhz3kb2pkbphqv5py	21	3	solely	solely	RB
work_6edatbslnjhz3kb2pkbphqv5py	21	4	to	to	TO
work_6edatbslnjhz3kb2pkbphqv5py	21	5	indicate	indicate	VB
work_6edatbslnjhz3kb2pkbphqv5py	21	6	this	this	DT
work_6edatbslnjhz3kb2pkbphqv5py	21	7	fact	fact	NN
work_6edatbslnjhz3kb2pkbphqv5py	21	8	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	22	1	I	-PRON-	PRP
work_6edatbslnjhz3kb2pkbphqv5py	22	2	This	this	DT
work_6edatbslnjhz3kb2pkbphqv5py	22	3	work	work	NN
work_6edatbslnjhz3kb2pkbphqv5py	22	4	was	be	VBD
work_6edatbslnjhz3kb2pkbphqv5py	22	5	supported	support	VBN
work_6edatbslnjhz3kb2pkbphqv5py	22	6	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	22	7	part	part	NN
work_6edatbslnjhz3kb2pkbphqv5py	22	8	by	by	IN
work_6edatbslnjhz3kb2pkbphqv5py	22	9	National	National	NNP
work_6edatbslnjhz3kb2pkbphqv5py	22	10	Cancer	Cancer	NNP
work_6edatbslnjhz3kb2pkbphqv5py	22	11	Institute	Institute	NNP
work_6edatbslnjhz3kb2pkbphqv5py	22	12	Grant	Grant	NNP
work_6edatbslnjhz3kb2pkbphqv5py	22	13	2R35CA	2R35CA	NNP
work_6edatbslnjhz3kb2pkbphqv5py	22	14	39844-	39844-	CD
work_6edatbslnjhz3kb2pkbphqv5py	22	15	1	1	CD
work_6edatbslnjhz3kb2pkbphqv5py	22	16	1	1	CD
work_6edatbslnjhz3kb2pkbphqv5py	22	17	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	22	18	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	22	19	Walther	Walther	NNP
work_6edatbslnjhz3kb2pkbphqv5py	22	20	Cancer	Cancer	NNP
work_6edatbslnjhz3kb2pkbphqv5py	22	21	Institute	Institute	NNP
work_6edatbslnjhz3kb2pkbphqv5py	22	22	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	22	23	was	be	VBD
work_6edatbslnjhz3kb2pkbphqv5py	22	24	presented	present	VBN
work_6edatbslnjhz3kb2pkbphqv5py	22	25	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	22	26	part	part	NN
work_6edatbslnjhz3kb2pkbphqv5py	22	27	at	at	IN
work_6edatbslnjhz3kb2pkbphqv5py	22	28	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	22	29	Annual	Annual	NNP
work_6edatbslnjhz3kb2pkbphqv5py	22	30	Meeting	Meeting	NNP
work_6edatbslnjhz3kb2pkbphqv5py	22	31	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	22	32	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	22	33	American	American	NNP
work_6edatbslnjhz3kb2pkbphqv5py	22	34	Society	Society	NNP
work_6edatbslnjhz3kb2pkbphqv5py	22	35	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	22	36	Clinical	Clinical	NNP
work_6edatbslnjhz3kb2pkbphqv5py	22	37	Oncology	Oncology	NNP
work_6edatbslnjhz3kb2pkbphqv5py	22	38	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	22	39	held	hold	VBD
work_6edatbslnjhz3kb2pkbphqv5py	22	40	May	May	NNP
work_6edatbslnjhz3kb2pkbphqv5py	22	41	1	1	CD
work_6edatbslnjhz3kb2pkbphqv5py	22	42	8	8	CD
work_6edatbslnjhz3kb2pkbphqv5py	22	43	-	-	SYM
work_6edatbslnjhz3kb2pkbphqv5py	22	44	21	21	CD
work_6edatbslnjhz3kb2pkbphqv5py	22	45	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	22	46	1996	1996	CD
work_6edatbslnjhz3kb2pkbphqv5py	22	47	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	22	48	Philadelphia	Philadelphia	NNP
work_6edatbslnjhz3kb2pkbphqv5py	22	49	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	22	50	PA	PA	NNP
work_6edatbslnjhz3kb2pkbphqv5py	22	51	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	22	52	2	2	CD
work_6edatbslnjhz3kb2pkbphqv5py	22	53	To	to	TO
work_6edatbslnjhz3kb2pkbphqv5py	22	54	whom	whom	WP
work_6edatbslnjhz3kb2pkbphqv5py	22	55	requests	request	VBZ
work_6edatbslnjhz3kb2pkbphqv5py	22	56	for	for	IN
work_6edatbslnjhz3kb2pkbphqv5py	22	57	reprints	reprint	NNS
work_6edatbslnjhz3kb2pkbphqv5py	22	58	should	should	MD
work_6edatbslnjhz3kb2pkbphqv5py	22	59	be	be	VB
work_6edatbslnjhz3kb2pkbphqv5py	22	60	addressed	address	VBN
work_6edatbslnjhz3kb2pkbphqv5py	22	61	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	22	62	at	at	IN
work_6edatbslnjhz3kb2pkbphqv5py	22	63	Hoosier	Hoosier	NNP
work_6edatbslnjhz3kb2pkbphqv5py	22	64	On-	On-	NNP
work_6edatbslnjhz3kb2pkbphqv5py	22	65	cobogy	cobogy	NN
work_6edatbslnjhz3kb2pkbphqv5py	22	66	Group	Group	NNP
work_6edatbslnjhz3kb2pkbphqv5py	22	67	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	22	68	3202	3202	CD
work_6edatbslnjhz3kb2pkbphqv5py	22	69	North	North	NNP
work_6edatbslnjhz3kb2pkbphqv5py	22	70	Meridian	Meridian	NNP
work_6edatbslnjhz3kb2pkbphqv5py	22	71	Street	Street	NNP
work_6edatbslnjhz3kb2pkbphqv5py	22	72	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	22	73	Indianapolis	Indianapolis	NNP
work_6edatbslnjhz3kb2pkbphqv5py	22	74	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	22	75	IN	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	22	76	46208-	46208-	CD
work_6edatbslnjhz3kb2pkbphqv5py	22	77	4646	4646	CD
work_6edatbslnjhz3kb2pkbphqv5py	22	78	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	23	1	INTRODUCTION	introduction	VB
work_6edatbslnjhz3kb2pkbphqv5py	23	2	Colorectal	colorectal	JJ
work_6edatbslnjhz3kb2pkbphqv5py	23	3	carcinoma	carcinoma	NN
work_6edatbslnjhz3kb2pkbphqv5py	23	4	is	be	VBZ
work_6edatbslnjhz3kb2pkbphqv5py	23	5	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	23	6	second	second	JJ
work_6edatbslnjhz3kb2pkbphqv5py	23	7	leading	leading	JJ
work_6edatbslnjhz3kb2pkbphqv5py	23	8	cause	cause	NN
work_6edatbslnjhz3kb2pkbphqv5py	23	9	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	23	10	cancer	cancer	NN
work_6edatbslnjhz3kb2pkbphqv5py	23	11	death	death	NN
work_6edatbslnjhz3kb2pkbphqv5py	23	12	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	23	13	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	23	14	United	United	NNP
work_6edatbslnjhz3kb2pkbphqv5py	23	15	States	States	NNP
work_6edatbslnjhz3kb2pkbphqv5py	23	16	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	24	1	In	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	24	2	1996	1996	CD
work_6edatbslnjhz3kb2pkbphqv5py	24	3	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	24	4	it	-PRON-	PRP
work_6edatbslnjhz3kb2pkbphqv5py	24	5	was	be	VBD
work_6edatbslnjhz3kb2pkbphqv5py	24	6	estimated	estimate	VBN
work_6edatbslnjhz3kb2pkbphqv5py	24	7	that	that	IN
work_6edatbslnjhz3kb2pkbphqv5py	24	8	1	1	CD
work_6edatbslnjhz3kb2pkbphqv5py	24	9	3	3	CD
work_6edatbslnjhz3kb2pkbphqv5py	24	10	1	1	CD
work_6edatbslnjhz3kb2pkbphqv5py	24	11	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	24	12	200	200	CD
work_6edatbslnjhz3kb2pkbphqv5py	24	13	new	new	JJ
work_6edatbslnjhz3kb2pkbphqv5py	24	14	cases	case	NNS
work_6edatbslnjhz3kb2pkbphqv5py	24	15	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	24	16	colorectal	colorectal	JJ
work_6edatbslnjhz3kb2pkbphqv5py	24	17	cancer	cancer	NN
work_6edatbslnjhz3kb2pkbphqv5py	24	18	would	would	MD
work_6edatbslnjhz3kb2pkbphqv5py	24	19	be	be	VB
work_6edatbslnjhz3kb2pkbphqv5py	24	20	diagnosed	diagnose	VBN
work_6edatbslnjhz3kb2pkbphqv5py	24	21	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	24	22	that	that	IN
work_6edatbslnjhz3kb2pkbphqv5py	24	23	54,900	54,900	CD
work_6edatbslnjhz3kb2pkbphqv5py	24	24	men	man	NNS
work_6edatbslnjhz3kb2pkbphqv5py	24	25	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	24	26	women	woman	NNS
work_6edatbslnjhz3kb2pkbphqv5py	24	27	would	would	MD
work_6edatbslnjhz3kb2pkbphqv5py	24	28	die	die	VB
work_6edatbslnjhz3kb2pkbphqv5py	24	29	from	from	IN
work_6edatbslnjhz3kb2pkbphqv5py	24	30	this	this	DT
work_6edatbslnjhz3kb2pkbphqv5py	24	31	disease	disease	NN
work_6edatbslnjhz3kb2pkbphqv5py	24	32	(	(	-LRB-
work_6edatbslnjhz3kb2pkbphqv5py	24	33	1	1	CD
work_6edatbslnjhz3kb2pkbphqv5py	24	34	)	)	-RRB-
work_6edatbslnjhz3kb2pkbphqv5py	24	35	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	25	1	Heidelberger	Heidelberger	NNP
work_6edatbslnjhz3kb2pkbphqv5py	25	2	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	25	3	colleagues	colleague	NNS
work_6edatbslnjhz3kb2pkbphqv5py	25	4	(	(	-LRB-
work_6edatbslnjhz3kb2pkbphqv5py	25	5	2	2	LS
work_6edatbslnjhz3kb2pkbphqv5py	25	6	)	)	-RRB-
work_6edatbslnjhz3kb2pkbphqv5py	25	7	at	at	IN
work_6edatbslnjhz3kb2pkbphqv5py	25	8	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	25	9	University	University	NNP
work_6edatbslnjhz3kb2pkbphqv5py	25	10	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	25	11	Wis-	Wis-	NNP
work_6edatbslnjhz3kb2pkbphqv5py	25	12	consin	consin	NN
work_6edatbslnjhz3kb2pkbphqv5py	25	13	first	first	RB
work_6edatbslnjhz3kb2pkbphqv5py	25	14	reported	report	VBD
work_6edatbslnjhz3kb2pkbphqv5py	25	15	clinical	clinical	JJ
work_6edatbslnjhz3kb2pkbphqv5py	25	16	trials	trial	NNS
work_6edatbslnjhz3kb2pkbphqv5py	25	17	with	with	IN
work_6edatbslnjhz3kb2pkbphqv5py	25	18	5-FU3	5-fu3	CD
work_6edatbslnjhz3kb2pkbphqv5py	25	19	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	25	20	1957	1957	CD
work_6edatbslnjhz3kb2pkbphqv5py	25	21	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	26	1	Since	since	IN
work_6edatbslnjhz3kb2pkbphqv5py	26	2	then	then	RB
work_6edatbslnjhz3kb2pkbphqv5py	26	3	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	26	4	5-FU	5-fu	CD
work_6edatbslnjhz3kb2pkbphqv5py	26	5	has	have	VBZ
work_6edatbslnjhz3kb2pkbphqv5py	26	6	been	be	VBN
work_6edatbslnjhz3kb2pkbphqv5py	26	7	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	26	8	mainstay	mainstay	NN
work_6edatbslnjhz3kb2pkbphqv5py	26	9	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	26	10	therapy	therapy	NN
work_6edatbslnjhz3kb2pkbphqv5py	26	11	for	for	IN
work_6edatbslnjhz3kb2pkbphqv5py	26	12	metastatic	metastatic	JJ
work_6edatbslnjhz3kb2pkbphqv5py	26	13	coborectal	coborectal	JJ
work_6edatbslnjhz3kb2pkbphqv5py	26	14	cancer	cancer	NN
work_6edatbslnjhz3kb2pkbphqv5py	26	15	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	27	1	However	however	RB
work_6edatbslnjhz3kb2pkbphqv5py	27	2	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	27	3	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	27	4	results	result	NNS
work_6edatbslnjhz3kb2pkbphqv5py	27	5	with	with	IN
work_6edatbslnjhz3kb2pkbphqv5py	27	6	single	single	JJ
work_6edatbslnjhz3kb2pkbphqv5py	27	7	agent	agent	NN
work_6edatbslnjhz3kb2pkbphqv5py	27	8	5-FU	5-fu	RBR
work_6edatbslnjhz3kb2pkbphqv5py	27	9	reveal	reveal	VB
work_6edatbslnjhz3kb2pkbphqv5py	27	10	only	only	RB
work_6edatbslnjhz3kb2pkbphqv5py	27	11	a	a	DT
work_6edatbslnjhz3kb2pkbphqv5py	27	12	10	10	CD
work_6edatbslnjhz3kb2pkbphqv5py	27	13	-	-	SYM
work_6edatbslnjhz3kb2pkbphqv5py	27	14	20	20	CD
work_6edatbslnjhz3kb2pkbphqv5py	27	15	%	%	NN
work_6edatbslnjhz3kb2pkbphqv5py	27	16	objective	objective	JJ
work_6edatbslnjhz3kb2pkbphqv5py	27	17	response	response	NN
work_6edatbslnjhz3kb2pkbphqv5py	27	18	rate	rate	NN
work_6edatbslnjhz3kb2pkbphqv5py	27	19	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	27	20	with	with	IN
work_6edatbslnjhz3kb2pkbphqv5py	27	21	no	no	DT
work_6edatbslnjhz3kb2pkbphqv5py	27	22	impact	impact	NN
work_6edatbslnjhz3kb2pkbphqv5py	27	23	on	on	IN
work_6edatbslnjhz3kb2pkbphqv5py	27	24	survival	survival	NN
work_6edatbslnjhz3kb2pkbphqv5py	27	25	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	28	1	Attempts	attempt	NNS
work_6edatbslnjhz3kb2pkbphqv5py	28	2	to	to	TO
work_6edatbslnjhz3kb2pkbphqv5py	28	3	improve	improve	VB
work_6edatbslnjhz3kb2pkbphqv5py	28	4	upon	upon	IN
work_6edatbslnjhz3kb2pkbphqv5py	28	5	this	this	DT
work_6edatbslnjhz3kb2pkbphqv5py	28	6	have	have	VBP
work_6edatbslnjhz3kb2pkbphqv5py	28	7	lead	lead	NN
work_6edatbslnjhz3kb2pkbphqv5py	28	8	to	to	IN
work_6edatbslnjhz3kb2pkbphqv5py	28	9	devel-	devel-	NNP
work_6edatbslnjhz3kb2pkbphqv5py	28	10	opment	opment	NNP
work_6edatbslnjhz3kb2pkbphqv5py	28	11	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	28	12	various	various	JJ
work_6edatbslnjhz3kb2pkbphqv5py	28	13	regimens	regimen	NNS
work_6edatbslnjhz3kb2pkbphqv5py	28	14	using	use	VBG
work_6edatbslnjhz3kb2pkbphqv5py	28	15	biochemical	biochemical	JJ
work_6edatbslnjhz3kb2pkbphqv5py	28	16	modulation	modulation	NN
work_6edatbslnjhz3kb2pkbphqv5py	28	17	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	28	18	5-FU	5-fu	CD
work_6edatbslnjhz3kb2pkbphqv5py	28	19	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	28	20	based	base	VBN
work_6edatbslnjhz3kb2pkbphqv5py	28	21	upon	upon	IN
work_6edatbslnjhz3kb2pkbphqv5py	28	22	laboratory	laboratory	NN
work_6edatbslnjhz3kb2pkbphqv5py	28	23	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	28	24	preclinical	preclinical	JJ
work_6edatbslnjhz3kb2pkbphqv5py	28	25	data	datum	NNS
work_6edatbslnjhz3kb2pkbphqv5py	28	26	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	29	1	The	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	29	2	most	most	RBS
work_6edatbslnjhz3kb2pkbphqv5py	29	3	popular	popular	JJ
work_6edatbslnjhz3kb2pkbphqv5py	29	4	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	29	5	these	these	DT
work_6edatbslnjhz3kb2pkbphqv5py	29	6	has	have	VBZ
work_6edatbslnjhz3kb2pkbphqv5py	29	7	been	be	VBN
work_6edatbslnjhz3kb2pkbphqv5py	29	8	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	29	9	combination	combination	NN
work_6edatbslnjhz3kb2pkbphqv5py	29	10	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	29	11	5-FU	5-fu	CD
work_6edatbslnjhz3kb2pkbphqv5py	29	12	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	29	13	leucov-	leucov-	NNP
work_6edatbslnjhz3kb2pkbphqv5py	29	14	orin	orin	NNP
work_6edatbslnjhz3kb2pkbphqv5py	29	15	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	29	16	based	base	VBN
work_6edatbslnjhz3kb2pkbphqv5py	29	17	upon	upon	IN
work_6edatbslnjhz3kb2pkbphqv5py	29	18	a	a	DT
work_6edatbslnjhz3kb2pkbphqv5py	29	19	sound	sound	JJ
work_6edatbslnjhz3kb2pkbphqv5py	29	20	preclinical	preclinical	JJ
work_6edatbslnjhz3kb2pkbphqv5py	29	21	pharmacological	pharmacological	JJ
work_6edatbslnjhz3kb2pkbphqv5py	29	22	rationale	rationale	NN
work_6edatbslnjhz3kb2pkbphqv5py	29	23	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	30	1	There	there	EX
work_6edatbslnjhz3kb2pkbphqv5py	30	2	have	have	VBP
work_6edatbslnjhz3kb2pkbphqv5py	30	3	been	be	VBN
work_6edatbslnjhz3kb2pkbphqv5py	30	4	various	various	JJ
work_6edatbslnjhz3kb2pkbphqv5py	30	5	schedules	schedule	NNS
work_6edatbslnjhz3kb2pkbphqv5py	30	6	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	30	7	5-FU	5-fu	CD
work_6edatbslnjhz3kb2pkbphqv5py	30	8	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	30	9	combination	combination	NN
work_6edatbslnjhz3kb2pkbphqv5py	30	10	with	with	IN
work_6edatbslnjhz3kb2pkbphqv5py	30	11	leucovorin	leucovorin	NNP
work_6edatbslnjhz3kb2pkbphqv5py	30	12	that	that	WDT
work_6edatbslnjhz3kb2pkbphqv5py	30	13	have	have	VBP
work_6edatbslnjhz3kb2pkbphqv5py	30	14	demonstrated	demonstrate	VBN
work_6edatbslnjhz3kb2pkbphqv5py	30	15	encouraging	encouraging	JJ
work_6edatbslnjhz3kb2pkbphqv5py	30	16	results	result	NNS
work_6edatbslnjhz3kb2pkbphqv5py	30	17	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	30	18	Phase	Phase	NNP
work_6edatbslnjhz3kb2pkbphqv5py	30	19	II	ii	CD
work_6edatbslnjhz3kb2pkbphqv5py	30	20	trials	trial	NNS
work_6edatbslnjhz3kb2pkbphqv5py	30	21	(	(	-LRB-
work_6edatbslnjhz3kb2pkbphqv5py	30	22	3	3	CD
work_6edatbslnjhz3kb2pkbphqv5py	30	23	)	)	-RRB-
work_6edatbslnjhz3kb2pkbphqv5py	30	24	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	31	1	Subsequently	subsequently	RB
work_6edatbslnjhz3kb2pkbphqv5py	31	2	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	31	3	these	these	DT
work_6edatbslnjhz3kb2pkbphqv5py	31	4	have	have	VBP
work_6edatbslnjhz3kb2pkbphqv5py	31	5	led	lead	VBN
work_6edatbslnjhz3kb2pkbphqv5py	31	6	to	to	IN
work_6edatbslnjhz3kb2pkbphqv5py	31	7	Phase	Phase	NNP
work_6edatbslnjhz3kb2pkbphqv5py	31	8	III	III	NNP
work_6edatbslnjhz3kb2pkbphqv5py	31	9	studies	study	NNS
work_6edatbslnjhz3kb2pkbphqv5py	31	10	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	31	11	metastatic	metastatic	JJ
work_6edatbslnjhz3kb2pkbphqv5py	31	12	coborectal	coborectal	JJ
work_6edatbslnjhz3kb2pkbphqv5py	31	13	cancer	cancer	NN
work_6edatbslnjhz3kb2pkbphqv5py	31	14	evaluating	evaluate	VBG
work_6edatbslnjhz3kb2pkbphqv5py	31	15	5-FU	5-fu	CD
work_6edatbslnjhz3kb2pkbphqv5py	31	16	(	(	-LRB-
work_6edatbslnjhz3kb2pkbphqv5py	31	17	as	as	IN
work_6edatbslnjhz3kb2pkbphqv5py	31	18	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	31	19	control	control	NN
work_6edatbslnjhz3kb2pkbphqv5py	31	20	arm	arm	NN
work_6edatbslnjhz3kb2pkbphqv5py	31	21	)	)	-RRB-
work_6edatbslnjhz3kb2pkbphqv5py	31	22	compared	compare	VBN
work_6edatbslnjhz3kb2pkbphqv5py	31	23	to	to	IN
work_6edatbslnjhz3kb2pkbphqv5py	31	24	5-FU	5-fu	CD
work_6edatbslnjhz3kb2pkbphqv5py	31	25	plus	plus	CC
work_6edatbslnjhz3kb2pkbphqv5py	31	26	leucovorin	leucovorin	NNP
work_6edatbslnjhz3kb2pkbphqv5py	31	27	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	32	1	There	there	EX
work_6edatbslnjhz3kb2pkbphqv5py	32	2	has	have	VBZ
work_6edatbslnjhz3kb2pkbphqv5py	32	3	been	be	VBN
work_6edatbslnjhz3kb2pkbphqv5py	32	4	a	a	DT
work_6edatbslnjhz3kb2pkbphqv5py	32	5	lack	lack	NN
work_6edatbslnjhz3kb2pkbphqv5py	32	6	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	32	7	congruence	congruence	NN
work_6edatbslnjhz3kb2pkbphqv5py	32	8	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	32	9	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	32	10	results	result	NNS
work_6edatbslnjhz3kb2pkbphqv5py	32	11	from	from	IN
work_6edatbslnjhz3kb2pkbphqv5py	32	12	these	these	DT
work_6edatbslnjhz3kb2pkbphqv5py	32	13	disparate	disparate	JJ
work_6edatbslnjhz3kb2pkbphqv5py	32	14	Phase	Phase	NNP
work_6edatbslnjhz3kb2pkbphqv5py	32	15	III	III	NNP
work_6edatbslnjhz3kb2pkbphqv5py	32	16	studies	study	NNS
work_6edatbslnjhz3kb2pkbphqv5py	32	17	(	(	-LRB-
work_6edatbslnjhz3kb2pkbphqv5py	32	18	4	4	CD
work_6edatbslnjhz3kb2pkbphqv5py	32	19	)	)	-RRB-
work_6edatbslnjhz3kb2pkbphqv5py	32	20	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	33	1	Review	review	NN
work_6edatbslnjhz3kb2pkbphqv5py	33	2	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	33	3	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	33	4	12	12	CD
work_6edatbslnjhz3kb2pkbphqv5py	33	5	published	publish	VBN
work_6edatbslnjhz3kb2pkbphqv5py	33	6	randomized	randomized	JJ
work_6edatbslnjhz3kb2pkbphqv5py	33	7	studies	study	NNS
work_6edatbslnjhz3kb2pkbphqv5py	33	8	comparing	compare	VBG
work_6edatbslnjhz3kb2pkbphqv5py	33	9	5-FU	5-fu	CD
work_6edatbslnjhz3kb2pkbphqv5py	33	10	with	with	IN
work_6edatbslnjhz3kb2pkbphqv5py	33	11	5-FU	5-fu	CD
work_6edatbslnjhz3kb2pkbphqv5py	33	12	plus	plus	CC
work_6edatbslnjhz3kb2pkbphqv5py	33	13	leucovorin	leucovorin	NNP
work_6edatbslnjhz3kb2pkbphqv5py	33	14	reveals	reveal	VBZ
work_6edatbslnjhz3kb2pkbphqv5py	33	15	that	that	IN
work_6edatbslnjhz3kb2pkbphqv5py	33	16	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	33	17	consistently	consistently	RB
work_6edatbslnjhz3kb2pkbphqv5py	33	18	higher	high	JJR
work_6edatbslnjhz3kb2pkbphqv5py	33	19	response	response	NN
work_6edatbslnjhz3kb2pkbphqv5py	33	20	rate	rate	NN
work_6edatbslnjhz3kb2pkbphqv5py	33	21	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	33	22	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	33	23	combination	combination	NN
work_6edatbslnjhz3kb2pkbphqv5py	33	24	regimen	regimen	NN
work_6edatbslnjhz3kb2pkbphqv5py	33	25	has	have	VBZ
work_6edatbslnjhz3kb2pkbphqv5py	33	26	failed	fail	VBN
work_6edatbslnjhz3kb2pkbphqv5py	33	27	to	to	TO
work_6edatbslnjhz3kb2pkbphqv5py	33	28	translate	translate	VB
work_6edatbslnjhz3kb2pkbphqv5py	33	29	into	into	IN
work_6edatbslnjhz3kb2pkbphqv5py	33	30	significant	significant	JJ
work_6edatbslnjhz3kb2pkbphqv5py	33	31	survival	survival	NN
work_6edatbslnjhz3kb2pkbphqv5py	33	32	advantage	advantage	NN
work_6edatbslnjhz3kb2pkbphqv5py	33	33	(	(	-LRB-
work_6edatbslnjhz3kb2pkbphqv5py	33	34	5	5	CD
work_6edatbslnjhz3kb2pkbphqv5py	33	35	-	-	SYM
work_6edatbslnjhz3kb2pkbphqv5py	33	36	16	16	CD
work_6edatbslnjhz3kb2pkbphqv5py	33	37	)	)	-RRB-
work_6edatbslnjhz3kb2pkbphqv5py	33	38	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	34	1	These	these	DT
work_6edatbslnjhz3kb2pkbphqv5py	34	2	studies	study	NNS
work_6edatbslnjhz3kb2pkbphqv5py	34	3	all	all	DT
work_6edatbslnjhz3kb2pkbphqv5py	34	4	used	use	VBD
work_6edatbslnjhz3kb2pkbphqv5py	34	5	5-FU	5-fu	CD
work_6edatbslnjhz3kb2pkbphqv5py	34	6	given	give	VBN
work_6edatbslnjhz3kb2pkbphqv5py	34	7	by	by	IN
work_6edatbslnjhz3kb2pkbphqv5py	34	8	iv	iv	PRP
work_6edatbslnjhz3kb2pkbphqv5py	34	9	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	35	1	push	push	NN
work_6edatbslnjhz3kb2pkbphqv5py	35	2	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	36	1	Only	only	RB
work_6edatbslnjhz3kb2pkbphqv5py	36	2	three	three	CD
work_6edatbslnjhz3kb2pkbphqv5py	36	3	studies	study	NNS
work_6edatbslnjhz3kb2pkbphqv5py	36	4	have	have	VBP
work_6edatbslnjhz3kb2pkbphqv5py	36	5	shown	show	VBN
work_6edatbslnjhz3kb2pkbphqv5py	36	6	marginal	marginal	JJ
work_6edatbslnjhz3kb2pkbphqv5py	36	7	survival	survival	NN
work_6edatbslnjhz3kb2pkbphqv5py	36	8	advantage	advantage	NN
work_6edatbslnjhz3kb2pkbphqv5py	36	9	for	for	IN
work_6edatbslnjhz3kb2pkbphqv5py	36	10	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	36	11	combi-	combi-	JJ
work_6edatbslnjhz3kb2pkbphqv5py	36	12	nation	nation	NN
work_6edatbslnjhz3kb2pkbphqv5py	36	13	over	over	IN
work_6edatbslnjhz3kb2pkbphqv5py	36	14	5-FU	5-fu	CD
work_6edatbslnjhz3kb2pkbphqv5py	36	15	alone	alone	JJ
work_6edatbslnjhz3kb2pkbphqv5py	36	16	(	(	-LRB-
work_6edatbslnjhz3kb2pkbphqv5py	36	17	1	1	CD
work_6edatbslnjhz3kb2pkbphqv5py	36	18	1	1	CD
work_6edatbslnjhz3kb2pkbphqv5py	36	19	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	36	20	1	1	CD
work_6edatbslnjhz3kb2pkbphqv5py	36	21	3	3	CD
work_6edatbslnjhz3kb2pkbphqv5py	36	22	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	36	23	15	15	CD
work_6edatbslnjhz3kb2pkbphqv5py	36	24	)	)	-RRB-
work_6edatbslnjhz3kb2pkbphqv5py	36	25	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	37	1	In	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	37	2	fact	fact	NN
work_6edatbslnjhz3kb2pkbphqv5py	37	3	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	37	4	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	37	5	one	one	CD
work_6edatbslnjhz3kb2pkbphqv5py	37	6	study	study	NN
work_6edatbslnjhz3kb2pkbphqv5py	37	7	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	37	8	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	37	9	benefit	benefit	NN
work_6edatbslnjhz3kb2pkbphqv5py	37	10	was	be	VBD
work_6edatbslnjhz3kb2pkbphqv5py	37	11	significant	significant	JJ
work_6edatbslnjhz3kb2pkbphqv5py	37	12	only	only	RB
work_6edatbslnjhz3kb2pkbphqv5py	37	13	for	for	IN
work_6edatbslnjhz3kb2pkbphqv5py	37	14	patients	patient	NNS
work_6edatbslnjhz3kb2pkbphqv5py	37	15	with	with	IN
work_6edatbslnjhz3kb2pkbphqv5py	37	16	nonmeasurable	nonmeasurable	JJ
work_6edatbslnjhz3kb2pkbphqv5py	37	17	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	37	18	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	37	19	hence	hence	RB
work_6edatbslnjhz3kb2pkbphqv5py	37	20	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	37	21	probably	probably	RB
work_6edatbslnjhz3kb2pkbphqv5py	37	22	low	low	JJ
work_6edatbslnjhz3kb2pkbphqv5py	37	23	volume	volume	NN
work_6edatbslnjhz3kb2pkbphqv5py	37	24	disease	disease	NN
work_6edatbslnjhz3kb2pkbphqv5py	37	25	(	(	-LRB-
work_6edatbslnjhz3kb2pkbphqv5py	37	26	1	1	CD
work_6edatbslnjhz3kb2pkbphqv5py	37	27	1	1	CD
work_6edatbslnjhz3kb2pkbphqv5py	37	28	)	)	-RRB-
work_6edatbslnjhz3kb2pkbphqv5py	37	29	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	38	1	Even	even	RB
work_6edatbslnjhz3kb2pkbphqv5py	38	2	a	a	DT
work_6edatbslnjhz3kb2pkbphqv5py	38	3	meta-	meta-	JJ
work_6edatbslnjhz3kb2pkbphqv5py	38	4	analysis	analysis	NN
work_6edatbslnjhz3kb2pkbphqv5py	38	5	failed	fail	VBD
work_6edatbslnjhz3kb2pkbphqv5py	38	6	to	to	TO
work_6edatbslnjhz3kb2pkbphqv5py	38	7	show	show	VB
work_6edatbslnjhz3kb2pkbphqv5py	38	8	any	any	DT
work_6edatbslnjhz3kb2pkbphqv5py	38	9	significant	significant	JJ
work_6edatbslnjhz3kb2pkbphqv5py	38	10	improvement	improvement	NN
work_6edatbslnjhz3kb2pkbphqv5py	38	11	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	38	12	survival	survival	NN
work_6edatbslnjhz3kb2pkbphqv5py	38	13	with	with	IN
work_6edatbslnjhz3kb2pkbphqv5py	38	14	5-FU	5-fu	CD
work_6edatbslnjhz3kb2pkbphqv5py	38	15	plus	plus	CC
work_6edatbslnjhz3kb2pkbphqv5py	38	16	leucovorin	leucovorin	NNP
work_6edatbslnjhz3kb2pkbphqv5py	38	17	(	(	-LRB-
work_6edatbslnjhz3kb2pkbphqv5py	38	18	17	17	CD
work_6edatbslnjhz3kb2pkbphqv5py	38	19	)	)	-RRB-
work_6edatbslnjhz3kb2pkbphqv5py	38	20	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	39	1	Furthermore	furthermore	RB
work_6edatbslnjhz3kb2pkbphqv5py	39	2	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	39	3	combining	combine	VBG
work_6edatbslnjhz3kb2pkbphqv5py	39	4	5-FU	5-fu	CD
work_6edatbslnjhz3kb2pkbphqv5py	39	5	with	with	IN
work_6edatbslnjhz3kb2pkbphqv5py	39	6	other	other	JJ
work_6edatbslnjhz3kb2pkbphqv5py	39	7	agents	agent	NNS
work_6edatbslnjhz3kb2pkbphqv5py	39	8	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	39	9	such	such	JJ
work_6edatbslnjhz3kb2pkbphqv5py	39	10	as	as	IN
work_6edatbslnjhz3kb2pkbphqv5py	39	11	cisplatin	cisplatin	NN
work_6edatbslnjhz3kb2pkbphqv5py	39	12	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	39	13	methotrexate	methotrexate	NN
work_6edatbslnjhz3kb2pkbphqv5py	39	14	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	39	15	PALA	PALA	NNP
work_6edatbslnjhz3kb2pkbphqv5py	39	16	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	39	17	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	39	18	thymidine	thymidine	NN
work_6edatbslnjhz3kb2pkbphqv5py	39	19	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	39	20	has	have	VBZ
work_6edatbslnjhz3kb2pkbphqv5py	39	21	not	not	RB
work_6edatbslnjhz3kb2pkbphqv5py	39	22	improved	improve	VBN
work_6edatbslnjhz3kb2pkbphqv5py	39	23	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	39	24	survival	survival	NN
work_6edatbslnjhz3kb2pkbphqv5py	39	25	statistics	statistic	NNS
work_6edatbslnjhz3kb2pkbphqv5py	39	26	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	39	27	metastatic	metastatic	JJ
work_6edatbslnjhz3kb2pkbphqv5py	39	28	coborectal	coborectal	JJ
work_6edatbslnjhz3kb2pkbphqv5py	39	29	cancer	cancer	NN
work_6edatbslnjhz3kb2pkbphqv5py	39	30	(	(	-LRB-
work_6edatbslnjhz3kb2pkbphqv5py	39	31	1	1	CD
work_6edatbslnjhz3kb2pkbphqv5py	39	32	8	8	CD
work_6edatbslnjhz3kb2pkbphqv5py	39	33	-20	-20	CD
work_6edatbslnjhz3kb2pkbphqv5py	39	34	)	)	-RRB-
work_6edatbslnjhz3kb2pkbphqv5py	39	35	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	40	1	Levamisole	Levamisole	NNP
work_6edatbslnjhz3kb2pkbphqv5py	40	2	is	be	VBZ
work_6edatbslnjhz3kb2pkbphqv5py	40	3	a	a	DT
work_6edatbslnjhz3kb2pkbphqv5py	40	4	pure	pure	JJ
work_6edatbslnjhz3kb2pkbphqv5py	40	5	chemical	chemical	NN
work_6edatbslnjhz3kb2pkbphqv5py	40	6	that	that	WDT
work_6edatbslnjhz3kb2pkbphqv5py	40	7	was	be	VBD
work_6edatbslnjhz3kb2pkbphqv5py	40	8	first	first	RB
work_6edatbslnjhz3kb2pkbphqv5py	40	9	used	use	VBN
work_6edatbslnjhz3kb2pkbphqv5py	40	10	as	as	IN
work_6edatbslnjhz3kb2pkbphqv5py	40	11	an	an	DT
work_6edatbslnjhz3kb2pkbphqv5py	40	12	antihelminthic	antihelminthic	JJ
work_6edatbslnjhz3kb2pkbphqv5py	40	13	drug	drug	NN
work_6edatbslnjhz3kb2pkbphqv5py	40	14	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	40	15	has	have	VBZ
work_6edatbslnjhz3kb2pkbphqv5py	40	16	documented	document	VBN
work_6edatbslnjhz3kb2pkbphqv5py	40	17	immunomodulatory	immunomodulatory	JJ
work_6edatbslnjhz3kb2pkbphqv5py	40	18	effects	effect	NNS
work_6edatbslnjhz3kb2pkbphqv5py	40	19	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	41	1	Verhacgen	Verhacgen	NNP
work_6edatbslnjhz3kb2pkbphqv5py	41	2	et	et	NNP
work_6edatbslnjhz3kb2pkbphqv5py	41	3	a	a	NN
work_6edatbslnjhz3kb2pkbphqv5py	41	4	!	!	.
work_6edatbslnjhz3kb2pkbphqv5py	41	5	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	42	1	(	(	-LRB-
work_6edatbslnjhz3kb2pkbphqv5py	42	2	2	2	CD
work_6edatbslnjhz3kb2pkbphqv5py	42	3	1	1	CD
work_6edatbslnjhz3kb2pkbphqv5py	42	4	)	)	-RRB-
work_6edatbslnjhz3kb2pkbphqv5py	42	5	initially	initially	RB
work_6edatbslnjhz3kb2pkbphqv5py	42	6	evaluated	evaluate	VBN
work_6edatbslnjhz3kb2pkbphqv5py	42	7	levamisole	levamisole	NN
work_6edatbslnjhz3kb2pkbphqv5py	42	8	versus	versus	IN
work_6edatbslnjhz3kb2pkbphqv5py	42	9	placebo	placebo	NN
work_6edatbslnjhz3kb2pkbphqv5py	42	10	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	42	11	a	a	DT
work_6edatbslnjhz3kb2pkbphqv5py	42	12	very	very	RB
work_6edatbslnjhz3kb2pkbphqv5py	42	13	small	small	JJ
work_6edatbslnjhz3kb2pkbphqv5py	42	14	patient	patient	JJ
work_6edatbslnjhz3kb2pkbphqv5py	42	15	population	population	NN
work_6edatbslnjhz3kb2pkbphqv5py	42	16	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	42	17	surgically	surgically	RB
work_6edatbslnjhz3kb2pkbphqv5py	42	18	resected	resect	VBN
work_6edatbslnjhz3kb2pkbphqv5py	42	19	colon	colon	NN
work_6edatbslnjhz3kb2pkbphqv5py	42	20	cancer	cancer	NN
work_6edatbslnjhz3kb2pkbphqv5py	42	21	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	42	22	demonstrated	demonstrate	VBD
work_6edatbslnjhz3kb2pkbphqv5py	42	23	a	a	DT
work_6edatbslnjhz3kb2pkbphqv5py	42	24	statistically	statistically	RB
work_6edatbslnjhz3kb2pkbphqv5py	42	25	signifi-	signifi-	JJ
work_6edatbslnjhz3kb2pkbphqv5py	42	26	ca	can	MD
work_6edatbslnjhz3kb2pkbphqv5py	42	27	nt	not	RB
work_6edatbslnjhz3kb2pkbphqv5py	42	28	survival	survival	VB
work_6edatbslnjhz3kb2pkbphqv5py	42	29	advantage	advantage	NN
work_6edatbslnjhz3kb2pkbphqv5py	42	30	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	43	1	The	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	43	2	Western	Western	NNP
work_6edatbslnjhz3kb2pkbphqv5py	43	3	Cancer	Cancer	NNP
work_6edatbslnjhz3kb2pkbphqv5py	43	4	Study	Study	NNP
work_6edatbslnjhz3kb2pkbphqv5py	43	5	Group	Group	NNP
work_6edatbslnjhz3kb2pkbphqv5py	43	6	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	43	7	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	43	8	European	European	NNP
work_6edatbslnjhz3kb2pkbphqv5py	43	9	Organization	Organization	NNP
work_6edatbslnjhz3kb2pkbphqv5py	43	10	for	for	IN
work_6edatbslnjhz3kb2pkbphqv5py	43	11	Research	Research	NNP
work_6edatbslnjhz3kb2pkbphqv5py	43	12	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	43	13	Treatment	Treatment	NNP
work_6edatbslnjhz3kb2pkbphqv5py	43	14	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	43	15	Can-	Can-	NNP
work_6edatbslnjhz3kb2pkbphqv5py	43	16	cer	cer	NN
work_6edatbslnjhz3kb2pkbphqv5py	43	17	compared	compare	VBN
work_6edatbslnjhz3kb2pkbphqv5py	43	18	levamisole	levamisole	NN
work_6edatbslnjhz3kb2pkbphqv5py	43	19	to	to	IN
work_6edatbslnjhz3kb2pkbphqv5py	43	20	placebo	placebo	NN
work_6edatbslnjhz3kb2pkbphqv5py	43	21	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	43	22	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	43	23	adjuvant	adjuvant	JJ
work_6edatbslnjhz3kb2pkbphqv5py	43	24	setting	setting	NN
work_6edatbslnjhz3kb2pkbphqv5py	43	25	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	43	26	found	find	VBD
work_6edatbslnjhz3kb2pkbphqv5py	43	27	no	no	DT
work_6edatbslnjhz3kb2pkbphqv5py	43	28	significant	significant	JJ
work_6edatbslnjhz3kb2pkbphqv5py	43	29	survival	survival	NN
work_6edatbslnjhz3kb2pkbphqv5py	43	30	benefit	benefit	NN
work_6edatbslnjhz3kb2pkbphqv5py	43	31	(	(	-LRB-
work_6edatbslnjhz3kb2pkbphqv5py	43	32	22	22	CD
work_6edatbslnjhz3kb2pkbphqv5py	43	33	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	43	34	23	23	CD
work_6edatbslnjhz3kb2pkbphqv5py	43	35	)	)	-RRB-
work_6edatbslnjhz3kb2pkbphqv5py	43	36	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	44	1	on	on	IN
work_6edatbslnjhz3kb2pkbphqv5py	44	2	April	April	NNP
work_6edatbslnjhz3kb2pkbphqv5py	44	3	5	5	CD
work_6edatbslnjhz3kb2pkbphqv5py	44	4	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	44	5	2021	2021	CD
work_6edatbslnjhz3kb2pkbphqv5py	44	6	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	45	1	©	©	NNP
work_6edatbslnjhz3kb2pkbphqv5py	45	2	1998	1998	CD
work_6edatbslnjhz3kb2pkbphqv5py	45	3	American	American	NNP
work_6edatbslnjhz3kb2pkbphqv5py	45	4	Association	Association	NNP
work_6edatbslnjhz3kb2pkbphqv5py	45	5	for	for	IN
work_6edatbslnjhz3kb2pkbphqv5py	45	6	Cancer	Cancer	NNP
work_6edatbslnjhz3kb2pkbphqv5py	45	7	Research.clincancerres.aacrjournals.org	research.clincancerres.aacrjournals.org	NN
work_6edatbslnjhz3kb2pkbphqv5py	45	8	Downloaded	download	VBN
work_6edatbslnjhz3kb2pkbphqv5py	45	9	from	from	IN
work_6edatbslnjhz3kb2pkbphqv5py	45	10	http://clincancerres.aacrjournals.org/	http://clincancerres.aacrjournals.org/	CD
work_6edatbslnjhz3kb2pkbphqv5py	45	11	936	936	CD
work_6edatbslnjhz3kb2pkbphqv5py	45	12	5-FU	5-fu	CD
work_6edatbslnjhz3kb2pkbphqv5py	45	13	+	+	SYM
work_6edatbslnjhz3kb2pkbphqv5py	45	14	/-	/-	.
work_6edatbslnjhz3kb2pkbphqv5py	45	15	Levamisole	levamisole	NN
work_6edatbslnjhz3kb2pkbphqv5py	45	16	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	45	17	Metastatic	Metastatic	NNP
work_6edatbslnjhz3kb2pkbphqv5py	45	18	Colorectal	Colorectal	NNP
work_6edatbslnjhz3kb2pkbphqv5py	45	19	Cancer	Cancer	NNP
work_6edatbslnjhz3kb2pkbphqv5py	45	20	The	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	45	21	major	major	JJ
work_6edatbslnjhz3kb2pkbphqv5py	45	22	interest	interest	NN
work_6edatbslnjhz3kb2pkbphqv5py	45	23	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	45	24	levamisole	levamisole	NN
work_6edatbslnjhz3kb2pkbphqv5py	45	25	as	as	IN
work_6edatbslnjhz3kb2pkbphqv5py	45	26	adjuvant	adjuvant	NN
work_6edatbslnjhz3kb2pkbphqv5py	45	27	therapy	therapy	NN
work_6edatbslnjhz3kb2pkbphqv5py	45	28	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	45	29	Duke	Duke	NNP
work_6edatbslnjhz3kb2pkbphqv5py	45	30	’s	’s	NNP
work_6edatbslnjhz3kb2pkbphqv5py	45	31	B	B	NNP
work_6edatbslnjhz3kb2pkbphqv5py	45	32	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	45	33	C	C	NNP
work_6edatbslnjhz3kb2pkbphqv5py	45	34	colon	colon	NN
work_6edatbslnjhz3kb2pkbphqv5py	45	35	cancer	cancer	NN
work_6edatbslnjhz3kb2pkbphqv5py	45	36	is	be	VBZ
work_6edatbslnjhz3kb2pkbphqv5py	45	37	because	because	IN
work_6edatbslnjhz3kb2pkbphqv5py	45	38	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	45	39	a	a	DT
work_6edatbslnjhz3kb2pkbphqv5py	45	40	positive	positive	JJ
work_6edatbslnjhz3kb2pkbphqv5py	45	41	NCCTG	NCCTG	NNP
work_6edatbslnjhz3kb2pkbphqv5py	45	42	study	study	NN
work_6edatbslnjhz3kb2pkbphqv5py	45	43	(	(	-LRB-
work_6edatbslnjhz3kb2pkbphqv5py	45	44	24	24	CD
work_6edatbslnjhz3kb2pkbphqv5py	45	45	)	)	-RRB-
work_6edatbslnjhz3kb2pkbphqv5py	45	46	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	45	47	a	a	DT
work_6edatbslnjhz3kb2pkbphqv5py	45	48	larger	large	JJR
work_6edatbslnjhz3kb2pkbphqv5py	45	49	confirmatory	confirmatory	NN
work_6edatbslnjhz3kb2pkbphqv5py	45	50	intergroup	intergroup	NNP
work_6edatbslnjhz3kb2pkbphqv5py	45	51	study	study	NN
work_6edatbslnjhz3kb2pkbphqv5py	45	52	(	(	-LRB-
work_6edatbslnjhz3kb2pkbphqv5py	45	53	25	25	CD
work_6edatbslnjhz3kb2pkbphqv5py	45	54	)	)	-RRB-
work_6edatbslnjhz3kb2pkbphqv5py	45	55	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	45	56	both	both	DT
work_6edatbslnjhz3kb2pkbphqv5py	45	57	demonstrating	demonstrate	VBG
work_6edatbslnjhz3kb2pkbphqv5py	45	58	a	a	DT
work_6edatbslnjhz3kb2pkbphqv5py	45	59	significant	significant	JJ
work_6edatbslnjhz3kb2pkbphqv5py	45	60	advantage	advantage	NN
work_6edatbslnjhz3kb2pkbphqv5py	45	61	for	for	IN
work_6edatbslnjhz3kb2pkbphqv5py	45	62	5-FU	5-fu	CD
work_6edatbslnjhz3kb2pkbphqv5py	45	63	plus	plus	CC
work_6edatbslnjhz3kb2pkbphqv5py	45	64	levamisole	levamisole	NN
work_6edatbslnjhz3kb2pkbphqv5py	45	65	over	over	IN
work_6edatbslnjhz3kb2pkbphqv5py	45	66	levamisole	levamisole	NN
work_6edatbslnjhz3kb2pkbphqv5py	45	67	alone	alone	RB
work_6edatbslnjhz3kb2pkbphqv5py	45	68	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	46	1	However	however	RB
work_6edatbslnjhz3kb2pkbphqv5py	46	2	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	46	3	this	this	DT
work_6edatbslnjhz3kb2pkbphqv5py	46	4	dose	dose	NN
work_6edatbslnjhz3kb2pkbphqv5py	46	5	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	46	6	schedule	schedule	NN
work_6edatbslnjhz3kb2pkbphqv5py	46	7	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	46	8	5-FU	5-fu	CD
work_6edatbslnjhz3kb2pkbphqv5py	46	9	plus	plus	JJ
work_6edatbslnjhz3kb2pkbphqv5py	46	10	levamisole	levamisole	NN
work_6edatbslnjhz3kb2pkbphqv5py	46	11	has	have	VBZ
work_6edatbslnjhz3kb2pkbphqv5py	46	12	never	never	RB
work_6edatbslnjhz3kb2pkbphqv5py	46	13	been	be	VBN
work_6edatbslnjhz3kb2pkbphqv5py	46	14	adequately	adequately	RB
work_6edatbslnjhz3kb2pkbphqv5py	46	15	tested	test	VBN
work_6edatbslnjhz3kb2pkbphqv5py	46	16	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	46	17	metastatic	metastatic	JJ
work_6edatbslnjhz3kb2pkbphqv5py	46	18	disease	disease	NN
work_6edatbslnjhz3kb2pkbphqv5py	46	19	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	47	1	Surprisingly	surprisingly	RB
work_6edatbslnjhz3kb2pkbphqv5py	47	2	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	47	3	there	there	EX
work_6edatbslnjhz3kb2pkbphqv5py	47	4	have	have	VBP
work_6edatbslnjhz3kb2pkbphqv5py	47	5	been	be	VBN
work_6edatbslnjhz3kb2pkbphqv5py	47	6	only	only	RB
work_6edatbslnjhz3kb2pkbphqv5py	47	7	three	three	CD
work_6edatbslnjhz3kb2pkbphqv5py	47	8	published	publish	VBN
work_6edatbslnjhz3kb2pkbphqv5py	47	9	Phase	Phase	NNP
work_6edatbslnjhz3kb2pkbphqv5py	47	10	III	III	NNP
work_6edatbslnjhz3kb2pkbphqv5py	47	11	studies	study	NNS
work_6edatbslnjhz3kb2pkbphqv5py	47	12	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	47	13	5-FU	5-fu	CD
work_6edatbslnjhz3kb2pkbphqv5py	47	14	plus	plus	JJ
work_6edatbslnjhz3kb2pkbphqv5py	47	15	levamisole	levamisole	NN
work_6edatbslnjhz3kb2pkbphqv5py	47	16	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	47	17	metastatic	metastatic	JJ
work_6edatbslnjhz3kb2pkbphqv5py	47	18	coborec-	coborec-	NN
work_6edatbslnjhz3kb2pkbphqv5py	47	19	tal	tal	JJ
work_6edatbslnjhz3kb2pkbphqv5py	47	20	cancer	cancer	NN
work_6edatbslnjhz3kb2pkbphqv5py	47	21	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	48	1	Borden	Borden	NNP
work_6edatbslnjhz3kb2pkbphqv5py	48	2	et	et	FW
work_6edatbslnjhz3kb2pkbphqv5py	48	3	al	al	NNP
work_6edatbslnjhz3kb2pkbphqv5py	48	4	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	49	1	(	(	-LRB-
work_6edatbslnjhz3kb2pkbphqv5py	49	2	26	26	CD
work_6edatbslnjhz3kb2pkbphqv5py	49	3	)	)	-RRB-
work_6edatbslnjhz3kb2pkbphqv5py	49	4	at	at	IN
work_6edatbslnjhz3kb2pkbphqv5py	49	5	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	49	6	University	University	NNP
work_6edatbslnjhz3kb2pkbphqv5py	49	7	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	49	8	Wisconsin	Wisconsin	NNP
work_6edatbslnjhz3kb2pkbphqv5py	49	9	published	publish	VBD
work_6edatbslnjhz3kb2pkbphqv5py	49	10	a	a	DT
work_6edatbslnjhz3kb2pkbphqv5py	49	11	positive	positive	JJ
work_6edatbslnjhz3kb2pkbphqv5py	49	12	study	study	NN
work_6edatbslnjhz3kb2pkbphqv5py	49	13	demonstrating	demonstrate	VBG
work_6edatbslnjhz3kb2pkbphqv5py	49	14	a	a	DT
work_6edatbslnjhz3kb2pkbphqv5py	49	15	survival	survival	NN
work_6edatbslnjhz3kb2pkbphqv5py	49	16	advantage	advantage	NN
work_6edatbslnjhz3kb2pkbphqv5py	49	17	for	for	IN
work_6edatbslnjhz3kb2pkbphqv5py	49	18	5-FU	5-fu	CD
work_6edatbslnjhz3kb2pkbphqv5py	49	19	plus	plus	CC
work_6edatbslnjhz3kb2pkbphqv5py	49	20	levamisole	levamisole	NN
work_6edatbslnjhz3kb2pkbphqv5py	49	21	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	49	22	whereas	whereas	IN
work_6edatbslnjhz3kb2pkbphqv5py	49	23	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	49	24	NCCTG	NCCTG	NNP
work_6edatbslnjhz3kb2pkbphqv5py	49	25	study	study	NN
work_6edatbslnjhz3kb2pkbphqv5py	49	26	was	be	VBD
work_6edatbslnjhz3kb2pkbphqv5py	49	27	neg-	neg-	RB
work_6edatbslnjhz3kb2pkbphqv5py	49	28	ative	ative	JJ
work_6edatbslnjhz3kb2pkbphqv5py	49	29	(	(	-LRB-
work_6edatbslnjhz3kb2pkbphqv5py	49	30	20	20	CD
work_6edatbslnjhz3kb2pkbphqv5py	49	31	)	)	-RRB-
work_6edatbslnjhz3kb2pkbphqv5py	49	32	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	50	1	However	however	RB
work_6edatbslnjhz3kb2pkbphqv5py	50	2	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	50	3	neither	neither	DT
work_6edatbslnjhz3kb2pkbphqv5py	50	4	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	50	5	these	these	DT
work_6edatbslnjhz3kb2pkbphqv5py	50	6	studies	study	NNS
work_6edatbslnjhz3kb2pkbphqv5py	50	7	these	these	DT
work_6edatbslnjhz3kb2pkbphqv5py	50	8	used	use	VBD
work_6edatbslnjhz3kb2pkbphqv5py	50	9	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	50	10	same	same	JJ
work_6edatbslnjhz3kb2pkbphqv5py	50	11	dosage	dosage	NN
work_6edatbslnjhz3kb2pkbphqv5py	50	12	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	50	13	schedule	schedule	NN
work_6edatbslnjhz3kb2pkbphqv5py	50	14	as	as	IN
work_6edatbslnjhz3kb2pkbphqv5py	50	15	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	50	16	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	50	17	successful	successful	JJ
work_6edatbslnjhz3kb2pkbphqv5py	50	18	adjuvant	adjuvant	JJ
work_6edatbslnjhz3kb2pkbphqv5py	50	19	trials	trial	NNS
work_6edatbslnjhz3kb2pkbphqv5py	50	20	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	51	1	The	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	51	2	study	study	NN
work_6edatbslnjhz3kb2pkbphqv5py	51	3	by	by	IN
work_6edatbslnjhz3kb2pkbphqv5py	51	4	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	51	5	Eastern	Eastern	NNP
work_6edatbslnjhz3kb2pkbphqv5py	51	6	Cooperative	Cooperative	NNP
work_6edatbslnjhz3kb2pkbphqv5py	51	7	Oncology	Oncology	NNP
work_6edatbslnjhz3kb2pkbphqv5py	51	8	Group	Group	NNP
work_6edatbslnjhz3kb2pkbphqv5py	51	9	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	51	10	published	publish	VBN
work_6edatbslnjhz3kb2pkbphqv5py	51	11	only	only	RB
work_6edatbslnjhz3kb2pkbphqv5py	51	12	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	51	13	abstract	abstract	JJ
work_6edatbslnjhz3kb2pkbphqv5py	51	14	form	form	NN
work_6edatbslnjhz3kb2pkbphqv5py	51	15	thus	thus	RB
work_6edatbslnjhz3kb2pkbphqv5py	51	16	far	far	RB
work_6edatbslnjhz3kb2pkbphqv5py	51	17	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	51	18	was	be	VBD
work_6edatbslnjhz3kb2pkbphqv5py	51	19	also	also	RB
work_6edatbslnjhz3kb2pkbphqv5py	51	20	negative	negative	JJ
work_6edatbslnjhz3kb2pkbphqv5py	51	21	(	(	-LRB-
work_6edatbslnjhz3kb2pkbphqv5py	51	22	27	27	CD
work_6edatbslnjhz3kb2pkbphqv5py	51	23	)	)	-RRB-
work_6edatbslnjhz3kb2pkbphqv5py	51	24	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	52	1	The	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	52	2	dose	dose	NN
work_6edatbslnjhz3kb2pkbphqv5py	52	3	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	52	4	schedule	schedule	NN
work_6edatbslnjhz3kb2pkbphqv5py	52	5	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	52	6	5-FU	5-fu	CD
work_6edatbslnjhz3kb2pkbphqv5py	52	7	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	52	8	levamisole	levamisole	NN
work_6edatbslnjhz3kb2pkbphqv5py	52	9	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	52	10	this	this	DT
work_6edatbslnjhz3kb2pkbphqv5py	52	11	trial	trial	NN
work_6edatbslnjhz3kb2pkbphqv5py	52	12	were	be	VBD
work_6edatbslnjhz3kb2pkbphqv5py	52	13	also	also	RB
work_6edatbslnjhz3kb2pkbphqv5py	52	14	different	different	JJ
work_6edatbslnjhz3kb2pkbphqv5py	52	15	from	from	IN
work_6edatbslnjhz3kb2pkbphqv5py	52	16	those	those	DT
work_6edatbslnjhz3kb2pkbphqv5py	52	17	used	use	VBN
work_6edatbslnjhz3kb2pkbphqv5py	52	18	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	52	19	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	52	20	adjuvant	adjuvant	JJ
work_6edatbslnjhz3kb2pkbphqv5py	52	21	studies	study	NNS
work_6edatbslnjhz3kb2pkbphqv5py	52	22	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	53	1	There	there	EX
work_6edatbslnjhz3kb2pkbphqv5py	53	2	are	be	VBP
work_6edatbslnjhz3kb2pkbphqv5py	53	3	few	few	JJ
work_6edatbslnjhz3kb2pkbphqv5py	53	4	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	53	5	if	if	IN
work_6edatbslnjhz3kb2pkbphqv5py	53	6	any	any	DT
work_6edatbslnjhz3kb2pkbphqv5py	53	7	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	53	8	examples	example	NNS
work_6edatbslnjhz3kb2pkbphqv5py	53	9	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	53	10	oncology	oncology	NN
work_6edatbslnjhz3kb2pkbphqv5py	53	11	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	53	12	which	which	WDT
work_6edatbslnjhz3kb2pkbphqv5py	53	13	a	a	DT
work_6edatbslnjhz3kb2pkbphqv5py	53	14	regimen	regimen	NN
work_6edatbslnjhz3kb2pkbphqv5py	53	15	that	that	WDT
work_6edatbslnjhz3kb2pkbphqv5py	53	16	provides	provide	VBZ
work_6edatbslnjhz3kb2pkbphqv5py	53	17	a	a	DT
work_6edatbslnjhz3kb2pkbphqv5py	53	18	significant	significant	JJ
work_6edatbslnjhz3kb2pkbphqv5py	53	19	survival	survival	NN
work_6edatbslnjhz3kb2pkbphqv5py	53	20	advantage	advantage	NN
work_6edatbslnjhz3kb2pkbphqv5py	53	21	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	53	22	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	53	23	adjuvant	adjuvant	JJ
work_6edatbslnjhz3kb2pkbphqv5py	53	24	setting	setting	NN
work_6edatbslnjhz3kb2pkbphqv5py	53	25	is	be	VBZ
work_6edatbslnjhz3kb2pkbphqv5py	53	26	not	not	RB
work_6edatbslnjhz3kb2pkbphqv5py	53	27	also	also	RB
work_6edatbslnjhz3kb2pkbphqv5py	53	28	effective	effective	JJ
work_6edatbslnjhz3kb2pkbphqv5py	53	29	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	53	30	metastatic	metastatic	JJ
work_6edatbslnjhz3kb2pkbphqv5py	53	31	disease	disease	NN
work_6edatbslnjhz3kb2pkbphqv5py	53	32	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	54	1	Therefore	therefore	RB
work_6edatbslnjhz3kb2pkbphqv5py	54	2	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	54	3	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	54	4	Hoosier	Hoosier	NNP
work_6edatbslnjhz3kb2pkbphqv5py	54	5	Oncology	Oncology	NNP
work_6edatbslnjhz3kb2pkbphqv5py	54	6	Group	Group	NNP
work_6edatbslnjhz3kb2pkbphqv5py	54	7	embarked	embark	VBD
work_6edatbslnjhz3kb2pkbphqv5py	54	8	upon	upon	IN
work_6edatbslnjhz3kb2pkbphqv5py	54	9	this	this	DT
work_6edatbslnjhz3kb2pkbphqv5py	54	10	study	study	NN
work_6edatbslnjhz3kb2pkbphqv5py	54	11	evaluating	evaluate	VBG
work_6edatbslnjhz3kb2pkbphqv5py	54	12	5-FU	5-fu	CD
work_6edatbslnjhz3kb2pkbphqv5py	54	13	plus	plus	CC
work_6edatbslnjhz3kb2pkbphqv5py	54	14	levamisole	levamisole	NN
work_6edatbslnjhz3kb2pkbphqv5py	54	15	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	54	16	previously	previously	RB
work_6edatbslnjhz3kb2pkbphqv5py	54	17	untreated	untreated	JJ
work_6edatbslnjhz3kb2pkbphqv5py	54	18	patients	patient	NNS
work_6edatbslnjhz3kb2pkbphqv5py	54	19	with	with	IN
work_6edatbslnjhz3kb2pkbphqv5py	54	20	metastatic	metastatic	JJ
work_6edatbslnjhz3kb2pkbphqv5py	54	21	colorectal	colorectal	JJ
work_6edatbslnjhz3kb2pkbphqv5py	54	22	cancer	cancer	NN
work_6edatbslnjhz3kb2pkbphqv5py	54	23	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	54	24	using	use	VBG
work_6edatbslnjhz3kb2pkbphqv5py	54	25	dosage	dosage	NN
work_6edatbslnjhz3kb2pkbphqv5py	54	26	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	54	27	schedule	schedule	NN
work_6edatbslnjhz3kb2pkbphqv5py	54	28	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	54	29	these	these	DT
work_6edatbslnjhz3kb2pkbphqv5py	54	30	agents	agent	NNS
work_6edatbslnjhz3kb2pkbphqv5py	54	31	that	that	WDT
work_6edatbslnjhz3kb2pkbphqv5py	54	32	were	be	VBD
work_6edatbslnjhz3kb2pkbphqv5py	54	33	identical	identical	JJ
work_6edatbslnjhz3kb2pkbphqv5py	54	34	to	to	IN
work_6edatbslnjhz3kb2pkbphqv5py	54	35	those	those	DT
work_6edatbslnjhz3kb2pkbphqv5py	54	36	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	54	37	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	54	38	adjuvant	adjuvant	JJ
work_6edatbslnjhz3kb2pkbphqv5py	54	39	trials	trial	NNS
work_6edatbslnjhz3kb2pkbphqv5py	54	40	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	55	1	PATIENTS	patient	NNS
work_6edatbslnjhz3kb2pkbphqv5py	55	2	AND	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	55	3	METHODS	methods	JJ
work_6edatbslnjhz3kb2pkbphqv5py	55	4	All	all	DT
work_6edatbslnjhz3kb2pkbphqv5py	55	5	patients	patient	NNS
work_6edatbslnjhz3kb2pkbphqv5py	55	6	had	have	VBD
work_6edatbslnjhz3kb2pkbphqv5py	55	7	histologically	histologically	RB
work_6edatbslnjhz3kb2pkbphqv5py	55	8	proven	prove	VBN
work_6edatbslnjhz3kb2pkbphqv5py	55	9	adenocarcinoma	adenocarcinoma	NN
work_6edatbslnjhz3kb2pkbphqv5py	55	10	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	55	11	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	55	12	colon	colon	NN
work_6edatbslnjhz3kb2pkbphqv5py	55	13	or	or	CC
work_6edatbslnjhz3kb2pkbphqv5py	55	14	rectum	rectum	NN
work_6edatbslnjhz3kb2pkbphqv5py	55	15	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	55	16	had	have	VBD
work_6edatbslnjhz3kb2pkbphqv5py	55	17	not	not	RB
work_6edatbslnjhz3kb2pkbphqv5py	55	18	received	receive	VBN
work_6edatbslnjhz3kb2pkbphqv5py	55	19	prior	prior	JJ
work_6edatbslnjhz3kb2pkbphqv5py	55	20	chemotherapy	chemotherapy	NN
work_6edatbslnjhz3kb2pkbphqv5py	55	21	for	for	IN
work_6edatbslnjhz3kb2pkbphqv5py	55	22	metastatic	metastatic	JJ
work_6edatbslnjhz3kb2pkbphqv5py	55	23	disease	disease	NN
work_6edatbslnjhz3kb2pkbphqv5py	55	24	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	56	1	Patients	patient	NNS
work_6edatbslnjhz3kb2pkbphqv5py	56	2	may	may	MD
work_6edatbslnjhz3kb2pkbphqv5py	56	3	have	have	VB
work_6edatbslnjhz3kb2pkbphqv5py	56	4	had	have	VBN
work_6edatbslnjhz3kb2pkbphqv5py	56	5	adjuvant	adjuvant	JJ
work_6edatbslnjhz3kb2pkbphqv5py	56	6	therapy	therapy	NN
work_6edatbslnjhz3kb2pkbphqv5py	56	7	but	but	CC
work_6edatbslnjhz3kb2pkbphqv5py	56	8	not	not	RB
work_6edatbslnjhz3kb2pkbphqv5py	56	9	within	within	IN
work_6edatbslnjhz3kb2pkbphqv5py	56	10	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	56	11	6	6	CD
work_6edatbslnjhz3kb2pkbphqv5py	56	12	months	month	NNS
work_6edatbslnjhz3kb2pkbphqv5py	56	13	prior	prior	RB
work_6edatbslnjhz3kb2pkbphqv5py	56	14	to	to	IN
work_6edatbslnjhz3kb2pkbphqv5py	56	15	registration	registration	NN
work_6edatbslnjhz3kb2pkbphqv5py	56	16	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	57	1	Patients	patient	NNS
work_6edatbslnjhz3kb2pkbphqv5py	57	2	with	with	IN
work_6edatbslnjhz3kb2pkbphqv5py	57	3	measurable	measurable	JJ
work_6edatbslnjhz3kb2pkbphqv5py	57	4	as	as	RB
work_6edatbslnjhz3kb2pkbphqv5py	57	5	well	well	RB
work_6edatbslnjhz3kb2pkbphqv5py	57	6	as	as	IN
work_6edatbslnjhz3kb2pkbphqv5py	57	7	nonmeasurable	nonmeasurable	JJ
work_6edatbslnjhz3kb2pkbphqv5py	57	8	disease	disease	NN
work_6edatbslnjhz3kb2pkbphqv5py	57	9	were	be	VBD
work_6edatbslnjhz3kb2pkbphqv5py	57	10	included	include	VBN
work_6edatbslnjhz3kb2pkbphqv5py	57	11	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	58	1	Measurable	measurable	JJ
work_6edatbslnjhz3kb2pkbphqv5py	58	2	disease	disease	NN
work_6edatbslnjhz3kb2pkbphqv5py	58	3	was	be	VBD
work_6edatbslnjhz3kb2pkbphqv5py	58	4	defined	define	VBN
work_6edatbslnjhz3kb2pkbphqv5py	58	5	as	as	IN
work_6edatbslnjhz3kb2pkbphqv5py	58	6	being	be	VBG
work_6edatbslnjhz3kb2pkbphqv5py	58	7	bidimensionally	bidimensionally	RB
work_6edatbslnjhz3kb2pkbphqv5py	58	8	meas-	meas-	.
work_6edatbslnjhz3kb2pkbphqv5py	58	9	urable	urable	JJ
work_6edatbslnjhz3kb2pkbphqv5py	58	10	on	on	IN
work_6edatbslnjhz3kb2pkbphqv5py	58	11	physical	physical	JJ
work_6edatbslnjhz3kb2pkbphqv5py	58	12	or	or	CC
work_6edatbslnjhz3kb2pkbphqv5py	58	13	roentgenographic	roentgenographic	JJ
work_6edatbslnjhz3kb2pkbphqv5py	58	14	examination	examination	NN
work_6edatbslnjhz3kb2pkbphqv5py	58	15	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	59	1	Malignant	malignant	JJ
work_6edatbslnjhz3kb2pkbphqv5py	59	2	hepatomegaly	hepatomegaly	NN
work_6edatbslnjhz3kb2pkbphqv5py	59	3	could	could	MD
work_6edatbslnjhz3kb2pkbphqv5py	59	4	be	be	VB
work_6edatbslnjhz3kb2pkbphqv5py	59	5	used	use	VBN
work_6edatbslnjhz3kb2pkbphqv5py	59	6	as	as	IN
work_6edatbslnjhz3kb2pkbphqv5py	59	7	measurable	measurable	JJ
work_6edatbslnjhz3kb2pkbphqv5py	59	8	disease	disease	NN
work_6edatbslnjhz3kb2pkbphqv5py	59	9	if	if	IN
work_6edatbslnjhz3kb2pkbphqv5py	59	10	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	59	11	liver	liver	NN
work_6edatbslnjhz3kb2pkbphqv5py	59	12	edge	edge	NN
work_6edatbslnjhz3kb2pkbphqv5py	59	13	was	be	VBD
work_6edatbslnjhz3kb2pkbphqv5py	59	14	palpable	palpable	JJ
work_6edatbslnjhz3kb2pkbphqv5py	59	15	at	at	IN
work_6edatbslnjhz3kb2pkbphqv5py	59	16	beast	beast	NN
work_6edatbslnjhz3kb2pkbphqv5py	59	17	5	5	CD
work_6edatbslnjhz3kb2pkbphqv5py	59	18	cm	cm	NNS
work_6edatbslnjhz3kb2pkbphqv5py	59	19	below	below	IN
work_6edatbslnjhz3kb2pkbphqv5py	59	20	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	59	21	costal	costal	JJ
work_6edatbslnjhz3kb2pkbphqv5py	59	22	margin	margin	NN
work_6edatbslnjhz3kb2pkbphqv5py	59	23	at	at	IN
work_6edatbslnjhz3kb2pkbphqv5py	59	24	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	59	25	right	right	JJ
work_6edatbslnjhz3kb2pkbphqv5py	59	26	midclavicubar	midclavicubar	NN
work_6edatbslnjhz3kb2pkbphqv5py	59	27	line	line	NN
work_6edatbslnjhz3kb2pkbphqv5py	59	28	or	or	CC
work_6edatbslnjhz3kb2pkbphqv5py	59	29	xiphoid	xiphoid	NN
work_6edatbslnjhz3kb2pkbphqv5py	59	30	on	on	IN
work_6edatbslnjhz3kb2pkbphqv5py	59	31	quiet	quiet	JJ
work_6edatbslnjhz3kb2pkbphqv5py	59	32	respiration	respiration	NN
work_6edatbslnjhz3kb2pkbphqv5py	59	33	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	60	1	The	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	60	2	liver	liver	NN
work_6edatbslnjhz3kb2pkbphqv5py	60	3	span	span	NN
work_6edatbslnjhz3kb2pkbphqv5py	60	4	should	should	MD
work_6edatbslnjhz3kb2pkbphqv5py	60	5	have	have	VB
work_6edatbslnjhz3kb2pkbphqv5py	60	6	been	be	VBN
work_6edatbslnjhz3kb2pkbphqv5py	60	7	greater	great	JJR
work_6edatbslnjhz3kb2pkbphqv5py	60	8	than	than	IN
work_6edatbslnjhz3kb2pkbphqv5py	60	9	12	12	CD
work_6edatbslnjhz3kb2pkbphqv5py	60	10	cm	cm	NNS
work_6edatbslnjhz3kb2pkbphqv5py	60	11	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	61	1	All	all	DT
work_6edatbslnjhz3kb2pkbphqv5py	61	2	patients	patient	NNS
work_6edatbslnjhz3kb2pkbphqv5py	61	3	had	have	VBD
work_6edatbslnjhz3kb2pkbphqv5py	61	4	a	a	DT
work_6edatbslnjhz3kb2pkbphqv5py	61	5	KPS	KPS	NNP
work_6edatbslnjhz3kb2pkbphqv5py	61	6	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	61	7	at	at	RB
work_6edatbslnjhz3kb2pkbphqv5py	61	8	least	least	RBS
work_6edatbslnjhz3kb2pkbphqv5py	61	9	50	50	CD
work_6edatbslnjhz3kb2pkbphqv5py	61	10	%	%	NN
work_6edatbslnjhz3kb2pkbphqv5py	61	11	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	61	12	as	as	RB
work_6edatbslnjhz3kb2pkbphqv5py	61	13	well	well	RB
work_6edatbslnjhz3kb2pkbphqv5py	61	14	as	as	IN
work_6edatbslnjhz3kb2pkbphqv5py	61	15	adequate	adequate	JJ
work_6edatbslnjhz3kb2pkbphqv5py	61	16	bone	bone	NN
work_6edatbslnjhz3kb2pkbphqv5py	61	17	marrow	marrow	NNP
work_6edatbslnjhz3kb2pkbphqv5py	61	18	reserve	reserve	NNP
work_6edatbslnjhz3kb2pkbphqv5py	61	19	(	(	-LRB-
work_6edatbslnjhz3kb2pkbphqv5py	61	20	absolute	absolute	NNP
work_6edatbslnjhz3kb2pkbphqv5py	61	21	granubocyte	granubocyte	NNP
work_6edatbslnjhz3kb2pkbphqv5py	61	22	count	count	NN
work_6edatbslnjhz3kb2pkbphqv5py	61	23	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	61	24	2,500	2,500	CD
work_6edatbslnjhz3kb2pkbphqv5py	61	25	cells	cell	NNS
work_6edatbslnjhz3kb2pkbphqv5py	61	26	/	/	SYM
work_6edatbslnjhz3kb2pkbphqv5py	61	27	mm3	mm3	NNS
work_6edatbslnjhz3kb2pkbphqv5py	61	28	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	61	29	platelet	platelet	NN
work_6edatbslnjhz3kb2pkbphqv5py	61	30	count	count	NN
work_6edatbslnjhz3kb2pkbphqv5py	61	31	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	61	32	125,0004i.l	125,0004i.l	NNP
work_6edatbslnjhz3kb2pkbphqv5py	61	33	)	)	-RRB-
work_6edatbslnjhz3kb2pkbphqv5py	61	34	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	62	1	Patients	patient	NNS
work_6edatbslnjhz3kb2pkbphqv5py	62	2	were	be	VBD
work_6edatbslnjhz3kb2pkbphqv5py	62	3	excluded	exclude	VBN
work_6edatbslnjhz3kb2pkbphqv5py	62	4	if	if	IN
work_6edatbslnjhz3kb2pkbphqv5py	62	5	they	-PRON-	PRP
work_6edatbslnjhz3kb2pkbphqv5py	62	6	had	have	VBD
work_6edatbslnjhz3kb2pkbphqv5py	62	7	a	a	DT
work_6edatbslnjhz3kb2pkbphqv5py	62	8	history	history	NN
work_6edatbslnjhz3kb2pkbphqv5py	62	9	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	62	10	prior	prior	JJ
work_6edatbslnjhz3kb2pkbphqv5py	62	11	malignancy	malignancy	NN
work_6edatbslnjhz3kb2pkbphqv5py	62	12	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	62	13	except	except	IN
work_6edatbslnjhz3kb2pkbphqv5py	62	14	squamous	squamous	JJ
work_6edatbslnjhz3kb2pkbphqv5py	62	15	or	or	CC
work_6edatbslnjhz3kb2pkbphqv5py	62	16	basal	basal	JJ
work_6edatbslnjhz3kb2pkbphqv5py	62	17	cell	cell	NN
work_6edatbslnjhz3kb2pkbphqv5py	62	18	carcinoma	carcinoma	NN
work_6edatbslnjhz3kb2pkbphqv5py	62	19	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	62	20	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	62	21	skin	skin	NN
work_6edatbslnjhz3kb2pkbphqv5py	62	22	or	or	CC
work_6edatbslnjhz3kb2pkbphqv5py	62	23	carcinoma	carcinoma	NN
work_6edatbslnjhz3kb2pkbphqv5py	62	24	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	62	25	situ	situ	NN
work_6edatbslnjhz3kb2pkbphqv5py	62	26	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	62	27	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	62	28	cervix	cervix	NN
work_6edatbslnjhz3kb2pkbphqv5py	62	29	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	62	30	unless	unless	IN
work_6edatbslnjhz3kb2pkbphqv5py	62	31	they	-PRON-	PRP
work_6edatbslnjhz3kb2pkbphqv5py	62	32	had	have	VBD
work_6edatbslnjhz3kb2pkbphqv5py	62	33	been	be	VBN
work_6edatbslnjhz3kb2pkbphqv5py	62	34	disease	disease	NN
work_6edatbslnjhz3kb2pkbphqv5py	62	35	-	-	HYPH
work_6edatbslnjhz3kb2pkbphqv5py	62	36	free	free	JJ
work_6edatbslnjhz3kb2pkbphqv5py	62	37	for	for	IN
work_6edatbslnjhz3kb2pkbphqv5py	62	38	at	at	RB
work_6edatbslnjhz3kb2pkbphqv5py	62	39	least	least	RBS
work_6edatbslnjhz3kb2pkbphqv5py	62	40	5	5	CD
work_6edatbslnjhz3kb2pkbphqv5py	62	41	years	year	NNS
work_6edatbslnjhz3kb2pkbphqv5py	62	42	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	63	1	Pretreatment	pretreatment	JJ
work_6edatbslnjhz3kb2pkbphqv5py	63	2	studies	study	NNS
work_6edatbslnjhz3kb2pkbphqv5py	63	3	included	include	VBD
work_6edatbslnjhz3kb2pkbphqv5py	63	4	complete	complete	JJ
work_6edatbslnjhz3kb2pkbphqv5py	63	5	history	history	NN
work_6edatbslnjhz3kb2pkbphqv5py	63	6	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	63	7	physi-	physi-	NN
work_6edatbslnjhz3kb2pkbphqv5py	63	8	cal	cal	NN
work_6edatbslnjhz3kb2pkbphqv5py	63	9	examination	examination	NN
work_6edatbslnjhz3kb2pkbphqv5py	63	10	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	63	11	complete	complete	JJ
work_6edatbslnjhz3kb2pkbphqv5py	63	12	blood	blood	NN
work_6edatbslnjhz3kb2pkbphqv5py	63	13	count	count	NN
work_6edatbslnjhz3kb2pkbphqv5py	63	14	including	include	VBG
work_6edatbslnjhz3kb2pkbphqv5py	63	15	WBC	WBC	NNP
work_6edatbslnjhz3kb2pkbphqv5py	63	16	differ-	differ-	XX
work_6edatbslnjhz3kb2pkbphqv5py	63	17	ential	ential	JJ
work_6edatbslnjhz3kb2pkbphqv5py	63	18	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	63	19	platelet	platelet	NN
work_6edatbslnjhz3kb2pkbphqv5py	63	20	counts	count	NNS
work_6edatbslnjhz3kb2pkbphqv5py	63	21	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	63	22	1	1	CD
work_6edatbslnjhz3kb2pkbphqv5py	63	23	2-channel	2-channel	CD
work_6edatbslnjhz3kb2pkbphqv5py	63	24	sequential	sequential	JJ
work_6edatbslnjhz3kb2pkbphqv5py	63	25	multiple	multiple	JJ
work_6edatbslnjhz3kb2pkbphqv5py	63	26	anal-	anal-	NNP
work_6edatbslnjhz3kb2pkbphqv5py	63	27	ysis	ysis	NN
work_6edatbslnjhz3kb2pkbphqv5py	63	28	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	63	29	carcinoembryonic	carcinoembryonic	JJ
work_6edatbslnjhz3kb2pkbphqv5py	63	30	antigen	antigen	NNP
work_6edatbslnjhz3kb2pkbphqv5py	63	31	measurement	measurement	NN
work_6edatbslnjhz3kb2pkbphqv5py	63	32	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	63	33	chest	chest	NN
work_6edatbslnjhz3kb2pkbphqv5py	63	34	X	x	NN
work_6edatbslnjhz3kb2pkbphqv5py	63	35	-	-	NN
work_6edatbslnjhz3kb2pkbphqv5py	63	36	ray	ray	NN
work_6edatbslnjhz3kb2pkbphqv5py	63	37	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	63	38	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	63	39	abdominal	abdominal	JJ
work_6edatbslnjhz3kb2pkbphqv5py	63	40	computerized	computerized	NN
work_6edatbslnjhz3kb2pkbphqv5py	63	41	tomographic	tomographic	JJ
work_6edatbslnjhz3kb2pkbphqv5py	63	42	scan	scan	NNP
work_6edatbslnjhz3kb2pkbphqv5py	63	43	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	64	1	During	during	IN
work_6edatbslnjhz3kb2pkbphqv5py	64	2	treatment	treatment	NN
work_6edatbslnjhz3kb2pkbphqv5py	64	3	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	64	4	patients	patient	NNS
work_6edatbslnjhz3kb2pkbphqv5py	64	5	were	be	VBD
work_6edatbslnjhz3kb2pkbphqv5py	64	6	evaluated	evaluate	VBN
work_6edatbslnjhz3kb2pkbphqv5py	64	7	by	by	IN
work_6edatbslnjhz3kb2pkbphqv5py	64	8	history	history	NN
work_6edatbslnjhz3kb2pkbphqv5py	64	9	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	64	10	physical	physical	JJ
work_6edatbslnjhz3kb2pkbphqv5py	64	11	examination	examination	NN
work_6edatbslnjhz3kb2pkbphqv5py	64	12	every	every	DT
work_6edatbslnjhz3kb2pkbphqv5py	64	13	4	4	CD
work_6edatbslnjhz3kb2pkbphqv5py	64	14	weeks	week	NNS
work_6edatbslnjhz3kb2pkbphqv5py	64	15	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	64	16	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	64	17	radiographs	radiograph	NNS
work_6edatbslnjhz3kb2pkbphqv5py	64	18	were	be	VBD
work_6edatbslnjhz3kb2pkbphqv5py	64	19	repeated	repeat	VBN
work_6edatbslnjhz3kb2pkbphqv5py	64	20	every	every	DT
work_6edatbslnjhz3kb2pkbphqv5py	64	21	8	8	CD
work_6edatbslnjhz3kb2pkbphqv5py	64	22	weeks	week	NNS
work_6edatbslnjhz3kb2pkbphqv5py	64	23	for	for	IN
work_6edatbslnjhz3kb2pkbphqv5py	64	24	tumor	tumor	NN
work_6edatbslnjhz3kb2pkbphqv5py	64	25	measurement	measurement	NN
work_6edatbslnjhz3kb2pkbphqv5py	64	26	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	65	1	In	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	65	2	addition	addition	NN
work_6edatbslnjhz3kb2pkbphqv5py	65	3	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	65	4	a	a	DT
work_6edatbslnjhz3kb2pkbphqv5py	65	5	complete	complete	JJ
work_6edatbslnjhz3kb2pkbphqv5py	65	6	blood	blood	NN
work_6edatbslnjhz3kb2pkbphqv5py	65	7	count	count	NN
work_6edatbslnjhz3kb2pkbphqv5py	65	8	includ-	includ-	NNP
work_6edatbslnjhz3kb2pkbphqv5py	65	9	ing	ing	NNP
work_6edatbslnjhz3kb2pkbphqv5py	65	10	WBC	WBC	NNP
work_6edatbslnjhz3kb2pkbphqv5py	65	11	differential	differential	NN
work_6edatbslnjhz3kb2pkbphqv5py	65	12	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	65	13	platelet	platelet	NN
work_6edatbslnjhz3kb2pkbphqv5py	65	14	count	count	NN
work_6edatbslnjhz3kb2pkbphqv5py	65	15	was	be	VBD
work_6edatbslnjhz3kb2pkbphqv5py	65	16	obtained	obtain	VBN
work_6edatbslnjhz3kb2pkbphqv5py	65	17	every	every	DT
work_6edatbslnjhz3kb2pkbphqv5py	65	18	week	week	NN
work_6edatbslnjhz3kb2pkbphqv5py	65	19	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	66	1	All	all	DT
work_6edatbslnjhz3kb2pkbphqv5py	66	2	patients	patient	NNS
work_6edatbslnjhz3kb2pkbphqv5py	66	3	provided	provide	VBD
work_6edatbslnjhz3kb2pkbphqv5py	66	4	written	write	VBN
work_6edatbslnjhz3kb2pkbphqv5py	66	5	informed	informed	JJ
work_6edatbslnjhz3kb2pkbphqv5py	66	6	consent	consent	NN
work_6edatbslnjhz3kb2pkbphqv5py	66	7	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	67	1	Eligible	eligible	JJ
work_6edatbslnjhz3kb2pkbphqv5py	67	2	patients	patient	NNS
work_6edatbslnjhz3kb2pkbphqv5py	67	3	were	be	VBD
work_6edatbslnjhz3kb2pkbphqv5py	67	4	stratified	stratify	VBN
work_6edatbslnjhz3kb2pkbphqv5py	67	5	by	by	IN
work_6edatbslnjhz3kb2pkbphqv5py	67	6	KPS	KPS	NNP
work_6edatbslnjhz3kb2pkbphqv5py	67	7	(	(	-LRB-
work_6edatbslnjhz3kb2pkbphqv5py	67	8	80	80	CD
work_6edatbslnjhz3kb2pkbphqv5py	67	9	-	-	SYM
work_6edatbslnjhz3kb2pkbphqv5py	67	10	100	100	CD
work_6edatbslnjhz3kb2pkbphqv5py	67	11	versus	versus	IN
work_6edatbslnjhz3kb2pkbphqv5py	67	12	50	50	CD
work_6edatbslnjhz3kb2pkbphqv5py	67	13	-	-	SYM
work_6edatbslnjhz3kb2pkbphqv5py	67	14	70	70	CD
work_6edatbslnjhz3kb2pkbphqv5py	67	15	)	)	-RRB-
work_6edatbslnjhz3kb2pkbphqv5py	67	16	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	67	17	presence	presence	NN
work_6edatbslnjhz3kb2pkbphqv5py	67	18	or	or	CC
work_6edatbslnjhz3kb2pkbphqv5py	67	19	absence	absence	NN
work_6edatbslnjhz3kb2pkbphqv5py	67	20	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	67	21	liver	liver	NN
work_6edatbslnjhz3kb2pkbphqv5py	67	22	metastases	metastasis	NNS
work_6edatbslnjhz3kb2pkbphqv5py	67	23	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	68	1	Patients	patient	NNS
work_6edatbslnjhz3kb2pkbphqv5py	68	2	were	be	VBD
work_6edatbslnjhz3kb2pkbphqv5py	68	3	then	then	RB
work_6edatbslnjhz3kb2pkbphqv5py	68	4	randomized	randomize	VBN
work_6edatbslnjhz3kb2pkbphqv5py	68	5	by	by	IN
work_6edatbslnjhz3kb2pkbphqv5py	68	6	telephone	telephone	NN
work_6edatbslnjhz3kb2pkbphqv5py	68	7	through	through	IN
work_6edatbslnjhz3kb2pkbphqv5py	68	8	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	68	9	Hoosier	Hoosier	NNP
work_6edatbslnjhz3kb2pkbphqv5py	68	10	Oncology	Oncology	NNP
work_6edatbslnjhz3kb2pkbphqv5py	68	11	Group	Group	NNP
work_6edatbslnjhz3kb2pkbphqv5py	68	12	office	office	NN
work_6edatbslnjhz3kb2pkbphqv5py	68	13	to	to	TO
work_6edatbslnjhz3kb2pkbphqv5py	68	14	receive	receive	VB
work_6edatbslnjhz3kb2pkbphqv5py	68	15	5-FU	5-fu	CD
work_6edatbslnjhz3kb2pkbphqv5py	68	16	alone	alone	JJ
work_6edatbslnjhz3kb2pkbphqv5py	68	17	or	or	CC
work_6edatbslnjhz3kb2pkbphqv5py	68	18	5-FU	5-fu	CD
work_6edatbslnjhz3kb2pkbphqv5py	68	19	plus	plus	JJ
work_6edatbslnjhz3kb2pkbphqv5py	68	20	levamisole	levamisole	NN
work_6edatbslnjhz3kb2pkbphqv5py	68	21	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	69	1	5-FU	5-fu	CD
work_6edatbslnjhz3kb2pkbphqv5py	69	2	was	be	VBD
work_6edatbslnjhz3kb2pkbphqv5py	69	3	administered	administer	VBN
work_6edatbslnjhz3kb2pkbphqv5py	69	4	at	at	IN
work_6edatbslnjhz3kb2pkbphqv5py	69	5	a	a	DT
work_6edatbslnjhz3kb2pkbphqv5py	69	6	dose	dose	NN
work_6edatbslnjhz3kb2pkbphqv5py	69	7	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	69	8	450	450	CD
work_6edatbslnjhz3kb2pkbphqv5py	69	9	mg	mg	NN
work_6edatbslnjhz3kb2pkbphqv5py	69	10	/	/	SYM
work_6edatbslnjhz3kb2pkbphqv5py	69	11	m2	m2	NNP
work_6edatbslnjhz3kb2pkbphqv5py	69	12	by	by	IN
work_6edatbslnjhz3kb2pkbphqv5py	69	13	iv	iv	NNP
work_6edatbslnjhz3kb2pkbphqv5py	69	14	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	70	1	push	push	VB
work_6edatbslnjhz3kb2pkbphqv5py	70	2	on	on	RP
work_6edatbslnjhz3kb2pkbphqv5py	70	3	days	day	NNS
work_6edatbslnjhz3kb2pkbphqv5py	70	4	1	1	CD
work_6edatbslnjhz3kb2pkbphqv5py	70	5	-	-	SYM
work_6edatbslnjhz3kb2pkbphqv5py	70	6	5	5	CD
work_6edatbslnjhz3kb2pkbphqv5py	70	7	;	;	:
work_6edatbslnjhz3kb2pkbphqv5py	70	8	thereafter	thereafter	RB
work_6edatbslnjhz3kb2pkbphqv5py	70	9	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	70	10	beginning	begin	VBG
work_6edatbslnjhz3kb2pkbphqv5py	70	11	on	on	IN
work_6edatbslnjhz3kb2pkbphqv5py	70	12	day	day	NN
work_6edatbslnjhz3kb2pkbphqv5py	70	13	29	29	CD
work_6edatbslnjhz3kb2pkbphqv5py	70	14	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	70	15	it	-PRON-	PRP
work_6edatbslnjhz3kb2pkbphqv5py	70	16	was	be	VBD
work_6edatbslnjhz3kb2pkbphqv5py	70	17	given	give	VBN
work_6edatbslnjhz3kb2pkbphqv5py	70	18	weekly	weekly	JJ
work_6edatbslnjhz3kb2pkbphqv5py	70	19	at	at	IN
work_6edatbslnjhz3kb2pkbphqv5py	70	20	15	15	CD
work_6edatbslnjhz3kb2pkbphqv5py	70	21	mg	mg	NNP
work_6edatbslnjhz3kb2pkbphqv5py	70	22	/	/	SYM
work_6edatbslnjhz3kb2pkbphqv5py	70	23	kg	kg	NNP
work_6edatbslnjhz3kb2pkbphqv5py	70	24	by	by	IN
work_6edatbslnjhz3kb2pkbphqv5py	70	25	iv	iv	PRP
work_6edatbslnjhz3kb2pkbphqv5py	70	26	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	71	1	push	push	NN
work_6edatbslnjhz3kb2pkbphqv5py	71	2	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	72	1	This	this	DT
work_6edatbslnjhz3kb2pkbphqv5py	72	2	was	be	VBD
work_6edatbslnjhz3kb2pkbphqv5py	72	3	identical	identical	JJ
work_6edatbslnjhz3kb2pkbphqv5py	72	4	for	for	IN
work_6edatbslnjhz3kb2pkbphqv5py	72	5	both	both	DT
work_6edatbslnjhz3kb2pkbphqv5py	72	6	arms	arm	NNS
work_6edatbslnjhz3kb2pkbphqv5py	72	7	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	73	1	Patients	patient	NNS
work_6edatbslnjhz3kb2pkbphqv5py	73	2	randomized	randomize	VBD
work_6edatbslnjhz3kb2pkbphqv5py	73	3	to	to	IN
work_6edatbslnjhz3kb2pkbphqv5py	73	4	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	73	5	combination	combination	NN
work_6edatbslnjhz3kb2pkbphqv5py	73	6	arm	arm	NN
work_6edatbslnjhz3kb2pkbphqv5py	73	7	received	receive	VBD
work_6edatbslnjhz3kb2pkbphqv5py	73	8	50	50	CD
work_6edatbslnjhz3kb2pkbphqv5py	73	9	mg	mg	NNP
work_6edatbslnjhz3kb2pkbphqv5py	73	10	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	73	11	levamisole	levamisole	NNP
work_6edatbslnjhz3kb2pkbphqv5py	73	12	p.o	p.o	NNP
work_6edatbslnjhz3kb2pkbphqv5py	73	13	.	.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	73	14	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	73	15	every	every	DT
work_6edatbslnjhz3kb2pkbphqv5py	73	16	8	8	CD
work_6edatbslnjhz3kb2pkbphqv5py	73	17	h	h	NN
work_6edatbslnjhz3kb2pkbphqv5py	73	18	for	for	IN
work_6edatbslnjhz3kb2pkbphqv5py	73	19	3	3	CD
work_6edatbslnjhz3kb2pkbphqv5py	73	20	days	day	NNS
work_6edatbslnjhz3kb2pkbphqv5py	73	21	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	73	22	every	every	DT
work_6edatbslnjhz3kb2pkbphqv5py	73	23	2	2	CD
work_6edatbslnjhz3kb2pkbphqv5py	73	24	weeks	week	NNS
work_6edatbslnjhz3kb2pkbphqv5py	73	25	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	74	1	The	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	74	2	total	total	JJ
work_6edatbslnjhz3kb2pkbphqv5py	74	3	duration	duration	NN
work_6edatbslnjhz3kb2pkbphqv5py	74	4	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	74	5	therapy	therapy	NN
work_6edatbslnjhz3kb2pkbphqv5py	74	6	was	be	VBD
work_6edatbslnjhz3kb2pkbphqv5py	74	7	26	26	CD
work_6edatbslnjhz3kb2pkbphqv5py	74	8	weeks	week	NNS
work_6edatbslnjhz3kb2pkbphqv5py	74	9	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	75	1	There	there	EX
work_6edatbslnjhz3kb2pkbphqv5py	75	2	was	be	VBD
work_6edatbslnjhz3kb2pkbphqv5py	75	3	no	no	DT
work_6edatbslnjhz3kb2pkbphqv5py	75	4	dose	dose	JJ
work_6edatbslnjhz3kb2pkbphqv5py	75	5	escalation	escalation	NN
work_6edatbslnjhz3kb2pkbphqv5py	75	6	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	75	7	5-FU	5-fu	CD
work_6edatbslnjhz3kb2pkbphqv5py	75	8	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	75	9	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	75	10	cross	cross	NN
work_6edatbslnjhz3kb2pkbphqv5py	75	11	-	-	HYPH
work_6edatbslnjhz3kb2pkbphqv5py	75	12	over	over	JJ
work_6edatbslnjhz3kb2pkbphqv5py	75	13	to	to	IN
work_6edatbslnjhz3kb2pkbphqv5py	75	14	5-FU	5-fu	CD
work_6edatbslnjhz3kb2pkbphqv5py	75	15	plus	plus	CC
work_6edatbslnjhz3kb2pkbphqv5py	75	16	levamisole	levamisole	NN
work_6edatbslnjhz3kb2pkbphqv5py	75	17	was	be	VBD
work_6edatbslnjhz3kb2pkbphqv5py	75	18	not	not	RB
work_6edatbslnjhz3kb2pkbphqv5py	75	19	allowed	allow	VBN
work_6edatbslnjhz3kb2pkbphqv5py	75	20	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	76	1	All	all	DT
work_6edatbslnjhz3kb2pkbphqv5py	76	2	patients	patient	NNS
work_6edatbslnjhz3kb2pkbphqv5py	76	3	with	with	IN
work_6edatbslnjhz3kb2pkbphqv5py	76	4	prior	prior	JJ
work_6edatbslnjhz3kb2pkbphqv5py	76	5	pelvic	pelvic	JJ
work_6edatbslnjhz3kb2pkbphqv5py	76	6	irradiation	irradiation	NN
work_6edatbslnjhz3kb2pkbphqv5py	76	7	received	receive	VBD
work_6edatbslnjhz3kb2pkbphqv5py	76	8	a	a	DT
work_6edatbslnjhz3kb2pkbphqv5py	76	9	25	25	CD
work_6edatbslnjhz3kb2pkbphqv5py	76	10	%	%	NN
work_6edatbslnjhz3kb2pkbphqv5py	76	11	reduction	reduction	NN
work_6edatbslnjhz3kb2pkbphqv5py	76	12	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	76	13	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	76	14	5-FU	5-fu	CD
work_6edatbslnjhz3kb2pkbphqv5py	76	15	dose	dose	VBP
work_6edatbslnjhz3kb2pkbphqv5py	76	16	initially	initially	RB
work_6edatbslnjhz3kb2pkbphqv5py	76	17	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	77	1	5-FU	5-fu	CD
work_6edatbslnjhz3kb2pkbphqv5py	77	2	was	be	VBD
work_6edatbslnjhz3kb2pkbphqv5py	77	3	given	give	VBN
work_6edatbslnjhz3kb2pkbphqv5py	77	4	as	as	IN
work_6edatbslnjhz3kb2pkbphqv5py	77	5	sched-	sched-	NN
work_6edatbslnjhz3kb2pkbphqv5py	77	6	uled	uled	JJ
work_6edatbslnjhz3kb2pkbphqv5py	77	7	if	if	IN
work_6edatbslnjhz3kb2pkbphqv5py	77	8	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	77	9	WBC	WBC	NNP
work_6edatbslnjhz3kb2pkbphqv5py	77	10	count	count	NN
work_6edatbslnjhz3kb2pkbphqv5py	77	11	was	be	VBD
work_6edatbslnjhz3kb2pkbphqv5py	77	12	greater	great	JJR
work_6edatbslnjhz3kb2pkbphqv5py	77	13	than	than	IN
work_6edatbslnjhz3kb2pkbphqv5py	77	14	3000	3000	CD
work_6edatbslnjhz3kb2pkbphqv5py	77	15	cells	cell	NNS
work_6edatbslnjhz3kb2pkbphqv5py	77	16	/	/	SYM
work_6edatbslnjhz3kb2pkbphqv5py	77	17	mm3	mm3	NNS
work_6edatbslnjhz3kb2pkbphqv5py	77	18	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	77	19	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	77	20	platelet	platelet	NN
work_6edatbslnjhz3kb2pkbphqv5py	77	21	count	count	NN
work_6edatbslnjhz3kb2pkbphqv5py	77	22	was	be	VBD
work_6edatbslnjhz3kb2pkbphqv5py	77	23	greater	great	JJR
work_6edatbslnjhz3kb2pkbphqv5py	77	24	than	than	IN
work_6edatbslnjhz3kb2pkbphqv5py	77	25	90,000	90,000	CD
work_6edatbslnjhz3kb2pkbphqv5py	77	26	/	/	SYM
work_6edatbslnjhz3kb2pkbphqv5py	77	27	gil	gil	NN
work_6edatbslnjhz3kb2pkbphqv5py	77	28	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	78	1	If	if	IN
work_6edatbslnjhz3kb2pkbphqv5py	78	2	counts	count	NNS
work_6edatbslnjhz3kb2pkbphqv5py	78	3	were	be	VBD
work_6edatbslnjhz3kb2pkbphqv5py	78	4	below	below	IN
work_6edatbslnjhz3kb2pkbphqv5py	78	5	these	these	DT
work_6edatbslnjhz3kb2pkbphqv5py	78	6	levels	level	NNS
work_6edatbslnjhz3kb2pkbphqv5py	78	7	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	78	8	treatment	treatment	NN
work_6edatbslnjhz3kb2pkbphqv5py	78	9	was	be	VBD
work_6edatbslnjhz3kb2pkbphqv5py	78	10	held	hold	VBN
work_6edatbslnjhz3kb2pkbphqv5py	78	11	until	until	IN
work_6edatbslnjhz3kb2pkbphqv5py	78	12	these	these	DT
work_6edatbslnjhz3kb2pkbphqv5py	78	13	levels	level	NNS
work_6edatbslnjhz3kb2pkbphqv5py	78	14	were	be	VBD
work_6edatbslnjhz3kb2pkbphqv5py	78	15	reached	reach	VBN
work_6edatbslnjhz3kb2pkbphqv5py	78	16	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	78	17	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	78	18	then	then	RB
work_6edatbslnjhz3kb2pkbphqv5py	78	19	it	-PRON-	PRP
work_6edatbslnjhz3kb2pkbphqv5py	78	20	was	be	VBD
work_6edatbslnjhz3kb2pkbphqv5py	78	21	initiated	initiate	VBN
work_6edatbslnjhz3kb2pkbphqv5py	78	22	with	with	IN
work_6edatbslnjhz3kb2pkbphqv5py	78	23	25	25	CD
work_6edatbslnjhz3kb2pkbphqv5py	78	24	%	%	NN
work_6edatbslnjhz3kb2pkbphqv5py	78	25	reduction	reduction	NN
work_6edatbslnjhz3kb2pkbphqv5py	78	26	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	78	27	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	78	28	5-FU	5-fu	CD
work_6edatbslnjhz3kb2pkbphqv5py	78	29	dose	dose	NN
work_6edatbslnjhz3kb2pkbphqv5py	78	30	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	79	1	If	if	IN
work_6edatbslnjhz3kb2pkbphqv5py	79	2	5-FU	5-fu	CD
work_6edatbslnjhz3kb2pkbphqv5py	79	3	was	be	VBD
work_6edatbslnjhz3kb2pkbphqv5py	79	4	delayed	delay	VBN
work_6edatbslnjhz3kb2pkbphqv5py	79	5	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	79	6	levamisole	levamisole	NNP
work_6edatbslnjhz3kb2pkbphqv5py	79	7	was	be	VBD
work_6edatbslnjhz3kb2pkbphqv5py	79	8	concomitantly	concomitantly	RB
work_6edatbslnjhz3kb2pkbphqv5py	79	9	delayed	delay	VBN
work_6edatbslnjhz3kb2pkbphqv5py	79	10	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	79	11	but	but	CC
work_6edatbslnjhz3kb2pkbphqv5py	79	12	its	-PRON-	PRP$
work_6edatbslnjhz3kb2pkbphqv5py	79	13	dose	dose	NN
work_6edatbslnjhz3kb2pkbphqv5py	79	14	was	be	VBD
work_6edatbslnjhz3kb2pkbphqv5py	79	15	not	not	RB
work_6edatbslnjhz3kb2pkbphqv5py	79	16	reduced	reduce	VBN
work_6edatbslnjhz3kb2pkbphqv5py	79	17	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	80	1	In	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	80	2	cases	case	NNS
work_6edatbslnjhz3kb2pkbphqv5py	80	3	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	80	4	severe	severe	JJ
work_6edatbslnjhz3kb2pkbphqv5py	80	5	diarrhea	diarrhea	NN
work_6edatbslnjhz3kb2pkbphqv5py	80	6	or	or	CC
work_6edatbslnjhz3kb2pkbphqv5py	80	7	stomatitis	stomatitis	RB
work_6edatbslnjhz3kb2pkbphqv5py	80	8	lasting	last	VBG
work_6edatbslnjhz3kb2pkbphqv5py	80	9	more	more	JJR
work_6edatbslnjhz3kb2pkbphqv5py	80	10	than	than	IN
work_6edatbslnjhz3kb2pkbphqv5py	80	11	3	3	CD
work_6edatbslnjhz3kb2pkbphqv5py	80	12	days	day	NNS
work_6edatbslnjhz3kb2pkbphqv5py	80	13	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	80	14	granubocytopenic	granubocytopenic	JJ
work_6edatbslnjhz3kb2pkbphqv5py	80	15	fever	fever	NN
work_6edatbslnjhz3kb2pkbphqv5py	80	16	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	80	17	or	or	CC
work_6edatbslnjhz3kb2pkbphqv5py	80	18	thrombocytopenia	thrombocytopenia	NN
work_6edatbslnjhz3kb2pkbphqv5py	80	19	requiring	require	VBG
work_6edatbslnjhz3kb2pkbphqv5py	80	20	platelet	platelet	NN
work_6edatbslnjhz3kb2pkbphqv5py	80	21	transfusion	transfusion	NN
work_6edatbslnjhz3kb2pkbphqv5py	80	22	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	80	23	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	80	24	dose	dose	NN
work_6edatbslnjhz3kb2pkbphqv5py	80	25	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	80	26	5-FU	5-fu	CD
work_6edatbslnjhz3kb2pkbphqv5py	80	27	was	be	VBD
work_6edatbslnjhz3kb2pkbphqv5py	80	28	reduced	reduce	VBN
work_6edatbslnjhz3kb2pkbphqv5py	80	29	by	by	IN
work_6edatbslnjhz3kb2pkbphqv5py	80	30	25	25	CD
work_6edatbslnjhz3kb2pkbphqv5py	80	31	%	%	NN
work_6edatbslnjhz3kb2pkbphqv5py	80	32	with	with	IN
work_6edatbslnjhz3kb2pkbphqv5py	80	33	no	no	DT
work_6edatbslnjhz3kb2pkbphqv5py	80	34	change	change	NN
work_6edatbslnjhz3kb2pkbphqv5py	80	35	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	80	36	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	80	37	bevamisole	bevamisole	NNP
work_6edatbslnjhz3kb2pkbphqv5py	80	38	dose	dose	NNP
work_6edatbslnjhz3kb2pkbphqv5py	80	39	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	81	1	A	a	DT
work_6edatbslnjhz3kb2pkbphqv5py	81	2	complete	complete	JJ
work_6edatbslnjhz3kb2pkbphqv5py	81	3	response	response	NN
work_6edatbslnjhz3kb2pkbphqv5py	81	4	was	be	VBD
work_6edatbslnjhz3kb2pkbphqv5py	81	5	defined	define	VBN
work_6edatbslnjhz3kb2pkbphqv5py	81	6	as	as	IN
work_6edatbslnjhz3kb2pkbphqv5py	81	7	complete	complete	JJ
work_6edatbslnjhz3kb2pkbphqv5py	81	8	disappear-	disappear-	FW
work_6edatbslnjhz3kb2pkbphqv5py	81	9	ance	ance	NN
work_6edatbslnjhz3kb2pkbphqv5py	81	10	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	81	11	all	all	DT
work_6edatbslnjhz3kb2pkbphqv5py	81	12	objective	objective	JJ
work_6edatbslnjhz3kb2pkbphqv5py	81	13	evidence	evidence	NN
work_6edatbslnjhz3kb2pkbphqv5py	81	14	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	81	15	disease	disease	NN
work_6edatbslnjhz3kb2pkbphqv5py	81	16	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	82	1	A	a	DT
work_6edatbslnjhz3kb2pkbphqv5py	82	2	partial	partial	JJ
work_6edatbslnjhz3kb2pkbphqv5py	82	3	response	response	NN
work_6edatbslnjhz3kb2pkbphqv5py	82	4	was	be	VBD
work_6edatbslnjhz3kb2pkbphqv5py	82	5	defined	define	VBN
work_6edatbslnjhz3kb2pkbphqv5py	82	6	as	as	IN
work_6edatbslnjhz3kb2pkbphqv5py	82	7	a	a	DT
work_6edatbslnjhz3kb2pkbphqv5py	82	8	decrease	decrease	NN
work_6edatbslnjhz3kb2pkbphqv5py	82	9	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	82	10	50	50	CD
work_6edatbslnjhz3kb2pkbphqv5py	82	11	%	%	NN
work_6edatbslnjhz3kb2pkbphqv5py	82	12	or	or	CC
work_6edatbslnjhz3kb2pkbphqv5py	82	13	more	more	JJR
work_6edatbslnjhz3kb2pkbphqv5py	82	14	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	82	15	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	82	16	sum	sum	NN
work_6edatbslnjhz3kb2pkbphqv5py	82	17	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	82	18	products	product	NNS
work_6edatbslnjhz3kb2pkbphqv5py	82	19	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	82	20	diameters	diameter	NNS
work_6edatbslnjhz3kb2pkbphqv5py	82	21	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	82	22	measurable	measurable	JJ
work_6edatbslnjhz3kb2pkbphqv5py	82	23	disease	disease	NN
work_6edatbslnjhz3kb2pkbphqv5py	82	24	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	83	1	When	when	WRB
work_6edatbslnjhz3kb2pkbphqv5py	83	2	malignant	malignant	JJ
work_6edatbslnjhz3kb2pkbphqv5py	83	3	hepatomeg-	hepatomeg-	NN
work_6edatbslnjhz3kb2pkbphqv5py	83	4	aly	aly	NNP
work_6edatbslnjhz3kb2pkbphqv5py	83	5	was	be	VBD
work_6edatbslnjhz3kb2pkbphqv5py	83	6	used	use	VBN
work_6edatbslnjhz3kb2pkbphqv5py	83	7	for	for	IN
work_6edatbslnjhz3kb2pkbphqv5py	83	8	tumor	tumor	NN
work_6edatbslnjhz3kb2pkbphqv5py	83	9	measurement	measurement	NN
work_6edatbslnjhz3kb2pkbphqv5py	83	10	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	83	11	at	at	IN
work_6edatbslnjhz3kb2pkbphqv5py	83	12	least	least	JJS
work_6edatbslnjhz3kb2pkbphqv5py	83	13	a	a	DT
work_6edatbslnjhz3kb2pkbphqv5py	83	14	30	30	CD
work_6edatbslnjhz3kb2pkbphqv5py	83	15	%	%	NN
work_6edatbslnjhz3kb2pkbphqv5py	83	16	decrease	decrease	NN
work_6edatbslnjhz3kb2pkbphqv5py	83	17	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	83	18	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	83	19	sum	sum	NN
work_6edatbslnjhz3kb2pkbphqv5py	83	20	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	83	21	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	83	22	measurements	measurement	NNS
work_6edatbslnjhz3kb2pkbphqv5py	83	23	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	83	24	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	83	25	liver	liver	NN
work_6edatbslnjhz3kb2pkbphqv5py	83	26	edge	edge	NN
work_6edatbslnjhz3kb2pkbphqv5py	83	27	below	below	IN
work_6edatbslnjhz3kb2pkbphqv5py	83	28	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	83	29	costal	costal	JJ
work_6edatbslnjhz3kb2pkbphqv5py	83	30	margin	margin	NN
work_6edatbslnjhz3kb2pkbphqv5py	83	31	at	at	IN
work_6edatbslnjhz3kb2pkbphqv5py	83	32	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	83	33	right	right	JJ
work_6edatbslnjhz3kb2pkbphqv5py	83	34	midclavicular	midclavicular	JJ
work_6edatbslnjhz3kb2pkbphqv5py	83	35	line	line	NN
work_6edatbslnjhz3kb2pkbphqv5py	83	36	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	83	37	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	83	38	xiphoid	xiphoid	NN
work_6edatbslnjhz3kb2pkbphqv5py	83	39	process	process	NN
work_6edatbslnjhz3kb2pkbphqv5py	83	40	was	be	VBD
work_6edatbslnjhz3kb2pkbphqv5py	83	41	required	require	VBN
work_6edatbslnjhz3kb2pkbphqv5py	83	42	for	for	IN
work_6edatbslnjhz3kb2pkbphqv5py	83	43	a	a	DT
work_6edatbslnjhz3kb2pkbphqv5py	83	44	PR	pr	NN
work_6edatbslnjhz3kb2pkbphqv5py	83	45	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	84	1	A	a	DT
work_6edatbslnjhz3kb2pkbphqv5py	84	2	decrease	decrease	NN
work_6edatbslnjhz3kb2pkbphqv5py	84	3	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	84	4	less	less	JJR
work_6edatbslnjhz3kb2pkbphqv5py	84	5	than	than	IN
work_6edatbslnjhz3kb2pkbphqv5py	84	6	50	50	CD
work_6edatbslnjhz3kb2pkbphqv5py	84	7	%	%	NN
work_6edatbslnjhz3kb2pkbphqv5py	84	8	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	84	9	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	84	10	sum	sum	NN
work_6edatbslnjhz3kb2pkbphqv5py	84	11	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	84	12	product	product	NN
work_6edatbslnjhz3kb2pkbphqv5py	84	13	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	84	14	diameters	diameter	NNS
work_6edatbslnjhz3kb2pkbphqv5py	84	15	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	84	16	measurable	measurable	JJ
work_6edatbslnjhz3kb2pkbphqv5py	84	17	disease	disease	NN
work_6edatbslnjhz3kb2pkbphqv5py	84	18	was	be	VBD
work_6edatbslnjhz3kb2pkbphqv5py	84	19	considered	consider	VBN
work_6edatbslnjhz3kb2pkbphqv5py	84	20	stable	stable	JJ
work_6edatbslnjhz3kb2pkbphqv5py	84	21	disease	disease	NN
work_6edatbslnjhz3kb2pkbphqv5py	84	22	provided	provide	VBD
work_6edatbslnjhz3kb2pkbphqv5py	84	23	no	no	DT
work_6edatbslnjhz3kb2pkbphqv5py	84	24	new	new	JJ
work_6edatbslnjhz3kb2pkbphqv5py	84	25	lesions	lesion	NNS
work_6edatbslnjhz3kb2pkbphqv5py	84	26	had	have	VBD
work_6edatbslnjhz3kb2pkbphqv5py	84	27	appeared	appear	VBN
work_6edatbslnjhz3kb2pkbphqv5py	84	28	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	84	29	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	84	30	an	an	DT
work_6edatbslnjhz3kb2pkbphqv5py	84	31	increase	increase	NN
work_6edatbslnjhz3kb2pkbphqv5py	84	32	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	84	33	25	25	CD
work_6edatbslnjhz3kb2pkbphqv5py	84	34	%	%	NN
work_6edatbslnjhz3kb2pkbphqv5py	84	35	or	or	CC
work_6edatbslnjhz3kb2pkbphqv5py	84	36	more	more	JJR
work_6edatbslnjhz3kb2pkbphqv5py	84	37	or	or	CC
work_6edatbslnjhz3kb2pkbphqv5py	84	38	appearance	appearance	NN
work_6edatbslnjhz3kb2pkbphqv5py	84	39	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	84	40	new	new	JJ
work_6edatbslnjhz3kb2pkbphqv5py	84	41	lesions	lesion	NNS
work_6edatbslnjhz3kb2pkbphqv5py	84	42	defined	define	VBN
work_6edatbslnjhz3kb2pkbphqv5py	84	43	progression	progression	NN
work_6edatbslnjhz3kb2pkbphqv5py	84	44	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	85	1	Survival	survival	NN
work_6edatbslnjhz3kb2pkbphqv5py	85	2	was	be	VBD
work_6edatbslnjhz3kb2pkbphqv5py	85	3	measured	measure	VBN
work_6edatbslnjhz3kb2pkbphqv5py	85	4	from	from	IN
work_6edatbslnjhz3kb2pkbphqv5py	85	5	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	85	6	date	date	NN
work_6edatbslnjhz3kb2pkbphqv5py	85	7	entered	enter	VBN
work_6edatbslnjhz3kb2pkbphqv5py	85	8	on	on	IN
work_6edatbslnjhz3kb2pkbphqv5py	85	9	study	study	NN
work_6edatbslnjhz3kb2pkbphqv5py	85	10	until	until	IN
work_6edatbslnjhz3kb2pkbphqv5py	85	11	death	death	NN
work_6edatbslnjhz3kb2pkbphqv5py	85	12	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	86	1	Remission	remission	NN
work_6edatbslnjhz3kb2pkbphqv5py	86	2	duration	duration	NN
work_6edatbslnjhz3kb2pkbphqv5py	86	3	was	be	VBD
work_6edatbslnjhz3kb2pkbphqv5py	86	4	measured	measure	VBN
work_6edatbslnjhz3kb2pkbphqv5py	86	5	from	from	IN
work_6edatbslnjhz3kb2pkbphqv5py	86	6	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	86	7	date	date	NN
work_6edatbslnjhz3kb2pkbphqv5py	86	8	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	86	9	doe-	doe-	JJ
work_6edatbslnjhz3kb2pkbphqv5py	86	10	umented	umented	JJ
work_6edatbslnjhz3kb2pkbphqv5py	86	11	response	response	NN
work_6edatbslnjhz3kb2pkbphqv5py	86	12	until	until	IN
work_6edatbslnjhz3kb2pkbphqv5py	86	13	relapse	relapse	NN
work_6edatbslnjhz3kb2pkbphqv5py	86	14	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	87	1	Patients	patient	NNS
work_6edatbslnjhz3kb2pkbphqv5py	87	2	who	who	WP
work_6edatbslnjhz3kb2pkbphqv5py	87	3	relapsed	relapse	VBD
work_6edatbslnjhz3kb2pkbphqv5py	87	4	were	be	VBD
work_6edatbslnjhz3kb2pkbphqv5py	87	5	treated	treat	VBN
work_6edatbslnjhz3kb2pkbphqv5py	87	6	at	at	IN
work_6edatbslnjhz3kb2pkbphqv5py	87	7	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	87	8	investigator	investigator	NN
work_6edatbslnjhz3kb2pkbphqv5py	87	9	’s	’s	POS
work_6edatbslnjhz3kb2pkbphqv5py	87	10	discretion	discretion	NN
work_6edatbslnjhz3kb2pkbphqv5py	87	11	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	88	1	Statistical	Statistical	NNP
work_6edatbslnjhz3kb2pkbphqv5py	88	2	Considerations	Considerations	NNPS
work_6edatbslnjhz3kb2pkbphqv5py	88	3	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	89	1	Descriptive	descriptive	JJ
work_6edatbslnjhz3kb2pkbphqv5py	89	2	statistics	statistic	NNS
work_6edatbslnjhz3kb2pkbphqv5py	89	3	are	be	VBP
work_6edatbslnjhz3kb2pkbphqv5py	89	4	re-	re-	RB
work_6edatbslnjhz3kb2pkbphqv5py	89	5	ported	port	VBN
work_6edatbslnjhz3kb2pkbphqv5py	89	6	as	as	IN
work_6edatbslnjhz3kb2pkbphqv5py	89	7	frequencies	frequency	NNS
work_6edatbslnjhz3kb2pkbphqv5py	89	8	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	89	9	medians	median	NNS
work_6edatbslnjhz3kb2pkbphqv5py	89	10	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	89	11	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	89	12	ranges	range	NNS
work_6edatbslnjhz3kb2pkbphqv5py	89	13	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	90	1	Grade	Grade	NNP
work_6edatbslnjhz3kb2pkbphqv5py	90	2	3/4	3/4	CD
work_6edatbslnjhz3kb2pkbphqv5py	90	3	toxicities	toxicity	NNS
work_6edatbslnjhz3kb2pkbphqv5py	90	4	were	be	VBD
work_6edatbslnjhz3kb2pkbphqv5py	90	5	compared	compare	VBN
work_6edatbslnjhz3kb2pkbphqv5py	90	6	between	between	IN
work_6edatbslnjhz3kb2pkbphqv5py	90	7	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	90	8	two	two	CD
work_6edatbslnjhz3kb2pkbphqv5py	90	9	arms	arm	NNS
work_6edatbslnjhz3kb2pkbphqv5py	90	10	(	(	-LRB-
work_6edatbslnjhz3kb2pkbphqv5py	90	11	5-Hi	5-hi	CD
work_6edatbslnjhz3kb2pkbphqv5py	90	12	versus	versus	IN
work_6edatbslnjhz3kb2pkbphqv5py	90	13	5-FU	5-fu	CD
work_6edatbslnjhz3kb2pkbphqv5py	90	14	+	+	SYM
work_6edatbslnjhz3kb2pkbphqv5py	90	15	levamisole	levamisole	NN
work_6edatbslnjhz3kb2pkbphqv5py	90	16	)	)	-RRB-
work_6edatbslnjhz3kb2pkbphqv5py	90	17	using	use	VBG
work_6edatbslnjhz3kb2pkbphqv5py	90	18	Fisher	Fisher	NNP
work_6edatbslnjhz3kb2pkbphqv5py	90	19	’s	’s	POS
work_6edatbslnjhz3kb2pkbphqv5py	90	20	exact	exact	JJ
work_6edatbslnjhz3kb2pkbphqv5py	90	21	test	test	NN
work_6edatbslnjhz3kb2pkbphqv5py	90	22	(	(	-LRB-
work_6edatbslnjhz3kb2pkbphqv5py	90	23	28	28	CD
work_6edatbslnjhz3kb2pkbphqv5py	90	24	)	)	-RRB-
work_6edatbslnjhz3kb2pkbphqv5py	90	25	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	91	1	Survival	survival	NN
work_6edatbslnjhz3kb2pkbphqv5py	91	2	was	be	VBD
work_6edatbslnjhz3kb2pkbphqv5py	91	3	defined	define	VBN
work_6edatbslnjhz3kb2pkbphqv5py	91	4	from	from	IN
work_6edatbslnjhz3kb2pkbphqv5py	91	5	date	date	NN
work_6edatbslnjhz3kb2pkbphqv5py	91	6	on	on	IN
work_6edatbslnjhz3kb2pkbphqv5py	91	7	study	study	NN
work_6edatbslnjhz3kb2pkbphqv5py	91	8	until	until	IN
work_6edatbslnjhz3kb2pkbphqv5py	91	9	date	date	NN
work_6edatbslnjhz3kb2pkbphqv5py	91	10	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	91	11	death	death	NN
work_6edatbslnjhz3kb2pkbphqv5py	91	12	or	or	CC
work_6edatbslnjhz3kb2pkbphqv5py	91	13	date	date	NN
work_6edatbslnjhz3kb2pkbphqv5py	91	14	last	last	JJ
work_6edatbslnjhz3kb2pkbphqv5py	91	15	known	know	VBN
work_6edatbslnjhz3kb2pkbphqv5py	91	16	alive	alive	JJ
work_6edatbslnjhz3kb2pkbphqv5py	91	17	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	92	1	Follow	follow	VB
work_6edatbslnjhz3kb2pkbphqv5py	92	2	-	-	HYPH
work_6edatbslnjhz3kb2pkbphqv5py	92	3	up	up	NNP
work_6edatbslnjhz3kb2pkbphqv5py	92	4	was	be	VBD
work_6edatbslnjhz3kb2pkbphqv5py	92	5	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	92	6	survival	survival	NN
work_6edatbslnjhz3kb2pkbphqv5py	92	7	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	92	8	all	all	DT
work_6edatbslnjhz3kb2pkbphqv5py	92	9	patients	patient	NNS
work_6edatbslnjhz3kb2pkbphqv5py	92	10	alive	alive	JJ
work_6edatbslnjhz3kb2pkbphqv5py	92	11	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	93	1	The	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	93	2	survival	survival	NN
work_6edatbslnjhz3kb2pkbphqv5py	93	3	curve	curve	NN
work_6edatbslnjhz3kb2pkbphqv5py	93	4	for	for	IN
work_6edatbslnjhz3kb2pkbphqv5py	93	5	each	each	DT
work_6edatbslnjhz3kb2pkbphqv5py	93	6	treatment	treatment	NN
work_6edatbslnjhz3kb2pkbphqv5py	93	7	arm	arm	NN
work_6edatbslnjhz3kb2pkbphqv5py	93	8	was	be	VBD
work_6edatbslnjhz3kb2pkbphqv5py	93	9	constructed	construct	VBN
work_6edatbslnjhz3kb2pkbphqv5py	93	10	using	use	VBG
work_6edatbslnjhz3kb2pkbphqv5py	93	11	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	93	12	Kaplan-	Kaplan-	NNP
work_6edatbslnjhz3kb2pkbphqv5py	93	13	Meier	Meier	NNP
work_6edatbslnjhz3kb2pkbphqv5py	93	14	product	product	NN
work_6edatbslnjhz3kb2pkbphqv5py	93	15	limit	limit	NN
work_6edatbslnjhz3kb2pkbphqv5py	93	16	method	method	NN
work_6edatbslnjhz3kb2pkbphqv5py	93	17	(	(	-LRB-
work_6edatbslnjhz3kb2pkbphqv5py	93	18	29	29	CD
work_6edatbslnjhz3kb2pkbphqv5py	93	19	)	)	-RRB-
work_6edatbslnjhz3kb2pkbphqv5py	93	20	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	94	1	Survival	survival	NN
work_6edatbslnjhz3kb2pkbphqv5py	94	2	curves	curve	NNS
work_6edatbslnjhz3kb2pkbphqv5py	94	3	between	between	IN
work_6edatbslnjhz3kb2pkbphqv5py	94	4	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	94	5	two	two	CD
work_6edatbslnjhz3kb2pkbphqv5py	94	6	treatment	treatment	NN
work_6edatbslnjhz3kb2pkbphqv5py	94	7	arms	arm	NNS
work_6edatbslnjhz3kb2pkbphqv5py	94	8	were	be	VBD
work_6edatbslnjhz3kb2pkbphqv5py	94	9	compared	compare	VBN
work_6edatbslnjhz3kb2pkbphqv5py	94	10	with	with	IN
work_6edatbslnjhz3kb2pkbphqv5py	94	11	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	94	12	log	log	NN
work_6edatbslnjhz3kb2pkbphqv5py	94	13	-	-	HYPH
work_6edatbslnjhz3kb2pkbphqv5py	94	14	rank	rank	NN
work_6edatbslnjhz3kb2pkbphqv5py	94	15	test	test	NN
work_6edatbslnjhz3kb2pkbphqv5py	94	16	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	94	17	survival	survival	NN
work_6edatbslnjhz3kb2pkbphqv5py	94	18	(	(	-LRB-
work_6edatbslnjhz3kb2pkbphqv5py	94	19	30	30	CD
work_6edatbslnjhz3kb2pkbphqv5py	94	20	)	)	-RRB-
work_6edatbslnjhz3kb2pkbphqv5py	94	21	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	95	1	The	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	95	2	association	association	NN
work_6edatbslnjhz3kb2pkbphqv5py	95	3	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	95	4	treatment	treatment	NN
work_6edatbslnjhz3kb2pkbphqv5py	95	5	arm	arm	NN
work_6edatbslnjhz3kb2pkbphqv5py	95	6	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	95	7	survival	survival	NN
work_6edatbslnjhz3kb2pkbphqv5py	95	8	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	95	9	adjusting	adjust	VBG
work_6edatbslnjhz3kb2pkbphqv5py	95	10	for	for	IN
work_6edatbslnjhz3kb2pkbphqv5py	95	11	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	95	12	stratification	stratification	NN
work_6edatbslnjhz3kb2pkbphqv5py	95	13	factors	factor	NNS
work_6edatbslnjhz3kb2pkbphqv5py	95	14	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	95	15	liver	liver	NN
work_6edatbslnjhz3kb2pkbphqv5py	95	16	metastases	metastasis	NNS
work_6edatbslnjhz3kb2pkbphqv5py	95	17	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	95	18	KPS	KPS	NNP
work_6edatbslnjhz3kb2pkbphqv5py	95	19	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	95	20	was	be	VBD
work_6edatbslnjhz3kb2pkbphqv5py	95	21	assessed	assess	VBN
work_6edatbslnjhz3kb2pkbphqv5py	95	22	by	by	IN
work_6edatbslnjhz3kb2pkbphqv5py	95	23	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	95	24	Wald	Wald	NNP
work_6edatbslnjhz3kb2pkbphqv5py	95	25	x2	x2	NN
work_6edatbslnjhz3kb2pkbphqv5py	95	26	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	95	27	Cox	Cox	NNP
work_6edatbslnjhz3kb2pkbphqv5py	95	28	’s	’s	POS
work_6edatbslnjhz3kb2pkbphqv5py	95	29	proportional	proportional	JJ
work_6edatbslnjhz3kb2pkbphqv5py	95	30	hazards	hazard	NNS
work_6edatbslnjhz3kb2pkbphqv5py	95	31	regression	regression	NN
work_6edatbslnjhz3kb2pkbphqv5py	95	32	(	(	-LRB-
work_6edatbslnjhz3kb2pkbphqv5py	95	33	31	31	CD
work_6edatbslnjhz3kb2pkbphqv5py	95	34	)	)	-RRB-
work_6edatbslnjhz3kb2pkbphqv5py	95	35	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	96	1	All	all	DT
work_6edatbslnjhz3kb2pkbphqv5py	96	2	tests	test	NNS
work_6edatbslnjhz3kb2pkbphqv5py	96	3	were	be	VBD
work_6edatbslnjhz3kb2pkbphqv5py	96	4	two	two	CD
work_6edatbslnjhz3kb2pkbphqv5py	96	5	-	-	HYPH
work_6edatbslnjhz3kb2pkbphqv5py	96	6	sided	sided	JJ
work_6edatbslnjhz3kb2pkbphqv5py	96	7	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	97	1	The	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	97	2	intention	intention	NN
work_6edatbslnjhz3kb2pkbphqv5py	97	3	-	-	HYPH
work_6edatbslnjhz3kb2pkbphqv5py	97	4	to	to	IN
work_6edatbslnjhz3kb2pkbphqv5py	97	5	-	-	HYPH
work_6edatbslnjhz3kb2pkbphqv5py	97	6	treat	treat	NN
work_6edatbslnjhz3kb2pkbphqv5py	97	7	principle	principle	NN
work_6edatbslnjhz3kb2pkbphqv5py	97	8	was	be	VBD
work_6edatbslnjhz3kb2pkbphqv5py	97	9	used	use	VBN
work_6edatbslnjhz3kb2pkbphqv5py	97	10	throughout	throughout	IN
work_6edatbslnjhz3kb2pkbphqv5py	97	11	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	98	1	RESULTS	RESULTS	NNP
work_6edatbslnjhz3kb2pkbphqv5py	98	2	From	from	IN
work_6edatbslnjhz3kb2pkbphqv5py	98	3	April	April	NNP
work_6edatbslnjhz3kb2pkbphqv5py	98	4	1990	1990	CD
work_6edatbslnjhz3kb2pkbphqv5py	98	5	through	through	IN
work_6edatbslnjhz3kb2pkbphqv5py	98	6	March	March	NNP
work_6edatbslnjhz3kb2pkbphqv5py	98	7	1995	1995	CD
work_6edatbslnjhz3kb2pkbphqv5py	98	8	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	98	9	199	199	CD
work_6edatbslnjhz3kb2pkbphqv5py	98	10	patients	patient	NNS
work_6edatbslnjhz3kb2pkbphqv5py	98	11	with	with	IN
work_6edatbslnjhz3kb2pkbphqv5py	98	12	metastatic	metastatic	JJ
work_6edatbslnjhz3kb2pkbphqv5py	98	13	adenocarcinoma	adenocarcinoma	NN
work_6edatbslnjhz3kb2pkbphqv5py	98	14	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	98	15	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	98	16	colon	colon	NN
work_6edatbslnjhz3kb2pkbphqv5py	98	17	or	or	CC
work_6edatbslnjhz3kb2pkbphqv5py	98	18	rectum	rectum	NN
work_6edatbslnjhz3kb2pkbphqv5py	98	19	were	be	VBD
work_6edatbslnjhz3kb2pkbphqv5py	98	20	entered	enter	VBN
work_6edatbslnjhz3kb2pkbphqv5py	98	21	on	on	IN
work_6edatbslnjhz3kb2pkbphqv5py	98	22	this	this	DT
work_6edatbslnjhz3kb2pkbphqv5py	98	23	trial	trial	NN
work_6edatbslnjhz3kb2pkbphqv5py	98	24	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	99	1	Of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	99	2	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	99	3	99	99	CD
work_6edatbslnjhz3kb2pkbphqv5py	99	4	patients	patient	NNS
work_6edatbslnjhz3kb2pkbphqv5py	99	5	randomized	randomize	VBN
work_6edatbslnjhz3kb2pkbphqv5py	99	6	to	to	IN
work_6edatbslnjhz3kb2pkbphqv5py	99	7	5-FU	5-fu	CD
work_6edatbslnjhz3kb2pkbphqv5py	99	8	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	99	9	4	4	CD
work_6edatbslnjhz3kb2pkbphqv5py	99	10	patients	patient	NNS
work_6edatbslnjhz3kb2pkbphqv5py	99	11	never	never	RB
work_6edatbslnjhz3kb2pkbphqv5py	99	12	received	receive	VBD
work_6edatbslnjhz3kb2pkbphqv5py	99	13	treatment	treatment	NN
work_6edatbslnjhz3kb2pkbphqv5py	99	14	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	99	15	1	1	CD
work_6edatbslnjhz3kb2pkbphqv5py	99	16	was	be	VBD
work_6edatbslnjhz3kb2pkbphqv5py	99	17	lost	lose	VBN
work_6edatbslnjhz3kb2pkbphqv5py	99	18	to	to	TO
work_6edatbslnjhz3kb2pkbphqv5py	99	19	follow	follow	VB
work_6edatbslnjhz3kb2pkbphqv5py	99	20	-	-	HYPH
work_6edatbslnjhz3kb2pkbphqv5py	99	21	up	up	NN
work_6edatbslnjhz3kb2pkbphqv5py	99	22	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	99	23	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	99	24	3	3	CD
work_6edatbslnjhz3kb2pkbphqv5py	99	25	had	have	VBD
work_6edatbslnjhz3kb2pkbphqv5py	99	26	on	on	IN
work_6edatbslnjhz3kb2pkbphqv5py	99	27	April	April	NNP
work_6edatbslnjhz3kb2pkbphqv5py	99	28	5	5	CD
work_6edatbslnjhz3kb2pkbphqv5py	99	29	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	99	30	2021	2021	CD
work_6edatbslnjhz3kb2pkbphqv5py	99	31	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	100	1	©	©	NNP
work_6edatbslnjhz3kb2pkbphqv5py	100	2	1998	1998	CD
work_6edatbslnjhz3kb2pkbphqv5py	100	3	American	American	NNP
work_6edatbslnjhz3kb2pkbphqv5py	100	4	Association	Association	NNP
work_6edatbslnjhz3kb2pkbphqv5py	100	5	for	for	IN
work_6edatbslnjhz3kb2pkbphqv5py	100	6	Cancer	Cancer	NNP
work_6edatbslnjhz3kb2pkbphqv5py	100	7	Research.clincancerres.aacrjournals.org	research.clincancerres.aacrjournals.org	NN
work_6edatbslnjhz3kb2pkbphqv5py	100	8	Downloaded	download	VBN
work_6edatbslnjhz3kb2pkbphqv5py	100	9	from	from	IN
work_6edatbslnjhz3kb2pkbphqv5py	100	10	http://clincancerres.aacrjournals.org/	http://clincancerres.aacrjournals.org/	NN
work_6edatbslnjhz3kb2pkbphqv5py	100	11	Table	table	NN
work_6edatbslnjhz3kb2pkbphqv5py	100	12	1	1	CD
work_6edatbslnjhz3kb2pkbphqv5py	100	13	Patient	patient	JJ
work_6edatbslnjhz3kb2pkbphqv5py	100	14	characteristics	characteristic	NNS
work_6edatbslnjhz3kb2pkbphqv5py	100	15	ap	ap	NNP
work_6edatbslnjhz3kb2pkbphqv5py	100	16	0.067	0.067	CD
work_6edatbslnjhz3kb2pkbphqv5py	100	17	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	100	18	bp	bp	NNP
work_6edatbslnjhz3kb2pkbphqv5py	100	19	0.0146	0.0146	CD
work_6edatbslnjhz3kb2pkbphqv5py	100	20	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	101	1	C	C	NNP
work_6edatbslnjhz3kb2pkbphqv5py	101	2	p	p	NN
work_6edatbslnjhz3kb2pkbphqv5py	101	3	treatment	treatment	NN
work_6edatbslnjhz3kb2pkbphqv5py	101	4	-	-	HYPH
work_6edatbslnjhz3kb2pkbphqv5py	101	5	related	relate	VBN
work_6edatbslnjhz3kb2pkbphqv5py	101	6	only	only	RB
work_6edatbslnjhz3kb2pkbphqv5py	101	7	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	102	1	a	a	DT
work_6edatbslnjhz3kb2pkbphqv5py	102	2	PD	PD	NNP
work_6edatbslnjhz3kb2pkbphqv5py	102	3	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	102	4	progressive	progressive	JJ
work_6edatbslnjhz3kb2pkbphqv5py	102	5	disease	disease	NN
work_6edatbslnjhz3kb2pkbphqv5py	102	6	;	;	:
work_6edatbslnjhz3kb2pkbphqv5py	102	7	PSR	PSR	NNP
work_6edatbslnjhz3kb2pkbphqv5py	102	8	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	102	9	poor	poor	JJ
work_6edatbslnjhz3kb2pkbphqv5py	102	10	subjective	subjective	JJ
work_6edatbslnjhz3kb2pkbphqv5py	102	11	response	response	NN
work_6edatbslnjhz3kb2pkbphqv5py	102	12	(	(	-LRB-
work_6edatbslnjhz3kb2pkbphqv5py	102	13	�	�	NNP
work_6edatbslnjhz3kb2pkbphqv5py	102	14	20	20	CD
work_6edatbslnjhz3kb2pkbphqv5py	102	15	%	%	NN
work_6edatbslnjhz3kb2pkbphqv5py	102	16	fall	fall	NN
work_6edatbslnjhz3kb2pkbphqv5py	102	17	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	102	18	KPS	KPS	NNP
work_6edatbslnjhz3kb2pkbphqv5py	102	19	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	102	20	10	10	CD
work_6edatbslnjhz3kb2pkbphqv5py	102	21	%	%	NN
work_6edatbslnjhz3kb2pkbphqv5py	102	22	weight	weight	NN
work_6edatbslnjhz3kb2pkbphqv5py	102	23	loss	loss	NN
work_6edatbslnjhz3kb2pkbphqv5py	102	24	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	102	25	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	102	26	increased	increase	VBN
work_6edatbslnjhz3kb2pkbphqv5py	102	27	pain	pain	NN
work_6edatbslnjhz3kb2pkbphqv5py	102	28	without	without	IN
work_6edatbslnjhz3kb2pkbphqv5py	102	29	radiographic	radiographic	JJ
work_6edatbslnjhz3kb2pkbphqv5py	102	30	documentation	documentation	NN
work_6edatbslnjhz3kb2pkbphqv5py	102	31	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	102	32	progression	progression	NN
work_6edatbslnjhz3kb2pkbphqv5py	102	33	)	)	-RRB-
work_6edatbslnjhz3kb2pkbphqv5py	102	34	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	103	1	b	b	LS
work_6edatbslnjhz3kb2pkbphqv5py	103	2	Not	not	RB
work_6edatbslnjhz3kb2pkbphqv5py	103	3	rebated	rebate	VBN
work_6edatbslnjhz3kb2pkbphqv5py	103	4	to	to	IN
work_6edatbslnjhz3kb2pkbphqv5py	103	5	disease	disease	NN
work_6edatbslnjhz3kb2pkbphqv5py	103	6	or	or	CC
work_6edatbslnjhz3kb2pkbphqv5py	103	7	therapy	therapy	NN
work_6edatbslnjhz3kb2pkbphqv5py	103	8	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	104	1	Clinical	Clinical	NNP
work_6edatbslnjhz3kb2pkbphqv5py	104	2	Cancer	Cancer	NNP
work_6edatbslnjhz3kb2pkbphqv5py	104	3	Research	Research	NNP
work_6edatbslnjhz3kb2pkbphqv5py	104	4	937	937	CD
work_6edatbslnjhz3kb2pkbphqv5py	104	5	5-Hi	5-hi	CD
work_6edatbslnjhz3kb2pkbphqv5py	104	6	5-Hi	5-hi	CD
work_6edatbslnjhz3kb2pkbphqv5py	104	7	+	+	SYM
work_6edatbslnjhz3kb2pkbphqv5py	104	8	levamisole	levamisole	NN
work_6edatbslnjhz3kb2pkbphqv5py	104	9	No	no	NN
work_6edatbslnjhz3kb2pkbphqv5py	104	10	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	105	1	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	105	2	patients	patient	NNS
work_6edatbslnjhz3kb2pkbphqv5py	105	3	registered	register	VBD
work_6edatbslnjhz3kb2pkbphqv5py	105	4	99	99	CD
work_6edatbslnjhz3kb2pkbphqv5py	105	5	100	100	CD
work_6edatbslnjhz3kb2pkbphqv5py	105	6	Sex	sex	NN
work_6edatbslnjhz3kb2pkbphqv5py	105	7	(	(	-LRB-
work_6edatbslnjhz3kb2pkbphqv5py	105	8	male	male	NN
work_6edatbslnjhz3kb2pkbphqv5py	105	9	/	/	SYM
work_6edatbslnjhz3kb2pkbphqv5py	105	10	female	female	JJ
work_6edatbslnjhz3kb2pkbphqv5py	105	11	)	)	-RRB-
work_6edatbslnjhz3kb2pkbphqv5py	105	12	62/37	62/37	CD
work_6edatbslnjhz3kb2pkbphqv5py	105	13	53/47	53/47	CD
work_6edatbslnjhz3kb2pkbphqv5py	105	14	Median	median	JJ
work_6edatbslnjhz3kb2pkbphqv5py	105	15	age	age	NN
work_6edatbslnjhz3kb2pkbphqv5py	105	16	(	(	-LRB-
work_6edatbslnjhz3kb2pkbphqv5py	105	17	yr	yr	NN
work_6edatbslnjhz3kb2pkbphqv5py	105	18	)	)	-RRB-
work_6edatbslnjhz3kb2pkbphqv5py	105	19	66	66	CD
work_6edatbslnjhz3kb2pkbphqv5py	105	20	65	65	CD
work_6edatbslnjhz3kb2pkbphqv5py	105	21	Range	Range	NNP
work_6edatbslnjhz3kb2pkbphqv5py	105	22	(	(	-LRB-
work_6edatbslnjhz3kb2pkbphqv5py	105	23	yr	yr	NN
work_6edatbslnjhz3kb2pkbphqv5py	105	24	)	)	-RRB-
work_6edatbslnjhz3kb2pkbphqv5py	105	25	20	20	CD
work_6edatbslnjhz3kb2pkbphqv5py	105	26	-	-	SYM
work_6edatbslnjhz3kb2pkbphqv5py	105	27	86	86	CD
work_6edatbslnjhz3kb2pkbphqv5py	105	28	27	27	CD
work_6edatbslnjhz3kb2pkbphqv5py	105	29	-	-	SYM
work_6edatbslnjhz3kb2pkbphqv5py	105	30	87	87	CD
work_6edatbslnjhz3kb2pkbphqv5py	105	31	KPS	KPS	NNP
work_6edatbslnjhz3kb2pkbphqv5py	105	32	50	50	CD
work_6edatbslnjhz3kb2pkbphqv5py	105	33	-	-	SYM
work_6edatbslnjhz3kb2pkbphqv5py	105	34	70	70	CD
work_6edatbslnjhz3kb2pkbphqv5py	105	35	24	24	CD
work_6edatbslnjhz3kb2pkbphqv5py	105	36	25	25	CD
work_6edatbslnjhz3kb2pkbphqv5py	105	37	80	80	CD
work_6edatbslnjhz3kb2pkbphqv5py	105	38	-	-	SYM
work_6edatbslnjhz3kb2pkbphqv5py	105	39	100	100	CD
work_6edatbslnjhz3kb2pkbphqv5py	105	40	75	75	CD
work_6edatbslnjhz3kb2pkbphqv5py	105	41	75	75	CD
work_6edatbslnjhz3kb2pkbphqv5py	105	42	Prior	prior	RB
work_6edatbslnjhz3kb2pkbphqv5py	105	43	pelvic	pelvic	JJ
work_6edatbslnjhz3kb2pkbphqv5py	105	44	Ri	Ri	NNP
work_6edatbslnjhz3kb2pkbphqv5py	105	45	”	"	''
work_6edatbslnjhz3kb2pkbphqv5py	105	46	'	'	''
work_6edatbslnjhz3kb2pkbphqv5py	105	47	10	10	CD
work_6edatbslnjhz3kb2pkbphqv5py	105	48	11	11	CD
work_6edatbslnjhz3kb2pkbphqv5py	105	49	Metastatic	metastatic	JJ
work_6edatbslnjhz3kb2pkbphqv5py	105	50	sites	site	NNS
work_6edatbslnjhz3kb2pkbphqv5py	105	51	Liver	Liver	NNP
work_6edatbslnjhz3kb2pkbphqv5py	105	52	79	79	CD
work_6edatbslnjhz3kb2pkbphqv5py	105	53	80	80	CD
work_6edatbslnjhz3kb2pkbphqv5py	105	54	Lung	Lung	NNP
work_6edatbslnjhz3kb2pkbphqv5py	105	55	28	28	CD
work_6edatbslnjhz3kb2pkbphqv5py	105	56	22	22	CD
work_6edatbslnjhz3kb2pkbphqv5py	105	57	Other	other	JJ
work_6edatbslnjhz3kb2pkbphqv5py	105	58	22	22	CD
work_6edatbslnjhz3kb2pkbphqv5py	105	59	25	25	CD
work_6edatbslnjhz3kb2pkbphqv5py	105	60	a	a	DT
work_6edatbslnjhz3kb2pkbphqv5py	105	61	RT	RT	NNP
work_6edatbslnjhz3kb2pkbphqv5py	105	62	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	105	63	radiotherapy	radiotherapy	NN
work_6edatbslnjhz3kb2pkbphqv5py	105	64	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	106	1	Table	table	NN
work_6edatbslnjhz3kb2pkbphqv5py	106	2	2	2	CD
work_6edatbslnjhz3kb2pkbphqv5py	106	3	Treatment	Treatment	NNP
work_6edatbslnjhz3kb2pkbphqv5py	106	4	compliance	compliance	NN
work_6edatbslnjhz3kb2pkbphqv5py	106	5	5-FU	5-fu	CD
work_6edatbslnjhz3kb2pkbphqv5py	106	6	5-nj	5-nj	CD
work_6edatbslnjhz3kb2pkbphqv5py	106	7	+	+	SYM
work_6edatbslnjhz3kb2pkbphqv5py	106	8	levamisole	levamisole	NN
work_6edatbslnjhz3kb2pkbphqv5py	106	9	(	(	-LRB-
work_6edatbslnjhz3kb2pkbphqv5py	106	10	n94	n94	NN
work_6edatbslnjhz3kb2pkbphqv5py	106	11	)	)	-RRB-
work_6edatbslnjhz3kb2pkbphqv5py	106	12	(	(	-LRB-
work_6edatbslnjhz3kb2pkbphqv5py	106	13	n	n	NNP
work_6edatbslnjhz3kb2pkbphqv5py	106	14	�	�	NNP
work_6edatbslnjhz3kb2pkbphqv5py	106	15	96	96	CD
work_6edatbslnjhz3kb2pkbphqv5py	106	16	)	)	-RRB-
work_6edatbslnjhz3kb2pkbphqv5py	106	17	Completed	complete	VBN
work_6edatbslnjhz3kb2pkbphqv5py	106	18	treatment	treatment	NN
work_6edatbslnjhz3kb2pkbphqv5py	106	19	32	32	CD
work_6edatbslnjhz3kb2pkbphqv5py	106	20	27	27	CD
work_6edatbslnjhz3kb2pkbphqv5py	106	21	Reasons	reason	NNS
work_6edatbslnjhz3kb2pkbphqv5py	106	22	for	for	IN
work_6edatbslnjhz3kb2pkbphqv5py	106	23	discontinuation	discontinuation	NN
work_6edatbslnjhz3kb2pkbphqv5py	106	24	PD	pd	NN
work_6edatbslnjhz3kb2pkbphqv5py	106	25	”	"	''
work_6edatbslnjhz3kb2pkbphqv5py	106	26	45	45	CD
work_6edatbslnjhz3kb2pkbphqv5py	106	27	48	48	CD
work_6edatbslnjhz3kb2pkbphqv5py	106	28	PSR	psr	NN
work_6edatbslnjhz3kb2pkbphqv5py	106	29	4	4	CD
work_6edatbslnjhz3kb2pkbphqv5py	106	30	1	1	CD
work_6edatbslnjhz3kb2pkbphqv5py	106	31	Toxicity	toxicity	NN
work_6edatbslnjhz3kb2pkbphqv5py	106	32	7	7	CD
work_6edatbslnjhz3kb2pkbphqv5py	106	33	12	12	CD
work_6edatbslnjhz3kb2pkbphqv5py	106	34	Noncompliance	noncompliance	NN
work_6edatbslnjhz3kb2pkbphqv5py	106	35	4	4	CD
work_6edatbslnjhz3kb2pkbphqv5py	106	36	5	5	CD
work_6edatbslnjhz3kb2pkbphqv5py	106	37	Death	death	NN
work_6edatbslnjhz3kb2pkbphqv5py	106	38	”	"	''
work_6edatbslnjhz3kb2pkbphqv5py	106	39	2	2	CD
work_6edatbslnjhz3kb2pkbphqv5py	106	40	4	4	CD
work_6edatbslnjhz3kb2pkbphqv5py	106	41	inadequate	inadequate	JJ
work_6edatbslnjhz3kb2pkbphqv5py	106	42	response	response	NN
work_6edatbslnjhz3kb2pkbphqv5py	106	43	data	datum	NNS
work_6edatbslnjhz3kb2pkbphqv5py	106	44	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	107	1	One	one	CD
work_6edatbslnjhz3kb2pkbphqv5py	107	2	hundred	hundred	CD
work_6edatbslnjhz3kb2pkbphqv5py	107	3	patients	patient	NNS
work_6edatbslnjhz3kb2pkbphqv5py	107	4	were	be	VBD
work_6edatbslnjhz3kb2pkbphqv5py	107	5	random-	random-	JJ
work_6edatbslnjhz3kb2pkbphqv5py	107	6	ized	ize	VBN
work_6edatbslnjhz3kb2pkbphqv5py	107	7	to	to	IN
work_6edatbslnjhz3kb2pkbphqv5py	107	8	5-Hi	5-hi	CD
work_6edatbslnjhz3kb2pkbphqv5py	107	9	plus	plus	CC
work_6edatbslnjhz3kb2pkbphqv5py	107	10	levamisole	levamisole	NN
work_6edatbslnjhz3kb2pkbphqv5py	107	11	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	107	12	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	107	13	whom	whom	WP
work_6edatbslnjhz3kb2pkbphqv5py	107	14	4	4	CD
work_6edatbslnjhz3kb2pkbphqv5py	107	15	never	never	RB
work_6edatbslnjhz3kb2pkbphqv5py	107	16	received	receive	VBD
work_6edatbslnjhz3kb2pkbphqv5py	107	17	treat-	treat-	JJ
work_6edatbslnjhz3kb2pkbphqv5py	107	18	ment	ment	NN
work_6edatbslnjhz3kb2pkbphqv5py	107	19	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	107	20	S	S	NNP
work_6edatbslnjhz3kb2pkbphqv5py	107	21	had	have	VBD
work_6edatbslnjhz3kb2pkbphqv5py	107	22	inadequate	inadequate	JJ
work_6edatbslnjhz3kb2pkbphqv5py	107	23	response	response	NN
work_6edatbslnjhz3kb2pkbphqv5py	107	24	data	datum	NNS
work_6edatbslnjhz3kb2pkbphqv5py	107	25	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	108	1	In	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	108	2	all	all	DT
work_6edatbslnjhz3kb2pkbphqv5py	108	3	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	108	4	182	182	CD
work_6edatbslnjhz3kb2pkbphqv5py	108	5	patients	patient	NNS
work_6edatbslnjhz3kb2pkbphqv5py	108	6	were	be	VBD
work_6edatbslnjhz3kb2pkbphqv5py	108	7	fully	fully	RB
work_6edatbslnjhz3kb2pkbphqv5py	108	8	evaluable	evaluable	JJ
work_6edatbslnjhz3kb2pkbphqv5py	108	9	for	for	IN
work_6edatbslnjhz3kb2pkbphqv5py	108	10	survival	survival	NN
work_6edatbslnjhz3kb2pkbphqv5py	108	11	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	108	12	response	response	NN
work_6edatbslnjhz3kb2pkbphqv5py	108	13	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	108	14	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	108	15	another	another	DT
work_6edatbslnjhz3kb2pkbphqv5py	108	16	8	8	CD
work_6edatbslnjhz3kb2pkbphqv5py	108	17	patients	patient	NNS
work_6edatbslnjhz3kb2pkbphqv5py	108	18	were	be	VBD
work_6edatbslnjhz3kb2pkbphqv5py	108	19	evaluable	evaluable	JJ
work_6edatbslnjhz3kb2pkbphqv5py	108	20	for	for	IN
work_6edatbslnjhz3kb2pkbphqv5py	108	21	survival	survival	NN
work_6edatbslnjhz3kb2pkbphqv5py	108	22	only	only	RB
work_6edatbslnjhz3kb2pkbphqv5py	108	23	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	109	1	Patient	patient	JJ
work_6edatbslnjhz3kb2pkbphqv5py	109	2	characteristics	characteristic	NNS
work_6edatbslnjhz3kb2pkbphqv5py	109	3	are	be	VBP
work_6edatbslnjhz3kb2pkbphqv5py	109	4	shown	show	VBN
work_6edatbslnjhz3kb2pkbphqv5py	109	5	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	109	6	Table	table	NN
work_6edatbslnjhz3kb2pkbphqv5py	109	7	1	1	CD
work_6edatbslnjhz3kb2pkbphqv5py	109	8	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	110	1	Patients	patient	NNS
work_6edatbslnjhz3kb2pkbphqv5py	110	2	on	on	IN
work_6edatbslnjhz3kb2pkbphqv5py	110	3	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	110	4	two	two	CD
work_6edatbslnjhz3kb2pkbphqv5py	110	5	arms	arm	NNS
work_6edatbslnjhz3kb2pkbphqv5py	110	6	were	be	VBD
work_6edatbslnjhz3kb2pkbphqv5py	110	7	well	well	RB
work_6edatbslnjhz3kb2pkbphqv5py	110	8	matched	match	VBN
work_6edatbslnjhz3kb2pkbphqv5py	110	9	for	for	IN
work_6edatbslnjhz3kb2pkbphqv5py	110	10	age	age	NN
work_6edatbslnjhz3kb2pkbphqv5py	110	11	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	110	12	KPS	KPS	NNP
work_6edatbslnjhz3kb2pkbphqv5py	110	13	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	110	14	presence	presence	NN
work_6edatbslnjhz3kb2pkbphqv5py	110	15	or	or	CC
work_6edatbslnjhz3kb2pkbphqv5py	110	16	absence	absence	NN
work_6edatbslnjhz3kb2pkbphqv5py	110	17	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	110	18	liver	liver	NN
work_6edatbslnjhz3kb2pkbphqv5py	110	19	metastases	metastasis	NNS
work_6edatbslnjhz3kb2pkbphqv5py	110	20	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	110	21	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	110	22	prior	prior	JJ
work_6edatbslnjhz3kb2pkbphqv5py	110	23	pelvic	pelvic	NNP
work_6edatbslnjhz3kb2pkbphqv5py	110	24	radiotherapy	radiotherapy	NN
work_6edatbslnjhz3kb2pkbphqv5py	110	25	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	111	1	Thirty	thirty	CD
work_6edatbslnjhz3kb2pkbphqv5py	111	2	-	-	HYPH
work_6edatbslnjhz3kb2pkbphqv5py	111	3	two	two	CD
work_6edatbslnjhz3kb2pkbphqv5py	111	4	patients	patient	NNS
work_6edatbslnjhz3kb2pkbphqv5py	111	5	on	on	IN
work_6edatbslnjhz3kb2pkbphqv5py	111	6	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	111	7	5-FU	5-fu	CD
work_6edatbslnjhz3kb2pkbphqv5py	111	8	arm	arm	NN
work_6edatbslnjhz3kb2pkbphqv5py	111	9	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	111	10	27	27	CD
work_6edatbslnjhz3kb2pkbphqv5py	111	11	on	on	IN
work_6edatbslnjhz3kb2pkbphqv5py	111	12	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	111	13	5-FU	5-fu	CD
work_6edatbslnjhz3kb2pkbphqv5py	111	14	plus	plus	JJ
work_6edatbslnjhz3kb2pkbphqv5py	111	15	levamisole	levamisole	NN
work_6edatbslnjhz3kb2pkbphqv5py	111	16	arm	arm	NN
work_6edatbslnjhz3kb2pkbphqv5py	111	17	completed	complete	VBD
work_6edatbslnjhz3kb2pkbphqv5py	111	18	26	26	CD
work_6edatbslnjhz3kb2pkbphqv5py	111	19	weeks	week	NNS
work_6edatbslnjhz3kb2pkbphqv5py	111	20	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	111	21	treatment	treatment	NN
work_6edatbslnjhz3kb2pkbphqv5py	111	22	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	112	1	Reasons	reason	NNS
work_6edatbslnjhz3kb2pkbphqv5py	112	2	for	for	IN
work_6edatbslnjhz3kb2pkbphqv5py	112	3	discontinuation	discontinuation	NN
work_6edatbslnjhz3kb2pkbphqv5py	112	4	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	112	5	therapy	therapy	NN
work_6edatbslnjhz3kb2pkbphqv5py	112	6	are	be	VBP
work_6edatbslnjhz3kb2pkbphqv5py	112	7	listed	list	VBN
work_6edatbslnjhz3kb2pkbphqv5py	112	8	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	112	9	Table	table	NN
work_6edatbslnjhz3kb2pkbphqv5py	112	10	2	2	CD
work_6edatbslnjhz3kb2pkbphqv5py	112	11	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	113	1	The	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	113	2	most	most	RBS
work_6edatbslnjhz3kb2pkbphqv5py	113	3	frequent	frequent	JJ
work_6edatbslnjhz3kb2pkbphqv5py	113	4	reason	reason	NN
work_6edatbslnjhz3kb2pkbphqv5py	113	5	for	for	IN
work_6edatbslnjhz3kb2pkbphqv5py	113	6	early	early	JJ
work_6edatbslnjhz3kb2pkbphqv5py	113	7	termination	termination	NN
work_6edatbslnjhz3kb2pkbphqv5py	113	8	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	113	9	chemotherapy	chemotherapy	NN
work_6edatbslnjhz3kb2pkbphqv5py	113	10	was	be	VBD
work_6edatbslnjhz3kb2pkbphqv5py	113	11	secondary	secondary	JJ
work_6edatbslnjhz3kb2pkbphqv5py	113	12	to	to	IN
work_6edatbslnjhz3kb2pkbphqv5py	113	13	tumor	tumor	NN
work_6edatbslnjhz3kb2pkbphqv5py	113	14	progression	progression	NN
work_6edatbslnjhz3kb2pkbphqv5py	113	15	during	during	IN
work_6edatbslnjhz3kb2pkbphqv5py	113	16	therapy	therapy	NN
work_6edatbslnjhz3kb2pkbphqv5py	113	17	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	114	1	Toxicity	toxicity	NN
work_6edatbslnjhz3kb2pkbphqv5py	114	2	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	115	1	The	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	115	2	toxicity	toxicity	NN
work_6edatbslnjhz3kb2pkbphqv5py	115	3	data	datum	NNS
work_6edatbslnjhz3kb2pkbphqv5py	115	4	are	be	VBP
work_6edatbslnjhz3kb2pkbphqv5py	115	5	shown	show	VBN
work_6edatbslnjhz3kb2pkbphqv5py	115	6	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	115	7	Table	table	NN
work_6edatbslnjhz3kb2pkbphqv5py	115	8	3	3	CD
work_6edatbslnjhz3kb2pkbphqv5py	115	9	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	116	1	This	this	DT
work_6edatbslnjhz3kb2pkbphqv5py	116	2	table	table	NN
work_6edatbslnjhz3kb2pkbphqv5py	116	3	reflects	reflect	VBZ
work_6edatbslnjhz3kb2pkbphqv5py	116	4	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	116	5	worst	bad	JJS
work_6edatbslnjhz3kb2pkbphqv5py	116	6	grade	grade	NN
work_6edatbslnjhz3kb2pkbphqv5py	116	7	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	116	8	toxicity	toxicity	NN
work_6edatbslnjhz3kb2pkbphqv5py	116	9	experienced	experience	VBN
work_6edatbslnjhz3kb2pkbphqv5py	116	10	by	by	IN
work_6edatbslnjhz3kb2pkbphqv5py	116	11	each	each	DT
work_6edatbslnjhz3kb2pkbphqv5py	116	12	patient	patient	NN
work_6edatbslnjhz3kb2pkbphqv5py	116	13	at	at	IN
work_6edatbslnjhz3kb2pkbphqv5py	116	14	any	any	DT
work_6edatbslnjhz3kb2pkbphqv5py	116	15	time	time	NN
work_6edatbslnjhz3kb2pkbphqv5py	116	16	while	while	IN
work_6edatbslnjhz3kb2pkbphqv5py	116	17	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	116	18	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	116	19	study	study	NN
work_6edatbslnjhz3kb2pkbphqv5py	116	20	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	117	1	The	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	117	2	higher	high	JJR
work_6edatbslnjhz3kb2pkbphqv5py	117	3	incidence	incidence	NN
work_6edatbslnjhz3kb2pkbphqv5py	117	4	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	117	5	grade	grade	NN
work_6edatbslnjhz3kb2pkbphqv5py	117	6	3/4	3/4	CD
work_6edatbslnjhz3kb2pkbphqv5py	117	7	diarrhea	diarrhea	NN
work_6edatbslnjhz3kb2pkbphqv5py	117	8	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	117	9	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	117	10	5-FU	5-fu	CD
work_6edatbslnjhz3kb2pkbphqv5py	117	11	plus	plus	JJ
work_6edatbslnjhz3kb2pkbphqv5py	117	12	levamisole	levamisole	NN
work_6edatbslnjhz3kb2pkbphqv5py	117	13	arm	arm	NN
work_6edatbslnjhz3kb2pkbphqv5py	117	14	was	be	VBD
work_6edatbslnjhz3kb2pkbphqv5py	117	15	statis-	statis-	VBN
work_6edatbslnjhz3kb2pkbphqv5py	117	16	tically	tically	RB
work_6edatbslnjhz3kb2pkbphqv5py	117	17	significant	significant	JJ
work_6edatbslnjhz3kb2pkbphqv5py	117	18	(	(	-LRB-
work_6edatbslnjhz3kb2pkbphqv5py	117	19	P	p	NN
work_6edatbslnjhz3kb2pkbphqv5py	117	20	=	=	SYM
work_6edatbslnjhz3kb2pkbphqv5py	117	21	0.0146	0.0146	CD
work_6edatbslnjhz3kb2pkbphqv5py	117	22	)	)	-RRB-
work_6edatbslnjhz3kb2pkbphqv5py	117	23	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	117	24	whereas	whereas	IN
work_6edatbslnjhz3kb2pkbphqv5py	117	25	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	117	26	difference	difference	NN
work_6edatbslnjhz3kb2pkbphqv5py	117	27	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	117	28	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	117	29	incidence	incidence	NN
work_6edatbslnjhz3kb2pkbphqv5py	117	30	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	117	31	grade	grade	NN
work_6edatbslnjhz3kb2pkbphqv5py	117	32	3/4	3/4	CD
work_6edatbslnjhz3kb2pkbphqv5py	117	33	granulocytopenia	granulocytopenia	NN
work_6edatbslnjhz3kb2pkbphqv5py	117	34	between	between	IN
work_6edatbslnjhz3kb2pkbphqv5py	117	35	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	117	36	two	two	CD
work_6edatbslnjhz3kb2pkbphqv5py	117	37	arms	arm	NNS
work_6edatbslnjhz3kb2pkbphqv5py	117	38	did	do	VBD
work_6edatbslnjhz3kb2pkbphqv5py	117	39	not	not	RB
work_6edatbslnjhz3kb2pkbphqv5py	117	40	reach	reach	VB
work_6edatbslnjhz3kb2pkbphqv5py	117	41	statistical	statistical	JJ
work_6edatbslnjhz3kb2pkbphqv5py	117	42	significance	significance	NN
work_6edatbslnjhz3kb2pkbphqv5py	117	43	(	(	-LRB-
work_6edatbslnjhz3kb2pkbphqv5py	117	44	P	p	NN
work_6edatbslnjhz3kb2pkbphqv5py	117	45	=	=	SYM
work_6edatbslnjhz3kb2pkbphqv5py	117	46	0.067	0.067	CD
work_6edatbslnjhz3kb2pkbphqv5py	117	47	)	)	-RRB-
work_6edatbslnjhz3kb2pkbphqv5py	117	48	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	118	1	There	there	EX
work_6edatbslnjhz3kb2pkbphqv5py	118	2	were	be	VBD
work_6edatbslnjhz3kb2pkbphqv5py	118	3	no	no	DT
work_6edatbslnjhz3kb2pkbphqv5py	118	4	treatment	treatment	NN
work_6edatbslnjhz3kb2pkbphqv5py	118	5	-	-	HYPH
work_6edatbslnjhz3kb2pkbphqv5py	118	6	related	relate	VBN
work_6edatbslnjhz3kb2pkbphqv5py	118	7	deaths	death	NNS
work_6edatbslnjhz3kb2pkbphqv5py	118	8	on	on	IN
work_6edatbslnjhz3kb2pkbphqv5py	118	9	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	118	10	5-FU	5-fu	CD
work_6edatbslnjhz3kb2pkbphqv5py	118	11	arm	arm	NN
work_6edatbslnjhz3kb2pkbphqv5py	118	12	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	118	13	whereas	whereas	IN
work_6edatbslnjhz3kb2pkbphqv5py	118	14	there	there	EX
work_6edatbslnjhz3kb2pkbphqv5py	118	15	were	be	VBD
work_6edatbslnjhz3kb2pkbphqv5py	118	16	four	four	CD
work_6edatbslnjhz3kb2pkbphqv5py	118	17	on	on	IN
work_6edatbslnjhz3kb2pkbphqv5py	118	18	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	118	19	combination	combination	NN
work_6edatbslnjhz3kb2pkbphqv5py	118	20	arm	arm	NN
work_6edatbslnjhz3kb2pkbphqv5py	118	21	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	119	1	Response	Response	NNP
work_6edatbslnjhz3kb2pkbphqv5py	119	2	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	119	3	Survival	Survival	NNP
work_6edatbslnjhz3kb2pkbphqv5py	119	4	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	120	1	There	there	EX
work_6edatbslnjhz3kb2pkbphqv5py	120	2	were	be	VBD
work_6edatbslnjhz3kb2pkbphqv5py	120	3	23	23	CD
work_6edatbslnjhz3kb2pkbphqv5py	120	4	objective	objective	JJ
work_6edatbslnjhz3kb2pkbphqv5py	120	5	re-	re-	JJ
work_6edatbslnjhz3kb2pkbphqv5py	120	6	sponses	sponse	NNS
work_6edatbslnjhz3kb2pkbphqv5py	120	7	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	120	8	1	1	CD
work_6edatbslnjhz3kb2pkbphqv5py	120	9	82	82	CD
work_6edatbslnjhz3kb2pkbphqv5py	120	10	fully	fully	RB
work_6edatbslnjhz3kb2pkbphqv5py	120	11	evaluable	evaluable	JJ
work_6edatbslnjhz3kb2pkbphqv5py	120	12	patients	patient	NNS
work_6edatbslnjhz3kb2pkbphqv5py	120	13	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	121	1	There	there	EX
work_6edatbslnjhz3kb2pkbphqv5py	121	2	was	be	VBD
work_6edatbslnjhz3kb2pkbphqv5py	121	3	one	one	CD
work_6edatbslnjhz3kb2pkbphqv5py	121	4	complete	complete	JJ
work_6edatbslnjhz3kb2pkbphqv5py	121	5	response	response	NN
work_6edatbslnjhz3kb2pkbphqv5py	121	6	on	on	IN
work_6edatbslnjhz3kb2pkbphqv5py	121	7	each	each	DT
work_6edatbslnjhz3kb2pkbphqv5py	121	8	arm	arm	NN
work_6edatbslnjhz3kb2pkbphqv5py	121	9	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	122	1	Overall	overall	RB
work_6edatbslnjhz3kb2pkbphqv5py	122	2	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	122	3	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	122	4	response	response	NN
work_6edatbslnjhz3kb2pkbphqv5py	122	5	rate	rate	NN
work_6edatbslnjhz3kb2pkbphqv5py	122	6	was	be	VBD
work_6edatbslnjhz3kb2pkbphqv5py	122	7	12	12	CD
work_6edatbslnjhz3kb2pkbphqv5py	122	8	%	%	NN
work_6edatbslnjhz3kb2pkbphqv5py	122	9	(	(	-LRB-
work_6edatbslnjhz3kb2pkbphqv5py	122	10	95	95	CD
work_6edatbslnjhz3kb2pkbphqv5py	122	11	%	%	NN
work_6edatbslnjhz3kb2pkbphqv5py	122	12	CI	ci	NN
work_6edatbslnjhz3kb2pkbphqv5py	122	13	=	=	SYM
work_6edatbslnjhz3kb2pkbphqv5py	122	14	6	6	CD
work_6edatbslnjhz3kb2pkbphqv5py	122	15	-	-	SYM
work_6edatbslnjhz3kb2pkbphqv5py	122	16	21	21	CD
work_6edatbslnjhz3kb2pkbphqv5py	122	17	%	%	NN
work_6edatbslnjhz3kb2pkbphqv5py	122	18	)	)	-RRB-
work_6edatbslnjhz3kb2pkbphqv5py	122	19	on	on	IN
work_6edatbslnjhz3kb2pkbphqv5py	122	20	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	122	21	5-FU	5-fu	CD
work_6edatbslnjhz3kb2pkbphqv5py	122	22	arm	arm	NN
work_6edatbslnjhz3kb2pkbphqv5py	122	23	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	122	24	13	13	CD
work_6edatbslnjhz3kb2pkbphqv5py	122	25	%	%	NN
work_6edatbslnjhz3kb2pkbphqv5py	122	26	(	(	-LRB-
work_6edatbslnjhz3kb2pkbphqv5py	122	27	95	95	CD
work_6edatbslnjhz3kb2pkbphqv5py	122	28	%	%	NN
work_6edatbslnjhz3kb2pkbphqv5py	122	29	CI	ci	NN
work_6edatbslnjhz3kb2pkbphqv5py	122	30	=	=	SYM
work_6edatbslnjhz3kb2pkbphqv5py	122	31	7	7	CD
work_6edatbslnjhz3kb2pkbphqv5py	122	32	-	-	SYM
work_6edatbslnjhz3kb2pkbphqv5py	122	33	22	22	CD
work_6edatbslnjhz3kb2pkbphqv5py	122	34	%	%	NN
work_6edatbslnjhz3kb2pkbphqv5py	122	35	)	)	-RRB-
work_6edatbslnjhz3kb2pkbphqv5py	122	36	on	on	IN
work_6edatbslnjhz3kb2pkbphqv5py	122	37	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	122	38	5-Ri	5-ri	CD
work_6edatbslnjhz3kb2pkbphqv5py	122	39	plus	plus	CC
work_6edatbslnjhz3kb2pkbphqv5py	122	40	levamisole	levamisole	NN
work_6edatbslnjhz3kb2pkbphqv5py	122	41	arm	arm	NN
work_6edatbslnjhz3kb2pkbphqv5py	122	42	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	123	1	The	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	123	2	median	median	JJ
work_6edatbslnjhz3kb2pkbphqv5py	123	3	duration	duration	NN
work_6edatbslnjhz3kb2pkbphqv5py	123	4	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	123	5	response	response	NN
work_6edatbslnjhz3kb2pkbphqv5py	123	6	Table	table	NN
work_6edatbslnjhz3kb2pkbphqv5py	123	7	3	3	CD
work_6edatbslnjhz3kb2pkbphqv5py	123	8	Toxicity	Toxicity	NNP
work_6edatbslnjhz3kb2pkbphqv5py	123	9	(	(	-LRB-
work_6edatbslnjhz3kb2pkbphqv5py	123	10	grade	grade	NN
work_6edatbslnjhz3kb2pkbphqv5py	123	11	3/4	3/4	CD
work_6edatbslnjhz3kb2pkbphqv5py	123	12	)	)	-RRB-
work_6edatbslnjhz3kb2pkbphqv5py	123	13	Percentage	percentage	NN
work_6edatbslnjhz3kb2pkbphqv5py	123	14	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	123	15	patients	patient	NNS
work_6edatbslnjhz3kb2pkbphqv5py	123	16	5-FU	5-fu	CD
work_6edatbslnjhz3kb2pkbphqv5py	123	17	5-Hi	5-hi	CD
work_6edatbslnjhz3kb2pkbphqv5py	123	18	+	+	SYM
work_6edatbslnjhz3kb2pkbphqv5py	123	19	levamisole	levamisole	NN
work_6edatbslnjhz3kb2pkbphqv5py	123	20	Anemia	Anemia	NNP
work_6edatbslnjhz3kb2pkbphqv5py	123	21	4	4	CD
work_6edatbslnjhz3kb2pkbphqv5py	123	22	1	1	CD
work_6edatbslnjhz3kb2pkbphqv5py	123	23	Granulocytopenia	Granulocytopenia	NNP
work_6edatbslnjhz3kb2pkbphqv5py	123	24	”	"	''
work_6edatbslnjhz3kb2pkbphqv5py	123	25	13	13	CD
work_6edatbslnjhz3kb2pkbphqv5py	123	26	24	24	CD
work_6edatbslnjhz3kb2pkbphqv5py	123	27	Thrombocytopenia	thrombocytopenia	NN
work_6edatbslnjhz3kb2pkbphqv5py	123	28	0	0	CD
work_6edatbslnjhz3kb2pkbphqv5py	123	29	2	2	CD
work_6edatbslnjhz3kb2pkbphqv5py	123	30	Nausea	nausea	NN
work_6edatbslnjhz3kb2pkbphqv5py	123	31	S	S	NNP
work_6edatbslnjhz3kb2pkbphqv5py	123	32	S	S	NNP
work_6edatbslnjhz3kb2pkbphqv5py	123	33	Vomiting	Vomiting	NNP
work_6edatbslnjhz3kb2pkbphqv5py	123	34	6	6	CD
work_6edatbslnjhz3kb2pkbphqv5py	123	35	3	3	CD
work_6edatbslnjhz3kb2pkbphqv5py	123	36	Diarrhea	Diarrhea	NNP
work_6edatbslnjhz3kb2pkbphqv5py	123	37	”	"	''
work_6edatbslnjhz3kb2pkbphqv5py	123	38	8	8	CD
work_6edatbslnjhz3kb2pkbphqv5py	123	39	21	21	CD
work_6edatbslnjhz3kb2pkbphqv5py	123	40	Stomatitis	stomatitis	NN
work_6edatbslnjhz3kb2pkbphqv5py	123	41	5	5	CD
work_6edatbslnjhz3kb2pkbphqv5py	123	42	7	7	CD
work_6edatbslnjhz3kb2pkbphqv5py	123	43	Infection	infection	NN
work_6edatbslnjhz3kb2pkbphqv5py	123	44	2	2	CD
work_6edatbslnjhz3kb2pkbphqv5py	123	45	5	5	CD
work_6edatbslnjhz3kb2pkbphqv5py	123	46	Fever	fever	NN
work_6edatbslnjhz3kb2pkbphqv5py	123	47	2	2	CD
work_6edatbslnjhz3kb2pkbphqv5py	123	48	1	1	CD
work_6edatbslnjhz3kb2pkbphqv5py	123	49	Neurological	neurological	JJ
work_6edatbslnjhz3kb2pkbphqv5py	123	50	1	1	CD
work_6edatbslnjhz3kb2pkbphqv5py	123	51	6	6	CD
work_6edatbslnjhz3kb2pkbphqv5py	123	52	Death	Death	NNP
work_6edatbslnjhz3kb2pkbphqv5py	123	53	’	'	''
work_6edatbslnjhz3kb2pkbphqv5py	123	54	0	0	CD
work_6edatbslnjhz3kb2pkbphqv5py	123	55	4	4	CD
work_6edatbslnjhz3kb2pkbphqv5py	123	56	on	on	IN
work_6edatbslnjhz3kb2pkbphqv5py	123	57	both	both	DT
work_6edatbslnjhz3kb2pkbphqv5py	123	58	arms	arm	NNS
work_6edatbslnjhz3kb2pkbphqv5py	123	59	was	be	VBD
work_6edatbslnjhz3kb2pkbphqv5py	123	60	18	18	CD
work_6edatbslnjhz3kb2pkbphqv5py	123	61	weeks	week	NNS
work_6edatbslnjhz3kb2pkbphqv5py	123	62	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	124	1	Thirty	thirty	CD
work_6edatbslnjhz3kb2pkbphqv5py	124	2	-	-	HYPH
work_6edatbslnjhz3kb2pkbphqv5py	124	3	eight	eight	CD
work_6edatbslnjhz3kb2pkbphqv5py	124	4	patients	patient	NNS
work_6edatbslnjhz3kb2pkbphqv5py	124	5	on	on	IN
work_6edatbslnjhz3kb2pkbphqv5py	124	6	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	124	7	5-Hi	5-hi	CD
work_6edatbslnjhz3kb2pkbphqv5py	124	8	arm	arm	NN
work_6edatbslnjhz3kb2pkbphqv5py	124	9	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	124	10	25	25	CD
work_6edatbslnjhz3kb2pkbphqv5py	124	11	patients	patient	NNS
work_6edatbslnjhz3kb2pkbphqv5py	124	12	on	on	IN
work_6edatbslnjhz3kb2pkbphqv5py	124	13	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	124	14	combination	combination	NN
work_6edatbslnjhz3kb2pkbphqv5py	124	15	arm	arm	NN
work_6edatbslnjhz3kb2pkbphqv5py	124	16	had	have	VBD
work_6edatbslnjhz3kb2pkbphqv5py	124	17	stable	stable	JJ
work_6edatbslnjhz3kb2pkbphqv5py	124	18	disease	disease	NN
work_6edatbslnjhz3kb2pkbphqv5py	124	19	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	125	1	The	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	125	2	median	median	JJ
work_6edatbslnjhz3kb2pkbphqv5py	125	3	time	time	NN
work_6edatbslnjhz3kb2pkbphqv5py	125	4	to	to	IN
work_6edatbslnjhz3kb2pkbphqv5py	125	5	progression	progression	NNP
work_6edatbslnjhz3kb2pkbphqv5py	125	6	was	be	VBD
work_6edatbslnjhz3kb2pkbphqv5py	125	7	1	1	CD
work_6edatbslnjhz3kb2pkbphqv5py	125	8	8	8	CD
work_6edatbslnjhz3kb2pkbphqv5py	125	9	weeks	week	NNS
work_6edatbslnjhz3kb2pkbphqv5py	125	10	on	on	IN
work_6edatbslnjhz3kb2pkbphqv5py	125	11	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	125	12	5-Hi	5-hi	CD
work_6edatbslnjhz3kb2pkbphqv5py	125	13	arm	arm	NN
work_6edatbslnjhz3kb2pkbphqv5py	125	14	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	125	15	13	13	CD
work_6edatbslnjhz3kb2pkbphqv5py	125	16	weeks	week	NNS
work_6edatbslnjhz3kb2pkbphqv5py	125	17	on	on	IN
work_6edatbslnjhz3kb2pkbphqv5py	125	18	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	125	19	5-Hi	5-hi	NN
work_6edatbslnjhz3kb2pkbphqv5py	125	20	plus	plus	CC
work_6edatbslnjhz3kb2pkbphqv5py	125	21	levamisole	levamisole	NN
work_6edatbslnjhz3kb2pkbphqv5py	125	22	arm	arm	NN
work_6edatbslnjhz3kb2pkbphqv5py	125	23	(	(	-LRB-
work_6edatbslnjhz3kb2pkbphqv5py	125	24	P	P	NNP
work_6edatbslnjhz3kb2pkbphqv5py	125	25	-	-	HYPH
work_6edatbslnjhz3kb2pkbphqv5py	125	26	0.06	0.06	NNP
work_6edatbslnjhz3kb2pkbphqv5py	125	27	)	)	-RRB-
work_6edatbslnjhz3kb2pkbphqv5py	125	28	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	126	1	Median	median	JJ
work_6edatbslnjhz3kb2pkbphqv5py	126	2	survival	survival	NN
work_6edatbslnjhz3kb2pkbphqv5py	126	3	was	be	VBD
work_6edatbslnjhz3kb2pkbphqv5py	126	4	48	48	CD
work_6edatbslnjhz3kb2pkbphqv5py	126	5	weeks	week	NNS
work_6edatbslnjhz3kb2pkbphqv5py	126	6	on	on	IN
work_6edatbslnjhz3kb2pkbphqv5py	126	7	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	126	8	5-Hi	5-hi	CD
work_6edatbslnjhz3kb2pkbphqv5py	126	9	arm	arm	NN
work_6edatbslnjhz3kb2pkbphqv5py	126	10	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	126	11	41	41	CD
work_6edatbslnjhz3kb2pkbphqv5py	126	12	weeks	week	NNS
work_6edatbslnjhz3kb2pkbphqv5py	126	13	on	on	IN
work_6edatbslnjhz3kb2pkbphqv5py	126	14	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	126	15	5-Hi	5-hi	NN
work_6edatbslnjhz3kb2pkbphqv5py	126	16	plus	plus	CC
work_6edatbslnjhz3kb2pkbphqv5py	126	17	levamisole	levamisole	NN
work_6edatbslnjhz3kb2pkbphqv5py	126	18	arm	arm	NN
work_6edatbslnjhz3kb2pkbphqv5py	126	19	(	(	-LRB-
work_6edatbslnjhz3kb2pkbphqv5py	126	20	Fig	fig	NN
work_6edatbslnjhz3kb2pkbphqv5py	126	21	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	127	1	1	1	LS
work_6edatbslnjhz3kb2pkbphqv5py	127	2	)	)	-RRB-
work_6edatbslnjhz3kb2pkbphqv5py	127	3	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	128	1	Survival	survival	NN
work_6edatbslnjhz3kb2pkbphqv5py	128	2	times	time	NNS
work_6edatbslnjhz3kb2pkbphqv5py	128	3	on	on	IN
work_6edatbslnjhz3kb2pkbphqv5py	128	4	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	128	5	two	two	CD
work_6edatbslnjhz3kb2pkbphqv5py	128	6	arms	arm	NNS
work_6edatbslnjhz3kb2pkbphqv5py	128	7	were	be	VBD
work_6edatbslnjhz3kb2pkbphqv5py	128	8	not	not	RB
work_6edatbslnjhz3kb2pkbphqv5py	128	9	significantly	significantly	RB
work_6edatbslnjhz3kb2pkbphqv5py	128	10	different	different	JJ
work_6edatbslnjhz3kb2pkbphqv5py	128	11	by	by	IN
work_6edatbslnjhz3kb2pkbphqv5py	128	12	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	128	13	log	log	NN
work_6edatbslnjhz3kb2pkbphqv5py	128	14	-	-	HYPH
work_6edatbslnjhz3kb2pkbphqv5py	128	15	rank	rank	NN
work_6edatbslnjhz3kb2pkbphqv5py	128	16	test	test	NN
work_6edatbslnjhz3kb2pkbphqv5py	128	17	(	(	-LRB-
work_6edatbslnjhz3kb2pkbphqv5py	128	18	P	p	NN
work_6edatbslnjhz3kb2pkbphqv5py	128	19	=	=	SYM
work_6edatbslnjhz3kb2pkbphqv5py	128	20	0.20	0.20	CD
work_6edatbslnjhz3kb2pkbphqv5py	128	21	)	)	-RRB-
work_6edatbslnjhz3kb2pkbphqv5py	128	22	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	129	1	In	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	129	2	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	129	3	Cox	Cox	NNP
work_6edatbslnjhz3kb2pkbphqv5py	129	4	proportional	proportional	JJ
work_6edatbslnjhz3kb2pkbphqv5py	129	5	hazards	hazard	NNS
work_6edatbslnjhz3kb2pkbphqv5py	129	6	regression	regression	NN
work_6edatbslnjhz3kb2pkbphqv5py	129	7	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	129	8	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	129	9	Wald	Wald	NNP
work_6edatbslnjhz3kb2pkbphqv5py	129	10	x2	x2	NNP
work_6edatbslnjhz3kb2pkbphqv5py	129	11	was	be	VBD
work_6edatbslnjhz3kb2pkbphqv5py	129	12	1.968	1.968	CD
work_6edatbslnjhz3kb2pkbphqv5py	129	13	(	(	-LRB-
work_6edatbslnjhz3kb2pkbphqv5py	129	14	P	p	NN
work_6edatbslnjhz3kb2pkbphqv5py	129	15	=	=	SYM
work_6edatbslnjhz3kb2pkbphqv5py	129	16	0.16	0.16	CD
work_6edatbslnjhz3kb2pkbphqv5py	129	17	;	;	:
work_6edatbslnjhz3kb2pkbphqv5py	129	18	1	1	CD
work_6edatbslnjhz3kb2pkbphqv5py	129	19	degree	degree	NN
work_6edatbslnjhz3kb2pkbphqv5py	129	20	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	129	21	freedom	freedom	NN
work_6edatbslnjhz3kb2pkbphqv5py	129	22	)	)	-RRB-
work_6edatbslnjhz3kb2pkbphqv5py	129	23	for	for	IN
work_6edatbslnjhz3kb2pkbphqv5py	129	24	treatment	treatment	NN
work_6edatbslnjhz3kb2pkbphqv5py	129	25	arm	arm	NN
work_6edatbslnjhz3kb2pkbphqv5py	129	26	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	129	27	adjusting	adjust	VBG
work_6edatbslnjhz3kb2pkbphqv5py	129	28	for	for	IN
work_6edatbslnjhz3kb2pkbphqv5py	129	29	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	129	30	stratification	stratification	NN
work_6edatbslnjhz3kb2pkbphqv5py	129	31	factors	factor	NNS
work_6edatbslnjhz3kb2pkbphqv5py	129	32	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	129	33	liver	liver	NNP
work_6edatbslnjhz3kb2pkbphqv5py	129	34	me-	me-	NN
work_6edatbslnjhz3kb2pkbphqv5py	129	35	tastases	tastase	NNS
work_6edatbslnjhz3kb2pkbphqv5py	129	36	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	129	37	KPS	KPS	NNP
work_6edatbslnjhz3kb2pkbphqv5py	129	38	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	130	1	At	at	IN
work_6edatbslnjhz3kb2pkbphqv5py	130	2	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	130	3	time	time	NN
work_6edatbslnjhz3kb2pkbphqv5py	130	4	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	130	5	analysis	analysis	NN
work_6edatbslnjhz3kb2pkbphqv5py	130	6	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	130	7	this	this	DT
work_6edatbslnjhz3kb2pkbphqv5py	130	8	data	datum	NNS
work_6edatbslnjhz3kb2pkbphqv5py	130	9	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	130	10	1	1	CD
work_6edatbslnjhz3kb2pkbphqv5py	130	11	1	1	CD
work_6edatbslnjhz3kb2pkbphqv5py	130	12	patients	patient	NNS
work_6edatbslnjhz3kb2pkbphqv5py	130	13	on	on	IN
work_6edatbslnjhz3kb2pkbphqv5py	130	14	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	130	15	5-Hi	5-hi	CD
work_6edatbslnjhz3kb2pkbphqv5py	130	16	arm	arm	NN
work_6edatbslnjhz3kb2pkbphqv5py	130	17	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	130	18	3	3	CD
work_6edatbslnjhz3kb2pkbphqv5py	130	19	on	on	IN
work_6edatbslnjhz3kb2pkbphqv5py	130	20	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	130	21	combination	combination	NN
work_6edatbslnjhz3kb2pkbphqv5py	130	22	arm	arm	NN
work_6edatbslnjhz3kb2pkbphqv5py	130	23	were	be	VBD
work_6edatbslnjhz3kb2pkbphqv5py	130	24	alive	alive	JJ
work_6edatbslnjhz3kb2pkbphqv5py	130	25	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	131	1	DISCUSSION	DISCUSSION	NNP
work_6edatbslnjhz3kb2pkbphqv5py	131	2	One	one	CD
work_6edatbslnjhz3kb2pkbphqv5py	131	3	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	131	4	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	131	5	basic	basic	JJ
work_6edatbslnjhz3kb2pkbphqv5py	131	6	principles	principle	NNS
work_6edatbslnjhz3kb2pkbphqv5py	131	7	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	131	8	medical	medical	JJ
work_6edatbslnjhz3kb2pkbphqv5py	131	9	oncology	oncology	NN
work_6edatbslnjhz3kb2pkbphqv5py	131	10	is	be	VBZ
work_6edatbslnjhz3kb2pkbphqv5py	131	11	that	that	IN
work_6edatbslnjhz3kb2pkbphqv5py	131	12	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	131	13	use	use	NN
work_6edatbslnjhz3kb2pkbphqv5py	131	14	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	131	15	a	a	DT
work_6edatbslnjhz3kb2pkbphqv5py	131	16	regimen	regimen	NN
work_6edatbslnjhz3kb2pkbphqv5py	131	17	to	to	TO
work_6edatbslnjhz3kb2pkbphqv5py	131	18	improve	improve	VB
work_6edatbslnjhz3kb2pkbphqv5py	131	19	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	131	20	surgical	surgical	JJ
work_6edatbslnjhz3kb2pkbphqv5py	131	21	cure	cure	NN
work_6edatbslnjhz3kb2pkbphqv5py	131	22	rate	rate	NN
work_6edatbslnjhz3kb2pkbphqv5py	131	23	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	131	24	a	a	DT
work_6edatbslnjhz3kb2pkbphqv5py	131	25	malig-	malig-	JJ
work_6edatbslnjhz3kb2pkbphqv5py	131	26	nancy	nancy	NN
work_6edatbslnjhz3kb2pkbphqv5py	131	27	is	be	VBZ
work_6edatbslnjhz3kb2pkbphqv5py	131	28	preceded	precede	VBN
work_6edatbslnjhz3kb2pkbphqv5py	131	29	by	by	IN
work_6edatbslnjhz3kb2pkbphqv5py	131	30	documented	document	VBN
work_6edatbslnjhz3kb2pkbphqv5py	131	31	efficacy	efficacy	NN
work_6edatbslnjhz3kb2pkbphqv5py	131	32	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	131	33	advanced	advanced	JJ
work_6edatbslnjhz3kb2pkbphqv5py	131	34	disease	disease	NN
work_6edatbslnjhz3kb2pkbphqv5py	131	35	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	132	1	However	however	RB
work_6edatbslnjhz3kb2pkbphqv5py	132	2	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	132	3	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	132	4	choice	choice	NN
work_6edatbslnjhz3kb2pkbphqv5py	132	5	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	132	6	5-Hi	5-hi	CD
work_6edatbslnjhz3kb2pkbphqv5py	132	7	plus	plus	CC
work_6edatbslnjhz3kb2pkbphqv5py	132	8	levamisole	levamisole	NN
work_6edatbslnjhz3kb2pkbphqv5py	132	9	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	132	10	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	132	11	adjuvant	adjuvant	JJ
work_6edatbslnjhz3kb2pkbphqv5py	132	12	NCCTG	NCCTG	NNP
work_6edatbslnjhz3kb2pkbphqv5py	132	13	trial	trial	NN
work_6edatbslnjhz3kb2pkbphqv5py	132	14	was	be	VBD
work_6edatbslnjhz3kb2pkbphqv5py	132	15	quite	quite	RB
work_6edatbslnjhz3kb2pkbphqv5py	132	16	empirical	empirical	JJ
work_6edatbslnjhz3kb2pkbphqv5py	132	17	(	(	-LRB-
work_6edatbslnjhz3kb2pkbphqv5py	132	18	24	24	CD
work_6edatbslnjhz3kb2pkbphqv5py	132	19	)	)	-RRB-
work_6edatbslnjhz3kb2pkbphqv5py	132	20	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	133	1	This	this	DT
work_6edatbslnjhz3kb2pkbphqv5py	133	2	dose	dose	NN
work_6edatbslnjhz3kb2pkbphqv5py	133	3	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	133	4	schedule	schedule	NN
work_6edatbslnjhz3kb2pkbphqv5py	133	5	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	133	6	these	these	DT
work_6edatbslnjhz3kb2pkbphqv5py	133	7	agents	agent	NNS
work_6edatbslnjhz3kb2pkbphqv5py	133	8	had	have	VBD
work_6edatbslnjhz3kb2pkbphqv5py	133	9	never	never	RB
work_6edatbslnjhz3kb2pkbphqv5py	133	10	been	be	VBN
work_6edatbslnjhz3kb2pkbphqv5py	133	11	adequately	adequately	RB
work_6edatbslnjhz3kb2pkbphqv5py	133	12	tested	test	VBN
work_6edatbslnjhz3kb2pkbphqv5py	133	13	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	133	14	metastatic	metastatic	JJ
work_6edatbslnjhz3kb2pkbphqv5py	133	15	coborectal	coborectal	JJ
work_6edatbslnjhz3kb2pkbphqv5py	133	16	cancer	cancer	NN
work_6edatbslnjhz3kb2pkbphqv5py	133	17	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	134	1	The	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	134	2	University	University	NNP
work_6edatbslnjhz3kb2pkbphqv5py	134	3	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	134	4	Wisconsin	Wisconsin	NNP
work_6edatbslnjhz3kb2pkbphqv5py	134	5	randomized	randomize	VBN
work_6edatbslnjhz3kb2pkbphqv5py	134	6	study	study	NN
work_6edatbslnjhz3kb2pkbphqv5py	134	7	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	134	8	5-Hi	5-hi	CD
work_6edatbslnjhz3kb2pkbphqv5py	134	9	versus	versus	IN
work_6edatbslnjhz3kb2pkbphqv5py	134	10	5-Hi	5-hi	CD
work_6edatbslnjhz3kb2pkbphqv5py	134	11	plus	plus	CC
work_6edatbslnjhz3kb2pkbphqv5py	134	12	levamisole	levamisole	NN
work_6edatbslnjhz3kb2pkbphqv5py	134	13	showed	show	VBD
work_6edatbslnjhz3kb2pkbphqv5py	134	14	a	a	DT
work_6edatbslnjhz3kb2pkbphqv5py	134	15	statistically	statistically	RB
work_6edatbslnjhz3kb2pkbphqv5py	134	16	significant	significant	JJ
work_6edatbslnjhz3kb2pkbphqv5py	134	17	advantage	advantage	NN
work_6edatbslnjhz3kb2pkbphqv5py	134	18	for	for	IN
work_6edatbslnjhz3kb2pkbphqv5py	134	19	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	134	20	combination	combination	NN
work_6edatbslnjhz3kb2pkbphqv5py	134	21	(	(	-LRB-
work_6edatbslnjhz3kb2pkbphqv5py	134	22	26	26	CD
work_6edatbslnjhz3kb2pkbphqv5py	134	23	)	)	-RRB-
work_6edatbslnjhz3kb2pkbphqv5py	134	24	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	135	1	However	however	RB
work_6edatbslnjhz3kb2pkbphqv5py	135	2	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	135	3	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	135	4	dosage	dosage	NN
work_6edatbslnjhz3kb2pkbphqv5py	135	5	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	135	6	schedule	schedule	NN
work_6edatbslnjhz3kb2pkbphqv5py	135	7	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	135	8	these	these	DT
work_6edatbslnjhz3kb2pkbphqv5py	135	9	agents	agent	NNS
work_6edatbslnjhz3kb2pkbphqv5py	135	10	was	be	VBD
work_6edatbslnjhz3kb2pkbphqv5py	135	11	different	different	JJ
work_6edatbslnjhz3kb2pkbphqv5py	135	12	from	from	IN
work_6edatbslnjhz3kb2pkbphqv5py	135	13	that	that	DT
work_6edatbslnjhz3kb2pkbphqv5py	135	14	used	use	VBN
work_6edatbslnjhz3kb2pkbphqv5py	135	15	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	135	16	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	135	17	successful	successful	JJ
work_6edatbslnjhz3kb2pkbphqv5py	135	18	adjuvant	adjuvant	JJ
work_6edatbslnjhz3kb2pkbphqv5py	135	19	trials	trial	NNS
work_6edatbslnjhz3kb2pkbphqv5py	135	20	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	136	1	Furthermore	furthermore	RB
work_6edatbslnjhz3kb2pkbphqv5py	136	2	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	136	3	only	only	RB
work_6edatbslnjhz3kb2pkbphqv5py	136	4	19	19	CD
work_6edatbslnjhz3kb2pkbphqv5py	136	5	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	136	6	72	72	CD
work_6edatbslnjhz3kb2pkbphqv5py	136	7	patients	patient	NNS
work_6edatbslnjhz3kb2pkbphqv5py	136	8	on	on	IN
work_6edatbslnjhz3kb2pkbphqv5py	136	9	this	this	DT
work_6edatbslnjhz3kb2pkbphqv5py	136	10	study	study	NN
work_6edatbslnjhz3kb2pkbphqv5py	136	11	had	have	VBD
work_6edatbslnjhz3kb2pkbphqv5py	136	12	measurable	measurable	JJ
work_6edatbslnjhz3kb2pkbphqv5py	136	13	disease	disease	NN
work_6edatbslnjhz3kb2pkbphqv5py	136	14	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	137	1	Adjustment	adjustment	NN
work_6edatbslnjhz3kb2pkbphqv5py	137	2	by	by	IN
work_6edatbslnjhz3kb2pkbphqv5py	137	3	a	a	DT
work_6edatbslnjhz3kb2pkbphqv5py	137	4	Cox	Cox	NNP
work_6edatbslnjhz3kb2pkbphqv5py	137	5	regression	regression	NN
work_6edatbslnjhz3kb2pkbphqv5py	137	6	model	model	NN
work_6edatbslnjhz3kb2pkbphqv5py	137	7	for	for	IN
work_6edatbslnjhz3kb2pkbphqv5py	137	8	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	137	9	influence	influence	NN
work_6edatbslnjhz3kb2pkbphqv5py	137	10	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	137	11	measurable	measurable	JJ
work_6edatbslnjhz3kb2pkbphqv5py	137	12	disease	disease	NN
work_6edatbslnjhz3kb2pkbphqv5py	137	13	re-	re-	RB
work_6edatbslnjhz3kb2pkbphqv5py	137	14	duced	duce	VBD
work_6edatbslnjhz3kb2pkbphqv5py	137	15	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	137	16	significance	significance	NN
work_6edatbslnjhz3kb2pkbphqv5py	137	17	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	137	18	treatment	treatment	NN
work_6edatbslnjhz3kb2pkbphqv5py	137	19	difference	difference	NN
work_6edatbslnjhz3kb2pkbphqv5py	137	20	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	138	1	The	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	138	2	NCCTG	NCCTG	NNP
work_6edatbslnjhz3kb2pkbphqv5py	138	3	study	study	NN
work_6edatbslnjhz3kb2pkbphqv5py	138	4	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	138	5	metastatic	metastatic	JJ
work_6edatbslnjhz3kb2pkbphqv5py	138	6	coborectal	coborectal	NN
work_6edatbslnjhz3kb2pkbphqv5py	138	7	cancer	cancer	NN
work_6edatbslnjhz3kb2pkbphqv5py	138	8	was	be	VBD
work_6edatbslnjhz3kb2pkbphqv5py	138	9	a	a	DT
work_6edatbslnjhz3kb2pkbphqv5py	138	10	5-arm	5-arm	NNP
work_6edatbslnjhz3kb2pkbphqv5py	138	11	trial	trial	NN
work_6edatbslnjhz3kb2pkbphqv5py	138	12	testing	test	VBG
work_6edatbslnjhz3kb2pkbphqv5py	138	13	5-Hi	5-hi	CD
work_6edatbslnjhz3kb2pkbphqv5py	138	14	against	against	IN
work_6edatbslnjhz3kb2pkbphqv5py	138	15	various	various	JJ
work_6edatbslnjhz3kb2pkbphqv5py	138	16	combinations	combination	NNS
work_6edatbslnjhz3kb2pkbphqv5py	138	17	with	with	IN
work_6edatbslnjhz3kb2pkbphqv5py	138	18	5-FU	5-fu	CD
work_6edatbslnjhz3kb2pkbphqv5py	138	19	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	138	20	included	include	VBD
work_6edatbslnjhz3kb2pkbphqv5py	138	21	a	a	DT
work_6edatbslnjhz3kb2pkbphqv5py	138	22	5-Hi	5-hi	CD
work_6edatbslnjhz3kb2pkbphqv5py	138	23	plus	plus	CC
work_6edatbslnjhz3kb2pkbphqv5py	138	24	levamisole	levamisole	NN
work_6edatbslnjhz3kb2pkbphqv5py	138	25	arm	arm	NN
work_6edatbslnjhz3kb2pkbphqv5py	138	26	(	(	-LRB-
work_6edatbslnjhz3kb2pkbphqv5py	138	27	20	20	CD
work_6edatbslnjhz3kb2pkbphqv5py	138	28	)	)	-RRB-
work_6edatbslnjhz3kb2pkbphqv5py	138	29	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	139	1	Again	again	RB
work_6edatbslnjhz3kb2pkbphqv5py	139	2	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	139	3	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	139	4	dosage	dosage	NN
work_6edatbslnjhz3kb2pkbphqv5py	139	5	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	139	6	schedule	schedule	NN
work_6edatbslnjhz3kb2pkbphqv5py	139	7	were	be	VBD
work_6edatbslnjhz3kb2pkbphqv5py	139	8	different	different	JJ
work_6edatbslnjhz3kb2pkbphqv5py	139	9	from	from	IN
work_6edatbslnjhz3kb2pkbphqv5py	139	10	those	those	DT
work_6edatbslnjhz3kb2pkbphqv5py	139	11	used	use	VBN
work_6edatbslnjhz3kb2pkbphqv5py	139	12	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	139	13	their	-PRON-	PRP$
work_6edatbslnjhz3kb2pkbphqv5py	139	14	subsequent	subsequent	JJ
work_6edatbslnjhz3kb2pkbphqv5py	139	15	adjuvant	adjuvant	JJ
work_6edatbslnjhz3kb2pkbphqv5py	139	16	study	study	NN
work_6edatbslnjhz3kb2pkbphqv5py	139	17	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	140	1	This	this	DT
work_6edatbslnjhz3kb2pkbphqv5py	140	2	study	study	NN
work_6edatbslnjhz3kb2pkbphqv5py	140	3	failed	fail	VBD
work_6edatbslnjhz3kb2pkbphqv5py	140	4	to	to	TO
work_6edatbslnjhz3kb2pkbphqv5py	140	5	demonstrate	demonstrate	VB
work_6edatbslnjhz3kb2pkbphqv5py	140	6	superiority	superiority	NN
work_6edatbslnjhz3kb2pkbphqv5py	140	7	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	140	8	any	any	DT
work_6edatbslnjhz3kb2pkbphqv5py	140	9	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	140	10	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	140	11	combination	combination	NN
work_6edatbslnjhz3kb2pkbphqv5py	140	12	arms	arm	NNS
work_6edatbslnjhz3kb2pkbphqv5py	140	13	over	over	IN
work_6edatbslnjhz3kb2pkbphqv5py	140	14	5-Hi	5-hi	CD
work_6edatbslnjhz3kb2pkbphqv5py	140	15	alone	alone	JJ
work_6edatbslnjhz3kb2pkbphqv5py	140	16	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	141	1	Remarkably	remarkably	RB
work_6edatbslnjhz3kb2pkbphqv5py	141	2	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	141	3	5-Hi	5-hi	CD
work_6edatbslnjhz3kb2pkbphqv5py	141	4	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	141	5	this	this	DT
work_6edatbslnjhz3kb2pkbphqv5py	141	6	study	study	NN
work_6edatbslnjhz3kb2pkbphqv5py	141	7	had	have	VBD
work_6edatbslnjhz3kb2pkbphqv5py	141	8	a	a	DT
work_6edatbslnjhz3kb2pkbphqv5py	141	9	response	response	NN
work_6edatbslnjhz3kb2pkbphqv5py	141	10	rate	rate	NN
work_6edatbslnjhz3kb2pkbphqv5py	141	11	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	141	12	30	30	CD
work_6edatbslnjhz3kb2pkbphqv5py	141	13	%	%	NN
work_6edatbslnjhz3kb2pkbphqv5py	141	14	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	141	15	which	which	WDT
work_6edatbslnjhz3kb2pkbphqv5py	141	16	is	be	VBZ
work_6edatbslnjhz3kb2pkbphqv5py	141	17	unusually	unusually	RB
work_6edatbslnjhz3kb2pkbphqv5py	141	18	high	high	JJ
work_6edatbslnjhz3kb2pkbphqv5py	141	19	for	for	IN
work_6edatbslnjhz3kb2pkbphqv5py	141	20	5-Hi	5-hi	CD
work_6edatbslnjhz3kb2pkbphqv5py	141	21	as	as	IN
work_6edatbslnjhz3kb2pkbphqv5py	141	22	a	a	DT
work_6edatbslnjhz3kb2pkbphqv5py	141	23	single	single	JJ
work_6edatbslnjhz3kb2pkbphqv5py	141	24	agent	agent	NN
work_6edatbslnjhz3kb2pkbphqv5py	141	25	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	141	26	metastatic	metastatic	JJ
work_6edatbslnjhz3kb2pkbphqv5py	141	27	coborectal	coborectal	JJ
work_6edatbslnjhz3kb2pkbphqv5py	141	28	cancer	cancer	NN
work_6edatbslnjhz3kb2pkbphqv5py	141	29	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	142	1	The	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	142	2	Eastern	Eastern	NNP
work_6edatbslnjhz3kb2pkbphqv5py	142	3	Cooperative	Cooperative	NNP
work_6edatbslnjhz3kb2pkbphqv5py	142	4	Oncology	Oncology	NNP
work_6edatbslnjhz3kb2pkbphqv5py	142	5	Group	Group	NNP
work_6edatbslnjhz3kb2pkbphqv5py	142	6	has	have	VBZ
work_6edatbslnjhz3kb2pkbphqv5py	142	7	reported	report	VBN
work_6edatbslnjhz3kb2pkbphqv5py	142	8	a	a	DT
work_6edatbslnjhz3kb2pkbphqv5py	142	9	trial	trial	NN
work_6edatbslnjhz3kb2pkbphqv5py	142	10	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	142	11	5-Hi	5-hi	CD
work_6edatbslnjhz3kb2pkbphqv5py	142	12	versus	versus	IN
work_6edatbslnjhz3kb2pkbphqv5py	142	13	5-Hi	5-hi	CD
work_6edatbslnjhz3kb2pkbphqv5py	142	14	plus	plus	CC
work_6edatbslnjhz3kb2pkbphqv5py	142	15	levamisole	levamisole	NN
work_6edatbslnjhz3kb2pkbphqv5py	142	16	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	142	17	meta-	meta-	JJ
work_6edatbslnjhz3kb2pkbphqv5py	142	18	static	static	JJ
work_6edatbslnjhz3kb2pkbphqv5py	142	19	colorectal	colorectal	JJ
work_6edatbslnjhz3kb2pkbphqv5py	142	20	cancer	cancer	NN
work_6edatbslnjhz3kb2pkbphqv5py	142	21	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	142	22	patients	patient	NNS
work_6edatbslnjhz3kb2pkbphqv5py	142	23	with	with	IN
work_6edatbslnjhz3kb2pkbphqv5py	142	24	nonmeasurabbe	nonmeasurabbe	NNP
work_6edatbslnjhz3kb2pkbphqv5py	142	25	disease	disease	NN
work_6edatbslnjhz3kb2pkbphqv5py	142	26	on	on	IN
work_6edatbslnjhz3kb2pkbphqv5py	142	27	April	April	NNP
work_6edatbslnjhz3kb2pkbphqv5py	142	28	5	5	CD
work_6edatbslnjhz3kb2pkbphqv5py	142	29	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	142	30	2021	2021	CD
work_6edatbslnjhz3kb2pkbphqv5py	142	31	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	143	1	©	©	NNP
work_6edatbslnjhz3kb2pkbphqv5py	143	2	1998	1998	CD
work_6edatbslnjhz3kb2pkbphqv5py	143	3	American	American	NNP
work_6edatbslnjhz3kb2pkbphqv5py	143	4	Association	Association	NNP
work_6edatbslnjhz3kb2pkbphqv5py	143	5	for	for	IN
work_6edatbslnjhz3kb2pkbphqv5py	143	6	Cancer	Cancer	NNP
work_6edatbslnjhz3kb2pkbphqv5py	143	7	Research.clincancerres.aacrjournals.org	research.clincancerres.aacrjournals.org	NN
work_6edatbslnjhz3kb2pkbphqv5py	143	8	Downloaded	download	VBN
work_6edatbslnjhz3kb2pkbphqv5py	143	9	from	from	IN
work_6edatbslnjhz3kb2pkbphqv5py	143	10	http://clincancerres.aacrjournals.org/	http://clincancerres.aacrjournals.org/	ADD
work_6edatbslnjhz3kb2pkbphqv5py	143	11	Log	Log	NNP
work_6edatbslnjhz3kb2pkbphqv5py	143	12	Rank	Rank	NNP
work_6edatbslnjhz3kb2pkbphqv5py	143	13	Test	Test	NNP
work_6edatbslnjhz3kb2pkbphqv5py	143	14	:	:	:
work_6edatbslnjhz3kb2pkbphqv5py	143	15	p	p	NN
work_6edatbslnjhz3kb2pkbphqv5py	143	16	=	=	SYM
work_6edatbslnjhz3kb2pkbphqv5py	143	17	0.20	0.20	CD
work_6edatbslnjhz3kb2pkbphqv5py	143	18	median	median	JJ
work_6edatbslnjhz3kb2pkbphqv5py	143	19	48	48	CD
work_6edatbslnjhz3kb2pkbphqv5py	143	20	41	41	CD
work_6edatbslnjhz3kb2pkbphqv5py	143	21	938	938	CD
work_6edatbslnjhz3kb2pkbphqv5py	143	22	5-FU	5-fu	CD
work_6edatbslnjhz3kb2pkbphqv5py	143	23	+	+	SYM
work_6edatbslnjhz3kb2pkbphqv5py	143	24	/-	/-	.
work_6edatbslnjhz3kb2pkbphqv5py	143	25	Levamisole	levamisole	NN
work_6edatbslnjhz3kb2pkbphqv5py	143	26	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	143	27	Metastatic	Metastatic	NNP
work_6edatbslnjhz3kb2pkbphqv5py	143	28	Colorectal	Colorectal	NNP
work_6edatbslnjhz3kb2pkbphqv5py	143	29	Cancer	Cancer	NNP
work_6edatbslnjhz3kb2pkbphqv5py	143	30	a	a	DT
work_6edatbslnjhz3kb2pkbphqv5py	143	31	0	0	CD
work_6edatbslnjhz3kb2pkbphqv5py	143	32	I.0	I.0	NNP
work_6edatbslnjhz3kb2pkbphqv5py	143	33	0.8	0.8	CD
work_6edatbslnjhz3kb2pkbphqv5py	143	34	0.6	0.6	CD
work_6edatbslnjhz3kb2pkbphqv5py	143	35	0.4	0.4	CD
work_6edatbslnjhz3kb2pkbphqv5py	143	36	0.2	0.2	CD
work_6edatbslnjhz3kb2pkbphqv5py	143	37	0.0	0.0	CD
work_6edatbslnjhz3kb2pkbphqv5py	143	38	Survival	survival	NN
work_6edatbslnjhz3kb2pkbphqv5py	143	39	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	143	40	Weeks	Weeks	NNP
work_6edatbslnjhz3kb2pkbphqv5py	143	41	arm	arm	NN
work_6edatbslnjhz3kb2pkbphqv5py	143	42	cnsr	cnsr	NN
work_6edatbslnjhz3kb2pkbphqv5py	143	43	death	death	NN
work_6edatbslnjhz3kb2pkbphqv5py	143	44	tot	tot	NN
work_6edatbslnjhz3kb2pkbphqv5py	143	45	-5-FU	-5-FU	:
work_6edatbslnjhz3kb2pkbphqv5py	143	46	11	11	CD
work_6edatbslnjhz3kb2pkbphqv5py	143	47	83	83	CD
work_6edatbslnjhz3kb2pkbphqv5py	143	48	94	94	CD
work_6edatbslnjhz3kb2pkbphqv5py	143	49	5-FU+Levamisole	5-fu+levamisole	CD
work_6edatbslnjhz3kb2pkbphqv5py	143	50	3	3	CD
work_6edatbslnjhz3kb2pkbphqv5py	143	51	93	93	CD
work_6edatbslnjhz3kb2pkbphqv5py	143	52	96	96	CD
work_6edatbslnjhz3kb2pkbphqv5py	143	53	Fig	fig	NN
work_6edatbslnjhz3kb2pkbphqv5py	143	54	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	144	1	I	-PRON-	PRP
work_6edatbslnjhz3kb2pkbphqv5py	144	2	Survival	Survival	NNP
work_6edatbslnjhz3kb2pkbphqv5py	144	3	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	145	1	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	145	2	found	find	VBD
work_6edatbslnjhz3kb2pkbphqv5py	145	3	no	no	DT
work_6edatbslnjhz3kb2pkbphqv5py	145	4	benefit	benefit	NN
work_6edatbslnjhz3kb2pkbphqv5py	145	5	for	for	IN
work_6edatbslnjhz3kb2pkbphqv5py	145	6	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	145	7	combination	combination	NN
work_6edatbslnjhz3kb2pkbphqv5py	145	8	(	(	-LRB-
work_6edatbslnjhz3kb2pkbphqv5py	145	9	27	27	CD
work_6edatbslnjhz3kb2pkbphqv5py	145	10	)	)	-RRB-
work_6edatbslnjhz3kb2pkbphqv5py	145	11	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	146	1	However	however	RB
work_6edatbslnjhz3kb2pkbphqv5py	146	2	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	146	3	this	this	DT
work_6edatbslnjhz3kb2pkbphqv5py	146	4	study	study	NN
work_6edatbslnjhz3kb2pkbphqv5py	146	5	has	have	VBZ
work_6edatbslnjhz3kb2pkbphqv5py	146	6	been	be	VBN
work_6edatbslnjhz3kb2pkbphqv5py	146	7	reported	report	VBN
work_6edatbslnjhz3kb2pkbphqv5py	146	8	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	146	9	abstract	abstract	JJ
work_6edatbslnjhz3kb2pkbphqv5py	146	10	form	form	NN
work_6edatbslnjhz3kb2pkbphqv5py	146	11	only	only	RB
work_6edatbslnjhz3kb2pkbphqv5py	146	12	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	146	13	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	146	14	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	146	15	doses	dose	NNS
work_6edatbslnjhz3kb2pkbphqv5py	146	16	are	be	VBP
work_6edatbslnjhz3kb2pkbphqv5py	146	17	different	different	JJ
work_6edatbslnjhz3kb2pkbphqv5py	146	18	from	from	IN
work_6edatbslnjhz3kb2pkbphqv5py	146	19	those	those	DT
work_6edatbslnjhz3kb2pkbphqv5py	146	20	used	use	VBN
work_6edatbslnjhz3kb2pkbphqv5py	146	21	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	146	22	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	146	23	NCCTG	NCCTG	NNP
work_6edatbslnjhz3kb2pkbphqv5py	146	24	(	(	-LRB-
work_6edatbslnjhz3kb2pkbphqv5py	146	25	24	24	CD
work_6edatbslnjhz3kb2pkbphqv5py	146	26	)	)	-RRB-
work_6edatbslnjhz3kb2pkbphqv5py	146	27	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	146	28	intergroup	intergroup	NNP
work_6edatbslnjhz3kb2pkbphqv5py	146	29	(	(	-LRB-
work_6edatbslnjhz3kb2pkbphqv5py	146	30	25	25	CD
work_6edatbslnjhz3kb2pkbphqv5py	146	31	)	)	-RRB-
work_6edatbslnjhz3kb2pkbphqv5py	146	32	studies	study	NNS
work_6edatbslnjhz3kb2pkbphqv5py	146	33	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	147	1	Therefore	therefore	RB
work_6edatbslnjhz3kb2pkbphqv5py	147	2	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	147	3	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	147	4	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	147	5	adjuvant	adjuvant	JJ
work_6edatbslnjhz3kb2pkbphqv5py	147	6	setting	setting	NN
work_6edatbslnjhz3kb2pkbphqv5py	147	7	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	147	8	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	147	9	success	success	NN
work_6edatbslnjhz3kb2pkbphqv5py	147	10	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	147	11	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	147	12	5-Hi	5-hi	CD
work_6edatbslnjhz3kb2pkbphqv5py	147	13	plus	plus	CC
work_6edatbslnjhz3kb2pkbphqv5py	147	14	levamisole	levamisole	NN
work_6edatbslnjhz3kb2pkbphqv5py	147	15	regimen	regiman	NNS
work_6edatbslnjhz3kb2pkbphqv5py	147	16	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	147	17	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	147	18	NCCTG	NCCTG	NNP
work_6edatbslnjhz3kb2pkbphqv5py	147	19	trial	trial	NN
work_6edatbslnjhz3kb2pkbphqv5py	147	20	(	(	-LRB-
work_6edatbslnjhz3kb2pkbphqv5py	147	21	24	24	CD
work_6edatbslnjhz3kb2pkbphqv5py	147	22	)	)	-RRB-
work_6edatbslnjhz3kb2pkbphqv5py	147	23	was	be	VBD
work_6edatbslnjhz3kb2pkbphqv5py	147	24	quite	quite	RB
work_6edatbslnjhz3kb2pkbphqv5py	147	25	surprising	surprising	JJ
work_6edatbslnjhz3kb2pkbphqv5py	147	26	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	147	27	bed	bed	NN
work_6edatbslnjhz3kb2pkbphqv5py	147	28	to	to	IN
work_6edatbslnjhz3kb2pkbphqv5py	147	29	some	some	DT
work_6edatbslnjhz3kb2pkbphqv5py	147	30	skepticism	skepticism	NN
work_6edatbslnjhz3kb2pkbphqv5py	147	31	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	148	1	However	however	RB
work_6edatbslnjhz3kb2pkbphqv5py	148	2	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	148	3	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	148	4	results	result	NNS
work_6edatbslnjhz3kb2pkbphqv5py	148	5	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	148	6	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	148	7	larger	large	JJR
work_6edatbslnjhz3kb2pkbphqv5py	148	8	intergroup	intergroup	NNP
work_6edatbslnjhz3kb2pkbphqv5py	148	9	study	study	NN
work_6edatbslnjhz3kb2pkbphqv5py	148	10	(	(	-LRB-
work_6edatbslnjhz3kb2pkbphqv5py	148	11	25	25	CD
work_6edatbslnjhz3kb2pkbphqv5py	148	12	)	)	-RRB-
work_6edatbslnjhz3kb2pkbphqv5py	148	13	established	establish	VBD
work_6edatbslnjhz3kb2pkbphqv5py	148	14	5-Hi	5-hi	CD
work_6edatbslnjhz3kb2pkbphqv5py	148	15	plus	plus	CC
work_6edatbslnjhz3kb2pkbphqv5py	148	16	levamisole	levamisole	NN
work_6edatbslnjhz3kb2pkbphqv5py	148	17	as	as	IN
work_6edatbslnjhz3kb2pkbphqv5py	148	18	standard	standard	JJ
work_6edatbslnjhz3kb2pkbphqv5py	148	19	adjuvant	adjuvant	NN
work_6edatbslnjhz3kb2pkbphqv5py	148	20	therapy	therapy	NN
work_6edatbslnjhz3kb2pkbphqv5py	148	21	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	148	22	completely	completely	RB
work_6edatbslnjhz3kb2pkbphqv5py	148	23	resected	resect	VBN
work_6edatbslnjhz3kb2pkbphqv5py	148	24	stage	stage	NN
work_6edatbslnjhz3kb2pkbphqv5py	148	25	III	iii	CD
work_6edatbslnjhz3kb2pkbphqv5py	148	26	colorectal	colorectal	JJ
work_6edatbslnjhz3kb2pkbphqv5py	148	27	cancer	cancer	NN
work_6edatbslnjhz3kb2pkbphqv5py	148	28	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	149	1	It	-PRON-	PRP
work_6edatbslnjhz3kb2pkbphqv5py	149	2	is	be	VBZ
work_6edatbslnjhz3kb2pkbphqv5py	149	3	unusual	unusual	JJ
work_6edatbslnjhz3kb2pkbphqv5py	149	4	for	for	IN
work_6edatbslnjhz3kb2pkbphqv5py	149	5	a	a	DT
work_6edatbslnjhz3kb2pkbphqv5py	149	6	regimen	regimen	NN
work_6edatbslnjhz3kb2pkbphqv5py	149	7	to	to	TO
work_6edatbslnjhz3kb2pkbphqv5py	149	8	prolong	prolong	JJ
work_6edatbslnjhz3kb2pkbphqv5py	149	9	survival	survival	NN
work_6edatbslnjhz3kb2pkbphqv5py	149	10	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	149	11	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	149	12	adjuvant	adjuvant	JJ
work_6edatbslnjhz3kb2pkbphqv5py	149	13	setting	setting	NN
work_6edatbslnjhz3kb2pkbphqv5py	149	14	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	149	15	have	have	VBP
work_6edatbslnjhz3kb2pkbphqv5py	149	16	no	no	DT
work_6edatbslnjhz3kb2pkbphqv5py	149	17	substantive	substantive	JJ
work_6edatbslnjhz3kb2pkbphqv5py	149	18	activity	activity	NN
work_6edatbslnjhz3kb2pkbphqv5py	149	19	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	149	20	metastatic	metastatic	JJ
work_6edatbslnjhz3kb2pkbphqv5py	149	21	disease	disease	NN
work_6edatbslnjhz3kb2pkbphqv5py	149	22	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	150	1	This	this	DT
work_6edatbslnjhz3kb2pkbphqv5py	150	2	trial	trial	NN
work_6edatbslnjhz3kb2pkbphqv5py	150	3	included	include	VBD
work_6edatbslnjhz3kb2pkbphqv5py	150	4	patients	patient	NNS
work_6edatbslnjhz3kb2pkbphqv5py	150	5	with	with	IN
work_6edatbslnjhz3kb2pkbphqv5py	150	6	metastatic	metastatic	JJ
work_6edatbslnjhz3kb2pkbphqv5py	150	7	colorectal	colorectal	JJ
work_6edatbslnjhz3kb2pkbphqv5py	150	8	cancer	cancer	NN
work_6edatbslnjhz3kb2pkbphqv5py	150	9	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	150	10	most	most	JJS
work_6edatbslnjhz3kb2pkbphqv5py	150	11	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	150	12	whom	whom	WP
work_6edatbslnjhz3kb2pkbphqv5py	150	13	had	have	VBD
work_6edatbslnjhz3kb2pkbphqv5py	150	14	good	good	JJ
work_6edatbslnjhz3kb2pkbphqv5py	150	15	performance	performance	NN
work_6edatbslnjhz3kb2pkbphqv5py	150	16	status	status	NN
work_6edatbslnjhz3kb2pkbphqv5py	150	17	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	151	1	Both	both	DT
work_6edatbslnjhz3kb2pkbphqv5py	151	2	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	151	3	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	151	4	patient	patient	JJ
work_6edatbslnjhz3kb2pkbphqv5py	151	5	groups	group	NNS
work_6edatbslnjhz3kb2pkbphqv5py	151	6	were	be	VBD
work_6edatbslnjhz3kb2pkbphqv5py	151	7	well	well	RB
work_6edatbslnjhz3kb2pkbphqv5py	151	8	matched	match	VBN
work_6edatbslnjhz3kb2pkbphqv5py	151	9	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	152	1	The	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	152	2	combination	combination	NN
work_6edatbslnjhz3kb2pkbphqv5py	152	3	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	152	4	5-FU	5-fu	CD
work_6edatbslnjhz3kb2pkbphqv5py	152	5	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	152	6	levamisole	levamisole	NNP
work_6edatbslnjhz3kb2pkbphqv5py	152	7	failed	fail	VBD
work_6edatbslnjhz3kb2pkbphqv5py	152	8	to	to	TO
work_6edatbslnjhz3kb2pkbphqv5py	152	9	demonstrate	demonstrate	VB
work_6edatbslnjhz3kb2pkbphqv5py	152	10	any	any	DT
work_6edatbslnjhz3kb2pkbphqv5py	152	11	superiority	superiority	NN
work_6edatbslnjhz3kb2pkbphqv5py	152	12	over	over	IN
work_6edatbslnjhz3kb2pkbphqv5py	152	13	5-FU	5-fu	CD
work_6edatbslnjhz3kb2pkbphqv5py	152	14	alone	alone	RB
work_6edatbslnjhz3kb2pkbphqv5py	152	15	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	152	16	terms	term	NNS
work_6edatbslnjhz3kb2pkbphqv5py	152	17	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	152	18	response	response	NN
work_6edatbslnjhz3kb2pkbphqv5py	152	19	rate	rate	NN
work_6edatbslnjhz3kb2pkbphqv5py	152	20	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	152	21	duration	duration	NN
work_6edatbslnjhz3kb2pkbphqv5py	152	22	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	152	23	remission	remission	NN
work_6edatbslnjhz3kb2pkbphqv5py	152	24	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	152	25	or	or	CC
work_6edatbslnjhz3kb2pkbphqv5py	152	26	sur-	sur-	RB
work_6edatbslnjhz3kb2pkbphqv5py	152	27	vival	vival	NN
work_6edatbslnjhz3kb2pkbphqv5py	152	28	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	153	1	Another	another	DT
work_6edatbslnjhz3kb2pkbphqv5py	153	2	interesting	interesting	JJ
work_6edatbslnjhz3kb2pkbphqv5py	153	3	aspect	aspect	NN
work_6edatbslnjhz3kb2pkbphqv5py	153	4	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	153	5	this	this	DT
work_6edatbslnjhz3kb2pkbphqv5py	153	6	trial	trial	NN
work_6edatbslnjhz3kb2pkbphqv5py	153	7	is	be	VBZ
work_6edatbslnjhz3kb2pkbphqv5py	153	8	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	153	9	toxicity	toxicity	NN
work_6edatbslnjhz3kb2pkbphqv5py	153	10	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	153	11	5-Hi	5-hi	CD
work_6edatbslnjhz3kb2pkbphqv5py	153	12	plus	plus	CC
work_6edatbslnjhz3kb2pkbphqv5py	153	13	levamisole	levamisole	NN
work_6edatbslnjhz3kb2pkbphqv5py	153	14	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	154	1	In	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	154	2	prior	prior	JJ
work_6edatbslnjhz3kb2pkbphqv5py	154	3	studies	study	NNS
work_6edatbslnjhz3kb2pkbphqv5py	154	4	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	154	5	coborectal	coborectal	JJ
work_6edatbslnjhz3kb2pkbphqv5py	154	6	cancer	cancer	NN
work_6edatbslnjhz3kb2pkbphqv5py	154	7	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	154	8	levamisole	levamisole	NN
work_6edatbslnjhz3kb2pkbphqv5py	154	9	has	have	VBZ
work_6edatbslnjhz3kb2pkbphqv5py	154	10	not	not	RB
work_6edatbslnjhz3kb2pkbphqv5py	154	11	been	be	VBN
work_6edatbslnjhz3kb2pkbphqv5py	154	12	shown	show	VBN
work_6edatbslnjhz3kb2pkbphqv5py	154	13	to	to	TO
work_6edatbslnjhz3kb2pkbphqv5py	154	14	have	have	VB
work_6edatbslnjhz3kb2pkbphqv5py	154	15	significant	significant	JJ
work_6edatbslnjhz3kb2pkbphqv5py	154	16	hematolog-	hematolog-	JJ
work_6edatbslnjhz3kb2pkbphqv5py	154	17	ical	ical	JJ
work_6edatbslnjhz3kb2pkbphqv5py	154	18	toxicity	toxicity	NN
work_6edatbslnjhz3kb2pkbphqv5py	154	19	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	154	20	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	154	21	only	only	JJ
work_6edatbslnjhz3kb2pkbphqv5py	154	22	minor	minor	JJ
work_6edatbslnjhz3kb2pkbphqv5py	154	23	nonhematological	nonhematological	JJ
work_6edatbslnjhz3kb2pkbphqv5py	154	24	toxicities	toxicity	NNS
work_6edatbslnjhz3kb2pkbphqv5py	154	25	such	such	JJ
work_6edatbslnjhz3kb2pkbphqv5py	154	26	as	as	IN
work_6edatbslnjhz3kb2pkbphqv5py	154	27	mild	mild	JJ
work_6edatbslnjhz3kb2pkbphqv5py	154	28	nausea	nausea	NN
work_6edatbslnjhz3kb2pkbphqv5py	154	29	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	154	30	stomatitis	stomatitis	NNP
work_6edatbslnjhz3kb2pkbphqv5py	154	31	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	154	32	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	154	33	diarrhea	diarrhea	NN
work_6edatbslnjhz3kb2pkbphqv5py	154	34	have	have	VBP
work_6edatbslnjhz3kb2pkbphqv5py	154	35	been	be	VBN
work_6edatbslnjhz3kb2pkbphqv5py	154	36	reported	report	VBN
work_6edatbslnjhz3kb2pkbphqv5py	154	37	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	155	1	Treat-	Treat-	NNP
work_6edatbslnjhz3kb2pkbphqv5py	155	2	ment	ment	JJ
work_6edatbslnjhz3kb2pkbphqv5py	155	3	-	-	HYPH
work_6edatbslnjhz3kb2pkbphqv5py	155	4	related	relate	VBN
work_6edatbslnjhz3kb2pkbphqv5py	155	5	deaths	death	NNS
work_6edatbslnjhz3kb2pkbphqv5py	155	6	were	be	VBD
work_6edatbslnjhz3kb2pkbphqv5py	155	7	rare	rare	JJ
work_6edatbslnjhz3kb2pkbphqv5py	155	8	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	155	9	these	these	DT
work_6edatbslnjhz3kb2pkbphqv5py	155	10	studies	study	NNS
work_6edatbslnjhz3kb2pkbphqv5py	155	11	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	156	1	Even	even	RB
work_6edatbslnjhz3kb2pkbphqv5py	156	2	trials	trial	NNS
work_6edatbslnjhz3kb2pkbphqv5py	156	3	that	that	WDT
work_6edatbslnjhz3kb2pkbphqv5py	156	4	have	have	VBP
work_6edatbslnjhz3kb2pkbphqv5py	156	5	tested	test	VBN
work_6edatbslnjhz3kb2pkbphqv5py	156	6	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	156	7	5-Hi	5-Hi	NNP
work_6edatbslnjhz3kb2pkbphqv5py	156	8	plus	plus	CC
work_6edatbslnjhz3kb2pkbphqv5py	156	9	levamisole	levamisole	NN
work_6edatbslnjhz3kb2pkbphqv5py	156	10	combination	combination	NN
work_6edatbslnjhz3kb2pkbphqv5py	156	11	have	have	VBP
work_6edatbslnjhz3kb2pkbphqv5py	156	12	not	not	RB
work_6edatbslnjhz3kb2pkbphqv5py	156	13	reported	report	VBN
work_6edatbslnjhz3kb2pkbphqv5py	156	14	any	any	DT
work_6edatbslnjhz3kb2pkbphqv5py	156	15	increase	increase	NN
work_6edatbslnjhz3kb2pkbphqv5py	156	16	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	156	17	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	156	18	usual	usual	JJ
work_6edatbslnjhz3kb2pkbphqv5py	156	19	5-Hi	5-hi	CD
work_6edatbslnjhz3kb2pkbphqv5py	156	20	toxicity	toxicity	NN
work_6edatbslnjhz3kb2pkbphqv5py	156	21	with	with	IN
work_6edatbslnjhz3kb2pkbphqv5py	156	22	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	156	23	com-	com-	NN
work_6edatbslnjhz3kb2pkbphqv5py	156	24	bination	bination	NN
work_6edatbslnjhz3kb2pkbphqv5py	156	25	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	157	1	Longr#{233}eet	Longr#{233}eet	NNP
work_6edatbslnjhz3kb2pkbphqv5py	157	2	al	al	NNP
work_6edatbslnjhz3kb2pkbphqv5py	157	3	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	158	1	(	(	-LRB-
work_6edatbslnjhz3kb2pkbphqv5py	158	2	32	32	CD
work_6edatbslnjhz3kb2pkbphqv5py	158	3	)	)	-RRB-
work_6edatbslnjhz3kb2pkbphqv5py	158	4	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	158	5	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	158	6	their	-PRON-	PRP$
work_6edatbslnjhz3kb2pkbphqv5py	158	7	studies	study	NNS
work_6edatbslnjhz3kb2pkbphqv5py	158	8	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	158	9	adjuvant	adjuvant	JJ
work_6edatbslnjhz3kb2pkbphqv5py	158	10	therapy	therapy	NN
work_6edatbslnjhz3kb2pkbphqv5py	158	11	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	158	12	Duke	Duke	NNP
work_6edatbslnjhz3kb2pkbphqv5py	158	13	’s	’s	NNP
work_6edatbslnjhz3kb2pkbphqv5py	158	14	B	B	NNP
work_6edatbslnjhz3kb2pkbphqv5py	158	15	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	158	16	C	C	NNP
work_6edatbslnjhz3kb2pkbphqv5py	158	17	coborectal	coborectal	NN
work_6edatbslnjhz3kb2pkbphqv5py	158	18	cancer	cancer	NN
work_6edatbslnjhz3kb2pkbphqv5py	158	19	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	158	20	found	find	VBD
work_6edatbslnjhz3kb2pkbphqv5py	158	21	a	a	DT
work_6edatbslnjhz3kb2pkbphqv5py	158	22	higher	high	JJR
work_6edatbslnjhz3kb2pkbphqv5py	158	23	incidence	incidence	NN
work_6edatbslnjhz3kb2pkbphqv5py	158	24	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	158	25	grade	grade	NN
work_6edatbslnjhz3kb2pkbphqv5py	158	26	III	III	NNP
work_6edatbslnjhz3kb2pkbphqv5py	158	27	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	158	28	iv	iv	NN
work_6edatbslnjhz3kb2pkbphqv5py	158	29	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	159	1	granulocytopenia	granulocytopenia	NNP
work_6edatbslnjhz3kb2pkbphqv5py	159	2	when	when	WRB
work_6edatbslnjhz3kb2pkbphqv5py	159	3	levamisole	levamisole	NNP
work_6edatbslnjhz3kb2pkbphqv5py	159	4	was	be	VBD
work_6edatbslnjhz3kb2pkbphqv5py	159	5	added	add	VBN
work_6edatbslnjhz3kb2pkbphqv5py	159	6	to	to	IN
work_6edatbslnjhz3kb2pkbphqv5py	159	7	5-Hi	5-hi	CD
work_6edatbslnjhz3kb2pkbphqv5py	159	8	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	160	1	In	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	160	2	our	-PRON-	PRP$
work_6edatbslnjhz3kb2pkbphqv5py	160	3	study	study	NN
work_6edatbslnjhz3kb2pkbphqv5py	160	4	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	160	5	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	160	6	incidence	incidence	NN
work_6edatbslnjhz3kb2pkbphqv5py	160	7	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	160	8	grade	grade	NN
work_6edatbslnjhz3kb2pkbphqv5py	160	9	3/4	3/4	CD
work_6edatbslnjhz3kb2pkbphqv5py	160	10	diarrhea	diarrhea	NN
work_6edatbslnjhz3kb2pkbphqv5py	160	11	was	be	VBD
work_6edatbslnjhz3kb2pkbphqv5py	160	12	significantly	significantly	RB
work_6edatbslnjhz3kb2pkbphqv5py	160	13	higher	high	JJR
work_6edatbslnjhz3kb2pkbphqv5py	160	14	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	160	15	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	160	16	5-FU	5-fu	CD
work_6edatbslnjhz3kb2pkbphqv5py	160	17	plus	plus	JJ
work_6edatbslnjhz3kb2pkbphqv5py	160	18	levamisole	levamisole	NN
work_6edatbslnjhz3kb2pkbphqv5py	160	19	arm	arm	NN
work_6edatbslnjhz3kb2pkbphqv5py	160	20	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	160	21	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	160	22	there	there	EX
work_6edatbslnjhz3kb2pkbphqv5py	160	23	was	be	VBD
work_6edatbslnjhz3kb2pkbphqv5py	160	24	a	a	DT
work_6edatbslnjhz3kb2pkbphqv5py	160	25	trend	trend	NN
work_6edatbslnjhz3kb2pkbphqv5py	160	26	toward	toward	IN
work_6edatbslnjhz3kb2pkbphqv5py	160	27	higher	high	JJR
work_6edatbslnjhz3kb2pkbphqv5py	160	28	incidence	incidence	NN
work_6edatbslnjhz3kb2pkbphqv5py	160	29	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	160	30	grade	grade	NNP
work_6edatbslnjhz3kb2pkbphqv5py	160	31	3/4	3/4	CD
work_6edatbslnjhz3kb2pkbphqv5py	160	32	granu-	granu-	NNP
work_6edatbslnjhz3kb2pkbphqv5py	160	33	locytopenia	locytopenia	NNP
work_6edatbslnjhz3kb2pkbphqv5py	160	34	as	as	RB
work_6edatbslnjhz3kb2pkbphqv5py	160	35	well	well	RB
work_6edatbslnjhz3kb2pkbphqv5py	160	36	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	161	1	Treatment	treatment	NN
work_6edatbslnjhz3kb2pkbphqv5py	161	2	compliance	compliance	NN
work_6edatbslnjhz3kb2pkbphqv5py	161	3	was	be	VBD
work_6edatbslnjhz3kb2pkbphqv5py	161	4	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	161	5	however	however	RB
work_6edatbslnjhz3kb2pkbphqv5py	161	6	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	161	7	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	161	8	same	same	JJ
work_6edatbslnjhz3kb2pkbphqv5py	161	9	as	as	IN
work_6edatbslnjhz3kb2pkbphqv5py	161	10	for	for	IN
work_6edatbslnjhz3kb2pkbphqv5py	161	11	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	161	12	5-Hi	5-hi	CD
work_6edatbslnjhz3kb2pkbphqv5py	161	13	arm	arm	NN
work_6edatbslnjhz3kb2pkbphqv5py	161	14	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	162	1	This	this	DT
work_6edatbslnjhz3kb2pkbphqv5py	162	2	study	study	NN
work_6edatbslnjhz3kb2pkbphqv5py	162	3	indirectly	indirectly	RB
work_6edatbslnjhz3kb2pkbphqv5py	162	4	raises	raise	VBZ
work_6edatbslnjhz3kb2pkbphqv5py	162	5	questions	question	NNS
work_6edatbslnjhz3kb2pkbphqv5py	162	6	about	about	IN
work_6edatbslnjhz3kb2pkbphqv5py	162	7	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	162	8	role	role	NN
work_6edatbslnjhz3kb2pkbphqv5py	162	9	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	162	10	levamisole	levamisole	NN
work_6edatbslnjhz3kb2pkbphqv5py	162	11	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	162	12	adjuvant	adjuvant	JJ
work_6edatbslnjhz3kb2pkbphqv5py	162	13	therapy	therapy	NN
work_6edatbslnjhz3kb2pkbphqv5py	162	14	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	162	15	colon	colon	NN
work_6edatbslnjhz3kb2pkbphqv5py	162	16	cancer	cancer	NN
work_6edatbslnjhz3kb2pkbphqv5py	162	17	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	163	1	There	there	EX
work_6edatbslnjhz3kb2pkbphqv5py	163	2	have	have	VBP
work_6edatbslnjhz3kb2pkbphqv5py	163	3	been	be	VBN
work_6edatbslnjhz3kb2pkbphqv5py	163	4	speculations	speculation	NNS
work_6edatbslnjhz3kb2pkbphqv5py	163	5	that	that	WDT
work_6edatbslnjhz3kb2pkbphqv5py	163	6	levamisole	levamisole	NN
work_6edatbslnjhz3kb2pkbphqv5py	163	7	has	have	VBZ
work_6edatbslnjhz3kb2pkbphqv5py	163	8	no	no	DT
work_6edatbslnjhz3kb2pkbphqv5py	163	9	role	role	NN
work_6edatbslnjhz3kb2pkbphqv5py	163	10	at	at	RB
work_6edatbslnjhz3kb2pkbphqv5py	163	11	all	all	RB
work_6edatbslnjhz3kb2pkbphqv5py	163	12	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	163	13	that	that	IN
work_6edatbslnjhz3kb2pkbphqv5py	163	14	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	163	15	successful	successful	JJ
work_6edatbslnjhz3kb2pkbphqv5py	163	16	adjuvant	adjuvant	JJ
work_6edatbslnjhz3kb2pkbphqv5py	163	17	studies	study	NNS
work_6edatbslnjhz3kb2pkbphqv5py	163	18	demonstrate	demonstrate	VBP
work_6edatbslnjhz3kb2pkbphqv5py	163	19	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	163	20	effectiveness	effectiveness	NN
work_6edatbslnjhz3kb2pkbphqv5py	163	21	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	163	22	more	more	RBR
work_6edatbslnjhz3kb2pkbphqv5py	163	23	intense	intense	JJ
work_6edatbslnjhz3kb2pkbphqv5py	163	24	administration	administration	NN
work_6edatbslnjhz3kb2pkbphqv5py	163	25	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	163	26	5-FU	5-fu	CD
work_6edatbslnjhz3kb2pkbphqv5py	163	27	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	163	28	properly	properly	RB
work_6edatbslnjhz3kb2pkbphqv5py	163	29	selected	select	VBN
work_6edatbslnjhz3kb2pkbphqv5py	163	30	pa-	pa-	JJ
work_6edatbslnjhz3kb2pkbphqv5py	163	31	tients	tient	NNS
work_6edatbslnjhz3kb2pkbphqv5py	163	32	(	(	-LRB-
work_6edatbslnjhz3kb2pkbphqv5py	163	33	33	33	CD
work_6edatbslnjhz3kb2pkbphqv5py	163	34	)	)	-RRB-
work_6edatbslnjhz3kb2pkbphqv5py	163	35	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	164	1	The	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	164	2	NCCTG	NCCTG	NNP
work_6edatbslnjhz3kb2pkbphqv5py	164	3	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	164	4	intergroup	intergroup	NNP
work_6edatbslnjhz3kb2pkbphqv5py	164	5	studies	study	NNS
work_6edatbslnjhz3kb2pkbphqv5py	164	6	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	164	7	adjuvant	adjuvant	JJ
work_6edatbslnjhz3kb2pkbphqv5py	164	8	therapy	therapy	NN
work_6edatbslnjhz3kb2pkbphqv5py	164	9	compared	compare	VBN
work_6edatbslnjhz3kb2pkbphqv5py	164	10	5-Hi	5-hi	CD
work_6edatbslnjhz3kb2pkbphqv5py	164	11	plus	plus	CC
work_6edatbslnjhz3kb2pkbphqv5py	164	12	levamisole	levamisole	NN
work_6edatbslnjhz3kb2pkbphqv5py	164	13	to	to	IN
work_6edatbslnjhz3kb2pkbphqv5py	164	14	levamisole	levamisole	NN
work_6edatbslnjhz3kb2pkbphqv5py	164	15	alone	alone	RB
work_6edatbslnjhz3kb2pkbphqv5py	164	16	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	164	17	did	do	VBD
work_6edatbslnjhz3kb2pkbphqv5py	164	18	not	not	RB
work_6edatbslnjhz3kb2pkbphqv5py	164	19	include	include	VB
work_6edatbslnjhz3kb2pkbphqv5py	164	20	a	a	DT
work_6edatbslnjhz3kb2pkbphqv5py	164	21	5-Hi	5-hi	CD
work_6edatbslnjhz3kb2pkbphqv5py	164	22	alone	alone	JJ
work_6edatbslnjhz3kb2pkbphqv5py	164	23	arm	arm	NN
work_6edatbslnjhz3kb2pkbphqv5py	164	24	(	(	-LRB-
work_6edatbslnjhz3kb2pkbphqv5py	164	25	24	24	CD
work_6edatbslnjhz3kb2pkbphqv5py	164	26	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	164	27	25	25	CD
work_6edatbslnjhz3kb2pkbphqv5py	164	28	)	)	-RRB-
work_6edatbslnjhz3kb2pkbphqv5py	164	29	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	165	1	More	more	RBR
work_6edatbslnjhz3kb2pkbphqv5py	165	2	recently	recently	RB
work_6edatbslnjhz3kb2pkbphqv5py	165	3	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	165	4	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	165	5	National	National	NNP
work_6edatbslnjhz3kb2pkbphqv5py	165	6	Surgical	Surgical	NNP
work_6edatbslnjhz3kb2pkbphqv5py	165	7	Adjuvant	Adjuvant	NNP
work_6edatbslnjhz3kb2pkbphqv5py	165	8	Breast	Breast	NNP
work_6edatbslnjhz3kb2pkbphqv5py	165	9	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	165	10	Bowel	Bowel	NNP
work_6edatbslnjhz3kb2pkbphqv5py	165	11	Project	Project	NNP
work_6edatbslnjhz3kb2pkbphqv5py	165	12	reported	report	VBD
work_6edatbslnjhz3kb2pkbphqv5py	165	13	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	165	14	results	result	NNS
work_6edatbslnjhz3kb2pkbphqv5py	165	15	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	165	16	their	-PRON-	PRP$
work_6edatbslnjhz3kb2pkbphqv5py	165	17	adjuvant	adjuvant	JJ
work_6edatbslnjhz3kb2pkbphqv5py	165	18	trial	trial	NN
work_6edatbslnjhz3kb2pkbphqv5py	165	19	comparing	compare	VBG
work_6edatbslnjhz3kb2pkbphqv5py	165	20	5-Hi	5-hi	CD
work_6edatbslnjhz3kb2pkbphqv5py	165	21	plus	plus	CC
work_6edatbslnjhz3kb2pkbphqv5py	165	22	leucov-	leucov-	JJ
work_6edatbslnjhz3kb2pkbphqv5py	165	23	orin	orin	NN
work_6edatbslnjhz3kb2pkbphqv5py	165	24	versus	versus	IN
work_6edatbslnjhz3kb2pkbphqv5py	165	25	5-Hi	5-hi	CD
work_6edatbslnjhz3kb2pkbphqv5py	165	26	plus	plus	CC
work_6edatbslnjhz3kb2pkbphqv5py	165	27	levamisole	levamisole	NN
work_6edatbslnjhz3kb2pkbphqv5py	165	28	versus	versus	IN
work_6edatbslnjhz3kb2pkbphqv5py	165	29	5-Hi	5-hi	CD
work_6edatbslnjhz3kb2pkbphqv5py	165	30	plus	plus	CC
work_6edatbslnjhz3kb2pkbphqv5py	165	31	leucovorin	leucovorin	NNP
work_6edatbslnjhz3kb2pkbphqv5py	165	32	plus	plus	CC
work_6edatbslnjhz3kb2pkbphqv5py	165	33	levamisole	levamisole	NNP
work_6edatbslnjhz3kb2pkbphqv5py	165	34	(	(	-LRB-
work_6edatbslnjhz3kb2pkbphqv5py	165	35	34	34	CD
work_6edatbslnjhz3kb2pkbphqv5py	165	36	)	)	-RRB-
work_6edatbslnjhz3kb2pkbphqv5py	165	37	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	166	1	The	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	166	2	5-Hi	5-hi	CD
work_6edatbslnjhz3kb2pkbphqv5py	166	3	plus	plus	CC
work_6edatbslnjhz3kb2pkbphqv5py	166	4	leucovorin	leucovorin	NNP
work_6edatbslnjhz3kb2pkbphqv5py	166	5	arm	arm	NN
work_6edatbslnjhz3kb2pkbphqv5py	166	6	was	be	VBD
work_6edatbslnjhz3kb2pkbphqv5py	166	7	ad-	ad-	VBN
work_6edatbslnjhz3kb2pkbphqv5py	166	8	ministered	minister	VBN
work_6edatbslnjhz3kb2pkbphqv5py	166	9	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	166	10	42-day	42-day	CD
work_6edatbslnjhz3kb2pkbphqv5py	166	11	cycles	cycle	NNS
work_6edatbslnjhz3kb2pkbphqv5py	166	12	for	for	IN
work_6edatbslnjhz3kb2pkbphqv5py	166	13	six	six	CD
work_6edatbslnjhz3kb2pkbphqv5py	166	14	courses	course	NNS
work_6edatbslnjhz3kb2pkbphqv5py	166	15	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	166	16	whereas	whereas	IN
work_6edatbslnjhz3kb2pkbphqv5py	166	17	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	166	18	levami-	levami-	NNP
work_6edatbslnjhz3kb2pkbphqv5py	166	19	sole	sole	NNP
work_6edatbslnjhz3kb2pkbphqv5py	166	20	containing	contain	VBG
work_6edatbslnjhz3kb2pkbphqv5py	166	21	arms	arm	NNS
work_6edatbslnjhz3kb2pkbphqv5py	166	22	were	be	VBD
work_6edatbslnjhz3kb2pkbphqv5py	166	23	administered	administer	VBN
work_6edatbslnjhz3kb2pkbphqv5py	166	24	for	for	IN
work_6edatbslnjhz3kb2pkbphqv5py	166	25	a	a	DT
work_6edatbslnjhz3kb2pkbphqv5py	166	26	period	period	NN
work_6edatbslnjhz3kb2pkbphqv5py	166	27	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	166	28	1	1	CD
work_6edatbslnjhz3kb2pkbphqv5py	166	29	year	year	NN
work_6edatbslnjhz3kb2pkbphqv5py	166	30	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	167	1	There	there	EX
work_6edatbslnjhz3kb2pkbphqv5py	167	2	was	be	VBD
work_6edatbslnjhz3kb2pkbphqv5py	167	3	a	a	DT
work_6edatbslnjhz3kb2pkbphqv5py	167	4	statistically	statistically	RB
work_6edatbslnjhz3kb2pkbphqv5py	167	5	significant	significant	JJ
work_6edatbslnjhz3kb2pkbphqv5py	167	6	advantage	advantage	NN
work_6edatbslnjhz3kb2pkbphqv5py	167	7	for	for	IN
work_6edatbslnjhz3kb2pkbphqv5py	167	8	5-FU	5-fu	CD
work_6edatbslnjhz3kb2pkbphqv5py	167	9	plus	plus	JJ
work_6edatbslnjhz3kb2pkbphqv5py	167	10	leucovorin	leucovorin	NNP
work_6edatbslnjhz3kb2pkbphqv5py	167	11	over	over	IN
work_6edatbslnjhz3kb2pkbphqv5py	167	12	5-Hi	5-hi	CD
work_6edatbslnjhz3kb2pkbphqv5py	167	13	plus	plus	CC
work_6edatbslnjhz3kb2pkbphqv5py	167	14	levamisole	levamisole	NN
work_6edatbslnjhz3kb2pkbphqv5py	167	15	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	167	16	terms	term	NNS
work_6edatbslnjhz3kb2pkbphqv5py	167	17	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	167	18	disease	disease	NN
work_6edatbslnjhz3kb2pkbphqv5py	167	19	-	-	HYPH
work_6edatbslnjhz3kb2pkbphqv5py	167	20	free	free	JJ
work_6edatbslnjhz3kb2pkbphqv5py	167	21	(	(	-LRB-
work_6edatbslnjhz3kb2pkbphqv5py	167	22	P	p	NN
work_6edatbslnjhz3kb2pkbphqv5py	167	23	<	<	XX
work_6edatbslnjhz3kb2pkbphqv5py	167	24	0.05	0.05	XX
work_6edatbslnjhz3kb2pkbphqv5py	167	25	)	)	-RRB-
work_6edatbslnjhz3kb2pkbphqv5py	167	26	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	167	27	overall	overall	JJ
work_6edatbslnjhz3kb2pkbphqv5py	167	28	(	(	-LRB-
work_6edatbslnjhz3kb2pkbphqv5py	167	29	P	p	NN
work_6edatbslnjhz3kb2pkbphqv5py	167	30	<	<	XX
work_6edatbslnjhz3kb2pkbphqv5py	167	31	0.05	0.05	XX
work_6edatbslnjhz3kb2pkbphqv5py	167	32	)	)	-RRB-
work_6edatbslnjhz3kb2pkbphqv5py	167	33	survival	survival	NN
work_6edatbslnjhz3kb2pkbphqv5py	167	34	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	168	1	The	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	168	2	addition	addition	NN
work_6edatbslnjhz3kb2pkbphqv5py	168	3	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	168	4	levamisole	levamisole	NN
work_6edatbslnjhz3kb2pkbphqv5py	168	5	did	do	VBD
work_6edatbslnjhz3kb2pkbphqv5py	168	6	not	not	RB
work_6edatbslnjhz3kb2pkbphqv5py	168	7	improve	improve	VB
work_6edatbslnjhz3kb2pkbphqv5py	168	8	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	168	9	results	result	NNS
work_6edatbslnjhz3kb2pkbphqv5py	168	10	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	168	11	5-Hi	5-hi	CD
work_6edatbslnjhz3kb2pkbphqv5py	168	12	plus	plus	CC
work_6edatbslnjhz3kb2pkbphqv5py	168	13	leucovorin	leucovorin	NNP
work_6edatbslnjhz3kb2pkbphqv5py	168	14	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	169	1	300	300	CD
work_6edatbslnjhz3kb2pkbphqv5py	169	2	Two	two	CD
work_6edatbslnjhz3kb2pkbphqv5py	169	3	other	other	JJ
work_6edatbslnjhz3kb2pkbphqv5py	169	4	trials	trial	NNS
work_6edatbslnjhz3kb2pkbphqv5py	169	5	evaluated	evaluate	VBD
work_6edatbslnjhz3kb2pkbphqv5py	169	6	5-Hi	5-hi	NN
work_6edatbslnjhz3kb2pkbphqv5py	169	7	plus	plus	CC
work_6edatbslnjhz3kb2pkbphqv5py	169	8	levamisole	levamisole	NN
work_6edatbslnjhz3kb2pkbphqv5py	169	9	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	170	1	The	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	170	2	NCCTG	NCCTG	NNP
work_6edatbslnjhz3kb2pkbphqv5py	170	3	evaluated	evaluate	VBD
work_6edatbslnjhz3kb2pkbphqv5py	170	4	5-FU	5-fu	CD
work_6edatbslnjhz3kb2pkbphqv5py	170	5	/	/	SYM
work_6edatbslnjhz3kb2pkbphqv5py	170	6	levamisole	levamisole	NN
work_6edatbslnjhz3kb2pkbphqv5py	170	7	(	(	-LRB-
work_6edatbslnjhz3kb2pkbphqv5py	170	8	6	6	CD
work_6edatbslnjhz3kb2pkbphqv5py	170	9	months	month	NNS
work_6edatbslnjhz3kb2pkbphqv5py	170	10	versus	versus	IN
work_6edatbslnjhz3kb2pkbphqv5py	170	11	12	12	CD
work_6edatbslnjhz3kb2pkbphqv5py	170	12	months	month	NNS
work_6edatbslnjhz3kb2pkbphqv5py	170	13	)	)	-RRB-
work_6edatbslnjhz3kb2pkbphqv5py	170	14	versus	versus	IN
work_6edatbslnjhz3kb2pkbphqv5py	170	15	5-FU	5-FU	NNP
work_6edatbslnjhz3kb2pkbphqv5py	170	16	/	/	SYM
work_6edatbslnjhz3kb2pkbphqv5py	170	17	leucovorin	leucovorin	NNP
work_6edatbslnjhz3kb2pkbphqv5py	170	18	/	/	SYM
work_6edatbslnjhz3kb2pkbphqv5py	170	19	levamisole	levamisole	NNP
work_6edatbslnjhz3kb2pkbphqv5py	170	20	(	(	-LRB-
work_6edatbslnjhz3kb2pkbphqv5py	170	21	6	6	CD
work_6edatbslnjhz3kb2pkbphqv5py	170	22	months	month	NNS
work_6edatbslnjhz3kb2pkbphqv5py	170	23	versus	versus	IN
work_6edatbslnjhz3kb2pkbphqv5py	170	24	12	12	CD
work_6edatbslnjhz3kb2pkbphqv5py	170	25	months	month	NNS
work_6edatbslnjhz3kb2pkbphqv5py	170	26	)	)	-RRB-
work_6edatbslnjhz3kb2pkbphqv5py	170	27	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	170	28	demonstrated	demonstrate	VBD
work_6edatbslnjhz3kb2pkbphqv5py	170	29	that	that	IN
work_6edatbslnjhz3kb2pkbphqv5py	170	30	6	6	CD
work_6edatbslnjhz3kb2pkbphqv5py	170	31	months	month	NNS
work_6edatbslnjhz3kb2pkbphqv5py	170	32	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	170	33	5-Hi	5-hi	CD
work_6edatbslnjhz3kb2pkbphqv5py	170	34	/	/	SYM
work_6edatbslnjhz3kb2pkbphqv5py	170	35	levamisole	levamisole	NN
work_6edatbslnjhz3kb2pkbphqv5py	170	36	was	be	VBD
work_6edatbslnjhz3kb2pkbphqv5py	170	37	inferior	inferior	JJ
work_6edatbslnjhz3kb2pkbphqv5py	170	38	to	to	IN
work_6edatbslnjhz3kb2pkbphqv5py	170	39	6	6	CD
work_6edatbslnjhz3kb2pkbphqv5py	170	40	months	month	NNS
work_6edatbslnjhz3kb2pkbphqv5py	170	41	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	170	42	5-Hilleucovorinllevamisole	5-hilleucovorinllevamisole	CD
work_6edatbslnjhz3kb2pkbphqv5py	170	43	(	(	-LRB-
work_6edatbslnjhz3kb2pkbphqv5py	170	44	35	35	CD
work_6edatbslnjhz3kb2pkbphqv5py	170	45	)	)	-RRB-
work_6edatbslnjhz3kb2pkbphqv5py	170	46	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	171	1	The	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	171	2	Eastern	Eastern	NNP
work_6edatbslnjhz3kb2pkbphqv5py	171	3	Cooperative	Cooperative	NNP
work_6edatbslnjhz3kb2pkbphqv5py	171	4	Oncology	Oncology	NNP
work_6edatbslnjhz3kb2pkbphqv5py	171	5	Group	Group	NNP
work_6edatbslnjhz3kb2pkbphqv5py	171	6	evaluated	evaluate	VBD
work_6edatbslnjhz3kb2pkbphqv5py	171	7	several	several	JJ
work_6edatbslnjhz3kb2pkbphqv5py	171	8	different	different	JJ
work_6edatbslnjhz3kb2pkbphqv5py	171	9	regimens	regimen	NNS
work_6edatbslnjhz3kb2pkbphqv5py	171	10	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	171	11	including	include	VBG
work_6edatbslnjhz3kb2pkbphqv5py	171	12	high	high	JJ
work_6edatbslnjhz3kb2pkbphqv5py	171	13	versus	versus	IN
work_6edatbslnjhz3kb2pkbphqv5py	171	14	low	low	JJ
work_6edatbslnjhz3kb2pkbphqv5py	171	15	dose	dose	NN
work_6edatbslnjhz3kb2pkbphqv5py	171	16	leucovorin	leucovorin	NNP
work_6edatbslnjhz3kb2pkbphqv5py	171	17	plus	plus	CC
work_6edatbslnjhz3kb2pkbphqv5py	171	18	5-Hi	5-Hi	NNP
work_6edatbslnjhz3kb2pkbphqv5py	171	19	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	171	20	5-FU	5-fu	CD
work_6edatbslnjhz3kb2pkbphqv5py	171	21	/	/	SYM
work_6edatbslnjhz3kb2pkbphqv5py	171	22	levamisole	levamisole	NN
work_6edatbslnjhz3kb2pkbphqv5py	171	23	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	171	24	5-Hillevamisolelleucovo-	5-Hillevamisolelleucovo-	NNP
work_6edatbslnjhz3kb2pkbphqv5py	171	25	rim	rim	NN
work_6edatbslnjhz3kb2pkbphqv5py	171	26	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	172	1	Six	six	CD
work_6edatbslnjhz3kb2pkbphqv5py	172	2	months	month	NNS
work_6edatbslnjhz3kb2pkbphqv5py	172	3	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	172	4	5-Hi	5-hi	CD
work_6edatbslnjhz3kb2pkbphqv5py	172	5	+	+	SYM
work_6edatbslnjhz3kb2pkbphqv5py	172	6	leucovorin	leucovorin	NNP
work_6edatbslnjhz3kb2pkbphqv5py	172	7	was	be	VBD
work_6edatbslnjhz3kb2pkbphqv5py	172	8	equivalent	equivalent	JJ
work_6edatbslnjhz3kb2pkbphqv5py	172	9	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	172	10	if	if	IN
work_6edatbslnjhz3kb2pkbphqv5py	172	11	not	not	RB
work_6edatbslnjhz3kb2pkbphqv5py	172	12	superior	superior	JJ
work_6edatbslnjhz3kb2pkbphqv5py	172	13	to	to	IN
work_6edatbslnjhz3kb2pkbphqv5py	172	14	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	172	15	12	12	CD
work_6edatbslnjhz3kb2pkbphqv5py	172	16	months	month	NNS
work_6edatbslnjhz3kb2pkbphqv5py	172	17	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	172	18	5-Hi	5-hi	CD
work_6edatbslnjhz3kb2pkbphqv5py	172	19	+	+	SYM
work_6edatbslnjhz3kb2pkbphqv5py	172	20	levamisole	levamisole	NN
work_6edatbslnjhz3kb2pkbphqv5py	172	21	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	172	22	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	172	23	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	172	24	addition	addition	NN
work_6edatbslnjhz3kb2pkbphqv5py	172	25	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	172	26	levamisole	levamisole	NN
work_6edatbslnjhz3kb2pkbphqv5py	172	27	to	to	IN
work_6edatbslnjhz3kb2pkbphqv5py	172	28	5-Hi	5-hi	CD
work_6edatbslnjhz3kb2pkbphqv5py	172	29	+	+	SYM
work_6edatbslnjhz3kb2pkbphqv5py	172	30	leucovorin	leucovorin	NNP
work_6edatbslnjhz3kb2pkbphqv5py	172	31	did	do	VBD
work_6edatbslnjhz3kb2pkbphqv5py	172	32	not	not	RB
work_6edatbslnjhz3kb2pkbphqv5py	172	33	provide	provide	VB
work_6edatbslnjhz3kb2pkbphqv5py	172	34	any	any	DT
work_6edatbslnjhz3kb2pkbphqv5py	172	35	addi-	addi-	JJ
work_6edatbslnjhz3kb2pkbphqv5py	172	36	tional	tional	JJ
work_6edatbslnjhz3kb2pkbphqv5py	172	37	benefit	benefit	NN
work_6edatbslnjhz3kb2pkbphqv5py	172	38	(	(	-LRB-
work_6edatbslnjhz3kb2pkbphqv5py	172	39	36	36	CD
work_6edatbslnjhz3kb2pkbphqv5py	172	40	)	)	-RRB-
work_6edatbslnjhz3kb2pkbphqv5py	172	41	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	173	1	In	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	173	2	conclusion	conclusion	NN
work_6edatbslnjhz3kb2pkbphqv5py	173	3	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	173	4	this	this	DT
work_6edatbslnjhz3kb2pkbphqv5py	173	5	cooperative	cooperative	JJ
work_6edatbslnjhz3kb2pkbphqv5py	173	6	group	group	NN
work_6edatbslnjhz3kb2pkbphqv5py	173	7	failed	fail	VBD
work_6edatbslnjhz3kb2pkbphqv5py	173	8	to	to	TO
work_6edatbslnjhz3kb2pkbphqv5py	173	9	demonstrate	demonstrate	VB
work_6edatbslnjhz3kb2pkbphqv5py	173	10	any	any	DT
work_6edatbslnjhz3kb2pkbphqv5py	173	11	advantage	advantage	NN
work_6edatbslnjhz3kb2pkbphqv5py	173	12	to	to	IN
work_6edatbslnjhz3kb2pkbphqv5py	173	13	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	173	14	addition	addition	NN
work_6edatbslnjhz3kb2pkbphqv5py	173	15	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	173	16	levamisole	levamisole	NN
work_6edatbslnjhz3kb2pkbphqv5py	173	17	to	to	IN
work_6edatbslnjhz3kb2pkbphqv5py	173	18	5-Hi	5-hi	CD
work_6edatbslnjhz3kb2pkbphqv5py	173	19	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	173	20	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	173	21	treatment	treatment	NN
work_6edatbslnjhz3kb2pkbphqv5py	173	22	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	173	23	metastatic	metastatic	JJ
work_6edatbslnjhz3kb2pkbphqv5py	173	24	colorectal	colorectal	JJ
work_6edatbslnjhz3kb2pkbphqv5py	173	25	cancer	cancer	NN
work_6edatbslnjhz3kb2pkbphqv5py	173	26	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	174	1	The	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	174	2	role	role	NN
work_6edatbslnjhz3kb2pkbphqv5py	174	3	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	174	4	if	if	IN
work_6edatbslnjhz3kb2pkbphqv5py	174	5	any	any	DT
work_6edatbslnjhz3kb2pkbphqv5py	174	6	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	174	7	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	174	8	levamisole	levamisole	NN
work_6edatbslnjhz3kb2pkbphqv5py	174	9	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	174	10	Duke	Duke	NNP
work_6edatbslnjhz3kb2pkbphqv5py	174	11	’s	’s	POS
work_6edatbslnjhz3kb2pkbphqv5py	174	12	C	C	NNP
work_6edatbslnjhz3kb2pkbphqv5py	174	13	colorectal	colorectal	JJ
work_6edatbslnjhz3kb2pkbphqv5py	174	14	cancer	cancer	NN
work_6edatbslnjhz3kb2pkbphqv5py	174	15	is	be	VBZ
work_6edatbslnjhz3kb2pkbphqv5py	174	16	further	far	RBR
work_6edatbslnjhz3kb2pkbphqv5py	174	17	questioned	question	VBN
work_6edatbslnjhz3kb2pkbphqv5py	174	18	by	by	IN
work_6edatbslnjhz3kb2pkbphqv5py	174	19	this	this	DT
work_6edatbslnjhz3kb2pkbphqv5py	174	20	negative	negative	JJ
work_6edatbslnjhz3kb2pkbphqv5py	174	21	study	study	NN
work_6edatbslnjhz3kb2pkbphqv5py	174	22	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	174	23	metastatic	metastatic	JJ
work_6edatbslnjhz3kb2pkbphqv5py	174	24	disease	disease	NN
work_6edatbslnjhz3kb2pkbphqv5py	174	25	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	175	1	APPENDIX	APPENDIX	NNP
work_6edatbslnjhz3kb2pkbphqv5py	175	2	Study	Study	NNP
work_6edatbslnjhz3kb2pkbphqv5py	175	3	Participants	Participants	NNPS
work_6edatbslnjhz3kb2pkbphqv5py	175	4	:	:	:
work_6edatbslnjhz3kb2pkbphqv5py	175	5	Arnett	Arnett	NNP
work_6edatbslnjhz3kb2pkbphqv5py	175	6	Clinic	Clinic	NNP
work_6edatbslnjhz3kb2pkbphqv5py	175	7	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	175	8	Lafayette	Lafayette	NNP
work_6edatbslnjhz3kb2pkbphqv5py	175	9	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	175	10	IN	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	175	11	;	;	:
work_6edatbslnjhz3kb2pkbphqv5py	175	12	Ball	Ball	NNP
work_6edatbslnjhz3kb2pkbphqv5py	175	13	Memorial	Memorial	NNP
work_6edatbslnjhz3kb2pkbphqv5py	175	14	Hospital	Hospital	NNP
work_6edatbslnjhz3kb2pkbphqv5py	175	15	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	175	16	Muncie	Muncie	NNP
work_6edatbslnjhz3kb2pkbphqv5py	175	17	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	175	18	IN	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	175	19	;	;	:
work_6edatbslnjhz3kb2pkbphqv5py	175	20	Community	Community	NNP
work_6edatbslnjhz3kb2pkbphqv5py	175	21	Hospitals	Hospitals	NNPS
work_6edatbslnjhz3kb2pkbphqv5py	175	22	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	175	23	Indianapolis	Indianapolis	NNP
work_6edatbslnjhz3kb2pkbphqv5py	175	24	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	175	25	IN	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	175	26	;	;	:
work_6edatbslnjhz3kb2pkbphqv5py	175	27	Consultants	Consultants	NNP
work_6edatbslnjhz3kb2pkbphqv5py	175	28	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	175	29	Blood	blood	NN
work_6edatbslnjhz3kb2pkbphqv5py	175	30	Disorders	Disorders	NNPS
work_6edatbslnjhz3kb2pkbphqv5py	175	31	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	175	32	Cancer	Cancer	NNP
work_6edatbslnjhz3kb2pkbphqv5py	175	33	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	175	34	Louisville	Louisville	NNP
work_6edatbslnjhz3kb2pkbphqv5py	175	35	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	175	36	KY	KY	NNP
work_6edatbslnjhz3kb2pkbphqv5py	175	37	;	;	:
work_6edatbslnjhz3kb2pkbphqv5py	175	38	Lewis	Lewis	NNP
work_6edatbslnjhz3kb2pkbphqv5py	175	39	Domke	Domke	NNP
work_6edatbslnjhz3kb2pkbphqv5py	175	40	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	175	41	M.D.	M.D.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	175	42	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	175	43	Merrillville	Merrillville	NNP
work_6edatbslnjhz3kb2pkbphqv5py	175	44	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	175	45	IN	IN	NNP
work_6edatbslnjhz3kb2pkbphqv5py	175	46	;	;	:
work_6edatbslnjhz3kb2pkbphqv5py	175	47	Juan	Juan	NNP
work_6edatbslnjhz3kb2pkbphqv5py	175	48	Correa	Correa	NNP
work_6edatbslnjhz3kb2pkbphqv5py	175	49	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	175	50	M.D.	M.D.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	175	51	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	175	52	Terre	Terre	NNP
work_6edatbslnjhz3kb2pkbphqv5py	175	53	Haute	Haute	NNP
work_6edatbslnjhz3kb2pkbphqv5py	175	54	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	175	55	IN	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	175	56	;	;	:
work_6edatbslnjhz3kb2pkbphqv5py	175	57	Ray	Ray	NNP
work_6edatbslnjhz3kb2pkbphqv5py	175	58	Drasga	Drasga	NNP
work_6edatbslnjhz3kb2pkbphqv5py	175	59	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	175	60	M.D.	M.D.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	175	61	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	175	62	Merrillville	Merrillville	NNP
work_6edatbslnjhz3kb2pkbphqv5py	175	63	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	175	64	IN	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	175	65	;	;	:
work_6edatbslnjhz3kb2pkbphqv5py	175	66	Elkhart	Elkhart	NNP
work_6edatbslnjhz3kb2pkbphqv5py	175	67	Clinic	Clinic	NNP
work_6edatbslnjhz3kb2pkbphqv5py	175	68	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	175	69	Elkhart	Elkhart	NNP
work_6edatbslnjhz3kb2pkbphqv5py	175	70	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	175	71	IN	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	175	72	;	;	:
work_6edatbslnjhz3kb2pkbphqv5py	175	73	Edward	Edward	NNP
work_6edatbslnjhz3kb2pkbphqv5py	175	74	Fox	Fox	NNP
work_6edatbslnjhz3kb2pkbphqv5py	175	75	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	175	76	M.D.	M.D.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	175	77	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	175	78	Evansville	Evansville	NNP
work_6edatbslnjhz3kb2pkbphqv5py	175	79	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	175	80	IN	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	175	81	;	;	:
work_6edatbslnjhz3kb2pkbphqv5py	175	82	Fort	Fort	NNP
work_6edatbslnjhz3kb2pkbphqv5py	175	83	Wayne	Wayne	NNP
work_6edatbslnjhz3kb2pkbphqv5py	175	84	Hematology	Hematology	NNP
work_6edatbslnjhz3kb2pkbphqv5py	175	85	/	/	SYM
work_6edatbslnjhz3kb2pkbphqv5py	175	86	Oncology	Oncology	NNP
work_6edatbslnjhz3kb2pkbphqv5py	175	87	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	175	88	Fort	Fort	NNP
work_6edatbslnjhz3kb2pkbphqv5py	175	89	Wayne	Wayne	NNP
work_6edatbslnjhz3kb2pkbphqv5py	175	90	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	175	91	IN	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	175	92	;	;	:
work_6edatbslnjhz3kb2pkbphqv5py	175	93	Galesburg	Galesburg	NNP
work_6edatbslnjhz3kb2pkbphqv5py	175	94	Clinic	Clinic	NNP
work_6edatbslnjhz3kb2pkbphqv5py	175	95	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	175	96	Galesburg	Galesburg	NNP
work_6edatbslnjhz3kb2pkbphqv5py	175	97	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	175	98	IL	IL	NNP
work_6edatbslnjhz3kb2pkbphqv5py	175	99	;	;	:
work_6edatbslnjhz3kb2pkbphqv5py	175	100	Georgia	Georgia	NNP
work_6edatbslnjhz3kb2pkbphqv5py	175	101	Hematology	Hematology	NNP
work_6edatbslnjhz3kb2pkbphqv5py	175	102	/	/	SYM
work_6edatbslnjhz3kb2pkbphqv5py	175	103	Oncology	Oncology	NNP
work_6edatbslnjhz3kb2pkbphqv5py	175	104	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	175	105	Atlanta	Atlanta	NNP
work_6edatbslnjhz3kb2pkbphqv5py	175	106	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	175	107	GA	GA	NNP
work_6edatbslnjhz3kb2pkbphqv5py	175	108	;	;	:
work_6edatbslnjhz3kb2pkbphqv5py	175	109	Alan	Alan	NNP
work_6edatbslnjhz3kb2pkbphqv5py	175	110	Grosbach	Grosbach	NNP
work_6edatbslnjhz3kb2pkbphqv5py	175	111	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	175	112	M.D.	M.D.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	175	113	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	175	114	Shreveport	Shreveport	NNP
work_6edatbslnjhz3kb2pkbphqv5py	175	115	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	175	116	LA	LA	NNP
work_6edatbslnjhz3kb2pkbphqv5py	175	117	;	;	:
work_6edatbslnjhz3kb2pkbphqv5py	175	118	Indiana	Indiana	NNP
work_6edatbslnjhz3kb2pkbphqv5py	175	119	University	University	NNP
work_6edatbslnjhz3kb2pkbphqv5py	175	120	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	175	121	Indianapolis	Indianapolis	NNP
work_6edatbslnjhz3kb2pkbphqv5py	175	122	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	175	123	IN	in	RB
work_6edatbslnjhz3kb2pkbphqv5py	175	124	;	;	:
work_6edatbslnjhz3kb2pkbphqv5py	175	125	Johnson	Johnson	NNP
work_6edatbslnjhz3kb2pkbphqv5py	175	126	Memorial	Memorial	NNP
work_6edatbslnjhz3kb2pkbphqv5py	175	127	Hospital	Hospital	NNP
work_6edatbslnjhz3kb2pkbphqv5py	175	128	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	175	129	Franklin	Franklin	NNP
work_6edatbslnjhz3kb2pkbphqv5py	175	130	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	175	131	IN	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	175	132	;	;	:
work_6edatbslnjhz3kb2pkbphqv5py	175	133	Thomas	Thomas	NNP
work_6edatbslnjhz3kb2pkbphqv5py	175	134	Lutz	Lutz	NNP
work_6edatbslnjhz3kb2pkbphqv5py	175	135	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	175	136	M.D.	M.D.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	175	137	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	175	138	Evansville	Evansville	NNP
work_6edatbslnjhz3kb2pkbphqv5py	175	139	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	175	140	IN	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	175	141	;	;	:
work_6edatbslnjhz3kb2pkbphqv5py	175	142	Memorial	Memorial	NNP
work_6edatbslnjhz3kb2pkbphqv5py	175	143	Hospital	Hospital	NNP
work_6edatbslnjhz3kb2pkbphqv5py	175	144	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	175	145	South	South	NNP
work_6edatbslnjhz3kb2pkbphqv5py	175	146	Bend	Bend	NNP
work_6edatbslnjhz3kb2pkbphqv5py	175	147	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	175	148	IN	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	175	149	;	;	:
work_6edatbslnjhz3kb2pkbphqv5py	175	150	Methodist	Methodist	NNP
work_6edatbslnjhz3kb2pkbphqv5py	175	151	Hospital	Hospital	NNP
work_6edatbslnjhz3kb2pkbphqv5py	175	152	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	175	153	Indianapolis	Indianapolis	NNP
work_6edatbslnjhz3kb2pkbphqv5py	175	154	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	175	155	IN	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	175	156	;	;	:
work_6edatbslnjhz3kb2pkbphqv5py	175	157	St.	St.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	175	158	Vincent	Vincent	NNP
work_6edatbslnjhz3kb2pkbphqv5py	175	159	’s	’s	POS
work_6edatbslnjhz3kb2pkbphqv5py	175	160	hospital	hospital	NN
work_6edatbslnjhz3kb2pkbphqv5py	175	161	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	175	162	Indianapolis	Indianapolis	NNP
work_6edatbslnjhz3kb2pkbphqv5py	175	163	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	175	164	IN	in	RB
work_6edatbslnjhz3kb2pkbphqv5py	175	165	;	;	:
work_6edatbslnjhz3kb2pkbphqv5py	175	166	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	175	167	Washington	Washington	NNP
work_6edatbslnjhz3kb2pkbphqv5py	175	168	University	University	NNP
work_6edatbslnjhz3kb2pkbphqv5py	175	169	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	175	170	St.	St.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	175	171	Louis	Louis	NNP
work_6edatbslnjhz3kb2pkbphqv5py	175	172	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	175	173	MO	MO	NNP
work_6edatbslnjhz3kb2pkbphqv5py	175	174	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	176	1	REFERENCES	reference	NNS
work_6edatbslnjhz3kb2pkbphqv5py	176	2	1	1	CD
work_6edatbslnjhz3kb2pkbphqv5py	176	3	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	177	1	Parker	Parker	NNP
work_6edatbslnjhz3kb2pkbphqv5py	177	2	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	177	3	S.	S.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	177	4	L.	L.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	177	5	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	177	6	Tong	Tong	NNP
work_6edatbslnjhz3kb2pkbphqv5py	177	7	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	177	8	T.	T.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	177	9	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	177	10	Bolden	Bolden	NNP
work_6edatbslnjhz3kb2pkbphqv5py	177	11	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	177	12	S.	S.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	177	13	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	177	14	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	177	15	Wingo	Wingo	NNP
work_6edatbslnjhz3kb2pkbphqv5py	177	16	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	177	17	P.	P.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	177	18	A.	A.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	178	1	Cancer	cancer	NN
work_6edatbslnjhz3kb2pkbphqv5py	178	2	statistics	statistic	NNS
work_6edatbslnjhz3kb2pkbphqv5py	178	3	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	178	4	1996	1996	CD
work_6edatbslnjhz3kb2pkbphqv5py	178	5	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	179	1	CA	CA	NNP
work_6edatbslnjhz3kb2pkbphqv5py	179	2	Cancer	Cancer	NNP
work_6edatbslnjhz3kb2pkbphqv5py	179	3	J.	J.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	180	1	Clin	Clin	NNP
work_6edatbslnjhz3kb2pkbphqv5py	180	2	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	180	3	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	180	4	46	46	CD
work_6edatbslnjhz3kb2pkbphqv5py	180	5	:	:	SYM
work_6edatbslnjhz3kb2pkbphqv5py	180	6	5	5	CD
work_6edatbslnjhz3kb2pkbphqv5py	180	7	-	-	SYM
work_6edatbslnjhz3kb2pkbphqv5py	180	8	27	27	CD
work_6edatbslnjhz3kb2pkbphqv5py	180	9	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	180	10	1996	1996	CD
work_6edatbslnjhz3kb2pkbphqv5py	180	11	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	180	12	on	on	IN
work_6edatbslnjhz3kb2pkbphqv5py	180	13	April	April	NNP
work_6edatbslnjhz3kb2pkbphqv5py	180	14	5	5	CD
work_6edatbslnjhz3kb2pkbphqv5py	180	15	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	180	16	2021	2021	CD
work_6edatbslnjhz3kb2pkbphqv5py	180	17	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	181	1	©	©	NNP
work_6edatbslnjhz3kb2pkbphqv5py	181	2	1998	1998	CD
work_6edatbslnjhz3kb2pkbphqv5py	181	3	American	American	NNP
work_6edatbslnjhz3kb2pkbphqv5py	181	4	Association	Association	NNP
work_6edatbslnjhz3kb2pkbphqv5py	181	5	for	for	IN
work_6edatbslnjhz3kb2pkbphqv5py	181	6	Cancer	Cancer	NNP
work_6edatbslnjhz3kb2pkbphqv5py	181	7	Research.clincancerres.aacrjournals.org	research.clincancerres.aacrjournals.org	NN
work_6edatbslnjhz3kb2pkbphqv5py	181	8	Downloaded	download	VBN
work_6edatbslnjhz3kb2pkbphqv5py	181	9	from	from	IN
work_6edatbslnjhz3kb2pkbphqv5py	181	10	http://clincancerres.aacrjournals.org/	http://clincancerres.aacrjournals.org/	ADD
work_6edatbslnjhz3kb2pkbphqv5py	181	11	Clinical	Clinical	NNP
work_6edatbslnjhz3kb2pkbphqv5py	181	12	Cancer	Cancer	NNP
work_6edatbslnjhz3kb2pkbphqv5py	181	13	Research	Research	NNP
work_6edatbslnjhz3kb2pkbphqv5py	181	14	939	939	CD
work_6edatbslnjhz3kb2pkbphqv5py	181	15	2	2	CD
work_6edatbslnjhz3kb2pkbphqv5py	181	16	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	182	1	Heidelberger	Heidelberger	NNP
work_6edatbslnjhz3kb2pkbphqv5py	182	2	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	182	3	C.	C.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	182	4	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	182	5	Chaudhari	Chaudhari	NNP
work_6edatbslnjhz3kb2pkbphqv5py	182	6	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	182	7	N.	N.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	182	8	K.	K.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	182	9	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	182	10	Danneberg	Danneberg	NNP
work_6edatbslnjhz3kb2pkbphqv5py	182	11	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	182	12	P.	P.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	182	13	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	182	14	et	et	NNP
work_6edatbslnjhz3kb2pkbphqv5py	182	15	al	al	NNP
work_6edatbslnjhz3kb2pkbphqv5py	182	16	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	183	1	Fluorinated	fluorinate	VBN
work_6edatbslnjhz3kb2pkbphqv5py	183	2	pyrimidine	pyrimidine	NN
work_6edatbslnjhz3kb2pkbphqv5py	183	3	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	184	1	A	a	DT
work_6edatbslnjhz3kb2pkbphqv5py	184	2	new	new	JJ
work_6edatbslnjhz3kb2pkbphqv5py	184	3	class	class	NN
work_6edatbslnjhz3kb2pkbphqv5py	184	4	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	184	5	tumor	tumor	NN
work_6edatbslnjhz3kb2pkbphqv5py	184	6	-	-	HYPH
work_6edatbslnjhz3kb2pkbphqv5py	184	7	inhibitory	inhibitory	NN
work_6edatbslnjhz3kb2pkbphqv5py	184	8	compounds	compound	NNS
work_6edatbslnjhz3kb2pkbphqv5py	184	9	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	185	1	Nature	nature	NN
work_6edatbslnjhz3kb2pkbphqv5py	185	2	(	(	-LRB-
work_6edatbslnjhz3kb2pkbphqv5py	185	3	Lond	Lond	NNP
work_6edatbslnjhz3kb2pkbphqv5py	185	4	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	186	1	)	)	-RRB-
work_6edatbslnjhz3kb2pkbphqv5py	186	2	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	186	3	179	179	CD
work_6edatbslnjhz3kb2pkbphqv5py	186	4	:	:	:
work_6edatbslnjhz3kb2pkbphqv5py	186	5	663	663	CD
work_6edatbslnjhz3kb2pkbphqv5py	186	6	-	-	SYM
work_6edatbslnjhz3kb2pkbphqv5py	186	7	666	666	CD
work_6edatbslnjhz3kb2pkbphqv5py	186	8	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	186	9	1957	1957	CD
work_6edatbslnjhz3kb2pkbphqv5py	186	10	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	187	1	3	3	LS
work_6edatbslnjhz3kb2pkbphqv5py	187	2	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	188	1	Grem	grem	VB
work_6edatbslnjhz3kb2pkbphqv5py	188	2	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	188	3	J.	J.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	188	4	L.	L.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	188	5	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	188	6	Hoth	Hoth	NNP
work_6edatbslnjhz3kb2pkbphqv5py	188	7	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	188	8	D.	D.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	188	9	F.	F.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	188	10	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	188	11	Hamilton	Hamilton	NNP
work_6edatbslnjhz3kb2pkbphqv5py	188	12	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	188	13	J.	J.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	188	14	M.	M.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	188	15	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	188	16	et	et	NNP
work_6edatbslnjhz3kb2pkbphqv5py	188	17	al	al	NNP
work_6edatbslnjhz3kb2pkbphqv5py	188	18	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	189	1	Overview	overview	NN
work_6edatbslnjhz3kb2pkbphqv5py	189	2	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	189	3	current	current	JJ
work_6edatbslnjhz3kb2pkbphqv5py	189	4	status	status	NN
work_6edatbslnjhz3kb2pkbphqv5py	189	5	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	189	6	future	future	JJ
work_6edatbslnjhz3kb2pkbphqv5py	189	7	direction	direction	NN
work_6edatbslnjhz3kb2pkbphqv5py	189	8	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	189	9	clinical	clinical	JJ
work_6edatbslnjhz3kb2pkbphqv5py	189	10	trials	trial	NNS
work_6edatbslnjhz3kb2pkbphqv5py	189	11	with	with	IN
work_6edatbslnjhz3kb2pkbphqv5py	189	12	5-fluorouracil	5-fluorouracil	CD
work_6edatbslnjhz3kb2pkbphqv5py	189	13	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	189	14	com-	com-	NN
work_6edatbslnjhz3kb2pkbphqv5py	189	15	bination	bination	NN
work_6edatbslnjhz3kb2pkbphqv5py	189	16	with	with	IN
work_6edatbslnjhz3kb2pkbphqv5py	189	17	folinic	folinic	NNP
work_6edatbslnjhz3kb2pkbphqv5py	189	18	acid	acid	NN
work_6edatbslnjhz3kb2pkbphqv5py	189	19	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	190	1	Cancer	Cancer	NNP
work_6edatbslnjhz3kb2pkbphqv5py	190	2	Treat	Treat	NNP
work_6edatbslnjhz3kb2pkbphqv5py	190	3	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	191	1	Rep.	Rep.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	191	2	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	191	3	71	71	CD
work_6edatbslnjhz3kb2pkbphqv5py	191	4	:	:	:
work_6edatbslnjhz3kb2pkbphqv5py	191	5	1249	1249	CD
work_6edatbslnjhz3kb2pkbphqv5py	191	6	-	-	SYM
work_6edatbslnjhz3kb2pkbphqv5py	191	7	1264	1264	CD
work_6edatbslnjhz3kb2pkbphqv5py	191	8	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	191	9	1987	1987	CD
work_6edatbslnjhz3kb2pkbphqv5py	191	10	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	192	1	4	4	LS
work_6edatbslnjhz3kb2pkbphqv5py	192	2	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	193	1	Einhorn	Einhorn	NNP
work_6edatbslnjhz3kb2pkbphqv5py	193	2	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	193	3	L.	L.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	193	4	H.	H.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	193	5	Improvements	Improvements	NNP
work_6edatbslnjhz3kb2pkbphqv5py	193	6	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	193	7	5-Hi	5-hi	CD
work_6edatbslnjhz3kb2pkbphqv5py	193	8	chemotherapy	chemotherapy	NN
work_6edatbslnjhz3kb2pkbphqv5py	193	9	?	?	.
work_6edatbslnjhz3kb2pkbphqv5py	194	1	J.	J.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	194	2	Clin	Clin	NNP
work_6edatbslnjhz3kb2pkbphqv5py	194	3	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	195	1	Oncol	Oncol	NNP
work_6edatbslnjhz3kb2pkbphqv5py	195	2	.	.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	195	3	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	195	4	7	7	CD
work_6edatbslnjhz3kb2pkbphqv5py	195	5	:	:	SYM
work_6edatbslnjhz3kb2pkbphqv5py	195	6	1377	1377	CD
work_6edatbslnjhz3kb2pkbphqv5py	195	7	-	-	SYM
work_6edatbslnjhz3kb2pkbphqv5py	195	8	1379	1379	CD
work_6edatbslnjhz3kb2pkbphqv5py	195	9	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	195	10	1989	1989	CD
work_6edatbslnjhz3kb2pkbphqv5py	195	11	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	196	1	5	5	CD
work_6edatbslnjhz3kb2pkbphqv5py	196	2	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	197	1	Nobile	Nobile	NNP
work_6edatbslnjhz3kb2pkbphqv5py	197	2	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	197	3	M.	M.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	197	4	T.	T.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	197	5	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	197	6	Rosso	Rosso	NNP
work_6edatbslnjhz3kb2pkbphqv5py	197	7	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	197	8	R.	R.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	197	9	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	197	10	Sertoli	Sertoli	NNP
work_6edatbslnjhz3kb2pkbphqv5py	197	11	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	197	12	M.	M.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	197	13	R.	R.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	197	14	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	197	15	et	et	NNP
work_6edatbslnjhz3kb2pkbphqv5py	197	16	al	al	NNP
work_6edatbslnjhz3kb2pkbphqv5py	197	17	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	198	1	Randomized	randomize	VBN
work_6edatbslnjhz3kb2pkbphqv5py	198	2	compar-	compar-	FW
work_6edatbslnjhz3kb2pkbphqv5py	198	3	ison	ison	NNP
work_6edatbslnjhz3kb2pkbphqv5py	198	4	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	198	5	weekly	weekly	NNP
work_6edatbslnjhz3kb2pkbphqv5py	198	6	bolus	bolus	NNP
work_6edatbslnjhz3kb2pkbphqv5py	198	7	5-fluorouracil	5-fluorouracil	CD
work_6edatbslnjhz3kb2pkbphqv5py	198	8	with	with	IN
work_6edatbslnjhz3kb2pkbphqv5py	198	9	or	or	CC
work_6edatbslnjhz3kb2pkbphqv5py	198	10	without	without	IN
work_6edatbslnjhz3kb2pkbphqv5py	198	11	leucovorin	leucovorin	NNP
work_6edatbslnjhz3kb2pkbphqv5py	198	12	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	198	13	metastatic	metastatic	JJ
work_6edatbslnjhz3kb2pkbphqv5py	198	14	coborectal	coborectal	JJ
work_6edatbslnjhz3kb2pkbphqv5py	198	15	carcinoma	carcinoma	NN
work_6edatbslnjhz3kb2pkbphqv5py	198	16	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	199	1	Eur	Eur	NNP
work_6edatbslnjhz3kb2pkbphqv5py	199	2	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	200	1	J.	J.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	201	1	Cancer	cancer	NN
work_6edatbslnjhz3kb2pkbphqv5py	201	2	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	201	3	28A	28a	CD
work_6edatbslnjhz3kb2pkbphqv5py	201	4	:	:	:
work_6edatbslnjhz3kb2pkbphqv5py	201	5	1823	1823	CD
work_6edatbslnjhz3kb2pkbphqv5py	201	6	-	-	SYM
work_6edatbslnjhz3kb2pkbphqv5py	201	7	1827	1827	CD
work_6edatbslnjhz3kb2pkbphqv5py	201	8	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	201	9	1992	1992	CD
work_6edatbslnjhz3kb2pkbphqv5py	201	10	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	202	1	6	6	CD
work_6edatbslnjhz3kb2pkbphqv5py	202	2	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	203	1	Petrelli	Petrelli	NNP
work_6edatbslnjhz3kb2pkbphqv5py	203	2	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	203	3	N.	N.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	203	4	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	203	5	Douglass	Douglass	NNP
work_6edatbslnjhz3kb2pkbphqv5py	203	6	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	203	7	H.	H.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	203	8	0	0	CD
work_6edatbslnjhz3kb2pkbphqv5py	203	9	.	.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	203	10	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	203	11	Herrera	Herrera	NNP
work_6edatbslnjhz3kb2pkbphqv5py	203	12	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	203	13	L.	L.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	203	14	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	203	15	et	et	FW
work_6edatbslnjhz3kb2pkbphqv5py	203	16	a	a	NN
work_6edatbslnjhz3kb2pkbphqv5py	203	17	!	!	.
work_6edatbslnjhz3kb2pkbphqv5py	203	18	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	204	1	The	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	204	2	modulation	modulation	NN
work_6edatbslnjhz3kb2pkbphqv5py	204	3	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	204	4	fluorouracil	fluorouracil	NN
work_6edatbslnjhz3kb2pkbphqv5py	204	5	with	with	IN
work_6edatbslnjhz3kb2pkbphqv5py	204	6	leucovorin	leucovorin	NNP
work_6edatbslnjhz3kb2pkbphqv5py	204	7	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	204	8	metastatic	metastatic	JJ
work_6edatbslnjhz3kb2pkbphqv5py	204	9	coborectal	coborectal	JJ
work_6edatbslnjhz3kb2pkbphqv5py	204	10	carcinoma	carcinoma	NN
work_6edatbslnjhz3kb2pkbphqv5py	204	11	:	:	:
work_6edatbslnjhz3kb2pkbphqv5py	204	12	a	a	DT
work_6edatbslnjhz3kb2pkbphqv5py	204	13	pro-	pro-	NN
work_6edatbslnjhz3kb2pkbphqv5py	204	14	spective	spective	JJ
work_6edatbslnjhz3kb2pkbphqv5py	204	15	randomized	randomized	JJ
work_6edatbslnjhz3kb2pkbphqv5py	204	16	phase	phase	NN
work_6edatbslnjhz3kb2pkbphqv5py	204	17	III	iii	CD
work_6edatbslnjhz3kb2pkbphqv5py	204	18	trial	trial	NN
work_6edatbslnjhz3kb2pkbphqv5py	204	19	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	205	1	J.	J.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	205	2	Clin	Clin	NNP
work_6edatbslnjhz3kb2pkbphqv5py	205	3	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	206	1	Oncol	Oncol	NNP
work_6edatbslnjhz3kb2pkbphqv5py	206	2	.	.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	206	3	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	206	4	7	7	CD
work_6edatbslnjhz3kb2pkbphqv5py	206	5	:	:	SYM
work_6edatbslnjhz3kb2pkbphqv5py	206	6	1419	1419	CD
work_6edatbslnjhz3kb2pkbphqv5py	206	7	-	-	SYM
work_6edatbslnjhz3kb2pkbphqv5py	206	8	1426	1426	CD
work_6edatbslnjhz3kb2pkbphqv5py	206	9	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	206	10	1989	1989	CD
work_6edatbslnjhz3kb2pkbphqv5py	206	11	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	207	1	7	7	LS
work_6edatbslnjhz3kb2pkbphqv5py	207	2	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	208	1	Petrelli	Petrelli	NNP
work_6edatbslnjhz3kb2pkbphqv5py	208	2	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	208	3	N.	N.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	208	4	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	208	5	Herrera	Herrera	NNP
work_6edatbslnjhz3kb2pkbphqv5py	208	6	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	208	7	L.	L.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	208	8	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	208	9	Rustum	Rustum	NNP
work_6edatbslnjhz3kb2pkbphqv5py	208	10	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	208	11	Y.	Y.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	208	12	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	208	13	Burke	Burke	NNP
work_6edatbslnjhz3kb2pkbphqv5py	208	14	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	208	15	P.	P.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	208	16	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	208	17	Creaven	Creaven	NNP
work_6edatbslnjhz3kb2pkbphqv5py	208	18	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	208	19	P.	P.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	208	20	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	208	21	Stulc	Stulc	NNP
work_6edatbslnjhz3kb2pkbphqv5py	208	22	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	208	23	J.	J.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	208	24	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	208	25	Emrich	Emrich	NNP
work_6edatbslnjhz3kb2pkbphqv5py	208	26	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	208	27	L.	L.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	208	28	J.	J.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	208	29	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	208	30	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	208	31	Mittelman	Mittelman	NNP
work_6edatbslnjhz3kb2pkbphqv5py	208	32	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	208	33	A.	a.	NN
work_6edatbslnjhz3kb2pkbphqv5py	209	1	A	a	DT
work_6edatbslnjhz3kb2pkbphqv5py	209	2	prospective	prospective	JJ
work_6edatbslnjhz3kb2pkbphqv5py	209	3	randomized	randomized	JJ
work_6edatbslnjhz3kb2pkbphqv5py	209	4	trial	trial	NN
work_6edatbslnjhz3kb2pkbphqv5py	209	5	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	209	6	5-fluorouracil	5-fluorouracil	CD
work_6edatbslnjhz3kb2pkbphqv5py	209	7	versus	versus	IN
work_6edatbslnjhz3kb2pkbphqv5py	209	8	5-fluorouracil	5-fluorouracil	CD
work_6edatbslnjhz3kb2pkbphqv5py	209	9	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	209	10	high	high	JJ
work_6edatbslnjhz3kb2pkbphqv5py	209	11	-	-	HYPH
work_6edatbslnjhz3kb2pkbphqv5py	209	12	dose	dose	NN
work_6edatbslnjhz3kb2pkbphqv5py	209	13	leucovorin	leucovorin	NN
work_6edatbslnjhz3kb2pkbphqv5py	209	14	versus	versus	IN
work_6edatbslnjhz3kb2pkbphqv5py	209	15	5-fluorouracib	5-fluorouracib	CD
work_6edatbslnjhz3kb2pkbphqv5py	209	16	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	209	17	methotrexate	methotrexate	NN
work_6edatbslnjhz3kb2pkbphqv5py	209	18	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	209	19	previously	previously	RB
work_6edatbslnjhz3kb2pkbphqv5py	209	20	untreated	untreated	JJ
work_6edatbslnjhz3kb2pkbphqv5py	209	21	patients	patient	NNS
work_6edatbslnjhz3kb2pkbphqv5py	209	22	with	with	IN
work_6edatbslnjhz3kb2pkbphqv5py	209	23	advanced	advanced	JJ
work_6edatbslnjhz3kb2pkbphqv5py	209	24	colorectal	colorectal	JJ
work_6edatbslnjhz3kb2pkbphqv5py	209	25	carcinoma	carcinoma	NN
work_6edatbslnjhz3kb2pkbphqv5py	209	26	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	210	1	J.	J.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	210	2	Clin	Clin	NNP
work_6edatbslnjhz3kb2pkbphqv5py	210	3	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	211	1	Oncol	Oncol	NNP
work_6edatbslnjhz3kb2pkbphqv5py	211	2	.	.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	211	3	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	211	4	5	5	CD
work_6edatbslnjhz3kb2pkbphqv5py	211	5	:	:	SYM
work_6edatbslnjhz3kb2pkbphqv5py	211	6	1559	1559	CD
work_6edatbslnjhz3kb2pkbphqv5py	211	7	-	-	SYM
work_6edatbslnjhz3kb2pkbphqv5py	211	8	1565	1565	CD
work_6edatbslnjhz3kb2pkbphqv5py	211	9	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	211	10	1987	1987	CD
work_6edatbslnjhz3kb2pkbphqv5py	211	11	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	212	1	8	8	LS
work_6edatbslnjhz3kb2pkbphqv5py	212	2	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	213	1	Valone	Valone	NNP
work_6edatbslnjhz3kb2pkbphqv5py	213	2	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	213	3	F.	F.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	213	4	H.	H.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	213	5	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	213	6	Friedman	Friedman	NNP
work_6edatbslnjhz3kb2pkbphqv5py	213	7	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	213	8	M.	M.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	213	9	A.	A.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	213	10	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	213	11	Wittlinger	Wittlinger	NNP
work_6edatbslnjhz3kb2pkbphqv5py	213	12	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	213	13	P.	P.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	213	14	S.	S.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	213	15	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	213	16	Drakes	Drakes	NNP
work_6edatbslnjhz3kb2pkbphqv5py	213	17	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	213	18	T.	T.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	213	19	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	213	20	Eisenberg	Eisenberg	NNP
work_6edatbslnjhz3kb2pkbphqv5py	213	21	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	213	22	P.	P.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	213	23	D.	D.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	213	24	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	213	25	Malec	Malec	NNP
work_6edatbslnjhz3kb2pkbphqv5py	213	26	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	213	27	M.	M.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	213	28	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	213	29	Hannigan	Hannigan	NNP
work_6edatbslnjhz3kb2pkbphqv5py	213	30	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	213	31	J.	J.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	213	32	F.	F.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	213	33	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	213	34	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	213	35	Brown	Brown	NNP
work_6edatbslnjhz3kb2pkbphqv5py	213	36	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	213	37	B.	B.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	213	38	W.	W.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	213	39	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	213	40	Jr.	Jr.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	214	1	Treatment	treatment	NN
work_6edatbslnjhz3kb2pkbphqv5py	214	2	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	214	3	patients	patient	NNS
work_6edatbslnjhz3kb2pkbphqv5py	214	4	with	with	IN
work_6edatbslnjhz3kb2pkbphqv5py	214	5	advanced	advanced	JJ
work_6edatbslnjhz3kb2pkbphqv5py	214	6	colorectal	colorectal	JJ
work_6edatbslnjhz3kb2pkbphqv5py	214	7	carcinomas	carcinoma	NNS
work_6edatbslnjhz3kb2pkbphqv5py	214	8	with	with	IN
work_6edatbslnjhz3kb2pkbphqv5py	214	9	flu-	flu-	NNS
work_6edatbslnjhz3kb2pkbphqv5py	214	10	orouracil	orouracil	NN
work_6edatbslnjhz3kb2pkbphqv5py	214	11	alone	alone	JJ
work_6edatbslnjhz3kb2pkbphqv5py	214	12	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	214	13	high	high	JJ
work_6edatbslnjhz3kb2pkbphqv5py	214	14	dose	dose	NN
work_6edatbslnjhz3kb2pkbphqv5py	214	15	leucovorin	leucovorin	NNP
work_6edatbslnjhz3kb2pkbphqv5py	214	16	plus	plus	CC
work_6edatbslnjhz3kb2pkbphqv5py	214	17	fluorouracil	fluorouracil	NN
work_6edatbslnjhz3kb2pkbphqv5py	214	18	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	214	19	or	or	CC
work_6edatbslnjhz3kb2pkbphqv5py	214	20	sequential	sequential	JJ
work_6edatbslnjhz3kb2pkbphqv5py	214	21	methotrexate	methotrexate	NN
work_6edatbslnjhz3kb2pkbphqv5py	214	22	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	214	23	fluorouracil	fluorouracil	NN
work_6edatbslnjhz3kb2pkbphqv5py	214	24	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	214	25	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	214	26	leucovorin	leucovorin	NNP
work_6edatbslnjhz3kb2pkbphqv5py	214	27	:	:	:
work_6edatbslnjhz3kb2pkbphqv5py	214	28	a	a	DT
work_6edatbslnjhz3kb2pkbphqv5py	214	29	randomized	randomized	JJ
work_6edatbslnjhz3kb2pkbphqv5py	214	30	trial	trial	NN
work_6edatbslnjhz3kb2pkbphqv5py	214	31	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	214	32	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	214	33	Northern	Northern	NNP
work_6edatbslnjhz3kb2pkbphqv5py	214	34	California	California	NNP
work_6edatbslnjhz3kb2pkbphqv5py	214	35	Oncology	Oncology	NNP
work_6edatbslnjhz3kb2pkbphqv5py	214	36	Group	Group	NNP
work_6edatbslnjhz3kb2pkbphqv5py	214	37	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	215	1	J.	J.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	215	2	Clin	Clin	NNP
work_6edatbslnjhz3kb2pkbphqv5py	215	3	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	216	1	Oncol	Oncol	NNP
work_6edatbslnjhz3kb2pkbphqv5py	216	2	.	.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	216	3	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	216	4	7	7	CD
work_6edatbslnjhz3kb2pkbphqv5py	216	5	:	:	SYM
work_6edatbslnjhz3kb2pkbphqv5py	216	6	1427	1427	CD
work_6edatbslnjhz3kb2pkbphqv5py	216	7	-	-	SYM
work_6edatbslnjhz3kb2pkbphqv5py	216	8	1436	1436	CD
work_6edatbslnjhz3kb2pkbphqv5py	216	9	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	216	10	1989	1989	CD
work_6edatbslnjhz3kb2pkbphqv5py	216	11	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	217	1	9	9	CD
work_6edatbslnjhz3kb2pkbphqv5py	217	2	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	218	1	Di	Di	NNP
work_6edatbslnjhz3kb2pkbphqv5py	218	2	Costanzo	Costanzo	NNP
work_6edatbslnjhz3kb2pkbphqv5py	218	3	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	218	4	F.	F.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	218	5	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	218	6	Bartolucci	Bartolucci	NNP
work_6edatbslnjhz3kb2pkbphqv5py	218	7	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	218	8	R.	R.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	218	9	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	218	10	Calabresi	Calabresi	NNP
work_6edatbslnjhz3kb2pkbphqv5py	218	11	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	218	12	F.	F.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	218	13	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	218	14	Sofra	Sofra	NNP
work_6edatbslnjhz3kb2pkbphqv5py	218	15	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	218	16	M.	M.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	218	17	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	218	18	Marzola	Marzola	NNP
work_6edatbslnjhz3kb2pkbphqv5py	218	19	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	218	20	M.	M.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	218	21	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	218	22	Belsanti	Belsanti	NNP
work_6edatbslnjhz3kb2pkbphqv5py	218	23	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	218	24	V.	V.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	218	25	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	218	26	Boni	Boni	NNP
work_6edatbslnjhz3kb2pkbphqv5py	218	27	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	218	28	C.	C.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	218	29	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	218	30	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	218	31	Bacchi	Bacchi	NNP
work_6edatbslnjhz3kb2pkbphqv5py	218	32	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	218	33	M.	M.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	218	34	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	218	35	Fluorouracil	Fluorouracil	NNP
work_6edatbslnjhz3kb2pkbphqv5py	218	36	-	-	:
work_6edatbslnjhz3kb2pkbphqv5py	218	37	alone	alone	RB
work_6edatbslnjhz3kb2pkbphqv5py	218	38	versus	versus	IN
work_6edatbslnjhz3kb2pkbphqv5py	218	39	high	high	RB
work_6edatbslnjhz3kb2pkbphqv5py	218	40	-	-	HYPH
work_6edatbslnjhz3kb2pkbphqv5py	218	41	dose	dose	NN
work_6edatbslnjhz3kb2pkbphqv5py	218	42	folinic	folinic	JJ
work_6edatbslnjhz3kb2pkbphqv5py	218	43	acid	acid	NN
work_6edatbslnjhz3kb2pkbphqv5py	218	44	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	218	45	fluorouracil	fluorouracil	NN
work_6edatbslnjhz3kb2pkbphqv5py	218	46	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	218	47	advanced	advanced	JJ
work_6edatbslnjhz3kb2pkbphqv5py	218	48	coborectal	coborectal	JJ
work_6edatbslnjhz3kb2pkbphqv5py	218	49	cancer	cancer	NN
work_6edatbslnjhz3kb2pkbphqv5py	218	50	:	:	:
work_6edatbslnjhz3kb2pkbphqv5py	218	51	a	a	DT
work_6edatbslnjhz3kb2pkbphqv5py	218	52	randomized	randomized	JJ
work_6edatbslnjhz3kb2pkbphqv5py	218	53	trial	trial	NN
work_6edatbslnjhz3kb2pkbphqv5py	218	54	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	218	55	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	218	56	Italian	Italian	NNP
work_6edatbslnjhz3kb2pkbphqv5py	218	57	Oncology	Oncology	NNP
work_6edatbslnjhz3kb2pkbphqv5py	218	58	Group	Group	NNP
work_6edatbslnjhz3kb2pkbphqv5py	218	59	for	for	IN
work_6edatbslnjhz3kb2pkbphqv5py	218	60	Clinical	Clinical	NNP
work_6edatbslnjhz3kb2pkbphqv5py	218	61	Research	Research	NNP
work_6edatbslnjhz3kb2pkbphqv5py	218	62	(	(	-LRB-
work_6edatbslnjhz3kb2pkbphqv5py	218	63	GOIRC	GOIRC	NNP
work_6edatbslnjhz3kb2pkbphqv5py	218	64	)	)	-RRB-
work_6edatbslnjhz3kb2pkbphqv5py	218	65	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	219	1	Ann	Ann	NNP
work_6edatbslnjhz3kb2pkbphqv5py	219	2	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	220	1	Oncol	Oncol	NNP
work_6edatbslnjhz3kb2pkbphqv5py	220	2	.	.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	220	3	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	220	4	3	3	CD
work_6edatbslnjhz3kb2pkbphqv5py	220	5	:	:	SYM
work_6edatbslnjhz3kb2pkbphqv5py	220	6	371	371	CD
work_6edatbslnjhz3kb2pkbphqv5py	220	7	-	-	SYM
work_6edatbslnjhz3kb2pkbphqv5py	220	8	376	376	CD
work_6edatbslnjhz3kb2pkbphqv5py	220	9	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	220	10	1992	1992	CD
work_6edatbslnjhz3kb2pkbphqv5py	220	11	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	221	1	10	10	CD
work_6edatbslnjhz3kb2pkbphqv5py	221	2	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	222	1	Labianca	Labianca	NNP
work_6edatbslnjhz3kb2pkbphqv5py	222	2	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	222	3	R.	R.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	222	4	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	222	5	Pancera	Pancera	NNP
work_6edatbslnjhz3kb2pkbphqv5py	222	6	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	223	1	G.	G.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	223	2	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	223	3	Aitini	Aitini	NNP
work_6edatbslnjhz3kb2pkbphqv5py	223	4	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	223	5	E.	E.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	223	6	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	223	7	et	et	NNP
work_6edatbslnjhz3kb2pkbphqv5py	223	8	al	al	NNP
work_6edatbslnjhz3kb2pkbphqv5py	223	9	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	224	1	Folinic	folinic	JJ
work_6edatbslnjhz3kb2pkbphqv5py	224	2	acid	acid	NN
work_6edatbslnjhz3kb2pkbphqv5py	224	3	+	+	CC
work_6edatbslnjhz3kb2pkbphqv5py	224	4	5-	5-	LS
work_6edatbslnjhz3kb2pkbphqv5py	224	5	fluorouracil	fluorouracil	NN
work_6edatbslnjhz3kb2pkbphqv5py	224	6	versus	versus	IN
work_6edatbslnjhz3kb2pkbphqv5py	224	7	equidose	equidose	JJ
work_6edatbslnjhz3kb2pkbphqv5py	224	8	5-Hi	5-hi	CD
work_6edatbslnjhz3kb2pkbphqv5py	224	9	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	224	10	advanced	advanced	JJ
work_6edatbslnjhz3kb2pkbphqv5py	224	11	colorectal	colorectal	JJ
work_6edatbslnjhz3kb2pkbphqv5py	224	12	cancer	cancer	NN
work_6edatbslnjhz3kb2pkbphqv5py	224	13	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	225	1	Phase	Phase	NNP
work_6edatbslnjhz3kb2pkbphqv5py	225	2	Ill	Ill	NNP
work_6edatbslnjhz3kb2pkbphqv5py	225	3	study	study	NN
work_6edatbslnjhz3kb2pkbphqv5py	225	4	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	225	5	“	"	``
work_6edatbslnjhz3kb2pkbphqv5py	225	6	GISCAD	GISCAD	NNP
work_6edatbslnjhz3kb2pkbphqv5py	225	7	”	"	''
work_6edatbslnjhz3kb2pkbphqv5py	225	8	(	(	-LRB-
work_6edatbslnjhz3kb2pkbphqv5py	225	9	Italian	Italian	NNP
work_6edatbslnjhz3kb2pkbphqv5py	225	10	Group	Group	NNP
work_6edatbslnjhz3kb2pkbphqv5py	225	11	for	for	IN
work_6edatbslnjhz3kb2pkbphqv5py	225	12	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	225	13	Study	Study	NNP
work_6edatbslnjhz3kb2pkbphqv5py	225	14	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	225	15	Digestive	Digestive	NNP
work_6edatbslnjhz3kb2pkbphqv5py	225	16	Tract	Tract	NNP
work_6edatbslnjhz3kb2pkbphqv5py	225	17	Cancer	Cancer	NNP
work_6edatbslnjhz3kb2pkbphqv5py	225	18	)	)	-RRB-
work_6edatbslnjhz3kb2pkbphqv5py	225	19	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	226	1	Ann	Ann	NNP
work_6edatbslnjhz3kb2pkbphqv5py	226	2	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	227	1	Oncol	Oncol	NNP
work_6edatbslnjhz3kb2pkbphqv5py	227	2	.	.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	227	3	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	227	4	2	2	CD
work_6edatbslnjhz3kb2pkbphqv5py	227	5	:	:	:
work_6edatbslnjhz3kb2pkbphqv5py	227	6	673	673	CD
work_6edatbslnjhz3kb2pkbphqv5py	227	7	-	-	SYM
work_6edatbslnjhz3kb2pkbphqv5py	227	8	679	679	CD
work_6edatbslnjhz3kb2pkbphqv5py	227	9	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	227	10	1991	1991	CD
work_6edatbslnjhz3kb2pkbphqv5py	227	11	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	228	1	11	11	CD
work_6edatbslnjhz3kb2pkbphqv5py	228	2	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	229	1	Poon	Poon	NNP
work_6edatbslnjhz3kb2pkbphqv5py	229	2	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	229	3	M.	M.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	229	4	A.	A.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	229	5	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	229	6	O’Connell	O’Connell	NNP
work_6edatbslnjhz3kb2pkbphqv5py	229	7	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	229	8	M.	M.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	229	9	J.	J.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	229	10	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	229	11	Moertel	Moertel	NNP
work_6edatbslnjhz3kb2pkbphqv5py	229	12	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	229	13	C.	C.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	229	14	G.	G.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	229	15	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	229	16	et	et	NNP
work_6edatbslnjhz3kb2pkbphqv5py	229	17	al	al	NNP
work_6edatbslnjhz3kb2pkbphqv5py	229	18	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	230	1	Biochemical	biochemical	JJ
work_6edatbslnjhz3kb2pkbphqv5py	230	2	modulation	modulation	NN
work_6edatbslnjhz3kb2pkbphqv5py	230	3	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	230	4	fluorouracil	fluorouracil	NN
work_6edatbslnjhz3kb2pkbphqv5py	230	5	:	:	:
work_6edatbslnjhz3kb2pkbphqv5py	230	6	evidence	evidence	NN
work_6edatbslnjhz3kb2pkbphqv5py	230	7	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	230	8	significant	significant	JJ
work_6edatbslnjhz3kb2pkbphqv5py	230	9	improvement	improvement	NN
work_6edatbslnjhz3kb2pkbphqv5py	230	10	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	230	11	survival	survival	NN
work_6edatbslnjhz3kb2pkbphqv5py	230	12	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	230	13	quality	quality	NN
work_6edatbslnjhz3kb2pkbphqv5py	230	14	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	230	15	life	life	NN
work_6edatbslnjhz3kb2pkbphqv5py	230	16	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	230	17	patients	patient	NNS
work_6edatbslnjhz3kb2pkbphqv5py	230	18	with	with	IN
work_6edatbslnjhz3kb2pkbphqv5py	230	19	advanced	advanced	JJ
work_6edatbslnjhz3kb2pkbphqv5py	230	20	coborectal	coborectal	JJ
work_6edatbslnjhz3kb2pkbphqv5py	230	21	carci-	carci-	NN
work_6edatbslnjhz3kb2pkbphqv5py	230	22	noma	noma	NNP
work_6edatbslnjhz3kb2pkbphqv5py	230	23	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	231	1	J.	J.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	231	2	Clin	Clin	NNP
work_6edatbslnjhz3kb2pkbphqv5py	231	3	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	232	1	Oncol	Oncol	NNP
work_6edatbslnjhz3kb2pkbphqv5py	232	2	.	.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	232	3	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	232	4	7	7	CD
work_6edatbslnjhz3kb2pkbphqv5py	232	5	:	:	SYM
work_6edatbslnjhz3kb2pkbphqv5py	232	6	1407	1407	CD
work_6edatbslnjhz3kb2pkbphqv5py	232	7	-	-	SYM
work_6edatbslnjhz3kb2pkbphqv5py	232	8	1418	1418	CD
work_6edatbslnjhz3kb2pkbphqv5py	232	9	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	232	10	1989	1989	CD
work_6edatbslnjhz3kb2pkbphqv5py	232	11	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	233	1	12	12	CD
work_6edatbslnjhz3kb2pkbphqv5py	233	2	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	234	1	Doroshow	Doroshow	NNP
work_6edatbslnjhz3kb2pkbphqv5py	234	2	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	234	3	J.	J.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	234	4	H.	H.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	234	5	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	234	6	Multhauf	Multhauf	NNP
work_6edatbslnjhz3kb2pkbphqv5py	234	7	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	234	8	P.	P.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	234	9	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	234	10	Leong	Leong	NNP
work_6edatbslnjhz3kb2pkbphqv5py	234	11	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	234	12	L.	L.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	234	13	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	234	14	et	et	NNP
work_6edatbslnjhz3kb2pkbphqv5py	234	15	al	al	NNP
work_6edatbslnjhz3kb2pkbphqv5py	234	16	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	235	1	Prospective	prospective	JJ
work_6edatbslnjhz3kb2pkbphqv5py	235	2	ran-	ran-	NN
work_6edatbslnjhz3kb2pkbphqv5py	235	3	domized	domize	VBD
work_6edatbslnjhz3kb2pkbphqv5py	235	4	comparison	comparison	NN
work_6edatbslnjhz3kb2pkbphqv5py	235	5	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	235	6	fluorouracil	fluorouracil	NNP
work_6edatbslnjhz3kb2pkbphqv5py	235	7	versus	versus	IN
work_6edatbslnjhz3kb2pkbphqv5py	235	8	fluorouracil	fluorouracil	NNP
work_6edatbslnjhz3kb2pkbphqv5py	235	9	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	235	10	high	high	JJ
work_6edatbslnjhz3kb2pkbphqv5py	235	11	-	-	HYPH
work_6edatbslnjhz3kb2pkbphqv5py	235	12	dose	dose	JJ
work_6edatbslnjhz3kb2pkbphqv5py	235	13	continuous	continuous	JJ
work_6edatbslnjhz3kb2pkbphqv5py	235	14	infusion	infusion	NN
work_6edatbslnjhz3kb2pkbphqv5py	235	15	leucovorin	leucovorin	NNP
work_6edatbslnjhz3kb2pkbphqv5py	235	16	calcium	calcium	NNP
work_6edatbslnjhz3kb2pkbphqv5py	235	17	for	for	IN
work_6edatbslnjhz3kb2pkbphqv5py	235	18	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	235	19	treatment	treatment	NN
work_6edatbslnjhz3kb2pkbphqv5py	235	20	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	235	21	advanced	advanced	JJ
work_6edatbslnjhz3kb2pkbphqv5py	235	22	measurable	measurable	JJ
work_6edatbslnjhz3kb2pkbphqv5py	235	23	coborectal	coborectal	JJ
work_6edatbslnjhz3kb2pkbphqv5py	235	24	cancer	cancer	NN
work_6edatbslnjhz3kb2pkbphqv5py	235	25	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	235	26	patients	patient	NNS
work_6edatbslnjhz3kb2pkbphqv5py	235	27	previously	previously	RB
work_6edatbslnjhz3kb2pkbphqv5py	235	28	unexposed	unexposed	JJ
work_6edatbslnjhz3kb2pkbphqv5py	235	29	to	to	IN
work_6edatbslnjhz3kb2pkbphqv5py	235	30	chem-	chem-	VB
work_6edatbslnjhz3kb2pkbphqv5py	235	31	otherapy	otherapy	NN
work_6edatbslnjhz3kb2pkbphqv5py	235	32	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	236	1	J.	J.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	236	2	Clin	Clin	NNP
work_6edatbslnjhz3kb2pkbphqv5py	236	3	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	237	1	Oncol	Oncol	NNP
work_6edatbslnjhz3kb2pkbphqv5py	237	2	.	.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	237	3	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	237	4	8	8	CD
work_6edatbslnjhz3kb2pkbphqv5py	237	5	:	:	SYM
work_6edatbslnjhz3kb2pkbphqv5py	237	6	491	491	CD
work_6edatbslnjhz3kb2pkbphqv5py	237	7	-	-	SYM
work_6edatbslnjhz3kb2pkbphqv5py	237	8	501	501	CD
work_6edatbslnjhz3kb2pkbphqv5py	237	9	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	237	10	1990	1990	CD
work_6edatbslnjhz3kb2pkbphqv5py	237	11	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	238	1	13	13	CD
work_6edatbslnjhz3kb2pkbphqv5py	238	2	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	239	1	Erlichman	Erlichman	NNP
work_6edatbslnjhz3kb2pkbphqv5py	239	2	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	239	3	C.	C.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	239	4	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	239	5	Fine	Fine	NNP
work_6edatbslnjhz3kb2pkbphqv5py	239	6	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	239	7	S.	S.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	239	8	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	239	9	Wong	Wong	NNP
work_6edatbslnjhz3kb2pkbphqv5py	239	10	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	239	11	A.	A.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	239	12	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	239	13	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	239	14	Elhakim	Elhakim	NNP
work_6edatbslnjhz3kb2pkbphqv5py	239	15	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	239	16	T.	T.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	239	17	A	a	DT
work_6edatbslnjhz3kb2pkbphqv5py	239	18	randomized	randomized	JJ
work_6edatbslnjhz3kb2pkbphqv5py	239	19	trial	trial	NN
work_6edatbslnjhz3kb2pkbphqv5py	239	20	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	239	21	fluorouracil	fluorouracil	NN
work_6edatbslnjhz3kb2pkbphqv5py	239	22	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	239	23	folinic	folinic	NN
work_6edatbslnjhz3kb2pkbphqv5py	239	24	acid	acid	NN
work_6edatbslnjhz3kb2pkbphqv5py	239	25	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	239	26	patients	patient	NNS
work_6edatbslnjhz3kb2pkbphqv5py	239	27	with	with	IN
work_6edatbslnjhz3kb2pkbphqv5py	239	28	metastatic	metastatic	JJ
work_6edatbslnjhz3kb2pkbphqv5py	239	29	colorectal	colorectal	JJ
work_6edatbslnjhz3kb2pkbphqv5py	239	30	carcinoma	carcinoma	NN
work_6edatbslnjhz3kb2pkbphqv5py	239	31	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	240	1	J.	J.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	240	2	Clin	Clin	NNP
work_6edatbslnjhz3kb2pkbphqv5py	240	3	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	241	1	Oncol	Oncol	NNP
work_6edatbslnjhz3kb2pkbphqv5py	241	2	.	.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	241	3	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	241	4	6	6	CD
work_6edatbslnjhz3kb2pkbphqv5py	241	5	:	:	SYM
work_6edatbslnjhz3kb2pkbphqv5py	241	6	469	469	CD
work_6edatbslnjhz3kb2pkbphqv5py	241	7	-	-	SYM
work_6edatbslnjhz3kb2pkbphqv5py	241	8	475	475	CD
work_6edatbslnjhz3kb2pkbphqv5py	241	9	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	241	10	1988	1988	CD
work_6edatbslnjhz3kb2pkbphqv5py	241	11	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	242	1	14	14	CD
work_6edatbslnjhz3kb2pkbphqv5py	242	2	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	243	1	Martoni	Martoni	NNP
work_6edatbslnjhz3kb2pkbphqv5py	243	2	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	243	3	A.	A.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	243	4	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	243	5	Cricca	Cricca	NNP
work_6edatbslnjhz3kb2pkbphqv5py	243	6	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	243	7	A.	A.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	243	8	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	243	9	Guaraldi	Guaraldi	NNP
work_6edatbslnjhz3kb2pkbphqv5py	243	10	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	243	11	M.	M.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	243	12	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	243	13	Covizzi	Covizzi	NNP
work_6edatbslnjhz3kb2pkbphqv5py	243	14	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	243	15	M.	M.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	243	16	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	243	17	Farris	Farris	NNP
work_6edatbslnjhz3kb2pkbphqv5py	243	18	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	243	19	A.	a.	NN
work_6edatbslnjhz3kb2pkbphqv5py	243	20	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	243	21	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	243	22	Pannuti	Pannuti	NNP
work_6edatbslnjhz3kb2pkbphqv5py	243	23	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	243	24	F.	F.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	243	25	Weekly	Weekly	NNP
work_6edatbslnjhz3kb2pkbphqv5py	243	26	regimen	regimen	NN
work_6edatbslnjhz3kb2pkbphqv5py	243	27	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	243	28	5-Hi	5-hi	CD
work_6edatbslnjhz3kb2pkbphqv5py	243	29	versus	versus	IN
work_6edatbslnjhz3kb2pkbphqv5py	243	30	5-Hi	5-hi	CD
work_6edatbslnjhz3kb2pkbphqv5py	243	31	+	+	CC
work_6edatbslnjhz3kb2pkbphqv5py	243	32	intermediate	intermediate	JJ
work_6edatbslnjhz3kb2pkbphqv5py	243	33	dose	dose	NN
work_6edatbslnjhz3kb2pkbphqv5py	243	34	folimc	folimc	NN
work_6edatbslnjhz3kb2pkbphqv5py	243	35	acid	acid	NN
work_6edatbslnjhz3kb2pkbphqv5py	243	36	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	243	37	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	243	38	treatment	treatment	NN
work_6edatbslnjhz3kb2pkbphqv5py	243	39	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	243	40	advanced	advanced	JJ
work_6edatbslnjhz3kb2pkbphqv5py	243	41	coborectal	coborectal	JJ
work_6edatbslnjhz3kb2pkbphqv5py	243	42	cancer	cancer	NN
work_6edatbslnjhz3kb2pkbphqv5py	243	43	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	244	1	Anticancer	Anticancer	NNP
work_6edatbslnjhz3kb2pkbphqv5py	244	2	Res	Res	NNP
work_6edatbslnjhz3kb2pkbphqv5py	244	3	.	.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	244	4	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	244	5	12	12	CD
work_6edatbslnjhz3kb2pkbphqv5py	244	6	:	:	SYM
work_6edatbslnjhz3kb2pkbphqv5py	244	7	607	607	CD
work_6edatbslnjhz3kb2pkbphqv5py	244	8	-	-	SYM
work_6edatbslnjhz3kb2pkbphqv5py	244	9	612	612	CD
work_6edatbslnjhz3kb2pkbphqv5py	244	10	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	244	11	1992	1992	CD
work_6edatbslnjhz3kb2pkbphqv5py	244	12	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	245	1	15	15	CD
work_6edatbslnjhz3kb2pkbphqv5py	245	2	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	246	1	Petrioli	Petrioli	NNP
work_6edatbslnjhz3kb2pkbphqv5py	246	2	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	246	3	R.	R.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	246	4	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	246	5	Lorenzi	Lorenzi	NNP
work_6edatbslnjhz3kb2pkbphqv5py	246	6	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	246	7	M.	M.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	246	8	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	246	9	Aquino	Aquino	NNP
work_6edatbslnjhz3kb2pkbphqv5py	246	10	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	246	11	A.	A.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	246	12	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	246	13	et	et	NNP
work_6edatbslnjhz3kb2pkbphqv5py	246	14	al	al	NNP
work_6edatbslnjhz3kb2pkbphqv5py	246	15	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	247	1	Treatment	treatment	NN
work_6edatbslnjhz3kb2pkbphqv5py	247	2	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	247	3	advanced	advanced	JJ
work_6edatbslnjhz3kb2pkbphqv5py	247	4	colorectal	colorectal	JJ
work_6edatbslnjhz3kb2pkbphqv5py	247	5	cancer	cancer	NN
work_6edatbslnjhz3kb2pkbphqv5py	247	6	with	with	IN
work_6edatbslnjhz3kb2pkbphqv5py	247	7	high	high	JJ
work_6edatbslnjhz3kb2pkbphqv5py	247	8	-	-	HYPH
work_6edatbslnjhz3kb2pkbphqv5py	247	9	dose	dose	NN
work_6edatbslnjhz3kb2pkbphqv5py	247	10	intensity	intensity	NN
work_6edatbslnjhz3kb2pkbphqv5py	247	11	folinic	folinic	NN
work_6edatbslnjhz3kb2pkbphqv5py	247	12	acid	acid	NN
work_6edatbslnjhz3kb2pkbphqv5py	247	13	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	247	14	5-fluorouracil	5-fluorouracil	CD
work_6edatbslnjhz3kb2pkbphqv5py	247	15	plus	plus	CC
work_6edatbslnjhz3kb2pkbphqv5py	247	16	supportive	supportive	JJ
work_6edatbslnjhz3kb2pkbphqv5py	247	17	care	care	NN
work_6edatbslnjhz3kb2pkbphqv5py	247	18	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	248	1	Eur	Eur	NNP
work_6edatbslnjhz3kb2pkbphqv5py	248	2	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	249	1	J.	J.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	250	1	Cancer	cancer	NN
work_6edatbslnjhz3kb2pkbphqv5py	250	2	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	250	3	31A	31a	CD
work_6edatbslnjhz3kb2pkbphqv5py	250	4	:	:	:
work_6edatbslnjhz3kb2pkbphqv5py	250	5	2105	2105	CD
work_6edatbslnjhz3kb2pkbphqv5py	250	6	-	-	SYM
work_6edatbslnjhz3kb2pkbphqv5py	250	7	2108	2108	CD
work_6edatbslnjhz3kb2pkbphqv5py	250	8	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	250	9	1995	1995	CD
work_6edatbslnjhz3kb2pkbphqv5py	250	10	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	251	1	16	16	CD
work_6edatbslnjhz3kb2pkbphqv5py	251	2	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	252	1	Steinke	Steinke	NNP
work_6edatbslnjhz3kb2pkbphqv5py	252	2	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	252	3	B.	B.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	252	4	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	252	5	Gunther	Gunther	NNP
work_6edatbslnjhz3kb2pkbphqv5py	252	6	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	252	7	E.	E.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	252	8	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	252	9	Hirschmann	Hirschmann	NNP
work_6edatbslnjhz3kb2pkbphqv5py	252	10	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	252	11	W.	W.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	252	12	D.	D.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	252	13	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	252	14	Sondern	Sondern	NNP
work_6edatbslnjhz3kb2pkbphqv5py	252	15	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	252	16	W.	W.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	252	17	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	252	18	Konic-	Konic-	NNP
work_6edatbslnjhz3kb2pkbphqv5py	252	19	zek	zek	NNP
work_6edatbslnjhz3kb2pkbphqv5py	252	20	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	252	21	K.	K.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	252	22	H.	H.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	252	23	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	252	24	Wander	Wander	NNP
work_6edatbslnjhz3kb2pkbphqv5py	252	25	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	252	26	H.	H.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	252	27	E.	E.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	252	28	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	252	29	Natt	Natt	NNP
work_6edatbslnjhz3kb2pkbphqv5py	252	30	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	252	31	F.	F.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	252	32	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	252	33	Wagner	Wagner	NNP
work_6edatbslnjhz3kb2pkbphqv5py	252	34	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	252	35	T.	T.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	252	36	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	252	37	Hinrichs	Hinrichs	NNP
work_6edatbslnjhz3kb2pkbphqv5py	252	38	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	252	39	H.	H.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	252	40	F.	F.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	252	41	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	252	42	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	252	43	Werdier	Werdier	NNP
work_6edatbslnjhz3kb2pkbphqv5py	252	44	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	252	45	D.	D.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	252	46	Fluorouracil	Fluorouracil	NNP
work_6edatbslnjhz3kb2pkbphqv5py	252	47	versus	versus	IN
work_6edatbslnjhz3kb2pkbphqv5py	252	48	folinic	folinic	NNP
work_6edatbslnjhz3kb2pkbphqv5py	252	49	acid	acid	NNP
work_6edatbslnjhz3kb2pkbphqv5py	252	50	/	/	SYM
work_6edatbslnjhz3kb2pkbphqv5py	252	51	fluorouracil	fluorouracil	NN
work_6edatbslnjhz3kb2pkbphqv5py	252	52	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	252	53	advanced	advanced	JJ
work_6edatbslnjhz3kb2pkbphqv5py	252	54	colorectal	colorectal	JJ
work_6edatbslnjhz3kb2pkbphqv5py	252	55	cancer	cancer	NN
work_6edatbslnjhz3kb2pkbphqv5py	252	56	:	:	:
work_6edatbslnjhz3kb2pkbphqv5py	252	57	preliminary	preliminary	JJ
work_6edatbslnjhz3kb2pkbphqv5py	252	58	results	result	NNS
work_6edatbslnjhz3kb2pkbphqv5py	252	59	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	252	60	a	a	DT
work_6edatbslnjhz3kb2pkbphqv5py	252	61	randomized	randomized	JJ
work_6edatbslnjhz3kb2pkbphqv5py	252	62	trial	trial	NN
work_6edatbslnjhz3kb2pkbphqv5py	252	63	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	253	1	Semin	Semin	NNP
work_6edatbslnjhz3kb2pkbphqv5py	253	2	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	254	1	Oncol	Oncol	NNP
work_6edatbslnjhz3kb2pkbphqv5py	254	2	.	.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	254	3	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	254	4	19	19	CD
work_6edatbslnjhz3kb2pkbphqv5py	254	5	:	:	SYM
work_6edatbslnjhz3kb2pkbphqv5py	254	6	141	141	CD
work_6edatbslnjhz3kb2pkbphqv5py	254	7	-	-	SYM
work_6edatbslnjhz3kb2pkbphqv5py	254	8	147	147	CD
work_6edatbslnjhz3kb2pkbphqv5py	254	9	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	254	10	1992	1992	CD
work_6edatbslnjhz3kb2pkbphqv5py	254	11	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	255	1	17	17	CD
work_6edatbslnjhz3kb2pkbphqv5py	255	2	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	256	1	The	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	256	2	Advanced	Advanced	NNP
work_6edatbslnjhz3kb2pkbphqv5py	256	3	Coborectal	Coborectal	NNP
work_6edatbslnjhz3kb2pkbphqv5py	256	4	Cancer	Cancer	NNP
work_6edatbslnjhz3kb2pkbphqv5py	256	5	Meta	Meta	NNP
work_6edatbslnjhz3kb2pkbphqv5py	256	6	-	-	HYPH
work_6edatbslnjhz3kb2pkbphqv5py	256	7	Analysis	Analysis	NNP
work_6edatbslnjhz3kb2pkbphqv5py	256	8	Project	Project	NNP
work_6edatbslnjhz3kb2pkbphqv5py	256	9	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	257	1	Modula-	modula-	IN
work_6edatbslnjhz3kb2pkbphqv5py	257	2	tion	tion	NN
work_6edatbslnjhz3kb2pkbphqv5py	257	3	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	257	4	fluorouracil	fluorouracil	NNP
work_6edatbslnjhz3kb2pkbphqv5py	257	5	by	by	IN
work_6edatbslnjhz3kb2pkbphqv5py	257	6	leucovorin	leucovorin	NNP
work_6edatbslnjhz3kb2pkbphqv5py	257	7	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	257	8	patients	patient	NNS
work_6edatbslnjhz3kb2pkbphqv5py	257	9	with	with	IN
work_6edatbslnjhz3kb2pkbphqv5py	257	10	advanced	advanced	JJ
work_6edatbslnjhz3kb2pkbphqv5py	257	11	colorectal	colorectal	JJ
work_6edatbslnjhz3kb2pkbphqv5py	257	12	cancer	cancer	NN
work_6edatbslnjhz3kb2pkbphqv5py	257	13	:	:	:
work_6edatbslnjhz3kb2pkbphqv5py	257	14	evidence	evidence	NN
work_6edatbslnjhz3kb2pkbphqv5py	257	15	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	257	16	terms	term	NNS
work_6edatbslnjhz3kb2pkbphqv5py	257	17	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	257	18	response	response	NN
work_6edatbslnjhz3kb2pkbphqv5py	257	19	rate	rate	NN
work_6edatbslnjhz3kb2pkbphqv5py	257	20	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	258	1	J.	J.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	258	2	Clin	Clin	NNP
work_6edatbslnjhz3kb2pkbphqv5py	258	3	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	259	1	Oncol	Oncol	NNP
work_6edatbslnjhz3kb2pkbphqv5py	259	2	.	.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	259	3	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	259	4	10	10	CD
work_6edatbslnjhz3kb2pkbphqv5py	259	5	:	:	:
work_6edatbslnjhz3kb2pkbphqv5py	259	6	896	896	CD
work_6edatbslnjhz3kb2pkbphqv5py	259	7	-	-	SYM
work_6edatbslnjhz3kb2pkbphqv5py	259	8	903	903	CD
work_6edatbslnjhz3kb2pkbphqv5py	259	9	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	259	10	1992	1992	CD
work_6edatbslnjhz3kb2pkbphqv5py	259	11	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	260	1	18	18	CD
work_6edatbslnjhz3kb2pkbphqv5py	260	2	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	261	1	Loehrer	Loehrer	NNP
work_6edatbslnjhz3kb2pkbphqv5py	261	2	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	261	3	P.	P.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	261	4	J.	J.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	261	5	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	261	6	Turner	Turner	NNP
work_6edatbslnjhz3kb2pkbphqv5py	261	7	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	261	8	S.	S.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	261	9	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	261	10	Kubilis	Kubilis	NNP
work_6edatbslnjhz3kb2pkbphqv5py	261	11	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	261	12	P.	P.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	261	13	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	261	14	Hui	Hui	NNP
work_6edatbslnjhz3kb2pkbphqv5py	261	15	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	261	16	S.	S.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	261	17	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	261	18	Correa	Correa	NNP
work_6edatbslnjhz3kb2pkbphqv5py	261	19	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	261	20	J.	J.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	261	21	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	261	22	Ansari	Ansari	NNP
work_6edatbslnjhz3kb2pkbphqv5py	261	23	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	261	24	R.	R.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	261	25	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	261	26	Stephens	Stephens	NNP
work_6edatbslnjhz3kb2pkbphqv5py	261	27	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	261	28	D.	D.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	261	29	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	261	30	Woodbum	Woodbum	NNP
work_6edatbslnjhz3kb2pkbphqv5py	261	31	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	261	32	R.	R.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	261	33	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	261	34	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	261	35	Meyers	Meyers	NNP
work_6edatbslnjhz3kb2pkbphqv5py	261	36	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	261	37	S.	S.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	261	38	A	A	NNP
work_6edatbslnjhz3kb2pkbphqv5py	261	39	prospective	prospective	JJ
work_6edatbslnjhz3kb2pkbphqv5py	261	40	randomized	randomized	JJ
work_6edatbslnjhz3kb2pkbphqv5py	261	41	trial	trial	NN
work_6edatbslnjhz3kb2pkbphqv5py	261	42	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	261	43	fluorouracil	fluorouracil	NNP
work_6edatbslnjhz3kb2pkbphqv5py	261	44	versus	versus	IN
work_6edatbslnjhz3kb2pkbphqv5py	261	45	fluorouracil	fluorouracil	NNP
work_6edatbslnjhz3kb2pkbphqv5py	261	46	plus	plus	CC
work_6edatbslnjhz3kb2pkbphqv5py	261	47	cisplatin	cisplatin	NN
work_6edatbslnjhz3kb2pkbphqv5py	261	48	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	261	49	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	261	50	treatment	treatment	NN
work_6edatbslnjhz3kb2pkbphqv5py	261	51	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	261	52	metastatic	metastatic	JJ
work_6edatbslnjhz3kb2pkbphqv5py	261	53	coborectal	coborectal	JJ
work_6edatbslnjhz3kb2pkbphqv5py	261	54	cancer	cancer	NN
work_6edatbslnjhz3kb2pkbphqv5py	261	55	:	:	:
work_6edatbslnjhz3kb2pkbphqv5py	261	56	a	a	DT
work_6edatbslnjhz3kb2pkbphqv5py	261	57	Hoosier	Hoosier	NNP
work_6edatbslnjhz3kb2pkbphqv5py	261	58	Oncology	Oncology	NNP
work_6edatbslnjhz3kb2pkbphqv5py	261	59	Group	Group	NNP
work_6edatbslnjhz3kb2pkbphqv5py	261	60	Trial	Trial	NNP
work_6edatbslnjhz3kb2pkbphqv5py	261	61	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	262	1	J.	J.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	262	2	Clin	Clin	NNP
work_6edatbslnjhz3kb2pkbphqv5py	262	3	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	263	1	Oncob	Oncob	NNP
work_6edatbslnjhz3kb2pkbphqv5py	263	2	.	.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	263	3	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	263	4	6	6	CD
work_6edatbslnjhz3kb2pkbphqv5py	263	5	:	:	SYM
work_6edatbslnjhz3kb2pkbphqv5py	263	6	642	642	CD
work_6edatbslnjhz3kb2pkbphqv5py	263	7	-	-	HYPH
work_6edatbslnjhz3kb2pkbphqv5py	263	8	648	648	CD
work_6edatbslnjhz3kb2pkbphqv5py	263	9	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	263	10	1988	1988	CD
work_6edatbslnjhz3kb2pkbphqv5py	263	11	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	264	1	19	19	CD
work_6edatbslnjhz3kb2pkbphqv5py	264	2	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	265	1	Labianca	Labianca	NNP
work_6edatbslnjhz3kb2pkbphqv5py	265	2	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	265	3	R.	R.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	265	4	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	265	5	Pancera	Pancera	NNP
work_6edatbslnjhz3kb2pkbphqv5py	265	6	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	265	7	G.	G.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	265	8	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	265	9	Cesana	Cesana	NNP
work_6edatbslnjhz3kb2pkbphqv5py	265	10	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	265	11	B.	B.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	265	12	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	265	13	et	et	NNP
work_6edatbslnjhz3kb2pkbphqv5py	265	14	al	al	NNP
work_6edatbslnjhz3kb2pkbphqv5py	265	15	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	266	1	Cisplatin	cisplatin	NN
work_6edatbslnjhz3kb2pkbphqv5py	266	2	+	+	SYM
work_6edatbslnjhz3kb2pkbphqv5py	266	3	5-fluorou-	5-fluorou-	NN
work_6edatbslnjhz3kb2pkbphqv5py	266	4	racil	racil	NN
work_6edatbslnjhz3kb2pkbphqv5py	266	5	versus	versus	IN
work_6edatbslnjhz3kb2pkbphqv5py	266	6	5-fluorouracil	5-fluorouracil	CD
work_6edatbslnjhz3kb2pkbphqv5py	266	7	alone	alone	RB
work_6edatbslnjhz3kb2pkbphqv5py	266	8	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	266	9	advanced	advanced	JJ
work_6edatbslnjhz3kb2pkbphqv5py	266	10	colorectal	colorectal	JJ
work_6edatbslnjhz3kb2pkbphqv5py	266	11	cancer	cancer	NN
work_6edatbslnjhz3kb2pkbphqv5py	266	12	:	:	:
work_6edatbslnjhz3kb2pkbphqv5py	266	13	a	a	DT
work_6edatbslnjhz3kb2pkbphqv5py	266	14	ran-	ran-	RB
work_6edatbslnjhz3kb2pkbphqv5py	266	15	domized	domize	VBN
work_6edatbslnjhz3kb2pkbphqv5py	266	16	study	study	NN
work_6edatbslnjhz3kb2pkbphqv5py	266	17	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	267	1	Eur	Eur	NNP
work_6edatbslnjhz3kb2pkbphqv5py	267	2	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	268	1	J.	J.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	269	1	Cancer	Cancer	NNP
work_6edatbslnjhz3kb2pkbphqv5py	269	2	Clin	Clin	NNP
work_6edatbslnjhz3kb2pkbphqv5py	269	3	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	270	1	Oncol	Oncol	NNP
work_6edatbslnjhz3kb2pkbphqv5py	270	2	.	.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	270	3	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	270	4	24	24	CD
work_6edatbslnjhz3kb2pkbphqv5py	270	5	:	:	SYM
work_6edatbslnjhz3kb2pkbphqv5py	270	6	1579	1579	CD
work_6edatbslnjhz3kb2pkbphqv5py	270	7	-	-	SYM
work_6edatbslnjhz3kb2pkbphqv5py	270	8	1581	1581	CD
work_6edatbslnjhz3kb2pkbphqv5py	270	9	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	270	10	1988	1988	CD
work_6edatbslnjhz3kb2pkbphqv5py	270	11	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	271	1	20	20	CD
work_6edatbslnjhz3kb2pkbphqv5py	271	2	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	272	1	Buroker	Buroker	NNP
work_6edatbslnjhz3kb2pkbphqv5py	272	2	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	272	3	1	1	CD
work_6edatbslnjhz3kb2pkbphqv5py	272	4	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	273	1	R.	R.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	273	2	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	273	3	Moertel	Moertel	NNP
work_6edatbslnjhz3kb2pkbphqv5py	273	4	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	273	5	C.	C.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	273	6	G.	G.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	273	7	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	273	8	Fleming	Fleming	NNP
work_6edatbslnjhz3kb2pkbphqv5py	273	9	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	273	10	T.	T.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	273	11	R.	R.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	273	12	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	273	13	et	et	NNP
work_6edatbslnjhz3kb2pkbphqv5py	273	14	al	al	NNP
work_6edatbslnjhz3kb2pkbphqv5py	273	15	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	274	1	A	a	DT
work_6edatbslnjhz3kb2pkbphqv5py	274	2	controlled	control	VBN
work_6edatbslnjhz3kb2pkbphqv5py	274	3	evaluation	evaluation	NN
work_6edatbslnjhz3kb2pkbphqv5py	274	4	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	274	5	recent	recent	JJ
work_6edatbslnjhz3kb2pkbphqv5py	274	6	approaches	approach	NNS
work_6edatbslnjhz3kb2pkbphqv5py	274	7	to	to	IN
work_6edatbslnjhz3kb2pkbphqv5py	274	8	biochemical	biochemical	JJ
work_6edatbslnjhz3kb2pkbphqv5py	274	9	modulation	modulation	NN
work_6edatbslnjhz3kb2pkbphqv5py	274	10	or	or	CC
work_6edatbslnjhz3kb2pkbphqv5py	274	11	enhance-	enhance-	JJ
work_6edatbslnjhz3kb2pkbphqv5py	274	12	ment	ment	NN
work_6edatbslnjhz3kb2pkbphqv5py	274	13	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	274	14	5-fluorouracil	5-fluorouracil	CD
work_6edatbslnjhz3kb2pkbphqv5py	274	15	therapy	therapy	NN
work_6edatbslnjhz3kb2pkbphqv5py	274	16	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	274	17	colorectal	colorectal	JJ
work_6edatbslnjhz3kb2pkbphqv5py	274	18	carcinoma	carcinoma	NN
work_6edatbslnjhz3kb2pkbphqv5py	274	19	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	275	1	J.	J.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	275	2	Clin	Clin	NNP
work_6edatbslnjhz3kb2pkbphqv5py	275	3	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	276	1	Oncob	Oncob	NNP
work_6edatbslnjhz3kb2pkbphqv5py	276	2	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	276	3	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	276	4	3	3	CD
work_6edatbslnjhz3kb2pkbphqv5py	276	5	:	:	SYM
work_6edatbslnjhz3kb2pkbphqv5py	276	6	1624	1624	CD
work_6edatbslnjhz3kb2pkbphqv5py	276	7	-	-	SYM
work_6edatbslnjhz3kb2pkbphqv5py	276	8	1631	1631	CD
work_6edatbslnjhz3kb2pkbphqv5py	276	9	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	276	10	1985	1985	CD
work_6edatbslnjhz3kb2pkbphqv5py	276	11	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	277	1	21	21	CD
work_6edatbslnjhz3kb2pkbphqv5py	277	2	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	278	1	Verhaegen	Verhaegen	NNP
work_6edatbslnjhz3kb2pkbphqv5py	278	2	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	278	3	H.	H.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	278	4	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	278	5	DeCree	DeCree	NNP
work_6edatbslnjhz3kb2pkbphqv5py	278	6	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	278	7	J.	J.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	278	8	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	278	9	DeCook	DeCook	NNP
work_6edatbslnjhz3kb2pkbphqv5py	278	10	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	278	11	W.	W.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	278	12	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	278	13	et	et	NNP
work_6edatbslnjhz3kb2pkbphqv5py	278	14	al	al	NNP
work_6edatbslnjhz3kb2pkbphqv5py	278	15	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	279	1	Levamisole	levamisole	NN
work_6edatbslnjhz3kb2pkbphqv5py	279	2	therapy	therapy	NN
work_6edatbslnjhz3kb2pkbphqv5py	279	3	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	279	4	patients	patient	NNS
work_6edatbslnjhz3kb2pkbphqv5py	279	5	with	with	IN
work_6edatbslnjhz3kb2pkbphqv5py	279	6	coborectal	coborectal	JJ
work_6edatbslnjhz3kb2pkbphqv5py	279	7	cancer	cancer	NN
work_6edatbslnjhz3kb2pkbphqv5py	279	8	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	280	1	In	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	280	2	:	:	:
work_6edatbslnjhz3kb2pkbphqv5py	280	3	W.	W.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	280	4	D.	D.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	280	5	Terry	Terry	NNP
work_6edatbslnjhz3kb2pkbphqv5py	280	6	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	280	7	S.	S.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	280	8	A.	A.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	280	9	Rosenberg	Rosenberg	NNP
work_6edatbslnjhz3kb2pkbphqv5py	280	10	(	(	-LRB-
work_6edatbslnjhz3kb2pkbphqv5py	280	11	eds	eds	XX
work_6edatbslnjhz3kb2pkbphqv5py	280	12	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	281	1	)	)	-RRB-
work_6edatbslnjhz3kb2pkbphqv5py	281	2	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	281	3	Immunotherapy	Immunotherapy	NNP
work_6edatbslnjhz3kb2pkbphqv5py	281	4	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	281	5	Human	Human	NNP
work_6edatbslnjhz3kb2pkbphqv5py	281	6	Cancer	Cancer	NNP
work_6edatbslnjhz3kb2pkbphqv5py	281	7	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	281	8	pp	pp	NNP
work_6edatbslnjhz3kb2pkbphqv5py	281	9	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	282	1	225	225	CD
work_6edatbslnjhz3kb2pkbphqv5py	282	2	-	-	SYM
work_6edatbslnjhz3kb2pkbphqv5py	282	3	229	229	CD
work_6edatbslnjhz3kb2pkbphqv5py	282	4	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	283	1	New	New	NNP
work_6edatbslnjhz3kb2pkbphqv5py	283	2	York	York	NNP
work_6edatbslnjhz3kb2pkbphqv5py	283	3	:	:	:
work_6edatbslnjhz3kb2pkbphqv5py	283	4	Elsevier	Elsevier	NNP
work_6edatbslnjhz3kb2pkbphqv5py	283	5	North	North	NNP
work_6edatbslnjhz3kb2pkbphqv5py	283	6	Holland	Holland	NNP
work_6edatbslnjhz3kb2pkbphqv5py	283	7	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	283	8	1982	1982	CD
work_6edatbslnjhz3kb2pkbphqv5py	283	9	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	284	1	22	22	CD
work_6edatbslnjhz3kb2pkbphqv5py	284	2	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	285	1	Chlebowski	Chlebowski	NNP
work_6edatbslnjhz3kb2pkbphqv5py	285	2	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	285	3	R.	R.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	285	4	T.	T.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	285	5	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	285	6	Nystrom	Nystrom	NNP
work_6edatbslnjhz3kb2pkbphqv5py	285	7	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	285	8	S.	S.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	285	9	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	285	10	Reynolds	Reynolds	NNP
work_6edatbslnjhz3kb2pkbphqv5py	285	11	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	285	12	R.	R.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	285	13	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	285	14	et	et	NNP
work_6edatbslnjhz3kb2pkbphqv5py	285	15	al	al	NNP
work_6edatbslnjhz3kb2pkbphqv5py	285	16	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	286	1	Long	long	JJ
work_6edatbslnjhz3kb2pkbphqv5py	286	2	-	-	HYPH
work_6edatbslnjhz3kb2pkbphqv5py	286	3	term	term	NN
work_6edatbslnjhz3kb2pkbphqv5py	286	4	survival	survival	NN
work_6edatbslnjhz3kb2pkbphqv5py	286	5	following	follow	VBG
work_6edatbslnjhz3kb2pkbphqv5py	286	6	levamisole	levamisole	NN
work_6edatbslnjhz3kb2pkbphqv5py	286	7	or	or	CC
work_6edatbslnjhz3kb2pkbphqv5py	286	8	placebo	placebo	NN
work_6edatbslnjhz3kb2pkbphqv5py	286	9	adjuvant	adjuvant	JJ
work_6edatbslnjhz3kb2pkbphqv5py	286	10	treatment	treatment	NN
work_6edatbslnjhz3kb2pkbphqv5py	286	11	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	286	12	coborec-	coborec-	NNP
work_6edatbslnjhz3kb2pkbphqv5py	286	13	tab	tab	NNP
work_6edatbslnjhz3kb2pkbphqv5py	286	14	cancer	cancer	NN
work_6edatbslnjhz3kb2pkbphqv5py	286	15	:	:	:
work_6edatbslnjhz3kb2pkbphqv5py	286	16	a	a	DT
work_6edatbslnjhz3kb2pkbphqv5py	286	17	Western	Western	NNP
work_6edatbslnjhz3kb2pkbphqv5py	286	18	Cancer	Cancer	NNP
work_6edatbslnjhz3kb2pkbphqv5py	286	19	Study	Study	NNP
work_6edatbslnjhz3kb2pkbphqv5py	286	20	group	group	NN
work_6edatbslnjhz3kb2pkbphqv5py	286	21	trial	trial	NN
work_6edatbslnjhz3kb2pkbphqv5py	286	22	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	287	1	Oncology	oncology	NN
work_6edatbslnjhz3kb2pkbphqv5py	287	2	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	287	3	45	45	CD
work_6edatbslnjhz3kb2pkbphqv5py	287	4	:	:	SYM
work_6edatbslnjhz3kb2pkbphqv5py	287	5	14	14	CD
work_6edatbslnjhz3kb2pkbphqv5py	287	6	1	1	CD
work_6edatbslnjhz3kb2pkbphqv5py	287	7	-	-	SYM
work_6edatbslnjhz3kb2pkbphqv5py	287	8	143	143	CD
work_6edatbslnjhz3kb2pkbphqv5py	287	9	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	287	10	1988	1988	CD
work_6edatbslnjhz3kb2pkbphqv5py	287	11	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	288	1	23	23	CD
work_6edatbslnjhz3kb2pkbphqv5py	288	2	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	289	1	Arnaud	Arnaud	NNP
work_6edatbslnjhz3kb2pkbphqv5py	289	2	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	289	3	J.	J.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	289	4	P.	P.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	289	5	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	289	6	Buyse	Buyse	NNP
work_6edatbslnjhz3kb2pkbphqv5py	289	7	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	289	8	M.	M.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	289	9	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	289	10	Nordlinger	Nordlinger	NNP
work_6edatbslnjhz3kb2pkbphqv5py	289	11	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	289	12	B.	B.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	289	13	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	289	14	Martin	Martin	NNP
work_6edatbslnjhz3kb2pkbphqv5py	289	15	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	289	16	F.	F.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	289	17	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	289	18	Pector	Pector	NNP
work_6edatbslnjhz3kb2pkbphqv5py	289	19	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	289	20	J.	J.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	289	21	C.	C.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	289	22	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	289	23	Zeitoun	Zeitoun	NNP
work_6edatbslnjhz3kb2pkbphqv5py	289	24	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	289	25	P.	P.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	289	26	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	289	27	Adboff	Adboff	NNP
work_6edatbslnjhz3kb2pkbphqv5py	289	28	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	289	29	A.	A.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	289	30	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	289	31	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	289	32	Duez	Duez	NNP
work_6edatbslnjhz3kb2pkbphqv5py	289	33	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	289	34	N.	N.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	289	35	Adjuvant	Adjuvant	NNP
work_6edatbslnjhz3kb2pkbphqv5py	289	36	therapy	therapy	NN
work_6edatbslnjhz3kb2pkbphqv5py	289	37	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	289	38	poor	poor	JJ
work_6edatbslnjhz3kb2pkbphqv5py	289	39	prog-	prog-	NNP
work_6edatbslnjhz3kb2pkbphqv5py	289	40	nosis	nosis	NN
work_6edatbslnjhz3kb2pkbphqv5py	289	41	colon	colon	NN
work_6edatbslnjhz3kb2pkbphqv5py	289	42	cancer	cancer	NN
work_6edatbslnjhz3kb2pkbphqv5py	289	43	with	with	IN
work_6edatbslnjhz3kb2pkbphqv5py	289	44	levamisole	levamisole	NN
work_6edatbslnjhz3kb2pkbphqv5py	289	45	:	:	:
work_6edatbslnjhz3kb2pkbphqv5py	289	46	results	result	NNS
work_6edatbslnjhz3kb2pkbphqv5py	289	47	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	289	48	an	an	DT
work_6edatbslnjhz3kb2pkbphqv5py	289	49	EORTC	EORTC	NNP
work_6edatbslnjhz3kb2pkbphqv5py	289	50	double	double	JJ
work_6edatbslnjhz3kb2pkbphqv5py	289	51	-	-	HYPH
work_6edatbslnjhz3kb2pkbphqv5py	289	52	blind	blind	RB
work_6edatbslnjhz3kb2pkbphqv5py	289	53	randomized	randomized	JJ
work_6edatbslnjhz3kb2pkbphqv5py	289	54	clinical	clinical	JJ
work_6edatbslnjhz3kb2pkbphqv5py	289	55	trial	trial	NN
work_6edatbslnjhz3kb2pkbphqv5py	289	56	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	290	1	Br	br	UH
work_6edatbslnjhz3kb2pkbphqv5py	290	2	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	291	1	J.	J.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	292	1	Surg	Surg	NNP
work_6edatbslnjhz3kb2pkbphqv5py	292	2	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	292	3	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	292	4	76	76	CD
work_6edatbslnjhz3kb2pkbphqv5py	292	5	:	:	:
work_6edatbslnjhz3kb2pkbphqv5py	292	6	284	284	CD
work_6edatbslnjhz3kb2pkbphqv5py	292	7	-	-	SYM
work_6edatbslnjhz3kb2pkbphqv5py	292	8	289	289	CD
work_6edatbslnjhz3kb2pkbphqv5py	292	9	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	292	10	1989	1989	CD
work_6edatbslnjhz3kb2pkbphqv5py	292	11	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	293	1	24	24	CD
work_6edatbslnjhz3kb2pkbphqv5py	293	2	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	294	1	Laurie	Laurie	NNP
work_6edatbslnjhz3kb2pkbphqv5py	294	2	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	294	3	J.	J.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	294	4	H.	H.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	294	5	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	294	6	Moertel	Moertel	NNP
work_6edatbslnjhz3kb2pkbphqv5py	294	7	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	294	8	C.	C.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	294	9	G.	G.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	294	10	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	294	11	Fleming	Fleming	NNP
work_6edatbslnjhz3kb2pkbphqv5py	294	12	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	294	13	T.	T.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	294	14	R.	R.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	294	15	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	294	16	et	et	NNP
work_6edatbslnjhz3kb2pkbphqv5py	294	17	al	al	NNP
work_6edatbslnjhz3kb2pkbphqv5py	294	18	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	295	1	Surgical	surgical	JJ
work_6edatbslnjhz3kb2pkbphqv5py	295	2	adjuvant	adjuvant	NN
work_6edatbslnjhz3kb2pkbphqv5py	295	3	therapy	therapy	NN
work_6edatbslnjhz3kb2pkbphqv5py	295	4	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	295	5	large	large	JJ
work_6edatbslnjhz3kb2pkbphqv5py	295	6	-	-	HYPH
work_6edatbslnjhz3kb2pkbphqv5py	295	7	bowel	bowel	NN
work_6edatbslnjhz3kb2pkbphqv5py	295	8	carcinoma	carcinoma	NN
work_6edatbslnjhz3kb2pkbphqv5py	295	9	:	:	:
work_6edatbslnjhz3kb2pkbphqv5py	295	10	an	an	DT
work_6edatbslnjhz3kb2pkbphqv5py	295	11	evaluation	evaluation	NN
work_6edatbslnjhz3kb2pkbphqv5py	295	12	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	295	13	levamisole	levamisole	NN
work_6edatbslnjhz3kb2pkbphqv5py	295	14	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	295	15	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	295	16	combination	combination	NN
work_6edatbslnjhz3kb2pkbphqv5py	295	17	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	295	18	levamisole	levamisole	NN
work_6edatbslnjhz3kb2pkbphqv5py	295	19	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	295	20	fluorouracil	fluorouracil	NN
work_6edatbslnjhz3kb2pkbphqv5py	295	21	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	296	1	J.	J.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	296	2	Clin	Clin	NNP
work_6edatbslnjhz3kb2pkbphqv5py	296	3	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	297	1	Oncol	Oncol	NNP
work_6edatbslnjhz3kb2pkbphqv5py	297	2	.	.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	297	3	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	297	4	7	7	CD
work_6edatbslnjhz3kb2pkbphqv5py	297	5	:	:	SYM
work_6edatbslnjhz3kb2pkbphqv5py	297	6	1447-	1447-	CD
work_6edatbslnjhz3kb2pkbphqv5py	297	7	1456	1456	CD
work_6edatbslnjhz3kb2pkbphqv5py	297	8	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	297	9	1989	1989	CD
work_6edatbslnjhz3kb2pkbphqv5py	297	10	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	298	1	25	25	CD
work_6edatbslnjhz3kb2pkbphqv5py	298	2	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	299	1	Moertel	Moertel	NNP
work_6edatbslnjhz3kb2pkbphqv5py	299	2	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	299	3	C.	C.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	299	4	G.	G.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	299	5	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	299	6	Fleming	Fleming	NNP
work_6edatbslnjhz3kb2pkbphqv5py	299	7	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	299	8	T.	T.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	299	9	R.	R.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	299	10	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	299	11	Macdonald	Macdonald	NNP
work_6edatbslnjhz3kb2pkbphqv5py	299	12	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	299	13	J.	J.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	299	14	S.	S.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	299	15	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	299	16	et	et	NNP
work_6edatbslnjhz3kb2pkbphqv5py	299	17	al	al	NNP
work_6edatbslnjhz3kb2pkbphqv5py	299	18	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	300	1	Fluorouracil	Fluorouracil	NNP
work_6edatbslnjhz3kb2pkbphqv5py	300	2	plus	plus	CC
work_6edatbslnjhz3kb2pkbphqv5py	300	3	levamisole	levamisole	NN
work_6edatbslnjhz3kb2pkbphqv5py	300	4	as	as	IN
work_6edatbslnjhz3kb2pkbphqv5py	300	5	effective	effective	JJ
work_6edatbslnjhz3kb2pkbphqv5py	300	6	adjuvant	adjuvant	NN
work_6edatbslnjhz3kb2pkbphqv5py	300	7	therapy	therapy	NN
work_6edatbslnjhz3kb2pkbphqv5py	300	8	after	after	IN
work_6edatbslnjhz3kb2pkbphqv5py	300	9	resection	resection	NN
work_6edatbslnjhz3kb2pkbphqv5py	300	10	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	300	11	stage	stage	NN
work_6edatbslnjhz3kb2pkbphqv5py	300	12	III	iii	CD
work_6edatbslnjhz3kb2pkbphqv5py	300	13	colon	colon	NN
work_6edatbslnjhz3kb2pkbphqv5py	300	14	carcinoma	carcinoma	NN
work_6edatbslnjhz3kb2pkbphqv5py	300	15	:	:	:
work_6edatbslnjhz3kb2pkbphqv5py	300	16	a	a	DT
work_6edatbslnjhz3kb2pkbphqv5py	300	17	final	final	JJ
work_6edatbslnjhz3kb2pkbphqv5py	300	18	report	report	NN
work_6edatbslnjhz3kb2pkbphqv5py	300	19	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	301	1	Ann	Ann	NNP
work_6edatbslnjhz3kb2pkbphqv5py	301	2	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	302	1	Intern	intern	NN
work_6edatbslnjhz3kb2pkbphqv5py	302	2	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	303	1	Med	Med	NNP
work_6edatbslnjhz3kb2pkbphqv5py	303	2	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	303	3	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	303	4	122	122	CD
work_6edatbslnjhz3kb2pkbphqv5py	303	5	:	:	SYM
work_6edatbslnjhz3kb2pkbphqv5py	303	6	321	321	CD
work_6edatbslnjhz3kb2pkbphqv5py	303	7	-	-	SYM
work_6edatbslnjhz3kb2pkbphqv5py	303	8	326	326	CD
work_6edatbslnjhz3kb2pkbphqv5py	303	9	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	303	10	1995	1995	CD
work_6edatbslnjhz3kb2pkbphqv5py	303	11	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	304	1	26	26	CD
work_6edatbslnjhz3kb2pkbphqv5py	304	2	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	305	1	Borden	Borden	NNP
work_6edatbslnjhz3kb2pkbphqv5py	305	2	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	305	3	E.	E.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	305	4	C.	C.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	305	5	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	305	6	Davis	Davis	NNP
work_6edatbslnjhz3kb2pkbphqv5py	305	7	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	305	8	T.	T.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	305	9	E.	E.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	305	10	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	305	11	Crowley	Crowley	NNP
work_6edatbslnjhz3kb2pkbphqv5py	305	12	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	305	13	J.	J.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	305	14	J.	J.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	305	15	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	305	16	et	et	NNP
work_6edatbslnjhz3kb2pkbphqv5py	305	17	al	al	NNP
work_6edatbslnjhz3kb2pkbphqv5py	305	18	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	306	1	Interim	interim	JJ
work_6edatbslnjhz3kb2pkbphqv5py	306	2	analysis	analysis	NN
work_6edatbslnjhz3kb2pkbphqv5py	306	3	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	306	4	a	a	DT
work_6edatbslnjhz3kb2pkbphqv5py	306	5	trial	trial	NN
work_6edatbslnjhz3kb2pkbphqv5py	306	6	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	306	7	levamisole	levamisole	NN
work_6edatbslnjhz3kb2pkbphqv5py	306	8	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	306	9	5-fluorouracil	5-fluorouracil	CD
work_6edatbslnjhz3kb2pkbphqv5py	306	10	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	306	11	metastatic	metastatic	JJ
work_6edatbslnjhz3kb2pkbphqv5py	306	12	colorectal	colorectal	JJ
work_6edatbslnjhz3kb2pkbphqv5py	306	13	carci-	carci-	NN
work_6edatbslnjhz3kb2pkbphqv5py	306	14	noma	noma	NNP
work_6edatbslnjhz3kb2pkbphqv5py	306	15	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	307	1	In	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	307	2	:	:	:
work_6edatbslnjhz3kb2pkbphqv5py	307	3	W.	W.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	307	4	D.	D.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	307	5	Terry	Terry	NNP
work_6edatbslnjhz3kb2pkbphqv5py	307	6	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	307	7	S.	S.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	307	8	A.	A.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	307	9	Rosenberg	Rosenberg	NNP
work_6edatbslnjhz3kb2pkbphqv5py	307	10	(	(	-LRB-
work_6edatbslnjhz3kb2pkbphqv5py	307	11	eds	eds	XX
work_6edatbslnjhz3kb2pkbphqv5py	307	12	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	308	1	)	)	-RRB-
work_6edatbslnjhz3kb2pkbphqv5py	308	2	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	308	3	Immunotherapy	Immunotherapy	NNP
work_6edatbslnjhz3kb2pkbphqv5py	308	4	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	308	5	Human	Human	NNP
work_6edatbslnjhz3kb2pkbphqv5py	308	6	Cancer	Cancer	NNP
work_6edatbslnjhz3kb2pkbphqv5py	308	7	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	308	8	pp	pp	NNP
work_6edatbslnjhz3kb2pkbphqv5py	308	9	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	309	1	231	231	CD
work_6edatbslnjhz3kb2pkbphqv5py	309	2	-	-	SYM
work_6edatbslnjhz3kb2pkbphqv5py	309	3	235	235	CD
work_6edatbslnjhz3kb2pkbphqv5py	309	4	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	310	1	New	New	NNP
work_6edatbslnjhz3kb2pkbphqv5py	310	2	York	York	NNP
work_6edatbslnjhz3kb2pkbphqv5py	310	3	:	:	:
work_6edatbslnjhz3kb2pkbphqv5py	310	4	Elsevier	Elsevier	NNP
work_6edatbslnjhz3kb2pkbphqv5py	310	5	North	North	NNP
work_6edatbslnjhz3kb2pkbphqv5py	310	6	Holland	Holland	NNP
work_6edatbslnjhz3kb2pkbphqv5py	310	7	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	310	8	1982	1982	CD
work_6edatbslnjhz3kb2pkbphqv5py	310	9	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	311	1	27	27	CD
work_6edatbslnjhz3kb2pkbphqv5py	311	2	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	312	1	Mansour	Mansour	NNP
work_6edatbslnjhz3kb2pkbphqv5py	312	2	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	312	3	E.	E.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	312	4	G.	G.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	312	5	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	312	6	Cnaan	Cnaan	NNP
work_6edatbslnjhz3kb2pkbphqv5py	312	7	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	312	8	A.	a.	NN
work_6edatbslnjhz3kb2pkbphqv5py	312	9	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	312	10	Davis	Davis	NNP
work_6edatbslnjhz3kb2pkbphqv5py	312	11	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	312	12	T.	T.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	312	13	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	312	14	et	et	NNP
work_6edatbslnjhz3kb2pkbphqv5py	312	15	al	al	NNP
work_6edatbslnjhz3kb2pkbphqv5py	312	16	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	313	1	Combined	combine	VBN
work_6edatbslnjhz3kb2pkbphqv5py	313	2	modality	modality	NN
work_6edatbslnjhz3kb2pkbphqv5py	313	3	therapy	therapy	NN
work_6edatbslnjhz3kb2pkbphqv5py	313	4	following	follow	VBG
work_6edatbslnjhz3kb2pkbphqv5py	313	5	resection	resection	NN
work_6edatbslnjhz3kb2pkbphqv5py	313	6	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	313	7	coborectal	coborectal	JJ
work_6edatbslnjhz3kb2pkbphqv5py	313	8	carcinoma	carcinoma	NN
work_6edatbslnjhz3kb2pkbphqv5py	313	9	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	313	10	patients	patient	NNS
work_6edatbslnjhz3kb2pkbphqv5py	313	11	with	with	IN
work_6edatbslnjhz3kb2pkbphqv5py	313	12	non	non	JJ
work_6edatbslnjhz3kb2pkbphqv5py	313	13	-	-	JJ
work_6edatbslnjhz3kb2pkbphqv5py	313	14	measurable	measurable	JJ
work_6edatbslnjhz3kb2pkbphqv5py	313	15	intra	intra	JJ
work_6edatbslnjhz3kb2pkbphqv5py	313	16	-	-	JJ
work_6edatbslnjhz3kb2pkbphqv5py	313	17	abdominal	abdominal	JJ
work_6edatbslnjhz3kb2pkbphqv5py	313	18	metastases	metastasis	NNS
work_6edatbslnjhz3kb2pkbphqv5py	313	19	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	314	1	An	an	DT
work_6edatbslnjhz3kb2pkbphqv5py	314	2	ECOG	ECOG	NNP
work_6edatbslnjhz3kb2pkbphqv5py	314	3	study	study	NN
work_6edatbslnjhz3kb2pkbphqv5py	314	4	3282	3282	CD
work_6edatbslnjhz3kb2pkbphqv5py	314	5	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	315	1	Proc	Proc	NNP
work_6edatbslnjhz3kb2pkbphqv5py	315	2	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	316	1	Am	Am	NNP
work_6edatbslnjhz3kb2pkbphqv5py	316	2	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	317	1	Soc	Soc	NNP
work_6edatbslnjhz3kb2pkbphqv5py	317	2	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	318	1	Clin	Clin	NNP
work_6edatbslnjhz3kb2pkbphqv5py	318	2	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	319	1	Oncol	Oncol	NNP
work_6edatbslnjhz3kb2pkbphqv5py	319	2	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	320	1	Annu	Annu	NNP
work_6edatbslnjhz3kb2pkbphqv5py	320	2	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	321	1	Meet	Meet	NNP
work_6edatbslnjhz3kb2pkbphqv5py	321	2	.	.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	321	3	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	321	4	9	9	CD
work_6edatbslnjhz3kb2pkbphqv5py	321	5	:	:	SYM
work_6edatbslnjhz3kb2pkbphqv5py	321	6	107	107	CD
work_6edatbslnjhz3kb2pkbphqv5py	321	7	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	321	8	1990	1990	CD
work_6edatbslnjhz3kb2pkbphqv5py	321	9	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	322	1	28	28	CD
work_6edatbslnjhz3kb2pkbphqv5py	322	2	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	323	1	Zar	Zar	NNP
work_6edatbslnjhz3kb2pkbphqv5py	323	2	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	323	3	J.	J.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	323	4	H.	H.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	323	5	Biostatistical	Biostatistical	NNP
work_6edatbslnjhz3kb2pkbphqv5py	323	6	Analysis	Analysis	NNP
work_6edatbslnjhz3kb2pkbphqv5py	323	7	(	(	-LRB-
work_6edatbslnjhz3kb2pkbphqv5py	323	8	2nd	2nd	NNP
work_6edatbslnjhz3kb2pkbphqv5py	323	9	ed	ed	NNP
work_6edatbslnjhz3kb2pkbphqv5py	323	10	)	)	-RRB-
work_6edatbslnjhz3kb2pkbphqv5py	323	11	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	323	12	pp	pp	NNP
work_6edatbslnjhz3kb2pkbphqv5py	323	13	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	324	1	138	138	CD
work_6edatbslnjhz3kb2pkbphqv5py	324	2	-	-	SYM
work_6edatbslnjhz3kb2pkbphqv5py	324	3	146	146	CD
work_6edatbslnjhz3kb2pkbphqv5py	324	4	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	324	5	290	290	CD
work_6edatbslnjhz3kb2pkbphqv5py	324	6	-	-	SYM
work_6edatbslnjhz3kb2pkbphqv5py	324	7	395	395	CD
work_6edatbslnjhz3kb2pkbphqv5py	324	8	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	325	1	Englewood	Englewood	NNP
work_6edatbslnjhz3kb2pkbphqv5py	325	2	Cliffs	Cliffs	NNPS
work_6edatbslnjhz3kb2pkbphqv5py	325	3	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	325	4	NJ	NJ	NNP
work_6edatbslnjhz3kb2pkbphqv5py	325	5	:	:	:
work_6edatbslnjhz3kb2pkbphqv5py	325	6	Prentice	Prentice	NNP
work_6edatbslnjhz3kb2pkbphqv5py	325	7	-	-	HYPH
work_6edatbslnjhz3kb2pkbphqv5py	325	8	Hall	Hall	NNP
work_6edatbslnjhz3kb2pkbphqv5py	325	9	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	325	10	1984	1984	CD
work_6edatbslnjhz3kb2pkbphqv5py	325	11	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	326	1	29	29	CD
work_6edatbslnjhz3kb2pkbphqv5py	326	2	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	327	1	Kaplan	Kaplan	NNP
work_6edatbslnjhz3kb2pkbphqv5py	327	2	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	327	3	E.	E.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	327	4	L.	L.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	327	5	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	327	6	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	327	7	Meier	Meier	NNP
work_6edatbslnjhz3kb2pkbphqv5py	327	8	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	327	9	P.	P.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	327	10	Nonparametric	Nonparametric	NNP
work_6edatbslnjhz3kb2pkbphqv5py	327	11	estimation	estimation	NN
work_6edatbslnjhz3kb2pkbphqv5py	327	12	from	from	IN
work_6edatbslnjhz3kb2pkbphqv5py	327	13	incom-	incom-	JJ
work_6edatbslnjhz3kb2pkbphqv5py	327	14	plete	plete	JJ
work_6edatbslnjhz3kb2pkbphqv5py	327	15	observations	observation	NNS
work_6edatbslnjhz3kb2pkbphqv5py	327	16	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	328	1	J.	J.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	329	1	Am	Am	NNP
work_6edatbslnjhz3kb2pkbphqv5py	329	2	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	330	1	Stat	stat	JJ
work_6edatbslnjhz3kb2pkbphqv5py	330	2	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	331	1	Assoc	Assoc	NNP
work_6edatbslnjhz3kb2pkbphqv5py	331	2	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	331	3	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	331	4	53	53	CD
work_6edatbslnjhz3kb2pkbphqv5py	331	5	:	:	SYM
work_6edatbslnjhz3kb2pkbphqv5py	331	6	457	457	CD
work_6edatbslnjhz3kb2pkbphqv5py	331	7	-	-	SYM
work_6edatbslnjhz3kb2pkbphqv5py	331	8	481	481	CD
work_6edatbslnjhz3kb2pkbphqv5py	331	9	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	331	10	1958	1958	CD
work_6edatbslnjhz3kb2pkbphqv5py	331	11	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	332	1	30	30	CD
work_6edatbslnjhz3kb2pkbphqv5py	332	2	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	333	1	Armitage	armitage	NN
work_6edatbslnjhz3kb2pkbphqv5py	333	2	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	333	3	P.	P.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	333	4	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	333	5	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	333	6	Berry	Berry	NNP
work_6edatbslnjhz3kb2pkbphqv5py	333	7	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	333	8	G.	G.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	333	9	Statistical	Statistical	NNP
work_6edatbslnjhz3kb2pkbphqv5py	333	10	Methods	Methods	NNPS
work_6edatbslnjhz3kb2pkbphqv5py	333	11	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	333	12	Medical	Medical	NNP
work_6edatbslnjhz3kb2pkbphqv5py	333	13	Re-	Re-	NNP
work_6edatbslnjhz3kb2pkbphqv5py	333	14	search	search	NN
work_6edatbslnjhz3kb2pkbphqv5py	333	15	(	(	-LRB-
work_6edatbslnjhz3kb2pkbphqv5py	333	16	2nd	2nd	NNP
work_6edatbslnjhz3kb2pkbphqv5py	333	17	ed	ed	NNP
work_6edatbslnjhz3kb2pkbphqv5py	333	18	)	)	-RRB-
work_6edatbslnjhz3kb2pkbphqv5py	333	19	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	333	20	pp	pp	NNP
work_6edatbslnjhz3kb2pkbphqv5py	333	21	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	334	1	427	427	CD
work_6edatbslnjhz3kb2pkbphqv5py	334	2	-	-	SYM
work_6edatbslnjhz3kb2pkbphqv5py	334	3	433	433	CD
work_6edatbslnjhz3kb2pkbphqv5py	334	4	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	335	1	Oxford	oxford	NN
work_6edatbslnjhz3kb2pkbphqv5py	335	2	:	:	:
work_6edatbslnjhz3kb2pkbphqv5py	335	3	Blackwell	Blackwell	NNP
work_6edatbslnjhz3kb2pkbphqv5py	335	4	Scientific	Scientific	NNP
work_6edatbslnjhz3kb2pkbphqv5py	335	5	Publica-	Publica-	NNP
work_6edatbslnjhz3kb2pkbphqv5py	335	6	tions	tion	NNS
work_6edatbslnjhz3kb2pkbphqv5py	335	7	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	335	8	1987	1987	CD
work_6edatbslnjhz3kb2pkbphqv5py	335	9	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	336	1	31	31	CD
work_6edatbslnjhz3kb2pkbphqv5py	336	2	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	337	1	Cox	Cox	NNP
work_6edatbslnjhz3kb2pkbphqv5py	337	2	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	337	3	D.	D.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	337	4	R.	R.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	337	5	Regression	Regression	NNP
work_6edatbslnjhz3kb2pkbphqv5py	337	6	models	model	NNS
work_6edatbslnjhz3kb2pkbphqv5py	337	7	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	337	8	life	life	NN
work_6edatbslnjhz3kb2pkbphqv5py	337	9	-	-	HYPH
work_6edatbslnjhz3kb2pkbphqv5py	337	10	tables	table	NNS
work_6edatbslnjhz3kb2pkbphqv5py	337	11	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	338	1	J.	J.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	338	2	R.	R.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	338	3	Stat	Stat	NNP
work_6edatbslnjhz3kb2pkbphqv5py	338	4	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	339	1	Soc	Soc	NNP
work_6edatbslnjhz3kb2pkbphqv5py	339	2	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	340	1	B	B	NNP
work_6edatbslnjhz3kb2pkbphqv5py	340	2	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	340	3	34	34	CD
work_6edatbslnjhz3kb2pkbphqv5py	340	4	:	:	SYM
work_6edatbslnjhz3kb2pkbphqv5py	340	5	187	187	CD
work_6edatbslnjhz3kb2pkbphqv5py	340	6	-	-	SYM
work_6edatbslnjhz3kb2pkbphqv5py	340	7	220	220	CD
work_6edatbslnjhz3kb2pkbphqv5py	340	8	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	340	9	1972	1972	CD
work_6edatbslnjhz3kb2pkbphqv5py	340	10	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	341	1	32	32	CD
work_6edatbslnjhz3kb2pkbphqv5py	341	2	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	342	1	Longr#{233}e	Longr#{233}e	NNP
work_6edatbslnjhz3kb2pkbphqv5py	342	2	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	342	3	L.	L.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	342	4	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	342	5	Focan	Focan	NNP
work_6edatbslnjhz3kb2pkbphqv5py	342	6	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	342	7	C.	C.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	342	8	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	342	9	Bury	Bury	NNP
work_6edatbslnjhz3kb2pkbphqv5py	342	10	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	342	11	J.	J.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	342	12	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	342	13	Beauduin	Beauduin	NNP
work_6edatbslnjhz3kb2pkbphqv5py	342	14	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	342	15	M.	M.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	342	16	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	342	17	Brohee	Brohee	NNP
work_6edatbslnjhz3kb2pkbphqv5py	342	18	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	342	19	D.	D.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	342	20	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	342	21	Du-	Du-	NNP
work_6edatbslnjhz3kb2pkbphqv5py	342	22	vivier	vivier	NN
work_6edatbslnjhz3kb2pkbphqv5py	342	23	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	342	24	A.	A.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	342	25	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	342	26	Lecomte	Lecomte	NNP
work_6edatbslnjhz3kb2pkbphqv5py	342	27	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	342	28	M.	M.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	342	29	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	342	30	Markiewicz	Markiewicz	NNP
work_6edatbslnjhz3kb2pkbphqv5py	342	31	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	342	32	S.	S.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	342	33	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	342	34	Vindevoghel	Vindevoghel	NNP
work_6edatbslnjhz3kb2pkbphqv5py	342	35	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	342	36	A.	a.	NN
work_6edatbslnjhz3kb2pkbphqv5py	342	37	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	342	38	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	342	39	Weerts	Weerts	NNP
work_6edatbslnjhz3kb2pkbphqv5py	342	40	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	342	41	J.	J.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	342	42	Levamisole	Levamisole	NNP
work_6edatbslnjhz3kb2pkbphqv5py	342	43	adds	add	VBZ
work_6edatbslnjhz3kb2pkbphqv5py	342	44	granulocyte	granulocyte	NN
work_6edatbslnjhz3kb2pkbphqv5py	342	45	toxicity	toxicity	NN
work_6edatbslnjhz3kb2pkbphqv5py	342	46	to	to	IN
work_6edatbslnjhz3kb2pkbphqv5py	342	47	5-Hi	5-hi	CD
work_6edatbslnjhz3kb2pkbphqv5py	342	48	based	base	VBN
work_6edatbslnjhz3kb2pkbphqv5py	342	49	chemotherapies	chemotherapy	NNS
work_6edatbslnjhz3kb2pkbphqv5py	342	50	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	342	51	adjuvant	adjuvant	JJ
work_6edatbslnjhz3kb2pkbphqv5py	342	52	treatment	treatment	NN
work_6edatbslnjhz3kb2pkbphqv5py	342	53	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	342	54	Dukes	Dukes	NNP
work_6edatbslnjhz3kb2pkbphqv5py	342	55	B	B	NNP
work_6edatbslnjhz3kb2pkbphqv5py	342	56	-	-	HYPH
work_6edatbslnjhz3kb2pkbphqv5py	342	57	C	C	NNP
work_6edatbslnjhz3kb2pkbphqv5py	342	58	coborectal	coborectal	NN
work_6edatbslnjhz3kb2pkbphqv5py	342	59	cancer	cancer	NN
work_6edatbslnjhz3kb2pkbphqv5py	342	60	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	343	1	A	a	DT
work_6edatbslnjhz3kb2pkbphqv5py	343	2	preliminary	preliminary	JJ
work_6edatbslnjhz3kb2pkbphqv5py	343	3	report	report	NN
work_6edatbslnjhz3kb2pkbphqv5py	343	4	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	344	1	Anticancer	Anticancer	NNP
work_6edatbslnjhz3kb2pkbphqv5py	344	2	Res	Res	NNP
work_6edatbslnjhz3kb2pkbphqv5py	344	3	.	.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	344	4	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	344	5	15	15	CD
work_6edatbslnjhz3kb2pkbphqv5py	344	6	:	:	SYM
work_6edatbslnjhz3kb2pkbphqv5py	344	7	1561	1561	CD
work_6edatbslnjhz3kb2pkbphqv5py	344	8	-	-	SYM
work_6edatbslnjhz3kb2pkbphqv5py	344	9	1564	1564	CD
work_6edatbslnjhz3kb2pkbphqv5py	344	10	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	344	11	1995	1995	CD
work_6edatbslnjhz3kb2pkbphqv5py	344	12	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	345	1	33	33	CD
work_6edatbslnjhz3kb2pkbphqv5py	345	2	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	346	1	Mayer	Mayer	NNP
work_6edatbslnjhz3kb2pkbphqv5py	346	2	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	346	3	R.	R.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	346	4	J.	J.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	347	1	Does	do	VBZ
work_6edatbslnjhz3kb2pkbphqv5py	347	2	adjuvant	adjuvant	JJ
work_6edatbslnjhz3kb2pkbphqv5py	347	3	therapy	therapy	NN
work_6edatbslnjhz3kb2pkbphqv5py	347	4	work	work	NN
work_6edatbslnjhz3kb2pkbphqv5py	347	5	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	347	6	colon	colon	NN
work_6edatbslnjhz3kb2pkbphqv5py	347	7	cancer	cancer	NN
work_6edatbslnjhz3kb2pkbphqv5py	347	8	?	?	.
work_6edatbslnjhz3kb2pkbphqv5py	348	1	N.	N.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	348	2	Engl	Engl	NNP
work_6edatbslnjhz3kb2pkbphqv5py	348	3	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	349	1	J.	J.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	350	1	Med	Med	NNP
work_6edatbslnjhz3kb2pkbphqv5py	350	2	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	350	3	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	350	4	322	322	CD
work_6edatbslnjhz3kb2pkbphqv5py	350	5	:	:	SYM
work_6edatbslnjhz3kb2pkbphqv5py	350	6	399	399	CD
work_6edatbslnjhz3kb2pkbphqv5py	350	7	-	-	SYM
work_6edatbslnjhz3kb2pkbphqv5py	350	8	401	401	CD
work_6edatbslnjhz3kb2pkbphqv5py	350	9	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	350	10	1990	1990	CD
work_6edatbslnjhz3kb2pkbphqv5py	350	11	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	351	1	34	34	CD
work_6edatbslnjhz3kb2pkbphqv5py	351	2	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	352	1	Wolmark	Wolmark	NNP
work_6edatbslnjhz3kb2pkbphqv5py	352	2	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	352	3	N.	N.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	352	4	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	352	5	Rockett	Rockett	NNP
work_6edatbslnjhz3kb2pkbphqv5py	352	6	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	352	7	H.	H.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	352	8	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	352	9	Mamounas	Mamounas	NNP
work_6edatbslnjhz3kb2pkbphqv5py	352	10	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	352	11	E.	E.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	352	12	P.	P.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	352	13	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	352	14	et	et	NNP
work_6edatbslnjhz3kb2pkbphqv5py	352	15	al	al	NNP
work_6edatbslnjhz3kb2pkbphqv5py	352	16	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	353	1	The	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	353	2	relative	relative	JJ
work_6edatbslnjhz3kb2pkbphqv5py	353	3	efficacy	efficacy	NN
work_6edatbslnjhz3kb2pkbphqv5py	353	4	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	353	5	s	s	NN
work_6edatbslnjhz3kb2pkbphqv5py	353	6	-	-	:
work_6edatbslnjhz3kb2pkbphqv5py	353	7	as	as	IN
work_6edatbslnjhz3kb2pkbphqv5py	353	8	+	+	SYM
work_6edatbslnjhz3kb2pkbphqv5py	353	9	leucovorin	leucovorin	NN
work_6edatbslnjhz3kb2pkbphqv5py	353	10	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	353	11	5-Hi	5-hi	CD
work_6edatbslnjhz3kb2pkbphqv5py	353	12	+	+	SYM
work_6edatbslnjhz3kb2pkbphqv5py	353	13	levamisole	levamisole	NN
work_6edatbslnjhz3kb2pkbphqv5py	353	14	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	353	15	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	353	16	5-Hi	5-hi	CD
work_6edatbslnjhz3kb2pkbphqv5py	353	17	+	+	SYM
work_6edatbslnjhz3kb2pkbphqv5py	353	18	leucovorin	leucovorin	NN
work_6edatbslnjhz3kb2pkbphqv5py	353	19	+	+	SYM
work_6edatbslnjhz3kb2pkbphqv5py	353	20	levamisole	levamisole	NN
work_6edatbslnjhz3kb2pkbphqv5py	353	21	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	353	22	patients	patient	NNS
work_6edatbslnjhz3kb2pkbphqv5py	353	23	with	with	IN
work_6edatbslnjhz3kb2pkbphqv5py	353	24	Duke	Duke	NNP
work_6edatbslnjhz3kb2pkbphqv5py	353	25	’s	’s	NNP
work_6edatbslnjhz3kb2pkbphqv5py	353	26	B	B	NNP
work_6edatbslnjhz3kb2pkbphqv5py	353	27	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	353	28	C	C	NNP
work_6edatbslnjhz3kb2pkbphqv5py	353	29	carcinoma	carcinoma	NN
work_6edatbslnjhz3kb2pkbphqv5py	353	30	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	353	31	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	353	32	colon	colon	NN
work_6edatbslnjhz3kb2pkbphqv5py	353	33	:	:	:
work_6edatbslnjhz3kb2pkbphqv5py	353	34	first	first	JJ
work_6edatbslnjhz3kb2pkbphqv5py	353	35	report	report	NN
work_6edatbslnjhz3kb2pkbphqv5py	353	36	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	353	37	NSABP	NSABP	NNP
work_6edatbslnjhz3kb2pkbphqv5py	353	38	C-04	c-04	CD
work_6edatbslnjhz3kb2pkbphqv5py	353	39	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	354	1	Proc	Proc	NNP
work_6edatbslnjhz3kb2pkbphqv5py	354	2	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	355	1	Am	Am	NNP
work_6edatbslnjhz3kb2pkbphqv5py	355	2	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	356	1	Soc	Soc	NNP
work_6edatbslnjhz3kb2pkbphqv5py	356	2	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	357	1	Clin	Clin	NNP
work_6edatbslnjhz3kb2pkbphqv5py	357	2	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	358	1	Oncol	Oncol	NNP
work_6edatbslnjhz3kb2pkbphqv5py	358	2	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	359	1	Annu	Annu	NNP
work_6edatbslnjhz3kb2pkbphqv5py	359	2	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	360	1	Meet	Meet	NNP
work_6edatbslnjhz3kb2pkbphqv5py	360	2	.	.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	360	3	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	360	4	15	15	CD
work_6edatbslnjhz3kb2pkbphqv5py	360	5	:	:	SYM
work_6edatbslnjhz3kb2pkbphqv5py	360	6	205	205	CD
work_6edatbslnjhz3kb2pkbphqv5py	360	7	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	360	8	1996	1996	CD
work_6edatbslnjhz3kb2pkbphqv5py	360	9	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	361	1	35	35	CD
work_6edatbslnjhz3kb2pkbphqv5py	361	2	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	362	1	O’Connell	O’Connell	NNP
work_6edatbslnjhz3kb2pkbphqv5py	362	2	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	362	3	M.	M.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	362	4	J.	J.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	362	5	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	362	6	Laurie	Laurie	NNP
work_6edatbslnjhz3kb2pkbphqv5py	362	7	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	362	8	J.	J.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	363	1	A.	A.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	363	2	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	363	3	Shepherd	Shepherd	NNP
work_6edatbslnjhz3kb2pkbphqv5py	363	4	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	363	5	L.	L.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	363	6	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	363	7	et	et	NNP
work_6edatbslnjhz3kb2pkbphqv5py	363	8	al	al	NNP
work_6edatbslnjhz3kb2pkbphqv5py	363	9	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	364	1	A	a	DT
work_6edatbslnjhz3kb2pkbphqv5py	364	2	prospective	prospective	JJ
work_6edatbslnjhz3kb2pkbphqv5py	364	3	evaluation	evaluation	NN
work_6edatbslnjhz3kb2pkbphqv5py	364	4	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	364	5	chemotherapy	chemotherapy	NN
work_6edatbslnjhz3kb2pkbphqv5py	364	6	duration	duration	NN
work_6edatbslnjhz3kb2pkbphqv5py	364	7	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	364	8	regimen	regimen	NN
work_6edatbslnjhz3kb2pkbphqv5py	364	9	as	as	IN
work_6edatbslnjhz3kb2pkbphqv5py	364	10	surgical	surgical	JJ
work_6edatbslnjhz3kb2pkbphqv5py	364	11	adjuvant	adjuvant	JJ
work_6edatbslnjhz3kb2pkbphqv5py	364	12	treatment	treatment	NN
work_6edatbslnjhz3kb2pkbphqv5py	364	13	for	for	IN
work_6edatbslnjhz3kb2pkbphqv5py	364	14	high	high	JJ
work_6edatbslnjhz3kb2pkbphqv5py	364	15	risk	risk	NN
work_6edatbslnjhz3kb2pkbphqv5py	364	16	colon	colon	NN
work_6edatbslnjhz3kb2pkbphqv5py	364	17	cancer	cancer	NN
work_6edatbslnjhz3kb2pkbphqv5py	364	18	:	:	:
work_6edatbslnjhz3kb2pkbphqv5py	364	19	a	a	DT
work_6edatbslnjhz3kb2pkbphqv5py	364	20	collaborative	collaborative	JJ
work_6edatbslnjhz3kb2pkbphqv5py	364	21	trial	trial	NN
work_6edatbslnjhz3kb2pkbphqv5py	364	22	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	364	23	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	364	24	North	North	NNP
work_6edatbslnjhz3kb2pkbphqv5py	364	25	Central	Central	NNP
work_6edatbslnjhz3kb2pkbphqv5py	364	26	Cancer	Cancer	NNP
work_6edatbslnjhz3kb2pkbphqv5py	364	27	Treatment	Treatment	NNP
work_6edatbslnjhz3kb2pkbphqv5py	364	28	Group	Group	NNP
work_6edatbslnjhz3kb2pkbphqv5py	364	29	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	364	30	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	364	31	National	National	NNP
work_6edatbslnjhz3kb2pkbphqv5py	364	32	Cancer	Cancer	NNP
work_6edatbslnjhz3kb2pkbphqv5py	364	33	Institute	Institute	NNP
work_6edatbslnjhz3kb2pkbphqv5py	364	34	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	364	35	Canada	Canada	NNP
work_6edatbslnjhz3kb2pkbphqv5py	364	36	Clinical	Clinical	NNP
work_6edatbslnjhz3kb2pkbphqv5py	364	37	Trials	Trials	NNPS
work_6edatbslnjhz3kb2pkbphqv5py	364	38	Group	Group	NNP
work_6edatbslnjhz3kb2pkbphqv5py	364	39	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	365	1	Proc	Proc	NNP
work_6edatbslnjhz3kb2pkbphqv5py	365	2	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	366	1	Am	Am	NNP
work_6edatbslnjhz3kb2pkbphqv5py	366	2	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	367	1	Soc	Soc	NNP
work_6edatbslnjhz3kb2pkbphqv5py	367	2	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	368	1	Clin	Clin	NNP
work_6edatbslnjhz3kb2pkbphqv5py	368	2	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	369	1	Oncol	Oncol	NNP
work_6edatbslnjhz3kb2pkbphqv5py	369	2	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	370	1	Annu	Annu	NNP
work_6edatbslnjhz3kb2pkbphqv5py	370	2	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	371	1	Meet	Meet	NNP
work_6edatbslnjhz3kb2pkbphqv5py	371	2	.	.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	371	3	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	371	4	15	15	CD
work_6edatbslnjhz3kb2pkbphqv5py	371	5	:	:	SYM
work_6edatbslnjhz3kb2pkbphqv5py	371	6	209	209	CD
work_6edatbslnjhz3kb2pkbphqv5py	371	7	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	371	8	1996	1996	CD
work_6edatbslnjhz3kb2pkbphqv5py	371	9	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	372	1	36	36	CD
work_6edatbslnjhz3kb2pkbphqv5py	372	2	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	373	1	Haller	Haller	NNP
work_6edatbslnjhz3kb2pkbphqv5py	373	2	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	373	3	D.	D.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	373	4	G.	G.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	373	5	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	373	6	Catalona	Catalona	NNP
work_6edatbslnjhz3kb2pkbphqv5py	373	7	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	373	8	P.	P.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	373	9	J.	J.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	373	10	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	373	11	MacDonald	MacDonald	NNP
work_6edatbslnjhz3kb2pkbphqv5py	373	12	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	373	13	J.	J.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	373	14	S.	S.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	373	15	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	373	16	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	373	17	Mayer	Mayer	NNP
work_6edatbslnjhz3kb2pkbphqv5py	373	18	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	373	19	R.	R.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	373	20	J.	J.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	373	21	Fluorouracil	Fluorouracil	NNP
work_6edatbslnjhz3kb2pkbphqv5py	373	22	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	373	23	leucovorin	leucovorin	NNP
work_6edatbslnjhz3kb2pkbphqv5py	373	24	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	373	25	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	373	26	levamisole	levamisole	NN
work_6edatbslnjhz3kb2pkbphqv5py	373	27	adjuvant	adjuvant	NN
work_6edatbslnjhz3kb2pkbphqv5py	373	28	therapy	therapy	NN
work_6edatbslnjhz3kb2pkbphqv5py	373	29	for	for	IN
work_6edatbslnjhz3kb2pkbphqv5py	373	30	colon	colon	NN
work_6edatbslnjhz3kb2pkbphqv5py	373	31	cancer	cancer	NN
work_6edatbslnjhz3kb2pkbphqv5py	373	32	:	:	:
work_6edatbslnjhz3kb2pkbphqv5py	373	33	four	four	CD
work_6edatbslnjhz3kb2pkbphqv5py	373	34	year	year	NN
work_6edatbslnjhz3kb2pkbphqv5py	373	35	results	result	NNS
work_6edatbslnjhz3kb2pkbphqv5py	373	36	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	373	37	INT-0089	INT-0089	NNP
work_6edatbslnjhz3kb2pkbphqv5py	373	38	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	374	1	Proc	Proc	NNP
work_6edatbslnjhz3kb2pkbphqv5py	374	2	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	375	1	Am	Am	NNP
work_6edatbslnjhz3kb2pkbphqv5py	375	2	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	376	1	Soc	Soc	NNP
work_6edatbslnjhz3kb2pkbphqv5py	376	2	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	377	1	Clin	Clin	NNP
work_6edatbslnjhz3kb2pkbphqv5py	377	2	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	378	1	Oncol	Oncol	NNP
work_6edatbslnjhz3kb2pkbphqv5py	378	2	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	379	1	Annu	Annu	NNP
work_6edatbslnjhz3kb2pkbphqv5py	379	2	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	380	1	Meet	Meet	NNP
work_6edatbslnjhz3kb2pkbphqv5py	380	2	.	.	NNP
work_6edatbslnjhz3kb2pkbphqv5py	380	3	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	380	4	16	16	CD
work_6edatbslnjhz3kb2pkbphqv5py	380	5	:	:	SYM
work_6edatbslnjhz3kb2pkbphqv5py	380	6	265	265	CD
work_6edatbslnjhz3kb2pkbphqv5py	380	7	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	380	8	1997	1997	CD
work_6edatbslnjhz3kb2pkbphqv5py	380	9	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	380	10	on	on	IN
work_6edatbslnjhz3kb2pkbphqv5py	380	11	April	April	NNP
work_6edatbslnjhz3kb2pkbphqv5py	380	12	5	5	CD
work_6edatbslnjhz3kb2pkbphqv5py	380	13	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	380	14	2021	2021	CD
work_6edatbslnjhz3kb2pkbphqv5py	380	15	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	381	1	©	©	NNP
work_6edatbslnjhz3kb2pkbphqv5py	381	2	1998	1998	CD
work_6edatbslnjhz3kb2pkbphqv5py	381	3	American	American	NNP
work_6edatbslnjhz3kb2pkbphqv5py	381	4	Association	Association	NNP
work_6edatbslnjhz3kb2pkbphqv5py	381	5	for	for	IN
work_6edatbslnjhz3kb2pkbphqv5py	381	6	Cancer	Cancer	NNP
work_6edatbslnjhz3kb2pkbphqv5py	381	7	Research.clincancerres.aacrjournals.org	research.clincancerres.aacrjournals.org	NN
work_6edatbslnjhz3kb2pkbphqv5py	381	8	Downloaded	download	VBN
work_6edatbslnjhz3kb2pkbphqv5py	381	9	from	from	IN
work_6edatbslnjhz3kb2pkbphqv5py	381	10	http://clincancerres.aacrjournals.org/	http://clincancerres.aacrjournals.org/	CD
work_6edatbslnjhz3kb2pkbphqv5py	381	11	1998;4:935	1998;4:935	CD
work_6edatbslnjhz3kb2pkbphqv5py	381	12	-	-	SYM
work_6edatbslnjhz3kb2pkbphqv5py	381	13	939	939	CD
work_6edatbslnjhz3kb2pkbphqv5py	381	14	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	382	1	Clin	Clin	NNP
work_6edatbslnjhz3kb2pkbphqv5py	382	2	Cancer	Cancer	NNP
work_6edatbslnjhz3kb2pkbphqv5py	382	3	Res	Res	NNP
work_6edatbslnjhz3kb2pkbphqv5py	382	4	M	M	NNP
work_6edatbslnjhz3kb2pkbphqv5py	382	5	T	T	NNP
work_6edatbslnjhz3kb2pkbphqv5py	382	6	Bandealy	Bandealy	NNP
work_6edatbslnjhz3kb2pkbphqv5py	382	7	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	382	8	R	R	NNP
work_6edatbslnjhz3kb2pkbphqv5py	382	9	Gonin	Gonin	NNP
work_6edatbslnjhz3kb2pkbphqv5py	382	10	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	382	11	P	P	NNP
work_6edatbslnjhz3kb2pkbphqv5py	382	12	J	J	NNP
work_6edatbslnjhz3kb2pkbphqv5py	382	13	Loehrer	Loehrer	NNP
work_6edatbslnjhz3kb2pkbphqv5py	382	14	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	382	15	et	et	NNP
work_6edatbslnjhz3kb2pkbphqv5py	382	16	al	al	NNP
work_6edatbslnjhz3kb2pkbphqv5py	382	17	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	383	1	colorectal	colorectal	JJ
work_6edatbslnjhz3kb2pkbphqv5py	383	2	cancer	cancer	NN
work_6edatbslnjhz3kb2pkbphqv5py	383	3	:	:	:
work_6edatbslnjhz3kb2pkbphqv5py	383	4	a	a	DT
work_6edatbslnjhz3kb2pkbphqv5py	383	5	Hoosier	Hoosier	NNP
work_6edatbslnjhz3kb2pkbphqv5py	383	6	Oncology	Oncology	NNP
work_6edatbslnjhz3kb2pkbphqv5py	383	7	Group	Group	NNP
work_6edatbslnjhz3kb2pkbphqv5py	383	8	trial	trial	NN
work_6edatbslnjhz3kb2pkbphqv5py	383	9	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	384	1	5-fluorouracil	5-fluorouracil	CD
work_6edatbslnjhz3kb2pkbphqv5py	384	2	plus	plus	CC
work_6edatbslnjhz3kb2pkbphqv5py	384	3	levamisole	levamisole	NN
work_6edatbslnjhz3kb2pkbphqv5py	384	4	in	in	IN
work_6edatbslnjhz3kb2pkbphqv5py	384	5	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	384	6	treatment	treatment	NN
work_6edatbslnjhz3kb2pkbphqv5py	384	7	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	384	8	metastatic	metastatic	JJ
work_6edatbslnjhz3kb2pkbphqv5py	384	9	Prospective	Prospective	NNP
work_6edatbslnjhz3kb2pkbphqv5py	384	10	randomized	randomized	JJ
work_6edatbslnjhz3kb2pkbphqv5py	384	11	trial	trial	NN
work_6edatbslnjhz3kb2pkbphqv5py	384	12	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	384	13	5-fluorouracil	5-fluorouracil	CD
work_6edatbslnjhz3kb2pkbphqv5py	384	14	versus	versus	IN
work_6edatbslnjhz3kb2pkbphqv5py	384	15	Updated	update	VBN
work_6edatbslnjhz3kb2pkbphqv5py	384	16	version	version	NN
work_6edatbslnjhz3kb2pkbphqv5py	384	17	http://clincancerres.aacrjournals.org/content/4/4/935	http://clincancerres.aacrjournals.org/content/4/4/935	.
work_6edatbslnjhz3kb2pkbphqv5py	384	18	Access	access	VB
work_6edatbslnjhz3kb2pkbphqv5py	384	19	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	384	20	most	most	RBS
work_6edatbslnjhz3kb2pkbphqv5py	384	21	recent	recent	JJ
work_6edatbslnjhz3kb2pkbphqv5py	384	22	version	version	NN
work_6edatbslnjhz3kb2pkbphqv5py	384	23	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	384	24	this	this	DT
work_6edatbslnjhz3kb2pkbphqv5py	384	25	article	article	NN
work_6edatbslnjhz3kb2pkbphqv5py	384	26	at	at	IN
work_6edatbslnjhz3kb2pkbphqv5py	384	27	:	:	:
work_6edatbslnjhz3kb2pkbphqv5py	384	28	E	e	NN
work_6edatbslnjhz3kb2pkbphqv5py	384	29	-	-	NN
work_6edatbslnjhz3kb2pkbphqv5py	384	30	mail	mail	NN
work_6edatbslnjhz3kb2pkbphqv5py	384	31	alerts	alert	NNS
work_6edatbslnjhz3kb2pkbphqv5py	384	32	related	relate	VBN
work_6edatbslnjhz3kb2pkbphqv5py	384	33	to	to	IN
work_6edatbslnjhz3kb2pkbphqv5py	384	34	this	this	DT
work_6edatbslnjhz3kb2pkbphqv5py	384	35	article	article	NN
work_6edatbslnjhz3kb2pkbphqv5py	384	36	or	or	CC
work_6edatbslnjhz3kb2pkbphqv5py	384	37	journal	journal	NN
work_6edatbslnjhz3kb2pkbphqv5py	384	38	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	384	39	Sign	sign	VB
work_6edatbslnjhz3kb2pkbphqv5py	384	40	up	up	RP
work_6edatbslnjhz3kb2pkbphqv5py	384	41	to	to	TO
work_6edatbslnjhz3kb2pkbphqv5py	384	42	receive	receive	VB
work_6edatbslnjhz3kb2pkbphqv5py	384	43	free	free	JJ
work_6edatbslnjhz3kb2pkbphqv5py	384	44	email	email	NN
work_6edatbslnjhz3kb2pkbphqv5py	384	45	-	-	HYPH
work_6edatbslnjhz3kb2pkbphqv5py	384	46	alerts	alert	NNS
work_6edatbslnjhz3kb2pkbphqv5py	384	47	Subscriptions	Subscriptions	NNPS
work_6edatbslnjhz3kb2pkbphqv5py	384	48	Reprints	Reprints	NNP
work_6edatbslnjhz3kb2pkbphqv5py	384	49	and	and	CC
work_6edatbslnjhz3kb2pkbphqv5py	384	50	.pubs@aacr.orgDepartment	.pubs@aacr.orgDepartment	.
work_6edatbslnjhz3kb2pkbphqv5py	384	51	at	at	IN
work_6edatbslnjhz3kb2pkbphqv5py	384	52	To	to	TO
work_6edatbslnjhz3kb2pkbphqv5py	384	53	order	order	VB
work_6edatbslnjhz3kb2pkbphqv5py	384	54	reprints	reprint	NNS
work_6edatbslnjhz3kb2pkbphqv5py	384	55	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	384	56	this	this	DT
work_6edatbslnjhz3kb2pkbphqv5py	384	57	article	article	NN
work_6edatbslnjhz3kb2pkbphqv5py	384	58	or	or	CC
work_6edatbslnjhz3kb2pkbphqv5py	384	59	to	to	TO
work_6edatbslnjhz3kb2pkbphqv5py	384	60	subscribe	subscribe	VB
work_6edatbslnjhz3kb2pkbphqv5py	384	61	to	to	IN
work_6edatbslnjhz3kb2pkbphqv5py	384	62	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	384	63	journal	journal	NN
work_6edatbslnjhz3kb2pkbphqv5py	384	64	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	384	65	contact	contact	VB
work_6edatbslnjhz3kb2pkbphqv5py	384	66	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	384	67	AACR	AACR	NNP
work_6edatbslnjhz3kb2pkbphqv5py	384	68	Publications	Publications	NNPS
work_6edatbslnjhz3kb2pkbphqv5py	384	69	Permissions	permission	NNS
work_6edatbslnjhz3kb2pkbphqv5py	384	70	Rightslink	rightslink	VBP
work_6edatbslnjhz3kb2pkbphqv5py	384	71	site	site	NN
work_6edatbslnjhz3kb2pkbphqv5py	384	72	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	385	1	Click	click	VB
work_6edatbslnjhz3kb2pkbphqv5py	385	2	on	on	IN
work_6edatbslnjhz3kb2pkbphqv5py	385	3	"	"	``
work_6edatbslnjhz3kb2pkbphqv5py	385	4	Request	Request	NNP
work_6edatbslnjhz3kb2pkbphqv5py	385	5	Permissions	permission	NNS
work_6edatbslnjhz3kb2pkbphqv5py	385	6	"	"	''
work_6edatbslnjhz3kb2pkbphqv5py	385	7	which	which	WDT
work_6edatbslnjhz3kb2pkbphqv5py	385	8	will	will	MD
work_6edatbslnjhz3kb2pkbphqv5py	385	9	take	take	VB
work_6edatbslnjhz3kb2pkbphqv5py	385	10	you	-PRON-	PRP
work_6edatbslnjhz3kb2pkbphqv5py	385	11	to	to	IN
work_6edatbslnjhz3kb2pkbphqv5py	385	12	the	the	DT
work_6edatbslnjhz3kb2pkbphqv5py	385	13	Copyright	Copyright	NNP
work_6edatbslnjhz3kb2pkbphqv5py	385	14	Clearance	Clearance	NNP
work_6edatbslnjhz3kb2pkbphqv5py	385	15	Center	Center	NNP
work_6edatbslnjhz3kb2pkbphqv5py	385	16	's	's	POS
work_6edatbslnjhz3kb2pkbphqv5py	385	17	(	(	-LRB-
work_6edatbslnjhz3kb2pkbphqv5py	385	18	CCC	CCC	NNP
work_6edatbslnjhz3kb2pkbphqv5py	385	19	)	)	-RRB-
work_6edatbslnjhz3kb2pkbphqv5py	385	20	.http://clincancerres.aacrjournals.org/content/4/4/935	.http://clincancerres.aacrjournals.org/content/4/4/935	.
work_6edatbslnjhz3kb2pkbphqv5py	385	21	To	to	TO
work_6edatbslnjhz3kb2pkbphqv5py	385	22	request	request	VB
work_6edatbslnjhz3kb2pkbphqv5py	385	23	permission	permission	NN
work_6edatbslnjhz3kb2pkbphqv5py	385	24	to	to	TO
work_6edatbslnjhz3kb2pkbphqv5py	385	25	re	re	VB
work_6edatbslnjhz3kb2pkbphqv5py	385	26	-	-	VB
work_6edatbslnjhz3kb2pkbphqv5py	385	27	use	use	VB
work_6edatbslnjhz3kb2pkbphqv5py	385	28	all	all	DT
work_6edatbslnjhz3kb2pkbphqv5py	385	29	or	or	CC
work_6edatbslnjhz3kb2pkbphqv5py	385	30	part	part	NN
work_6edatbslnjhz3kb2pkbphqv5py	385	31	of	of	IN
work_6edatbslnjhz3kb2pkbphqv5py	385	32	this	this	DT
work_6edatbslnjhz3kb2pkbphqv5py	385	33	article	article	NN
work_6edatbslnjhz3kb2pkbphqv5py	385	34	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	385	35	use	use	VB
work_6edatbslnjhz3kb2pkbphqv5py	385	36	this	this	DT
work_6edatbslnjhz3kb2pkbphqv5py	385	37	link	link	NN
work_6edatbslnjhz3kb2pkbphqv5py	385	38	on	on	IN
work_6edatbslnjhz3kb2pkbphqv5py	385	39	April	April	NNP
work_6edatbslnjhz3kb2pkbphqv5py	385	40	5	5	CD
work_6edatbslnjhz3kb2pkbphqv5py	385	41	,	,	,
work_6edatbslnjhz3kb2pkbphqv5py	385	42	2021	2021	CD
work_6edatbslnjhz3kb2pkbphqv5py	385	43	.	.	.
work_6edatbslnjhz3kb2pkbphqv5py	386	1	©	©	NNP
work_6edatbslnjhz3kb2pkbphqv5py	386	2	1998	1998	CD
work_6edatbslnjhz3kb2pkbphqv5py	386	3	American	American	NNP
work_6edatbslnjhz3kb2pkbphqv5py	386	4	Association	Association	NNP
work_6edatbslnjhz3kb2pkbphqv5py	386	5	for	for	IN
work_6edatbslnjhz3kb2pkbphqv5py	386	6	Cancer	Cancer	NNP
work_6edatbslnjhz3kb2pkbphqv5py	386	7	Research.clincancerres.aacrjournals.org	research.clincancerres.aacrjournals.org	NN
work_6edatbslnjhz3kb2pkbphqv5py	386	8	Downloaded	download	VBN
work_6edatbslnjhz3kb2pkbphqv5py	386	9	from	from	IN
work_6edatbslnjhz3kb2pkbphqv5py	386	10	http://clincancerres.aacrjournals.org/content/4/4/935	http://clincancerres.aacrjournals.org/content/4/4/935	NNS
work_6edatbslnjhz3kb2pkbphqv5py	386	11	http://clincancerres.aacrjournals.org/cgi/alerts	http://clincancerres.aacrjournals.org/cgi/alert	NNS
work_6edatbslnjhz3kb2pkbphqv5py	386	12	mailto:pubs@aacr.org	mailto:pubs@aacr.org	NNP
work_6edatbslnjhz3kb2pkbphqv5py	386	13	http://clincancerres.aacrjournals.org/content/4/4/935	http://clincancerres.aacrjournals.org/content/4/4/935	NNP
work_6edatbslnjhz3kb2pkbphqv5py	386	14	http://clincancerres.aacrjournals.org/	http://clincancerres.aacrjournals.org/	ADD